{"4a9a5082fd9d497d6fd49740d4e9195cbad82fd7": [["The current health emergency caused by the COVID19 pandemic has caused an abrupt reduction in all ordinary endoscopic activities [1] .", [["COVID19", "CHEMICAL", 43, 50], ["an abrupt reduction", "PROBLEM", 71, 90], ["abrupt", "OBSERVATION_MODIFIER", 74, 80], ["reduction", "OBSERVATION_MODIFIER", 81, 90]]], ["Our endoscopy unit, usually overloaded with procedures, has reduced its activities to immediate urgencies only, as recommended by position statements of many scientific societies [2] [3] [4] .", [["[2] [3] [4]", "SIMPLE_CHEMICAL", 179, 190], ["procedures", "TREATMENT", 44, 54], ["overloaded", "OBSERVATION", 28, 38]]]], "2754417d4d5968ec32e9632160ba166c0ccf404c": [["BackgroundAbout 15-30% of pregnant women are colonised with Group B streptococcus (GBS) in the genital and gastrointestinal tract.", [["genital", "ANATOMY", 95, 102], ["gastrointestinal tract", "ANATOMY", 107, 129], ["Group B streptococcus", "DISEASE", 60, 81], ["GBS", "DISEASE", 83, 86], ["genital and gastrointestinal tract", "DISEASE", 95, 129], ["women", "ORGANISM", 35, 40], ["Group B streptococcus", "ORGANISM", 60, 81], ["genital", "ORGANISM_SUBDIVISION", 95, 102], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 107, 129], ["women", "SPECIES", 35, 40], ["BackgroundAbout", "TEST", 0, 15], ["Group B streptococcus (GBS) in the genital and gastrointestinal tract", "PROBLEM", 60, 129], ["genital", "ANATOMY", 95, 102], ["gastrointestinal tract", "ANATOMY", 107, 129]]], ["Of the babies born to GBS colonised women, half of the babies will get colonised with GBS.", [["GBS", "DISEASE", 22, 25], ["GBS", "DISEASE", 86, 89], ["babies", "ORGANISM", 7, 13], ["women", "ORGANISM", 36, 41], ["babies", "ORGANISM", 55, 61], ["women", "SPECIES", 36, 41], ["GBS", "PROBLEM", 86, 89]]], ["Two-thirds of invasive infections occur in 0-6 days of life [early-onset GBS infections (EOGBS)] and a third occur within 7-90 days after birth [late-onset GBS infections (LOGBS)].", [["infections", "DISEASE", 23, 33], ["GBS infections", "DISEASE", 73, 87], ["EOGBS", "DISEASE", 89, 94], ["GBS infections", "DISEASE", 156, 170], ["LOGBS", "DISEASE", 172, 177], ["invasive infections", "PROBLEM", 14, 33], ["GBS infections", "PROBLEM", 73, 87], ["GBS infections", "PROBLEM", 156, 170], ["invasive", "OBSERVATION_MODIFIER", 14, 22], ["infections", "OBSERVATION", 23, 33], ["GBS", "OBSERVATION_MODIFIER", 73, 76], ["infections", "OBSERVATION", 77, 87], ["GBS", "OBSERVATION_MODIFIER", 156, 159], ["infections", "OBSERVATION", 160, 170]]], ["1 Pneumonia, septicaemia and meningitis are the commonest invasive infections.", [["Pneumonia", "DISEASE", 2, 11], ["septicaemia", "DISEASE", 13, 24], ["meningitis", "DISEASE", 29, 39], ["infections", "DISEASE", 67, 77], ["Pneumonia", "PROBLEM", 2, 11], ["septicaemia", "PROBLEM", 13, 24], ["meningitis", "PROBLEM", 29, 39], ["the commonest invasive infections", "PROBLEM", 44, 77], ["Pneumonia", "OBSERVATION", 2, 11], ["septicaemia", "OBSERVATION", 13, 24], ["meningitis", "OBSERVATION", 29, 39], ["commonest", "OBSERVATION_MODIFIER", 48, 57], ["invasive", "OBSERVATION_MODIFIER", 58, 66], ["infections", "OBSERVATION", 67, 77]]], ["A paper by Schuchat in 1998 on the pattern of GBS infection in the neonate before the universal adoption of screening in the United States (US) reported that 30% occurred in preterm babies, and 70% in otherwise healthy term babies.", [["GBS infection", "DISEASE", 46, 59], ["neonate", "ORGANISM", 67, 74], ["babies", "ORGANISM", 224, 230], ["GBS infection", "PROBLEM", 46, 59], ["GBS", "OBSERVATION_MODIFIER", 46, 49], ["infection", "OBSERVATION", 50, 59]]], ["2 In developed countries where intrapartum prophylaxis is used for prevention, the relative proportion of EOGBS and LOGBS is changing.", [["LOGBS", "DISEASE", 116, 121], ["intrapartum prophylaxis", "TREATMENT", 31, 54], ["EOGBS", "TEST", 106, 111], ["LOGBS", "PROBLEM", 116, 121]]], ["In the United Kingdom (UK), a recent survey in 2014-2015 when compared with a similar survey in 2000, showed that the proportion EOGBS fell from 66.4% in 2000 to 60.4% in 2014-2015.", [["a recent survey", "TEST", 28, 43], ["the proportion EOGBS", "TEST", 114, 134]]], ["During the same period, LOGBS increased from 33.6% in 2000 to 39.6% in 2014-2015.", [["LOGBS", "TEST", 24, 29], ["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["3 Similarly, the rate of LOGBS infection (0.31/1000 live births) is higher than EOGBS infection (0.23/1000 live births) in the US.BackgroundThe falling incidence of early versus late onset disease is usually attributed to prevention of early onset disease by intrapartum antibiotic To screen or not to screen women for Group B Streptococcus (Streptococcus agalactiae) to prevent early onset sepsis in newborns: recent advances in the unresolved debate prophylaxis and the absence of such an effect on late onset disease.", [["LOGBS infection", "DISEASE", 25, 40], ["infection", "DISEASE", 86, 95], ["sepsis", "DISEASE", 391, 397], ["women", "ORGANISM", 309, 314], ["Group B Streptococcus", "ORGANISM", 319, 340], ["Streptococcus agalactiae", "ORGANISM", 342, 366], ["women", "SPECIES", 309, 314], ["Streptococcus agalactiae", "SPECIES", 342, 366], ["Streptococcus agalactiae", "SPECIES", 342, 366], ["LOGBS infection", "PROBLEM", 25, 40], ["EOGBS infection", "PROBLEM", 80, 95], ["late onset disease", "PROBLEM", 178, 196], ["early onset disease", "PROBLEM", 236, 255], ["intrapartum antibiotic", "TREATMENT", 259, 281], ["Group B Streptococcus (Streptococcus agalactiae", "PROBLEM", 319, 366], ["early onset sepsis", "PROBLEM", 379, 397], ["debate prophylaxis", "TREATMENT", 445, 463], ["late onset disease", "PROBLEM", 501, 519], ["LOGBS", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40], ["higher", "OBSERVATION_MODIFIER", 68, 74], ["infection", "OBSERVATION", 86, 95], ["falling", "OBSERVATION_MODIFIER", 144, 151], ["late onset", "OBSERVATION_MODIFIER", 178, 188], ["disease", "OBSERVATION", 189, 196], ["usually attributed to", "UNCERTAINTY", 200, 221], ["onset", "OBSERVATION_MODIFIER", 385, 390], ["sepsis", "OBSERVATION", 391, 397]]], ["4 It is estimated that worldwide about 22 million women carry GBS with an estimated 410,000 infections in newborns every year, with at least 147,000 still births and infant deaths globally.BackgroundFurthermore, the same study estimated that there were 33,000 cases of invasive GBS disease in pregnant or postpartum women, and 57,000 foetal infections/stillbirths.", [["GBS", "DISEASE", 62, 65], ["infections", "DISEASE", 92, 102], ["deaths", "DISEASE", 173, 179], ["GBS disease", "DISEASE", 278, 289], ["foetal infections", "DISEASE", 334, 351], ["stillbirths", "DISEASE", 352, 363], ["women", "ORGANISM", 50, 55], ["newborns", "ORGANISM", 106, 114], ["women", "ORGANISM", 316, 321], ["women", "SPECIES", 50, 55], ["infant", "SPECIES", 166, 172], ["women", "SPECIES", 316, 321], ["GBS", "PROBLEM", 62, 65], ["an estimated 410,000 infections", "PROBLEM", 71, 102], ["the same study", "TEST", 212, 226], ["invasive GBS disease", "PROBLEM", 269, 289], ["foetal infections", "PROBLEM", 334, 351], ["stillbirths", "PROBLEM", 352, 363], ["infections", "OBSERVATION", 92, 102], ["invasive", "OBSERVATION_MODIFIER", 269, 277], ["GBS disease", "OBSERVATION", 278, 289], ["infections", "OBSERVATION", 341, 351]]], ["Up to 3.5 million preterm births may be attributable to GBS.", [["GBS", "DISEASE", 56, 59], ["GBS", "PROBLEM", 56, 59], ["may be attributable to", "UNCERTAINTY", 33, 55], ["GBS", "OBSERVATION", 56, 59]]], ["5 Currently, it is widely agreed that the only effective way to prevent EOGBS is to give intrapartum antibiotic prophylaxis (IAP) to the mothers.", [["EOGBS", "DISEASE", 72, 77], ["EOGBS", "PROBLEM", 72, 77], ["intrapartum antibiotic prophylaxis", "TREATMENT", 89, 123]]], ["IAP has an efficacy of >80% in prevention of EOGBS.", [["EOGBS", "DISEASE", 45, 50], ["IAP", "TEST", 0, 3], ["EOGBS", "PROBLEM", 45, 50], ["efficacy", "OBSERVATION_MODIFIER", 11, 19]]], ["6 However, there is considerable disagreement and debate about the best way of identifying women who need IAP.", [["women", "ORGANISM", 91, 96], ["IAP", "GENE_OR_GENE_PRODUCT", 106, 109], ["women", "SPECIES", 91, 96], ["IAP", "TEST", 106, 109], ["considerable", "OBSERVATION_MODIFIER", 20, 32], ["disagreement", "OBSERVATION", 33, 45]]], ["7 In tandem, there is an emerging debate regarding the impact of IAP on the microbiome of the newborn.", [["IAP", "GENE_OR_GENE_PRODUCT", 65, 68], ["IAP", "PROTEIN", 65, 68], ["IAP", "OBSERVATION", 65, 68], ["newborn", "ANATOMY", 94, 101]]], ["8 In this article, we discuss some of the key research papers published in the period 2015-2019 that have addressed the relative merits and disadvantages of screening versus risk-factor-based strategies for identification of women requiring IAP.", [["women", "ORGANISM", 225, 230], ["IAP", "GENE_OR_GENE_PRODUCT", 241, 244], ["women", "SPECIES", 225, 230], ["screening", "TEST", 157, 166], ["IAP", "TREATMENT", 241, 244]]], ["Importantly, the papers were selected to provide a general overview of the debate rather than to undertake a systematic review or in-depth discussion of the components or variations of the two strategies.", [["a systematic review", "TEST", 107, 126]]], ["We have also excluded systematic reviews or studies based on meta-analysis of trials.", [["systematic reviews", "TEST", 22, 40], ["studies", "TEST", 44, 51], ["trials", "TREATMENT", 78, 84]]], ["Discussion regarding vaccines for prevention of EOGBS and effect of IAP on the neonatal microbiome is outside the scope of this paper.EOGBS prevention strategies used worldwideUntil recently there was no review of EOGBS prevention strategies used worldwide.", [["EOGBS", "DISEASE", 48, 53], ["IAP", "GENE_OR_GENE_PRODUCT", 68, 71], ["vaccines", "TREATMENT", 21, 29], ["EOGBS", "PROBLEM", 48, 53], ["IAP", "TREATMENT", 68, 71], ["EOGBS prevention strategies", "TREATMENT", 134, 161], ["EOGBS prevention strategies", "TREATMENT", 214, 241]]], ["Le Doare et al. reviewed GBS screening policies and IAP implementation worldwide.", [["GBS screening", "TEST", 25, 38], ["IAP implementation", "TREATMENT", 52, 70]]], ["Of these, over 60% had an IAP policy; a majority used screening (58%) while the rest used the presence of risk factors to guide IAP.", [["IAP", "GENE_OR_GENE_PRODUCT", 128, 131], ["IAP", "PROTEIN", 128, 131], ["an IAP policy", "TREATMENT", 23, 36], ["screening", "TEST", 54, 63]]], ["Coverage was considerably higher with screening (80%) compared with riskfactor-based IAP (29%).", [["screening", "TEST", 38, 47], ["IAP", "TEST", 85, 88]]], ["The authors concluded that there was considerable heterogeneity in IAP screening policies and coverage worldwide.", [["IAP screening policies", "TREATMENT", 67, 89], ["considerable", "OBSERVATION_MODIFIER", 37, 49], ["heterogeneity", "OBSERVATION", 50, 63]]], ["Screening-based guidelines used in many parts of the world are derived from EOGBS Prevention Guidelines recommended by Centers for Disease Control in the US (CDC) While the guidelines primarily recommend IAP based on antenatal GBS screening, they also recommend giving IAP to women with risk factors such as GBS bacteriuria during pregnancy or a history of a previous GBS-infected newborn.", [["GBS bacteriuria", "DISEASE", 308, 323], ["GBS-infected", "DISEASE", 368, 380], ["IAP", "GENE_OR_GENE_PRODUCT", 269, 272], ["women", "ORGANISM", 276, 281], ["newborn", "ORGANISM", 381, 388], ["women", "SPECIES", 276, 281], ["IAP", "TREATMENT", 204, 207], ["antenatal GBS screening", "TEST", 217, 240], ["IAP", "TREATMENT", 269, 272], ["risk factors", "PROBLEM", 287, 299], ["GBS bacteriuria", "PROBLEM", 308, 323], ["a previous GBS-infected newborn", "PROBLEM", 357, 388], ["GBS", "OBSERVATION", 368, 371], ["infected", "OBSERVATION", 372, 380]]], ["In addition, CDC recommends that if the prenatal GBS culture result is unknown when labour starts, intrapartum antibiotic prophylaxis is indicated for women who have risk factors for GBS early onset disease (EOD).", [["GBS", "DISEASE", 183, 186], ["EOD", "DISEASE", 208, 211], ["women", "ORGANISM", 151, 156], ["women", "SPECIES", 151, 156], ["the prenatal GBS culture", "TEST", 36, 60], ["labour", "PROBLEM", 84, 90], ["intrapartum antibiotic prophylaxis", "TREATMENT", 99, 133], ["risk factors", "PROBLEM", 166, 178], ["GBS early onset disease", "PROBLEM", 183, 206]]], ["These include at-risk women who present in labour with a substantial risk of preterm birth, who have preterm prelabour rupture of membranes (PPROM) or rupture of membranes for 18 or more hours at term, or who present with intrapartum fever [temperature 100.4\u00b0F (38\u00b0C) or higher.", [["membranes", "ANATOMY", 130, 139], ["membranes", "ANATOMY", 162, 171], ["preterm birth", "DISEASE", 77, 90], ["rupture of membranes", "DISEASE", 119, 139], ["PPROM", "DISEASE", 141, 146], ["rupture of membranes", "DISEASE", 151, 171], ["intrapartum fever", "DISEASE", 222, 239], ["women", "ORGANISM", 22, 27], ["membranes", "CELLULAR_COMPONENT", 130, 139], ["membranes", "CELLULAR_COMPONENT", 162, 171], ["women", "SPECIES", 22, 27], ["preterm birth", "PROBLEM", 77, 90], ["preterm prelabour rupture of membranes", "PROBLEM", 101, 139], ["PPROM", "PROBLEM", 141, 146], ["rupture of membranes", "PROBLEM", 151, 171], ["intrapartum fever", "PROBLEM", 222, 239], ["temperature", "TEST", 241, 252], ["rupture", "OBSERVATION", 119, 126], ["rupture", "OBSERVATION", 151, 158]]], ["10 Thus the CDC guidelines recommend a 'combined' approach with emphasis on screening.EOGBS prevention strategies used worldwideCDC guidelines state that the culture method is the gold standard for identifying GBS.", [["GBS", "DISEASE", 210, 213], ["a 'combined' approach", "TREATMENT", 37, 58], ["screening", "TEST", 76, 85], ["the culture method", "TEST", 154, 172], ["GBS", "PROBLEM", 210, 213]]], ["The guidelines also recommend using selective enrichment broth prior to culturing on solid agar media.", [["selective enrichment broth", "TREATMENT", 36, 62], ["solid agar media", "TREATMENT", 85, 101]]], ["Cultures can take up to 48 to 72 h and therefore can be done only during the antenatal period.", [["Cultures", "TEST", 0, 8]]], ["It is now well recognised that antenatal cultures do not accurately predict intrapartum GBS carriage.EOGBS prevention strategies used worldwideIn the past decade, the availability of rapid nucleic acid amplification tests (NAATs) with very high specificity and sensitivity has made it possible to test women at the beginning of labour (intrapartum) with results available within a couple of hours.", [["GBS", "DISEASE", 88, 91], ["nucleic acid", "CHEMICAL", 189, 201], ["women", "ORGANISM", 302, 307], ["women", "SPECIES", 302, 307], ["antenatal cultures", "TEST", 31, 49], ["intrapartum GBS carriage", "PROBLEM", 76, 100], ["EOGBS prevention strategies", "TREATMENT", 101, 128], ["rapid nucleic acid amplification tests", "TEST", 183, 221]]], ["11 This is particularly useful for testing women who have not been previously screened or who present in pre-term labour.", [["women", "ORGANISM", 43, 48], ["women", "SPECIES", 43, 48]]], ["However, NAATs require expensive equipment and reagents that may not be available in resource poor countries.", [["NAATs", "SIMPLE_CHEMICAL", 9, 14], ["expensive equipment", "TREATMENT", 23, 42], ["reagents", "TREATMENT", 47, 55]]], ["The biggest disadvantage of NAATs is that they do not provide information regarding antibiotic susceptibility of the GBS strains, which is important for deciding the antibiotic treatment options in penicillin allergic women and surveillance of antimicrobial resistance. journals.sagepub.com/home/tai 3Efficacy of screening-versus risk-based strategy: which of these two strategies is better?To this day, there are no randomised controlled trials to compare the efficacy of the two strategies.Efficacy of screening-versus risk-based strategy: which of these two strategies is better?Recently, the National Institute of Health Research (NIHR) commissioned a cluster randomized trial in the UK to compare the effectiveness of the two strategies.", [["GBS", "DISEASE", 117, 120], ["penicillin", "CHEMICAL", 198, 208], ["allergic", "DISEASE", 209, 217], ["penicillin", "CHEMICAL", 198, 208], ["NAATs", "SIMPLE_CHEMICAL", 28, 33], ["penicillin", "SIMPLE_CHEMICAL", 198, 208], ["women", "ORGANISM", 218, 223], ["women", "SPECIES", 218, 223], ["the GBS strains", "PROBLEM", 113, 128], ["the antibiotic treatment options", "TREATMENT", 162, 194], ["penicillin allergic women", "TREATMENT", 198, 223], ["antimicrobial resistance", "TREATMENT", 244, 268], ["screening", "TEST", 313, 322], ["randomised controlled trials", "TREATMENT", 417, 445], ["screening", "TEST", 504, 513], ["a cluster randomized trial", "TREATMENT", 654, 680], ["biggest", "OBSERVATION_MODIFIER", 4, 11], ["antimicrobial resistance", "OBSERVATION", 244, 268], ["no", "UNCERTAINTY", 414, 416]]], ["The NIHR-funded study (GBS-3 Trial) will measure the effectiveness of two tests to identify group B streptococcus in late pregnancy or labour compared with the current UK approach of identifying pregnant women with 'risk factors' for their newborn developing the infection.", [["streptococcus", "DISEASE", 100, 113], ["infection", "DISEASE", 263, 272], ["B streptococcus", "ORGANISM", 98, 113], ["women", "ORGANISM", 204, 209], ["women", "SPECIES", 204, 209], ["The NIHR", "TEST", 0, 8], ["funded study", "TEST", 9, 21], ["GBS", "TEST", 23, 26], ["two tests", "TEST", 70, 79], ["group B streptococcus", "PROBLEM", 92, 113], ["late pregnancy", "PROBLEM", 117, 131], ["labour", "PROBLEM", 135, 141], ["the infection", "PROBLEM", 259, 272], ["infection", "OBSERVATION", 263, 272]]], ["The trial was due to commence in April 2020 but recruitment has been delayed due to the Covid 19 pandemic (https://www.nihr.ac.uk/news/newscreening-trial-aims-to-improve-detection-andtreatment-for-group-b-strep-in-pregnant-women/ 20283 accessed 03-05-2020).Efficacy of screening-versus risk-based strategy: which of these two strategies is better?In the absence of randomised trials, virtually all the reports published thus far are based on observational 'before-after' studies.", [["screening", "TEST", 269, 278], ["randomised trials", "TREATMENT", 365, 382], ["' studies", "TEST", 469, 478]]], ["The following are a brief description of some of the studies published recently.Efficacy of screening-versus risk-based strategy: which of these two strategies is better?In Germany, the national guidelines changed from risk factor based IAP ( The annual incidence in 2015 and 2016 was significantly higher than in any previous year (p < 0.0001), coinciding with the discontinuation of routine universal maternal GBS screening.", [["the studies", "TEST", 49, 60], ["screening", "TEST", 92, 101], ["routine universal maternal GBS screening", "TEST", 385, 425]]], ["They found that neonates of unscreened mothers were more likely to present with EOD (p = 0.005).", [["EOD", "DISEASE", 80, 83], ["neonates", "ORGANISM", 16, 24], ["mothers", "ORGANISM", 39, 46]]], ["They concluded that incidence of neonatal GBS infection in Saudi Arabia is similar to the worldwide incidence.", [["GBS infection", "DISEASE", 42, 55], ["neonatal GBS infection", "PROBLEM", 33, 55], ["neonatal", "OBSERVATION_MODIFIER", 33, 41], ["GBS", "OBSERVATION_MODIFIER", 42, 45], ["infection", "OBSERVATION", 46, 55]]], ["Importantly, like Rao et al., they observed that discontinuation of universal antenatal screening was significantly associated with an increase in EOGBS incidence.", [["universal antenatal screening", "TEST", 68, 97], ["an increase in EOGBS incidence", "PROBLEM", 132, 162], ["increase", "OBSERVATION_MODIFIER", 135, 143]]], ["19 While Africa has the highest burden of EOGBS infection in the world, there are continuing challenges in implementing intrapartum prophylaxis, both using risk-based or screening-based strategies due to limited resources.", [["EOGBS infection", "DISEASE", 42, 57], ["EOGBS infection", "PROBLEM", 42, 57], ["intrapartum prophylaxis", "TREATMENT", 120, 143], ["screening", "TEST", 170, 179], ["EOGBS", "OBSERVATION_MODIFIER", 42, 47], ["infection", "OBSERVATION", 48, 57]]], ["20 It is clear that only vaccines can provide a realistic solution for prevention of GBS related infant mortality in most parts of Africa.", [["GBS", "DISEASE", 85, 88], ["vaccines", "TREATMENT", 25, 33], ["a realistic solution", "TREATMENT", 46, 66], ["GBS", "PROBLEM", 85, 88], ["infant mortality", "PROBLEM", 97, 113], ["clear", "OBSERVATION", 9, 14], ["GBS", "OBSERVATION", 85, 88]]], ["Maternal GBS vaccination could be a safe, cost-effective strategy and prevent 30-55% deaths in low-income sub-Saharan Africa.", [["deaths", "DISEASE", 85, 91], ["Maternal GBS vaccination", "PROBLEM", 0, 24], ["cost-effective strategy", "TREATMENT", 42, 65]]], ["21 In summary, many observational studies appear to find a screening-based strategy more efficacious in preventing EOGBS than a risk-based strategy.", [["EOGBS", "DISEASE", 115, 120], ["many observational studies", "TEST", 15, 41], ["a screening", "TEST", 57, 68], ["EOGBS", "PROBLEM", 115, 120]]], ["However, experience in New Zealand suggests that risk-based strategy can be effective, 12 although in the UK, the EOGBS rates have gone up despite the introduction of risk-based strategy in 2003.", [["the EOGBS rates", "TEST", 110, 125]]], ["13 Adverse effects Today the principal debate regarding the relative merits of the two strategies has shifted from efficacy to adverse effects of IAP.", [["IAP", "GENE_OR_GENE_PRODUCT", 146, 149], ["IAP", "PROTEIN", 146, 149], ["IAP", "TREATMENT", 146, 149]]], ["While both strategies offer IAP to mothers, it is argued that a screening-based strategy exposes more mothers to antibiotics than risk-based strategy and as a result, are more likely to suffer adverse effects.", [["IAP", "GENE_OR_GENE_PRODUCT", 28, 31], ["a screening", "TEST", 62, 73], ["antibiotics", "TREATMENT", 113, 124], ["adverse effects", "PROBLEM", 193, 208]]], ["22 Does screening-based strategy lead to more women getting IAP than with a risk-based strategy?Efficacy of screening-versus risk-based strategy: which of these two strategies is better?A key modelling study based on primary data by Kaambwa et al. showed that a similar number of patients would receive antibiotics using either strategy.", [["women", "ORGANISM", 46, 51], ["patients", "ORGANISM", 280, 288], ["women", "SPECIES", 46, 51], ["patients", "SPECIES", 280, 288], ["screening", "TEST", 108, 117], ["A key modelling study", "TEST", 186, 207], ["primary data", "TEST", 217, 229], ["antibiotics", "TREATMENT", 303, 314]]], ["Of the 1400 women recruited into the study, 22.1% women had risk factors whereas journals.sagepub.com/home/tai 5 21% screened women were GBS carriers.", [["GBS", "DISEASE", 137, 140], ["women", "ORGANISM", 12, 17], ["women", "ORGANISM", 50, 55], ["women", "ORGANISM", 126, 131], ["women", "SPECIES", 12, 17], ["women", "SPECIES", 50, 55], ["women", "SPECIES", 126, 131], ["the study", "TEST", 33, 42], ["risk factors", "PROBLEM", 60, 72], ["GBS carriers", "PROBLEM", 137, 149]]], ["The sensitivity and specificity of risk-based IAP were 31% and 80%, respectively, compared with antenatal screening cultures which had sensitivity and specificity of 76% and 95%, respectively.", [["The sensitivity", "TEST", 0, 15], ["risk", "TEST", 35, 39], ["IAP", "TEST", 46, 49], ["antenatal screening cultures", "TEST", 96, 124], ["sensitivity", "TEST", 135, 146], ["specificity", "TEST", 151, 162]]], ["These findings indicate that just as many women would receive IAP with both strategies but using a riskbased strategy, IAP would be unnecessarily given to 69% of women who are not GBS carriers.", [["GBS", "DISEASE", 180, 183], ["women", "ORGANISM", 42, 47], ["women", "ORGANISM", 162, 167], ["women", "SPECIES", 42, 47], ["women", "SPECIES", 162, 167], ["IAP", "TREATMENT", 62, 65], ["both strategies", "TREATMENT", 71, 86], ["a riskbased strategy", "TREATMENT", 97, 117], ["IAP", "TREATMENT", 119, 122], ["GBS carriers", "PROBLEM", 180, 192]]], ["Furthermore, the authors concluded that riskbased IAP was not cost effective.", [["riskbased IAP", "PROBLEM", 40, 53]]], ["23 Turning to adverse effects, Seedat et al. observed in a systematic review that despite a wide range of adverse events occurring following IAP, the evidence was inconsistent and at high risk of bias.", [["adverse events", "PROBLEM", 106, 120], ["IAP", "TREATMENT", 141, 144]]], ["Seven observational studies showed that IAP for maternal GBS colonization altered the infant microbiome but significance of these changes on clinical outcomes was not described and, as such, the importance of these alterations is unclear.", [["GBS", "DISEASE", 57, 60], ["IAP", "GENE_OR_GENE_PRODUCT", 40, 43], ["infant", "SPECIES", 86, 92], ["Seven observational studies", "TEST", 0, 27], ["IAP", "TEST", 40, 43], ["maternal GBS colonization", "PROBLEM", 48, 73], ["these alterations", "PROBLEM", 209, 226]]], ["The authors noted there was also observational evidence for increased antimicrobial resistance; however, studies were at high or unclear risk of bias.", [["increased antimicrobial resistance", "PROBLEM", 60, 94], ["studies", "TEST", 105, 112], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["antimicrobial resistance", "OBSERVATION", 70, 94]]], ["22 Millions of doses of penicillin or ampicillin have been given as IAP clinically significant resistance to penicillin or ampicillin has not been reported.", [["penicillin", "CHEMICAL", 24, 34], ["ampicillin", "CHEMICAL", 38, 48], ["penicillin", "CHEMICAL", 109, 119], ["ampicillin", "CHEMICAL", 123, 133], ["penicillin", "CHEMICAL", 24, 34], ["ampicillin", "CHEMICAL", 38, 48], ["penicillin", "CHEMICAL", 109, 119], ["ampicillin", "CHEMICAL", 123, 133], ["penicillin", "SIMPLE_CHEMICAL", 24, 34], ["ampicillin", "SIMPLE_CHEMICAL", 38, 48], ["penicillin", "SIMPLE_CHEMICAL", 109, 119], ["ampicillin", "SIMPLE_CHEMICAL", 123, 133], ["penicillin", "TREATMENT", 24, 34], ["ampicillin", "TREATMENT", 38, 48], ["penicillin", "TREATMENT", 109, 119], ["ampicillin", "TREATMENT", 123, 133]]], ["Although penicillin-resistant GBS have been reported in respiratory isolates from patients in Japan, they were not detected in GBS strains isolated from mothers or their babies.", [["penicillin", "CHEMICAL", 9, 19], ["GBS", "DISEASE", 30, 33], ["penicillin", "CHEMICAL", 9, 19], ["penicillin", "SIMPLE_CHEMICAL", 9, 19], ["patients", "ORGANISM", 82, 90], ["mothers", "ORGANISM", 153, 160], ["patients", "SPECIES", 82, 90], ["penicillin", "TREATMENT", 9, 19], ["resistant GBS", "PROBLEM", 20, 33], ["GBS strains", "PROBLEM", 127, 138]]], ["26 Recently however, Moroi et al. determined the minimum inhibitory concentration of seven \u03b2-lactam antibiotics for 477 GBS isolates derived from vaginal/ rectal swabs from pregnant women.", [["vaginal", "ANATOMY", 146, 153], ["rectal swabs", "ANATOMY", 155, 167], ["\u03b2-lactam", "CHEMICAL", 91, 99], ["\u03b2-lactam", "CHEMICAL", 91, 99], ["\u03b2-lactam", "SIMPLE_CHEMICAL", 91, 99], ["vaginal", "ORGANISM_SUBDIVISION", 146, 153], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 155, 167], ["women", "ORGANISM", 182, 187], ["women", "SPECIES", 182, 187], ["seven \u03b2-lactam antibiotics", "TREATMENT", 85, 111], ["GBS isolates", "PROBLEM", 120, 132], ["vaginal/ rectal swabs", "TREATMENT", 146, 167], ["vaginal", "ANATOMY", 146, 153], ["rectal", "ANATOMY", 155, 161]]], ["All the 477 isolates were susceptible to penicillin G and ampicillin.", [["penicillin G", "CHEMICAL", 41, 53], ["ampicillin", "CHEMICAL", 58, 68], ["penicillin G", "CHEMICAL", 41, 53], ["ampicillin", "CHEMICAL", 58, 68], ["penicillin G", "SIMPLE_CHEMICAL", 41, 53], ["ampicillin", "SIMPLE_CHEMICAL", 58, 68], ["penicillin G", "TREATMENT", 41, 53], ["ampicillin", "TREATMENT", 58, 68]]], ["Five isolates showed reduced ceftibuten susceptibility.", [["ceftibuten", "CHEMICAL", 29, 39], ["ceftibuten", "CHEMICAL", 29, 39], ["ceftibuten", "SIMPLE_CHEMICAL", 29, 39], ["Five isolates", "TEST", 0, 13], ["reduced ceftibuten susceptibility", "PROBLEM", 21, 54], ["reduced", "OBSERVATION_MODIFIER", 21, 28], ["ceftibuten susceptibility", "OBSERVATION", 29, 54]]], ["Each of these isolates possessed a single amino acid substitution in the penicillin binding protein, PBP2X, and some of the substitutions which had been previously found in GBS strains with reduced penicillin susceptibility.", [["amino acid", "CHEMICAL", 42, 52], ["penicillin", "CHEMICAL", 73, 83], ["GBS", "DISEASE", 173, 176], ["penicillin", "CHEMICAL", 198, 208], ["amino acid", "CHEMICAL", 42, 52], ["penicillin", "CHEMICAL", 73, 83], ["penicillin", "CHEMICAL", 198, 208], ["amino acid", "AMINO_ACID", 42, 52], ["penicillin binding protein", "GENE_OR_GENE_PRODUCT", 73, 99], ["PBP2X", "GENE_OR_GENE_PRODUCT", 101, 106], ["penicillin", "SIMPLE_CHEMICAL", 198, 208], ["penicillin binding protein", "PROTEIN", 73, 99], ["PBP2X", "PROTEIN", 101, 106], ["these isolates", "TREATMENT", 8, 22], ["a single amino acid substitution", "TREATMENT", 33, 65], ["the penicillin binding protein", "TREATMENT", 69, 99], ["PBP2X", "TREATMENT", 101, 106], ["the substitutions", "PROBLEM", 120, 137], ["GBS strains", "PROBLEM", 173, 184], ["reduced penicillin susceptibility", "PROBLEM", 190, 223], ["acid substitution", "OBSERVATION", 48, 65], ["reduced", "OBSERVATION_MODIFIER", 190, 197], ["penicillin susceptibility", "OBSERVATION", 198, 223]]], ["It is unclear if this will eventually lead to penicillin resistance in GBS.", [["penicillin", "CHEMICAL", 46, 56], ["GBS", "DISEASE", 71, 74], ["penicillin", "CHEMICAL", 46, 56], ["penicillin", "SIMPLE_CHEMICAL", 46, 56], ["penicillin resistance in GBS", "PROBLEM", 46, 74]]], ["27 A major concern has been that IAP increases the risk of anaphylactic reaction to penicillin.", [["anaphylactic reaction", "DISEASE", 59, 80], ["penicillin", "CHEMICAL", 84, 94], ["penicillin", "CHEMICAL", 84, 94], ["IAP", "GENE_OR_GENE_PRODUCT", 33, 36], ["penicillin", "SIMPLE_CHEMICAL", 84, 94], ["IAP", "PROBLEM", 33, 36], ["anaphylactic reaction", "PROBLEM", 59, 80], ["penicillin", "TREATMENT", 84, 94], ["anaphylactic reaction", "OBSERVATION", 59, 80]]], ["To date, there have been very few confirmed reports of anaphylaxis in women who received penicillin or ampicillin as IAP.", [["anaphylaxis", "DISEASE", 55, 66], ["penicillin", "CHEMICAL", 89, 99], ["ampicillin", "CHEMICAL", 103, 113], ["penicillin", "CHEMICAL", 89, 99], ["ampicillin", "CHEMICAL", 103, 113], ["women", "ORGANISM", 70, 75], ["penicillin", "SIMPLE_CHEMICAL", 89, 99], ["ampicillin", "SIMPLE_CHEMICAL", 103, 113], ["women", "SPECIES", 70, 75], ["anaphylaxis", "PROBLEM", 55, 66], ["penicillin", "TREATMENT", 89, 99], ["ampicillin", "TREATMENT", 103, 113], ["IAP", "TREATMENT", 117, 120], ["anaphylaxis", "OBSERVATION", 55, 66]]], ["In this context, a recent study by McCall et al. is important.", [["a recent study", "TEST", 17, 31]]], ["28 They estimated the incidence of anaphylaxis in pregnancy and described the management and outcomes in the UK using the UK Obstetric Surveillance System.", [["anaphylaxis", "DISEASE", 35, 46], ["anaphylaxis in pregnancy", "PROBLEM", 35, 59], ["anaphylaxis", "OBSERVATION", 35, 46]]], ["All pregnant women who had anaphylaxis between 1 October 2012 and 30 September 2015 were included.", [["anaphylaxis", "DISEASE", 27, 38], ["women", "ORGANISM", 13, 18], ["women", "SPECIES", 13, 18], ["anaphylaxis", "PROBLEM", 27, 38]]], ["There were 37 confirmed cases of anaphylaxis in pregnancy but only one due to IAP given for prevention of EOGBS.", [["anaphylaxis", "DISEASE", 33, 44], ["EOGBS", "DISEASE", 106, 111], ["anaphylaxis in pregnancy", "PROBLEM", 33, 57], ["IAP", "TREATMENT", 78, 81], ["EOGBS", "PROBLEM", 106, 111], ["anaphylaxis", "OBSERVATION", 33, 44]]], ["This anaphylactic reaction did not prove to be fatal for the mother or the baby.", [["anaphylactic reaction", "DISEASE", 5, 26], ["This anaphylactic reaction", "PROBLEM", 0, 26]]], ["The authors concluded that the overall low incidence was reassuring given the large proportion of the pregnant population that receive prophylactic antibiotics during delivery.ConclusionOverall, we believe that screening-based IAP is more efficacious than risk-based IAP and is the preferred option in developed countries.", [["the pregnant population", "PROBLEM", 98, 121], ["prophylactic antibiotics", "TREATMENT", 135, 159], ["delivery", "TREATMENT", 167, 175], ["screening", "TEST", 211, 220]]], ["Rapid availability of results using NAATs may enable use of these tests to accurately target IAP to GBS colonized women in the intrapartum period.", [["GBS", "DISEASE", 100, 103], ["IAP", "GENE_OR_GENE_PRODUCT", 93, 96], ["women", "ORGANISM", 114, 119], ["women", "SPECIES", 114, 119], ["these tests", "TEST", 60, 71]]], ["At a practical level, there are major challenges in implementing screening-based IAP in low income countries with poor laboratory support.", [["implementing screening", "TEST", 52, 74], ["major", "OBSERVATION_MODIFIER", 32, 37], ["challenges", "OBSERVATION", 38, 48]]], ["It must be acknowledged that IAP-based prevention has many limitations.", [["IAP-based prevention", "TREATMENT", 29, 49]]], ["IAP is not effective in prevention of late-onset GBS infection in babies, premature deliveries and still births due to GBS infection.", [["GBS infection", "DISEASE", 49, 62], ["GBS infection", "DISEASE", 119, 132], ["babies", "ORGANISM", 66, 72], ["IAP", "TEST", 0, 3], ["late-onset GBS infection in babies", "PROBLEM", 38, 72], ["premature deliveries", "PROBLEM", 74, 94], ["GBS infection", "PROBLEM", 119, 132], ["not", "UNCERTAINTY", 7, 10], ["effective", "OBSERVATION_MODIFIER", 11, 20], ["late", "OBSERVATION_MODIFIER", 38, 42], ["onset", "OBSERVATION_MODIFIER", 43, 48], ["GBS", "OBSERVATION_MODIFIER", 49, 52], ["infection", "OBSERVATION", 53, 62], ["GBS", "OBSERVATION_MODIFIER", 119, 122], ["infection", "OBSERVATION", 123, 132]]], ["There are also growing concerns regarding the possible impact of IAP on neonatal microbiota and emergence of antimicrobial resistance.", [["IAP", "GENE_OR_GENE_PRODUCT", 65, 68], ["impact of IAP", "PROBLEM", 55, 68], ["neonatal microbiota", "TREATMENT", 72, 91], ["antimicrobial resistance", "TREATMENT", 109, 133], ["IAP", "OBSERVATION", 65, 68], ["antimicrobial resistance", "OBSERVATION", 109, 133]]], ["While resistance to clindamycin has risen considerably in the recent years, GBS strains from pregnant women have remained susceptible to penicillin.", [["clindamycin", "CHEMICAL", 20, 31], ["penicillin", "CHEMICAL", 137, 147], ["clindamycin", "CHEMICAL", 20, 31], ["penicillin", "CHEMICAL", 137, 147], ["clindamycin", "SIMPLE_CHEMICAL", 20, 31], ["GBS strains", "ORGANISM", 76, 87], ["women", "ORGANISM", 102, 107], ["penicillin", "SIMPLE_CHEMICAL", 137, 147], ["women", "SPECIES", 102, 107], ["clindamycin", "TREATMENT", 20, 31], ["GBS strains", "PROBLEM", 76, 87], ["pregnant women", "PROBLEM", 93, 107], ["penicillin", "TREATMENT", 137, 147]]], ["Reassuringly, a recent study from the UK has shown that anaphylactic reaction to penicillin is very rare in women who received IAP.ConclusionAlternative strategies, principally maternal immunization against GBS would avoid use of IAP.", [["anaphylactic reaction", "DISEASE", 56, 77], ["penicillin", "CHEMICAL", 81, 91], ["GBS", "DISEASE", 207, 210], ["penicillin", "CHEMICAL", 81, 91], ["penicillin", "SIMPLE_CHEMICAL", 81, 91], ["women", "ORGANISM", 108, 113], ["IAP", "GENE_OR_GENE_PRODUCT", 230, 233], ["IAP", "PROTEIN", 230, 233], ["women", "SPECIES", 108, 113], ["a recent study", "TEST", 14, 28], ["anaphylactic reaction", "PROBLEM", 56, 77], ["penicillin", "TREATMENT", 81, 91], ["IAP", "TREATMENT", 127, 130], ["ConclusionAlternative strategies", "TREATMENT", 131, 163], ["maternal immunization", "TREATMENT", 177, 198], ["GBS", "PROBLEM", 207, 210], ["IAP", "TREATMENT", 230, 233], ["anaphylactic reaction", "OBSERVATION", 56, 77]]], ["A recent modelling study estimated that a maternal vaccine with 80% efficacy and 90% coverage could prevent 107,000 (Uncertainty Range, 20,000-198,000) stillbirths and infant deaths.", [["stillbirths", "DISEASE", 152, 163], ["deaths", "DISEASE", 175, 181], ["infant", "SPECIES", 168, 174], ["A recent modelling study", "TEST", 0, 24], ["a maternal vaccine", "TREATMENT", 40, 58]]], ["5 Unfortunately, no vaccines are currently available for routine use.", [["vaccines", "TREATMENT", 20, 28]]], ["Until such time vaccines are available, IAP-based prevention of EOGBS is the only game in town!Author contributionsGGR and PK contributed equally to writing and reviewing the final manuscript.Conflict of interest statementGR is a member of medical advisory committee of the charity, Group B Streptococcus Support (GBSS)", [["EOGBS", "DISEASE", 64, 69], ["such time vaccines", "TREATMENT", 6, 24], ["IAP", "TEST", 40, 43], ["Group B Streptococcus Support", "TREATMENT", 283, 312]]]], "58e5b4767a000ba416763edd6ca1c5f1fba9a42c": [["IntroductionIn February, 2003, two family members were admitted to intensive care wards in Hong Kong Special Administrative Region with influenza-like respiratory illness.", [["respiratory", "ANATOMY", 151, 162], ["influenza-like respiratory illness", "DISEASE", 136, 170], ["influenza", "PROBLEM", 136, 145], ["respiratory illness", "PROBLEM", 151, 170], ["influenza", "OBSERVATION", 136, 145], ["respiratory illness", "OBSERVATION", 151, 170]]], ["Avian-like H5N1 influenza viruses were isolated from both patients, one of whom succumbed to infection.", [["influenza viruses", "DISEASE", 16, 33], ["infection", "DISEASE", 93, 102], ["Avian-like H5N1 influenza viruses", "ORGANISM", 0, 33], ["patients", "ORGANISM", 58, 66], ["Avian", "SPECIES", 0, 5], ["H5N1 influenza viruses", "SPECIES", 11, 33], ["patients", "SPECIES", 58, 66], ["H5N1 influenza viruses", "SPECIES", 11, 33], ["H5N1 influenza viruses", "PROBLEM", 11, 33], ["infection", "PROBLEM", 93, 102], ["H5N1", "OBSERVATION", 11, 15], ["infection", "OBSERVATION", 93, 102]]], ["This was the first time since 1997 that H5N1 viruses had been identified in human beings, and WHO responded by issuing a pandemic alert.", [["H5N1 viruses", "DISEASE", 40, 52], ["H5N1", "ORGANISM", 40, 44], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["H5N1 viruses", "SPECIES", 40, 52], ["human", "SPECIES", 76, 81], ["H5N1 viruses", "PROBLEM", 40, 52], ["H5N1", "OBSERVATION", 40, 44]]], ["Candidate vaccines were immediately sought.", [["Candidate vaccines", "TREATMENT", 0, 18]]], ["The recent outbreak of severe acute respiratory syndrome (SARS) had been a striking example of the rapid and global spread of an emerging infectious disease.", [["acute respiratory syndrome", "DISEASE", 30, 56], ["SARS", "DISEASE", 58, 62], ["infectious disease", "DISEASE", 138, 156], ["severe acute respiratory syndrome", "PROBLEM", 23, 56], ["SARS", "PROBLEM", 58, 62], ["an emerging infectious disease", "PROBLEM", 126, 156], ["outbreak", "OBSERVATION_MODIFIER", 11, 19], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["respiratory syndrome", "OBSERVATION", 36, 56], ["rapid", "OBSERVATION_MODIFIER", 99, 104], ["global", "OBSERVATION_MODIFIER", 109, 115], ["spread", "OBSERVATION_MODIFIER", 116, 122], ["infectious", "OBSERVATION", 138, 148]]], ["However, even the effects of SARS could be dwarfed by those that could arise with the emergence of an influenza pandemic.IntroductionInfection caused by the influenza A virus is a zoonosis, and the animal reservoir of this virus is the aquatic bird populations of the world.", [["SARS", "DISEASE", 29, 33], ["influenza pandemic", "DISEASE", 102, 120], ["Infection", "DISEASE", 133, 142], ["influenza A virus", "DISEASE", 157, 174], ["zoonosis", "DISEASE", 180, 188], ["influenza A virus", "ORGANISM", 157, 174], ["influenza A virus", "SPECIES", 157, 174], ["influenza A virus", "SPECIES", 157, 174], ["SARS", "PROBLEM", 29, 33], ["an influenza pandemic", "PROBLEM", 99, 120], ["IntroductionInfection", "PROBLEM", 121, 142], ["the influenza A virus", "PROBLEM", 153, 174], ["a zoonosis", "PROBLEM", 178, 188], ["this virus", "PROBLEM", 218, 228], ["influenza", "OBSERVATION", 102, 111], ["Infection", "OBSERVATION", 133, 142]]], ["The compelling epidemiological link between the presence of the virus in poultry in live-bird markets and the appearance of H5N1 in human beings in 1997 suggested that influenza A viruses can be transmitted directly from avian species to man and can cause severe respiratory disease.", [["respiratory", "ANATOMY", 263, 274], ["H5N1", "DISEASE", 124, 128], ["influenza A viruses", "DISEASE", 168, 187], ["respiratory disease", "DISEASE", 263, 282], ["H5N1", "ORGANISM", 124, 128], ["human", "ORGANISM", 132, 137], ["influenza A viruses", "ORGANISM", 168, 187], ["man", "ORGANISM", 238, 241], ["human", "SPECIES", 132, 137], ["man", "SPECIES", 238, 241], ["human", "SPECIES", 132, 137], ["influenza A viruses", "SPECIES", 168, 187], ["the virus", "PROBLEM", 60, 69], ["H5N1", "PROBLEM", 124, 128], ["influenza A viruses", "PROBLEM", 168, 187], ["severe respiratory disease", "PROBLEM", 256, 282], ["virus", "OBSERVATION", 64, 69], ["H5N1", "OBSERVATION", 124, 128], ["influenza", "OBSERVATION", 168, 177], ["severe", "OBSERVATION_MODIFIER", 256, 262], ["respiratory disease", "OBSERVATION", 263, 282]]], ["[1] [2] [3] Although control of the 1997 outbreak was achieved by culling millions of birds in the Hong Kong markets, 4 this episode demonstrated that the capability for an effective global response to emerging influenza threats was poor because of technical, legislative, and infrastructural limitations.", [["influenza", "DISEASE", 211, 220], ["emerging influenza threats", "PROBLEM", 202, 228]]], ["A disturbing finding that emerged from this event was that the scientific community was unable to produce an effective vaccine even after several years.IntroductionThe inactivated human influenza vaccines in use today are derived from essentially modified viruses.", [["human", "ORGANISM", 180, 185], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 180, 185], ["Introduction", "TREATMENT", 152, 164], ["The inactivated human influenza vaccines", "TREATMENT", 164, 204], ["viruses", "OBSERVATION", 256, 263]]], ["By exploiting the segmented nature of the influenza A genome, vaccine manufacturers and the laboratories of the WHO influenza network have produced a reassortant virus carrying the circulating virus's gene segments that encode haemagglutinin and neuraminidase, the major targets of neutralising antibodies.", [["haemagglutinin", "GENE_OR_GENE_PRODUCT", 227, 241], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 246, 259], ["influenza A genome", "DNA", 42, 60], ["haemagglutinin", "PROTEIN", 227, 241], ["neuraminidase", "PROTEIN", 246, 259], ["neutralising antibodies", "PROTEIN", 282, 305], ["influenza A", "SPECIES", 42, 53], ["reassortant virus", "SPECIES", 150, 167], ["the influenza A genome", "TREATMENT", 38, 60], ["vaccine manufacturers", "TREATMENT", 62, 83], ["the laboratories", "TEST", 88, 104], ["the WHO influenza network", "PROBLEM", 108, 133], ["a reassortant virus", "PROBLEM", 148, 167], ["haemagglutinin", "TREATMENT", 227, 241], ["neuraminidase", "TREATMENT", 246, 259], ["neutralising antibodies", "PROBLEM", 282, 305], ["influenza", "OBSERVATION", 42, 51], ["neutralising antibodies", "OBSERVATION", 282, 305]]], ["The remaining six-gene segments are supplied from PR8, a laboratoryadapted avirulent H1N1 strain.", [["PR8", "ORGANISM", 50, 53], ["avirulent H1N1 strain", "ORGANISM", 75, 96], ["PR8", "PROBLEM", 50, 53], ["a laboratoryadapted avirulent H1N1 strain", "PROBLEM", 55, 96], ["segments", "ANATOMY_MODIFIER", 23, 31], ["avirulent", "OBSERVATION_MODIFIER", 75, 84], ["H1N1 strain", "OBSERVATION", 85, 96]]], ["5 The resulting reassortant virus has the antigenic properties of the circulating strain and the safety and high-yield properties of PR8.IntroductionThe first batch of inactivated material against the 1997 H5N1 virus was not ready for clinical trial until 7 months after the second case of human infection arose, and even today the effectiveness of vaccine against this virus has not been proven.", [["infection", "DISEASE", 296, 305], ["reassortant virus", "ORGANISM", 16, 33], ["PR8", "ORGANISM", 133, 136], ["1997 H5N1 virus", "ORGANISM", 201, 216], ["human", "ORGANISM", 290, 295], ["H5N1 virus", "SPECIES", 206, 216], ["human", "SPECIES", 290, 295], ["reassortant virus", "SPECIES", 16, 33], ["1997 H5N1 virus", "SPECIES", 201, 216], ["human", "SPECIES", 290, 295], ["The resulting reassortant virus", "PROBLEM", 2, 33], ["the circulating strain", "PROBLEM", 66, 88], ["The first batch of inactivated material", "TREATMENT", 149, 188], ["H5N1 virus", "PROBLEM", 206, 216], ["human infection", "PROBLEM", 290, 305], ["vaccine", "TREATMENT", 349, 356], ["this virus", "PROBLEM", 365, 375], ["reassortant", "OBSERVATION_MODIFIER", 16, 27], ["virus", "OBSERVATION", 28, 33], ["circulating strain", "OBSERVATION", 70, 88], ["infection", "OBSERVATION", 296, 305]]], ["6 A key reason for this delay in the production of an H5N1-specific vaccine was the nature of the virus itself.", [["H5N1", "ORGANISM", 54, 58], ["this delay", "PROBLEM", 19, 29], ["an H5N1-specific vaccine", "TREATMENT", 51, 75], ["virus", "OBSERVATION", 98, 103]]], ["The H5N1 virus is highly pathogenic in human beings and poultry.", [["H5N1 virus", "ORGANISM", 4, 14], ["human", "ORGANISM", 39, 44], ["H5N1 virus", "SPECIES", 4, 14], ["human", "SPECIES", 39, 44], ["H5N1 virus", "SPECIES", 4, 14], ["human", "SPECIES", 39, 44], ["The H5N1 virus", "PROBLEM", 0, 14], ["H5N1 virus", "OBSERVATION", 4, 14], ["highly", "OBSERVATION_MODIFIER", 18, 24], ["pathogenic", "OBSERVATION", 25, 35]]], ["The agent must be handled only under conditions of at least biosafety level 3 (BSL3), and it can kill fertilised chicken eggs, the standard medium for the reassortment and Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines propagation of influenza virus before its inactivation and formulation for use in vaccines.", [["eggs", "ANATOMY", 121, 125], ["influenza", "DISEASE", 257, 266], ["influenza virus", "DISEASE", 291, 306], ["BSL3", "GENE_OR_GENE_PRODUCT", 79, 83], ["chicken", "ORGANISM", 113, 120], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 121, 125], ["influenza virus", "ORGANISM", 291, 306], ["chicken", "SPECIES", 113, 120], ["influenza virus", "SPECIES", 291, 306], ["chicken", "SPECIES", 113, 120], ["influenza virus", "SPECIES", 291, 306], ["influenza vaccines", "TREATMENT", 257, 275], ["influenza virus", "PROBLEM", 291, 306], ["its inactivation", "TREATMENT", 314, 330]]], ["These same traits are present in the 2003 H5N1 virus.IntroductionThe pathogenic nature of these H5N1 viruses is linked to the presence of additional basic residues in haemagglutinin at the site of cleavage, a step required for haemagglutinin activation and, thus, for virus entry into cells.", [["cells", "ANATOMY", 285, 290], ["H5N1 viruses", "DISEASE", 96, 108], ["2003 H5N1 virus", "ORGANISM", 37, 52], ["H5N1 viruses", "ORGANISM", 96, 108], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 167, 181], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 227, 241], ["cells", "CELL", 285, 290], ["haemagglutinin", "PROTEIN", 167, 181], ["haemagglutinin", "PROTEIN", 227, 241], ["H5N1 virus", "SPECIES", 42, 52], ["H5N1 virus", "SPECIES", 42, 52], ["these H5N1 viruses", "PROBLEM", 90, 108], ["additional basic residues in haemagglutinin", "PROBLEM", 138, 181], ["haemagglutinin activation", "PROBLEM", 227, 252], ["virus entry into cells", "PROBLEM", 268, 290], ["H5N1 viruses", "OBSERVATION", 96, 108], ["basic", "OBSERVATION_MODIFIER", 149, 154], ["residues", "OBSERVATION", 155, 163]]], ["[7] [8] [9] To overcome the high pathogenicity of the virus, polybasic aminoacids have to be eliminated.", [["aminoacids", "CHEMICAL", 71, 81], ["polybasic aminoacids", "SIMPLE_CHEMICAL", 61, 81], ["the high pathogenicity of the virus", "PROBLEM", 24, 59], ["polybasic aminoacids", "TREATMENT", 61, 81]]], ["A rapid, reproducible system to achieve these modifications-ie, plasmid-based reverse genetics-has been developed only in the past 4-5 years [10] [11] [12] The potential benefits of reverse genetics for the generation and attenuation of vaccine candidates against highly pathogenic and low pathogenic influenza viruses are enormous.", [["low pathogenic influenza viruses", "DISEASE", 286, 318], ["influenza viruses", "ORGANISM", 301, 318], ["plasmid", "DNA", 64, 71], ["A rapid, reproducible system", "PROBLEM", 0, 28], ["these modifications", "TREATMENT", 40, 59], ["vaccine candidates", "TREATMENT", 237, 255], ["highly pathogenic and low pathogenic influenza viruses", "PROBLEM", 264, 318], ["low pathogenic", "OBSERVATION_MODIFIER", 286, 300], ["influenza viruses", "OBSERVATION", 301, 318]]], ["[13] [14] [15] However, the host specificity of the RNA polymerase I promoter used in the influenza reverse-genetics systems and the required use of an approved cell line limits the practical options for the system's use in the manufacture of human vaccines.", [["cell line", "ANATOMY", 161, 170], ["[13] [14] [15]", "SIMPLE_CHEMICAL", 0, 14], ["RNA polymerase I", "GENE_OR_GENE_PRODUCT", 52, 68], ["cell line", "CELL", 161, 170], ["human", "ORGANISM", 243, 248], ["RNA polymerase I promoter", "DNA", 52, 77], ["human", "SPECIES", 243, 248], ["human", "SPECIES", 243, 248], ["the RNA polymerase I promoter", "TREATMENT", 48, 77], ["an approved cell line", "TREATMENT", 149, 170], ["human vaccines", "TREATMENT", 243, 257], ["cell line", "OBSERVATION", 161, 170]]], ["The vaccine-candidate reference virus stock described in this report has been produced entirely on a cell substrate licensed for the manufacture of human vaccine, and as such, is-to our knowledge-the first reverse genetically derived influenza vaccine suitable for testing in clinical trials.", [["cell", "ANATOMY", 101, 105], ["cell", "CELL", 101, 105], ["human", "ORGANISM", 148, 153], ["influenza", "ORGANISM", 234, 243], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["The vaccine", "TREATMENT", 0, 11], ["reference virus stock", "TREATMENT", 22, 43], ["a cell substrate", "TREATMENT", 99, 115], ["human vaccine", "TREATMENT", 148, 161], ["influenza vaccine", "TREATMENT", 234, 251]]], ["We describe the construction of a vaccine reference virus in Good Manufacturing Practice (GMP)-grade facilities in less than 4 weeks from the time of virus isolation.", [["GMP", "CHEMICAL", 90, 93], ["a vaccine reference virus", "TREATMENT", 32, 57], ["virus isolation", "TREATMENT", 150, 165]]], ["Our findings highlight the speed with which new technologies can be implemented in response to influenza pandemic alerts.Cells and A/Puerto Rico/8/34 plasmidsWe obtained WHO-approved Vero cells (WHO-Vero, X38, p134) from the American Type Culture Collection (Manassas, Virginia, USA).", [["Cells", "ANATOMY", 121, 126], ["Vero cells", "ANATOMY", 183, 193], ["Cells", "CELL", 121, 126], ["Vero cells", "CELL", 183, 193], ["WHO-Vero", "CELL", 195, 203], ["X38", "CELL", 205, 208], ["Vero cells", "CELL_LINE", 183, 193], ["A/Puerto Rico/8/34 plasmidsWe", "SPECIES", 131, 160], ["influenza pandemic alerts", "PROBLEM", 95, 120]]], ["Passage-142 cells (five passages since their removal from a working cell bank) were used for the rescue of the vaccine-candidate virus.", [["Passage-142 cells", "ANATOMY", 0, 17], ["cell", "ANATOMY", 68, 72], ["Passage-142 cells", "CELL", 0, 17], ["cell", "CELL", 68, 72], ["Passage-142 cells", "CELL_LINE", 0, 17], ["their removal", "TREATMENT", 39, 52], ["a working cell bank", "TREATMENT", 58, 77], ["the vaccine", "TREATMENT", 107, 118], ["virus", "PROBLEM", 129, 134], ["142 cells", "OBSERVATION_MODIFIER", 8, 17]]], ["The plasmids containing the genes from PR8 have been described elsewhere.", [["plasmids", "ANATOMY", 4, 12], ["PR8", "ORGANISM", 39, 42], ["plasmids", "DNA", 4, 12], ["The plasmids", "TREATMENT", 0, 12], ["PR8", "TREATMENT", 39, 42], ["plasmids", "OBSERVATION", 4, 12]]], ["13 Virus propagation, RNA extraction, PCR amplification, and haemagglutinin and neuraminidase gene cloning We obtained A/Hong Kong/213/03 (H5N1) that had been passaged in eggs from the WHO influenza network.", [["influenza", "DISEASE", 189, 198], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 61, 75], ["Hong Kong/213/03 (H5N1", "ORGANISM", 121, 143], ["Hong Kong/213/03 (H5N1", "SPECIES", 121, 143], ["Virus propagation", "TREATMENT", 3, 20], ["RNA extraction", "TREATMENT", 22, 36], ["PCR amplification", "TREATMENT", 38, 55], ["haemagglutinin", "TREATMENT", 61, 75], ["neuraminidase gene cloning", "TREATMENT", 80, 106], ["H5N1", "PROBLEM", 139, 143]]], ["The virus was isolated and propagated in 10-day-old embryonated chicken eggs.", [["eggs", "ANATOMY", 72, 76], ["chicken", "ORGANISM", 64, 71], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 72, 76], ["chicken", "SPECIES", 64, 71], ["chicken", "SPECIES", 64, 71], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["Total RNA was extracted from infected allantoic fluid with use of the RNeasy kit (Qiagen, Valencia, CA, USA) in accordance with manufacturer's instructions.", [["allantoic fluid", "ANATOMY", 38, 53], ["allantoic fluid", "ORGANISM_SUBSTANCE", 38, 53], ["Total RNA", "PROBLEM", 0, 9], ["infected allantoic fluid", "PROBLEM", 29, 53], ["the RNeasy kit", "TREATMENT", 66, 80], ["infected", "OBSERVATION_MODIFIER", 29, 37], ["allantoic fluid", "OBSERVATION", 38, 53]]], ["Reverse transcription was carried out with the uni12 primer (5\u0408-AGCA AAAGCAGG-3\u0408) and AMV reverse transcriptase (Roche, Indiana Biochemicals Indianapolis, USA).", [["AMV reverse transcriptase", "GENE_OR_GENE_PRODUCT", 86, 111], ["uni12 primer", "DNA", 47, 59], ["3\u0408", "DNA", 78, 80], ["AMV reverse transcriptase", "PROTEIN", 86, 111], ["the uni12 primer", "TREATMENT", 43, 59], ["AAAGCAGG", "TEST", 69, 77]]], ["The removal of the connecting peptide of the haemagglutinin was done with use of PCR with the following primer sets: (1) Bm-HA-1 (5\u0408-TATTCGTCTCAGGGAGCAA AAGCAGGGG-3\u0408) and 739\u232cR (5\u0408-TAATCGTC TCGTTTCAATTTGAGGGCTATTTCTGAGCC-3\u0408); and (2) 739\u232cF (5\u0408-TAATCGTCTCTGAAA CTAGAGGATTATTTGGAGCTATAGC-3\u0408) and Bm-NS-890r (5\u0408-ATATCGTCTCGTATTAGTAG AAACAAGGGTGTTTT-3\u0408).Cells and A/Puerto Rico/8/34 plasmidsWe amplified the neuraminidase gene of A/Hong Kong/213/03 using the primer pair Ba-NA-1 (5\u0408-TATTGGTCTC AGGGAGCAAAAGCAGGAGT-3\u0408) and Ba-NA-1413r (5\u0408-ATATGGTCTCGTATTAGTAGAAACAAG GAGTTTTTT-3\u0408).", [["Cells", "ANATOMY", 350, 355], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 45, 59], ["Bm-HA-1", "GENE_OR_GENE_PRODUCT", 121, 128], ["Bm-NS-890r", "GENE_OR_GENE_PRODUCT", 294, 304], ["Cells", "CELL", 350, 355], ["Ba-NA-1", "GENE_OR_GENE_PRODUCT", 467, 474], ["Ba-NA-1413r", "GENE_OR_GENE_PRODUCT", 518, 529], ["haemagglutinin", "PROTEIN", 45, 59], ["8/34 plasmids", "DNA", 374, 387], ["neuraminidase gene", "DNA", 404, 422], ["primer pair Ba-NA-1", "DNA", 455, 474], ["Ba-NA-1413r", "DNA", 518, 529], ["5\u0408", "DNA", 531, 533], ["Bm-NS-890r", "SPECIES", 294, 304], ["A/Puerto Rico/8/34", "SPECIES", 360, 378], ["A/Hong Kong/213/03", "SPECIES", 426, 444], ["The removal", "TREATMENT", 0, 11], ["the haemagglutinin", "TREATMENT", 41, 59], ["PCR", "TEST", 81, 84], ["Bm", "TEST", 121, 123], ["HA", "TEST", 124, 126], ["AAGCAGGGG", "TEST", 153, 162], ["TCGTTTCAATTTGAGGGCTATTTCTGAGCC", "TEST", 190, 220], ["CTAGAGGATTATTTGGAGCTATAGC", "TEST", 260, 285], ["Bm", "TEST", 294, 296], ["NS", "TEST", 297, 299], ["AAACAAGGGTGTTTT", "TEST", 330, 345], ["the primer pair Ba-NA", "TEST", 451, 472], ["AGGGAGCAAAAGCAGGAGT", "TEST", 490, 509], ["Ba-NA", "TEST", 518, 523], ["Bm", "ANATOMY", 294, 296]]], ["PCR products were purified and cloned into the vector pHW2000 as described previously.", [["PCR products", "DNA", 0, 12], ["vector pHW2000", "DNA", 47, 61], ["PCR products", "TREATMENT", 0, 12]]], ["11Rescue of virus from Vero cellsThe rescue of infectious virus from cloned cDNA was done under GMP conditions.", [["Vero cells", "ANATOMY", 23, 33], ["GMP", "CHEMICAL", 96, 99], ["GMP", "CHEMICAL", 96, 99], ["Vero cells", "CELL", 23, 33], ["GMP", "SIMPLE_CHEMICAL", 96, 99], ["Vero cells", "CELL_LINE", 23, 33], ["cloned cDNA", "DNA", 69, 80], ["virus", "PROBLEM", 12, 17], ["Vero cells", "PROBLEM", 23, 33], ["infectious virus", "PROBLEM", 47, 63], ["cloned cDNA", "TEST", 69, 80], ["virus", "OBSERVATION", 12, 17], ["Vero cells", "OBSERVATION", 23, 33], ["infectious", "OBSERVATION", 47, 57]]], ["Vero cells were grown to 70% confluency in a 75 cm 2 flask, trypsinised (with trypsin-versene), and resuspended in 10 mL of Opti-MEM I (Invitrogen, Carlsbad CA, USA).", [["Vero cells", "ANATOMY", 0, 10], ["trypsin-versene", "CHEMICAL", 78, 93], ["Vero cells", "CELL", 0, 10], ["trypsin-versene", "SIMPLE_CHEMICAL", 78, 93], ["Vero cells", "CELL_LINE", 0, 10], ["trypsin", "PROTEIN", 78, 85], ["Vero cells", "PROBLEM", 0, 10], ["trypsin", "TEST", 78, 85], ["75 cm", "OBSERVATION_MODIFIER", 45, 50]]], ["To 2 mL of cell suspension we added 20 mL of fresh Opti-MEM I; then, we added 3 mL of this diluted suspension to each well of a six-well tissue culture plate (about 1\u03eb10 6 cells per well).", [["cell", "ANATOMY", 11, 15], ["cells", "ANATOMY", 172, 177], ["cell", "CELL", 11, 15], ["tissue", "TISSUE", 137, 143], ["cells", "CELL", 172, 177], ["cell suspension", "TREATMENT", 11, 26], ["this diluted suspension", "TREATMENT", 86, 109], ["a six-well tissue culture plate", "TREATMENT", 126, 157]]], ["The plates were incubated at 37\u00b0C overnight.", [["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The next day, 1 g of each plasmid and 16 L of TransIT LT-1 transfection reagent (Panvera, Madison, WI, USA) were added to Opti-MEM I to a final volume of 200 L and the mixture incubated at room temperature for 45 min.", [["plasmid", "ANATOMY", 26, 33], ["Opti-MEM I", "PROTEIN", 122, 132], ["each plasmid", "TREATMENT", 21, 33], ["TransIT LT", "TREATMENT", 46, 56]]], ["After incubation, the medium was removed from one well of the six-well plate, 800 L of Opti-MEM I added to the transfection mix, and this mixture added dropwise to the cells.", [["cells", "ANATOMY", 168, 173], ["cells", "CELL", 168, 173], ["Opti-MEM I", "PROTEIN", 87, 97], ["Opti-MEM I", "TREATMENT", 87, 97], ["the transfection mix", "TREATMENT", 107, 127]]], ["6 h later, the DNA-transfection mixture was replaced by Opti-MEM I. 24 h after transfection, 1 mL of Opti-MEM I that contained 1 g/mL L-(tosylamido-2phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin (Worthington Biochemicals, Lakewood, NJ, USA) was added to the cells.", [["cells", "ANATOMY", 269, 274], ["L-(tosylamido-2phenyl) ethyl chloromethyl ketone", "CHEMICAL", 134, 182], ["TPCK", "CHEMICAL", 184, 188], ["L-(tosylamido-2phenyl) ethyl chloromethyl ketone", "CHEMICAL", 134, 182], ["TPCK", "CHEMICAL", 184, 188], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["L-(tosylamido-2phenyl) ethyl chloromethyl ketone", "SIMPLE_CHEMICAL", 134, 182], ["TPCK", "SIMPLE_CHEMICAL", 184, 188], ["trypsin", "SIMPLE_CHEMICAL", 198, 205], ["cells", "CELL", 269, 274], ["the DNA-transfection mixture", "TREATMENT", 11, 39], ["tosylamido-2phenyl) ethyl chloromethyl ketone (TPCK", "TREATMENT", 137, 188], ["trypsin (Worthington Biochemicals", "TREATMENT", 198, 231], ["NJ, USA)", "TREATMENT", 243, 251]]], ["About 72 h after the addition of TPCK-trypsin, the culture supernatants were harvested and clarified by low-speed centrifugation; we then injected 100 L of the clarified supernatant into the allantoic cavity of individual 10-day-old pathogen-free embryonated research grade eggs (Charles River SPAFAS, North Franklin, CT, USA).Pathogenicity testing in chickensTen 4-week-old chickens received intravenous injections of 0\u00b71 mL diluted virus (dilution ratio, 1/10).", [["supernatants", "ANATOMY", 59, 71], ["supernatant", "ANATOMY", 170, 181], ["allantoic cavity", "ANATOMY", 191, 207], ["intravenous", "ANATOMY", 393, 404], ["TPCK", "CHEMICAL", 33, 37], ["TPCK", "CHEMICAL", 33, 37], ["TPCK-trypsin", "SIMPLE_CHEMICAL", 33, 45], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 191, 207], ["chickens", "ORGANISM", 352, 360], ["chickens", "ORGANISM", 375, 383], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 393, 404], ["trypsin", "PROTEIN", 38, 45], ["chickens", "SPECIES", 352, 360], ["chickens", "SPECIES", 375, 383], ["chickens", "SPECIES", 352, 360], ["chickens", "SPECIES", 375, 383], ["TPCK-trypsin", "TREATMENT", 33, 45], ["the culture supernatants", "TEST", 47, 71], ["low-speed centrifugation", "TREATMENT", 104, 128], ["old pathogen", "PROBLEM", 229, 241], ["free embryonated research grade eggs", "PROBLEM", 242, 278], ["Pathogenicity testing", "TEST", 327, 348], ["intravenous injections", "TREATMENT", 393, 415], ["0\u00b71 mL diluted virus (dilution ratio", "TREATMENT", 419, 455], ["allantoic cavity", "ANATOMY", 191, 207]]], ["We monitored chickens for signs of disease for 10 days using the Intravenous Pathogenicity Index, approved by the Office of International Epizooites (OIE).", [["chickens", "ORGANISM", 13, 21], ["chickens", "SPECIES", 13, 21], ["chickens", "SPECIES", 13, 21], ["disease", "PROBLEM", 35, 42], ["the Intravenous Pathogenicity Index", "PROBLEM", 61, 96], ["disease", "OBSERVATION", 35, 42]]], ["Additionally, we took tracheal and cloacal swabs (in 1 mL of media) 3 days and 5 days after infection, and we did assays for the presence of virus by injection of 0\u00b71 mL into all of three 10-day-old embryonated chicken eggs.", [["tracheal", "ANATOMY", 22, 30], ["cloacal swabs", "ANATOMY", 35, 48], ["eggs", "ANATOMY", 219, 223], ["infection", "DISEASE", 92, 101], ["tracheal", "MULTI-TISSUE_STRUCTURE", 22, 30], ["cloacal swabs", "MULTI-TISSUE_STRUCTURE", 35, 48], ["chicken", "ORGANISM", 211, 218], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 219, 223], ["chicken", "SPECIES", 211, 218], ["chicken", "SPECIES", 211, 218], ["tracheal and cloacal swabs", "TREATMENT", 22, 48], ["infection", "PROBLEM", 92, 101], ["virus", "PROBLEM", 141, 146], ["embryonated chicken eggs", "TREATMENT", 199, 223], ["tracheal", "ANATOMY", 22, 30]]], ["Haemagglutination activity in the allantoic fluid of these eggs was assessed after incubation at 35\u00b0C for 2 days.Pathogenicity testing in chickensPathogenicity testing in ferrets We tested pathogenicity of the vaccine in five young adult male ferrets (Marshall's Farms, North Rose, NY, USA) aged 4-8 months (weight about 1\u00b75 kg) that were shown by haemagglutination inhibition assays to be seronegative for currently circulating human influenza A viruses (H3N2, H1N1) and H5N1 viruses.", [["allantoic fluid", "ANATOMY", 34, 49], ["eggs", "ANATOMY", 59, 63], ["influenza A viruses", "DISEASE", 435, 454], ["H5N1 viruses", "DISEASE", 472, 484], ["allantoic fluid", "ORGANISM_SUBSTANCE", 34, 49], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 59, 63], ["chickens", "ORGANISM", 138, 146], ["ferrets", "ORGANISM", 171, 178], ["ferrets", "ORGANISM", 243, 250], ["human influenza A viruses", "ORGANISM", 429, 454], ["H3N2, H1N1", "ORGANISM", 456, 466], ["H5N1 viruses", "ORGANISM", 472, 484], ["chickens", "SPECIES", 138, 146], ["ferrets", "SPECIES", 171, 178], ["ferrets", "SPECIES", 243, 250], ["human", "SPECIES", 429, 434], ["influenza A viruses", "SPECIES", 435, 454], ["H5N1", "SPECIES", 472, 476], ["chickens", "SPECIES", 138, 146], ["ferrets", "SPECIES", 171, 178], ["human influenza A viruses", "SPECIES", 429, 454], ["H5N1 viruses", "SPECIES", 472, 484], ["Haemagglutination activity", "PROBLEM", 0, 26], ["these eggs", "TREATMENT", 53, 63], ["Pathogenicity testing", "TEST", 113, 134], ["chickensPathogenicity testing", "TEST", 138, 167], ["the vaccine", "TREATMENT", 206, 217], ["weight", "TEST", 308, 314], ["haemagglutination inhibition assays", "TEST", 348, 383], ["circulating human influenza A viruses", "PROBLEM", 417, 454], ["H3N2", "PROBLEM", 456, 460], ["H1N1", "PROBLEM", 462, 466], ["H5N1 viruses", "PROBLEM", 472, 484], ["allantoic", "ANATOMY_MODIFIER", 34, 43], ["fluid", "OBSERVATION", 44, 49], ["H5N1 viruses", "OBSERVATION", 472, 484]]], ["We anaesthetised the ferrets with inhaled isoflurane, and they were then infected intranasally with 10 6 50% egg infectious dose (EID 50 )/mL of vaccine reassortant virus or wildtype virus.", [["intranasally", "ANATOMY", 82, 94], ["isoflurane", "CHEMICAL", 42, 52], ["isoflurane", "CHEMICAL", 42, 52], ["ferrets", "ORGANISM", 21, 28], ["isoflurane", "SIMPLE_CHEMICAL", 42, 52], ["reassortant virus", "ORGANISM", 153, 170], ["wildtype virus", "ORGANISM", 174, 188], ["ferrets", "SPECIES", 21, 28], ["vaccine reassortant virus", "SPECIES", 145, 170], ["reassortant virus", "SPECIES", 153, 170], ["inhaled isoflurane", "TREATMENT", 34, 52], ["vaccine reassortant virus", "PROBLEM", 145, 170], ["wildtype virus", "PROBLEM", 174, 188]]], ["We monitored the ferrets once per day for signs of sneezing, inappetence, and inactivity, and we recorded rectal temperatures and bodyweights.", [["rectal", "ANATOMY", 106, 112], ["sneezing", "DISEASE", 51, 59], ["inappetence", "DISEASE", 61, 72], ["ferrets", "ORGANISM", 17, 24], ["rectal", "ORGANISM_SUBDIVISION", 106, 112], ["ferrets", "SPECIES", 17, 24], ["sneezing", "PROBLEM", 51, 59], ["inappetence", "PROBLEM", 61, 72], ["inactivity", "PROBLEM", 78, 88], ["rectal temperatures", "TEST", 106, 125], ["bodyweights", "TEST", 130, 141], ["sneezing", "OBSERVATION", 51, 59]]], ["3, 5, and 7 days after infection, the ferrets were anaesthetised with ketamine (25 mg/kg), and we collected nasal washes using 1 mL of sterile phosphatebuffered saline (PBS) containing antibiotics.", [["nasal", "ANATOMY", 108, 113], ["infection", "DISEASE", 23, 32], ["ketamine", "CHEMICAL", 70, 78], ["ketamine", "CHEMICAL", 70, 78], ["ferrets", "ORGANISM", 38, 45], ["ketamine", "SIMPLE_CHEMICAL", 70, 78], ["phosphatebuffered saline", "SIMPLE_CHEMICAL", 143, 167], ["ferrets", "SPECIES", 38, 45], ["ferrets", "SPECIES", 38, 45], ["infection", "PROBLEM", 23, 32], ["ketamine", "TREATMENT", 70, 78], ["nasal washes", "TREATMENT", 108, 120], ["sterile phosphatebuffered saline (PBS)", "TREATMENT", 135, 173], ["antibiotics", "TREATMENT", 185, 196], ["infection", "OBSERVATION", 23, 32]]], ["We measured titres of virus in these washes with EID 50 assays.Pathogenicity testing in chickensTo further assess the pathogenicity of the viruses, we collected tissue samples from lungs, brain, olfactory bulb, spleen, and intestine for virus isolation and histopathological analysis at the time of death or in the case of three ferrets, after euthanasia at day 3 after infection.", [["tissue samples", "ANATOMY", 161, 175], ["lungs", "ANATOMY", 181, 186], ["brain", "ANATOMY", 188, 193], ["olfactory bulb", "ANATOMY", 195, 209], ["spleen", "ANATOMY", 211, 217], ["intestine", "ANATOMY", 223, 232], ["death", "DISEASE", 299, 304], ["infection", "DISEASE", 370, 379], ["chickens", "ORGANISM", 88, 96], ["tissue samples", "TISSUE", 161, 175], ["lungs", "ORGAN", 181, 186], ["brain", "ORGAN", 188, 193], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 195, 209], ["spleen", "ORGAN", 211, 217], ["intestine", "ORGAN", 223, 232], ["ferrets", "ORGANISM", 329, 336], ["chickens", "SPECIES", 88, 96], ["ferrets", "SPECIES", 329, 336], ["chickens", "SPECIES", 88, 96], ["ferrets", "SPECIES", 329, 336], ["virus", "TREATMENT", 22, 27], ["Pathogenicity testing", "TEST", 63, 84], ["the viruses", "PROBLEM", 135, 146], ["collected tissue samples from lungs, brain, olfactory bulb", "TEST", 151, 209], ["virus isolation", "TREATMENT", 237, 252], ["histopathological analysis", "TEST", 257, 283], ["infection", "PROBLEM", 370, 379], ["viruses", "OBSERVATION", 139, 146], ["lungs", "ANATOMY", 181, 186], ["brain", "ANATOMY", 188, 193], ["olfactory bulb", "ANATOMY", 195, 209], ["spleen", "ANATOMY", 211, 217], ["intestine", "ANATOMY", 223, 232], ["infection", "OBSERVATION", 370, 379]]], ["The tissues were fixed in 10% neutral buffer formalin, processed and embedded in paraffin, sectioned at 5 g, stained with haematoxylin and eosin and examined by light microscopy in a blinded fashion.Stability testing in eggsTo test the stability of the vaccine virus on propagation, we made 16 consecutive passages of the virus in embryonated chicken eggs.", [["tissues", "ANATOMY", 4, 11], ["eggs", "ANATOMY", 351, 355], ["formalin", "CHEMICAL", 45, 53], ["paraffin", "CHEMICAL", 81, 89], ["haematoxylin", "CHEMICAL", 122, 134], ["eosin", "CHEMICAL", 139, 144], ["tissues", "TISSUE", 4, 11], ["haematoxylin", "SIMPLE_CHEMICAL", 122, 134], ["chicken", "ORGANISM", 343, 350], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 351, 355], ["chicken", "SPECIES", 343, 350], ["chicken", "SPECIES", 343, 350], ["10% neutral buffer formalin", "TREATMENT", 26, 53], ["haematoxylin", "TREATMENT", 122, 134], ["light microscopy", "TEST", 161, 177], ["Stability testing", "TEST", 199, 216], ["the vaccine virus", "PROBLEM", 249, 266], ["the virus", "TREATMENT", 318, 327], ["embryonated chicken eggs", "TREATMENT", 331, 355], ["tissues", "ANATOMY", 4, 11], ["fixed", "OBSERVATION_MODIFIER", 17, 22]]], ["A 10 -4 dilution of the virus was made in PBS, and 0\u00b71 mL of the solution was injected into the allantoic cavities of all of four 10-day-old embryonated chicken eggs.", [["allantoic cavities", "ANATOMY", 96, 114], ["eggs", "ANATOMY", 161, 165], ["allantoic cavities", "MULTI-TISSUE_STRUCTURE", 96, 114], ["chicken", "ORGANISM", 153, 160], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 161, 165], ["chicken", "SPECIES", 153, 160], ["chicken", "SPECIES", 153, 160], ["A 10 -4 dilution of the virus", "TREATMENT", 0, 29], ["PBS", "TREATMENT", 42, 45], ["the solution", "TREATMENT", 61, 73], ["allantoic cavities", "ANATOMY", 96, 114]]], ["Eggs were incubated at 35\u00baC for 1\u00b75-2 days.", [["Eggs", "ANATOMY", 0, 4], ["Eggs", "ORGANISM_SUBSTANCE", 0, 4], ["Eggs", "TEST", 0, 4]]], ["After incubation, each egg was candled to determine embryo viability before chilling at 4\u00baC.", [["egg", "ANATOMY", 23, 26], ["embryo", "ANATOMY", 52, 58], ["egg", "ORGANISM_SUBSTANCE", 23, 26], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 52, 58], ["each egg", "TREATMENT", 18, 26], ["embryo viability", "PROBLEM", 52, 68]]], ["We harvested 2 mL of allantoic fluid from each egg harvested, and samples were pooled together, tested for haemagglutination activity, and then reinjected into another four eggs.Role of the funding sourceThe sponsor had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report or decision to submit this manuscript for publication.Alteration of haemagglutinin cleavage site and virus rescueThe first challenge we faced in producing a vaccine against A/Hong Kong/213/03 (H5N1) was to attenuate the virus in preparation for mass production.", [["allantoic fluid", "ANATOMY", 21, 36], ["egg", "ANATOMY", 47, 50], ["samples", "ANATOMY", 66, 73], ["eggs", "ANATOMY", 173, 177], ["allantoic fluid", "ORGANISM_SUBSTANCE", 21, 36], ["egg", "ORGANISM_SUBSTANCE", 47, 50], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 399, 413], ["A/Hong Kong/213/03", "ORGANISM", 504, 522], ["H5N1", "ORGANISM", 524, 528], ["haemagglutinin cleavage site", "PROTEIN", 399, 427], ["A/Hong Kong/213/03 (H5N1", "SPECIES", 504, 528], ["allantoic fluid from each egg harvested", "TREATMENT", 21, 60], ["samples", "TEST", 66, 73], ["haemagglutination activity", "TEST", 107, 133], ["Alteration of haemagglutinin cleavage site", "PROBLEM", 385, 427], ["virus rescue", "TREATMENT", 432, 444], ["a vaccine", "TREATMENT", 486, 495], ["H5N1", "PROBLEM", 524, 528], ["the virus", "PROBLEM", 547, 556], ["mass production", "PROBLEM", 576, 591], ["fluid", "OBSERVATION", 31, 36], ["mass", "OBSERVATION", 576, 580]]], ["Previous experiences have shown that removal of the basic aminoacids at the haemagglutinin cleavage site substantially attenuates pathogenic influenza viruses.", [["influenza viruses", "DISEASE", 141, 158], ["aminoacids", "CHEMICAL", 58, 68], ["influenza viruses", "ORGANISM", 141, 158], ["haemagglutinin cleavage site", "PROTEIN", 76, 104], ["removal", "TREATMENT", 37, 44], ["the basic aminoacids", "TREATMENT", 48, 68], ["the haemagglutinin cleavage site", "PROBLEM", 72, 104], ["pathogenic influenza viruses", "PROBLEM", 130, 158], ["attenuates", "OBSERVATION_MODIFIER", 119, 129], ["pathogenic", "OBSERVATION_MODIFIER", 130, 140], ["influenza viruses", "OBSERVATION", 141, 158]]], ["[15] [16] [17] Using a PCR-based mutagenesis approach, we replaced the cleavage site encoded by the haemagglutinin gene of A/Hong Kong/213/03 (H5N1) with that of the avirulent A/teal/Hong Kong/W312/97 (H6N1) (figure 1); this modified haemagglutinin gene and the neuraminidase gene of A/Hong Kong/213/03 (H5N1) were cloned individually into the vector pHW2000.", [["haemagglutinin", "GENE_OR_GENE_PRODUCT", 100, 114], ["A/Hong Kong/213/03 (H5N1", "ORGANISM", 123, 147], ["A/teal", "ORGANISM", 176, 182], ["Hong Kong/W312/97 (H6N1", "ORGANISM", 183, 206], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 234, 248], ["A/Hong Kong/213/03 (H5N1", "ORGANISM", 284, 308], ["cleavage site", "DNA", 71, 84], ["haemagglutinin gene", "DNA", 100, 119], ["modified haemagglutinin gene", "DNA", 225, 253], ["neuraminidase gene", "DNA", 262, 280], ["vector pHW2000", "DNA", 344, 358], ["A/Hong Kong/213/03 (H5N1", "SPECIES", 123, 147], ["A/teal", "SPECIES", 176, 182], ["Hong Kong/W312/97 (H6N1)", "SPECIES", 183, 207], ["A/Hong Kong/213/03 (H5N1", "SPECIES", 284, 308], ["a PCR-based mutagenesis approach", "TREATMENT", 21, 53], ["the cleavage site", "PROBLEM", 67, 84], ["this modified haemagglutinin gene", "TREATMENT", 220, 253]]], ["11 The two resulting plasmids and the six plasmids encoding the remaining proteins of PR8 13 were transfected into WHOapproved Vero cells under GMP conditions to rescue the vaccine seed virus, \u232c213/PR8.", [["plasmids", "ANATOMY", 21, 29], ["plasmids", "ANATOMY", 42, 50], ["Vero cells", "ANATOMY", 127, 137], ["GMP", "CHEMICAL", 144, 147], ["GMP", "CHEMICAL", 144, 147], ["PR8 13", "ORGANISM", 86, 92], ["Vero cells", "CELL", 127, 137], ["GMP", "SIMPLE_CHEMICAL", 144, 147], ["seed virus", "ORGANISM", 181, 191], ["PR8", "ORGANISM", 198, 201], ["plasmids", "DNA", 21, 29], ["plasmids", "DNA", 42, 50], ["PR8 13", "PROTEIN", 86, 92], ["WHOapproved Vero cells", "CELL_LINE", 115, 137], ["The two resulting plasmids", "TREATMENT", 3, 29], ["the six plasmids", "TREATMENT", 34, 50], ["GMP conditions", "TREATMENT", 144, 158], ["the vaccine seed virus", "TREATMENT", 169, 191], ["plasmids", "OBSERVATION", 21, 29], ["Vero cells", "OBSERVATION", 127, 137]]], ["36-48 h after transfection, isolated areas of cytopathic effect could be seen on the Vero monolayers.", [["Vero monolayers", "ANATOMY", 85, 100], ["Vero monolayers", "CELL", 85, 100], ["Vero monolayers", "CELL_LINE", 85, 100], ["transfection", "TREATMENT", 14, 26], ["cytopathic effect", "PROBLEM", 46, 63], ["areas", "OBSERVATION_MODIFIER", 37, 42], ["cytopathic effect", "OBSERVATION", 46, 63]]], ["Although addition of further 1 g aliquots of TPCK-treated trypsin every 24 h led to a proportional increase in the cytopathic effect, it was not required for successful virus rescue.", [["TPCK", "CHEMICAL", 45, 49], ["TPCK", "CHEMICAL", 45, 49], ["TPCK", "SIMPLE_CHEMICAL", 45, 49], ["trypsin", "GENE_OR_GENE_PRODUCT", 58, 65], ["trypsin", "PROTEIN", 58, 65], ["further 1 g aliquots of TPCK", "TREATMENT", 21, 49], ["trypsin", "TREATMENT", 58, 65], ["a proportional increase", "PROBLEM", 84, 107], ["the cytopathic effect", "PROBLEM", 111, 132], ["successful virus rescue", "TREATMENT", 158, 181], ["increase", "OBSERVATION_MODIFIER", 99, 107], ["cytopathic effect", "OBSERVATION", 115, 132]]], ["The candidate vaccine strain grew to high titres on subsequent amplification in eggs (haemagglutination titres of 1024-2048) and did not cause embryo death.", [["eggs", "ANATOMY", 80, 84], ["embryo", "ANATOMY", 143, 149], ["embryo death", "DISEASE", 143, 155], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 143, 149], ["The candidate vaccine strain", "TREATMENT", 0, 28], ["high titres", "PROBLEM", 37, 48], ["subsequent amplification in eggs", "PROBLEM", 52, 84], ["haemagglutination titres", "TEST", 86, 110], ["embryo death", "PROBLEM", 143, 155], ["embryo death", "OBSERVATION", 143, 155]]], ["The vaccine seed virus was unable to form plaques on Madin-Darby canine kidney (MDCK) cells in the absence of trypsin, a trait consistent with that of influenza viruses that lack the polybasic cleavage site, and was antigenically indistinguishable from the parental H5N1 virus in haemagglutination inhibition assays.", [["plaques", "ANATOMY", 42, 49], ["canine kidney (MDCK) cells", "ANATOMY", 65, 91], ["influenza viruses", "DISEASE", 151, 168], ["seed virus", "ORGANISM", 12, 22], ["Madin-Darby canine kidney (MDCK) cells", "CELL", 53, 91], ["trypsin", "GENE_OR_GENE_PRODUCT", 110, 117], ["influenza viruses", "ORGANISM", 151, 168], ["parental H5N1 virus", "ORGANISM", 257, 276], ["Madin-Darby canine kidney (MDCK) cells", "CELL_LINE", 53, 91], ["trypsin", "PROTEIN", 110, 117], ["polybasic cleavage site", "PROTEIN", 183, 206], ["H5N1 virus", "SPECIES", 266, 276], ["canine", "SPECIES", 65, 71], ["H5N1 virus", "SPECIES", 266, 276], ["The vaccine seed virus", "PROBLEM", 0, 22], ["plaques", "PROBLEM", 42, 49], ["Madin", "TREATMENT", 53, 58], ["trypsin", "PROBLEM", 110, 117], ["a trait", "PROBLEM", 119, 126], ["influenza viruses", "PROBLEM", 151, 168], ["the polybasic cleavage site", "PROBLEM", 179, 206], ["the parental H5N1 virus", "PROBLEM", 253, 276], ["haemagglutination inhibition assays", "TEST", 280, 315], ["plaques", "OBSERVATION", 42, 49], ["kidney", "ANATOMY", 72, 78], ["consistent with", "UNCERTAINTY", 127, 142], ["influenza", "OBSERVATION", 151, 160], ["polybasic cleavage", "OBSERVATION", 183, 201], ["H5N1 virus", "OBSERVATION", 266, 276]]], ["The rescued virus was fully sequenced and was identical to the plasmids used in its creation.Pathogenicity testing of the candidate reference virusTo assess the pathogenicity of the H5N1 vaccine seed virus, we compared the properties of this virus with those of the wildtype A/Hong Kong/213/03 (H5N1) in ferrets and in chickens.", [["plasmids", "ANATOMY", 63, 71], ["H5N1", "ORGANISM", 182, 186], ["vaccine seed virus", "ORGANISM", 187, 205], ["wildtype A/Hong Kong/213/03 (H5N1", "ORGANISM", 266, 299], ["ferrets", "ORGANISM", 304, 311], ["chickens", "ORGANISM", 319, 327], ["plasmids", "DNA", 63, 71], ["H5N1 vaccine seed virus", "SPECIES", 182, 205], ["ferrets", "SPECIES", 304, 311], ["chickens", "SPECIES", 319, 327], ["H5N1 vaccine seed virus", "SPECIES", 182, 205], ["Hong Kong/213/03 (H5N1", "SPECIES", 277, 299], ["ferrets", "SPECIES", 304, 311], ["chickens", "SPECIES", 319, 327], ["The rescued virus", "TREATMENT", 0, 17], ["the plasmids", "TREATMENT", 59, 71], ["Pathogenicity testing", "TEST", 93, 114], ["the H5N1 vaccine seed virus", "TREATMENT", 178, 205], ["this virus", "PROBLEM", 237, 247], ["virus", "OBSERVATION", 12, 17]]], ["By stark contrast with the wildtype virus, which was lethal to all chickens within 48 h of infection, intravenous administration of a 1/10 dilution of \u232c213/PR8 did not result in any signs of infection in chickens, and we were unable to detect any virus in swabs of cloacae or tracheae from inoculated birds.", [["intravenous", "ANATOMY", 102, 113], ["tracheae", "ANATOMY", 276, 284], ["infection", "DISEASE", 91, 100], ["infection", "DISEASE", 191, 200], ["wildtype virus", "ORGANISM", 27, 41], ["chickens", "ORGANISM", 67, 75], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 102, 113], ["PR8", "ORGANISM", 156, 159], ["chickens", "ORGANISM", 204, 212], ["cloacae", "ORGANISM", 265, 272], ["tracheae", "ORGAN", 276, 284], ["birds", "ORGANISM", 301, 306], ["chickens", "SPECIES", 67, 75], ["chickens", "SPECIES", 204, 212], ["chickens", "SPECIES", 67, 75], ["chickens", "SPECIES", 204, 212], ["the wildtype virus", "PROBLEM", 23, 41], ["infection", "PROBLEM", 91, 100], ["intravenous administration", "TREATMENT", 102, 128], ["infection in chickens", "PROBLEM", 191, 212], ["any virus", "PROBLEM", 243, 252], ["cloacae", "PROBLEM", 265, 272], ["tracheae", "PROBLEM", 276, 284], ["infection", "OBSERVATION", 91, 100], ["infection", "OBSERVATION", 191, 200], ["cloacae", "OBSERVATION", 265, 272], ["tracheae", "ANATOMY", 276, 284], ["inoculated birds", "OBSERVATION", 290, 306]]], ["Compared with A/Hong Kong/213/03 (H5N1), \u232c213/PR8 was attenuated in ferrets that had been inoculated intranasally with 10 6 EID 50 of virus.", [["intranasally", "ANATOMY", 101, 113], ["A/Hong Kong/213/03 (H5N1)", "ORGANISM", 14, 39], ["\u232c213/PR8", "ORGANISM", 41, 49], ["ferrets", "ORGANISM", 68, 75], ["ferrets", "SPECIES", 68, 75], ["A/Hong Kong/213/03 (H5N1", "SPECIES", 14, 38], ["ferrets", "SPECIES", 68, 75], ["virus", "PROBLEM", 134, 139]]], ["Ferrets infected with A/Hong Kong/213/03 had inappetence and weight loss (figure 2), with one infected animal dying 6 days after infection and a second killed 10 days after infection because of hind-limb paralysis.", [["Ferrets", "ANATOMY", 0, 7], ["hind-limb", "ANATOMY", 194, 203], ["weight loss", "DISEASE", 61, 72], ["infection", "DISEASE", 129, 138], ["infection", "DISEASE", 173, 182], ["paralysis", "DISEASE", 204, 213], ["A/Hong Kong", "ORGANISM", 22, 33], ["hind-", "ORGANISM_SUBDIVISION", 194, 199], ["limb", "ORGANISM_SUBDIVISION", 199, 203], ["A/Hong Kong/213/03", "SPECIES", 22, 40], ["inappetence", "PROBLEM", 45, 56], ["weight loss", "PROBLEM", 61, 72], ["infection", "PROBLEM", 129, 138], ["infection", "PROBLEM", 173, 182], ["hind-limb paralysis", "PROBLEM", 194, 213], ["hind", "ANATOMY", 194, 198], ["limb", "ANATOMY", 199, 203], ["paralysis", "OBSERVATION", 204, 213]]], ["Infection in these animals was characterised by viral shedding until 7 days after infection and replication of virus in the lower respiratory tract and olfactory bulb (as determined by virus isolation).", [["lower respiratory tract", "ANATOMY", 124, 147], ["olfactory bulb", "ANATOMY", 152, 166], ["infection", "DISEASE", 82, 91], ["lower", "ORGANISM_SUBDIVISION", 124, 129], ["respiratory tract", "ORGANISM_SUBDIVISION", 130, 147], ["olfactory bulb", "ORGAN", 152, 166], ["Infection", "PROBLEM", 0, 9], ["viral shedding", "PROBLEM", 48, 62], ["infection", "PROBLEM", 82, 91], ["replication of virus in the lower respiratory tract", "PROBLEM", 96, 147], ["viral", "OBSERVATION_MODIFIER", 48, 53], ["virus", "OBSERVATION", 111, 116], ["lower", "ANATOMY_MODIFIER", 124, 129], ["respiratory tract", "ANATOMY", 130, 147], ["olfactory bulb", "ANATOMY", 152, 166]]], ["In the A/Hong Kong/213/03 infected animals, there was a mild mononuclear cell infiltrate in the meninges and tracheal submucosal mucous glands and an extensive bronchopneumonia.", [["mononuclear cell", "ANATOMY", 61, 77], ["meninges", "ANATOMY", 96, 104], ["tracheal submucosal mucous glands", "ANATOMY", 109, 142], ["bronchopneumonia", "DISEASE", 160, 176], ["A/Hong Kong/213/03", "ORGANISM", 7, 25], ["animals", "ORGANISM", 35, 42], ["mononuclear cell", "CELL", 61, 77], ["meninges", "TISSUE", 96, 104], ["tracheal submucosal mucous glands", "ORGAN", 109, 142], ["A/Hong Kong/213/03", "SPECIES", 7, 25], ["a mild mononuclear cell infiltrate in the meninges", "PROBLEM", 54, 104], ["tracheal submucosal mucous glands", "PROBLEM", 109, 142], ["an extensive bronchopneumonia", "PROBLEM", 147, 176], ["mild", "OBSERVATION_MODIFIER", 56, 60], ["mononuclear cell infiltrate", "OBSERVATION", 61, 88], ["meninges", "ANATOMY", 96, 104], ["tracheal", "ANATOMY", 109, 117], ["submucosal", "ANATOMY_MODIFIER", 118, 128], ["mucous glands", "ANATOMY", 129, 142], ["extensive", "OBSERVATION_MODIFIER", 150, 159], ["bronchopneumonia", "OBSERVATION", 160, 176]]], ["The pneumatic infiltrate progressed in severity from the bronchi to the pleura.", [["bronchi", "ANATOMY", 57, 64], ["pleura", "ANATOMY", 72, 78], ["bronchi", "MULTI-TISSUE_STRUCTURE", 57, 64], ["pleura", "ORGAN", 72, 78], ["The pneumatic infiltrate", "PROBLEM", 0, 24], ["pneumatic", "OBSERVATION_MODIFIER", 4, 13], ["infiltrate", "OBSERVATION", 14, 24], ["severity", "OBSERVATION_MODIFIER", 39, 47], ["bronchi", "ANATOMY", 57, 64], ["pleura", "ANATOMY", 72, 78]]], ["The bronchi and bronchioles contained sloughed necrotic epithelial cells, numerous mononuclear cells, and a few neutrophils.", [["bronchi", "ANATOMY", 4, 11], ["bronchioles", "ANATOMY", 16, 27], ["necrotic epithelial cells", "ANATOMY", 47, 72], ["mononuclear cells", "ANATOMY", 83, 100], ["neutrophils", "ANATOMY", 112, 123], ["necrotic", "DISEASE", 47, 55], ["bronchi", "MULTI-TISSUE_STRUCTURE", 4, 11], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 16, 27], ["necrotic epithelial cells", "CELL", 47, 72], ["mononuclear cells", "CELL", 83, 100], ["neutrophils", "CELL", 112, 123], ["sloughed necrotic epithelial cells", "CELL_TYPE", 38, 72], ["mononuclear cells", "CELL_TYPE", 83, 100], ["neutrophils", "CELL_TYPE", 112, 123], ["sloughed necrotic epithelial cells", "PROBLEM", 38, 72], ["numerous mononuclear cells", "PROBLEM", 74, 100], ["bronchi", "ANATOMY", 4, 11], ["bronchioles", "ANATOMY", 16, 27], ["sloughed", "OBSERVATION_MODIFIER", 38, 46], ["necrotic epithelial cells", "OBSERVATION", 47, 72], ["numerous", "OBSERVATION_MODIFIER", 74, 82], ["mononuclear cells", "OBSERVATION", 83, 100], ["few", "OBSERVATION_MODIFIER", 108, 111], ["neutrophils", "OBSERVATION", 112, 123]]], ["The alveoli were consolidated with inflammatory cells and fibrin (figure 3).", [["alveoli", "ANATOMY", 4, 11], ["inflammatory cells", "ANATOMY", 35, 53], ["alveoli", "MULTI-TISSUE_STRUCTURE", 4, 11], ["cells", "CELL", 48, 53], ["fibrin", "GENE_OR_GENE_PRODUCT", 58, 64], ["inflammatory cells", "CELL_TYPE", 35, 53], ["fibrin", "PROTEIN", 58, 64], ["inflammatory cells", "PROBLEM", 35, 53], ["fibrin", "PROBLEM", 58, 64], ["alveoli", "ANATOMY", 4, 11], ["consolidated", "OBSERVATION", 17, 29], ["inflammatory cells", "OBSERVATION", 35, 53], ["fibrin", "OBSERVATION_MODIFIER", 58, 64]]], ["By contrast, those ferrets infected with \u232c213/PR8 did not lose weight (figure 2) and seemed to remain healthy during the study (14 days) ( figure 3) .", [["ferrets", "ORGANISM", 19, 26], ["PR8", "ORGANISM", 46, 49], ["ferrets", "SPECIES", 19, 26], ["the study", "TEST", 117, 126]]], ["Virus was detected in the nasal washes of these animals at 5 days but not 7 days after infection, and virus was recovered from the upper respiratory tract only.", [["nasal", "ANATOMY", 26, 31], ["upper respiratory tract", "ANATOMY", 131, 154], ["infection", "DISEASE", 87, 96], ["Virus", "ORGANISM", 0, 5], ["nasal", "ORGANISM_SUBDIVISION", 26, 31], ["upper respiratory", "ORGANISM_SUBDIVISION", 131, 148], ["tract", "ORGANISM_SUBDIVISION", 149, 154], ["Virus", "PROBLEM", 0, 5], ["infection", "PROBLEM", 87, 96], ["virus", "PROBLEM", 102, 107], ["nasal", "ANATOMY", 26, 31], ["infection", "OBSERVATION", 87, 96], ["upper", "ANATOMY_MODIFIER", 131, 136], ["respiratory tract", "ANATOMY", 137, 154]]], ["By light microscopy, the meninges and trachea of the \u232c213/PR8 infected ferrets did not have an inflammatory infiltrate and only a few neutrophils were noted occasionally in pulmonary bronchi.", [["meninges", "ANATOMY", 25, 33], ["trachea", "ANATOMY", 38, 45], ["neutrophils", "ANATOMY", 134, 145], ["pulmonary bronchi", "ANATOMY", 173, 190], ["meninges", "ORGAN", 25, 33], ["trachea", "ORGAN", 38, 45], ["\u232c213/PR8", "ORGANISM", 53, 61], ["ferrets", "ORGANISM", 71, 78], ["neutrophils", "CELL", 134, 145], ["pulmonary bronchi", "MULTI-TISSUE_STRUCTURE", 173, 190], ["neutrophils", "CELL_TYPE", 134, 145], ["ferrets", "SPECIES", 71, 78], ["light microscopy", "TEST", 3, 19], ["the meninges", "TEST", 21, 33], ["an inflammatory infiltrate", "PROBLEM", 92, 118], ["a few neutrophils", "PROBLEM", 128, 145], ["meninges", "ANATOMY", 25, 33], ["trachea", "ANATOMY", 38, 45], ["inflammatory", "OBSERVATION_MODIFIER", 95, 107], ["infiltrate", "OBSERVATION", 108, 118], ["few", "OBSERVATION_MODIFIER", 130, 133], ["neutrophils", "OBSERVATION", 134, 145], ["pulmonary bronchi", "ANATOMY", 173, 190]]], ["Our results clearly show that \u232c213/PR8 was attenuated.", [["PR8", "ORGANISM", 35, 38]]], ["In view of our findings, this virus can be safely handled with standard precautions in BSL2 containment facilities.Stability of non-pathogenic phenotypeBecause the mechanisms and requirements for the accumulation of basic aminoacids at the haemagglutinin cleavage site are not entirely understood, we wanted to confirm that the altered cleavage site remained stable on multiple passages in embryonated chicken eggs.", [["eggs", "ANATOMY", 410, 414], ["aminoacids", "CHEMICAL", 222, 232], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 240, 254], ["chicken", "ORGANISM", 402, 409], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 410, 414], ["haemagglutinin cleavage site", "DNA", 240, 268], ["chicken", "SPECIES", 402, 409], ["chicken", "SPECIES", 402, 409], ["this virus", "PROBLEM", 25, 35], ["standard precautions", "TREATMENT", 63, 83], ["non-pathogenic phenotypeBecause the mechanisms", "PROBLEM", 128, 174], ["basic aminoacids", "TREATMENT", 216, 232], ["the haemagglutinin cleavage site", "TREATMENT", 236, 268], ["the altered cleavage site", "PROBLEM", 324, 349], ["embryonated chicken eggs", "TREATMENT", 390, 414], ["non-pathogenic phenotypeBecause", "OBSERVATION", 128, 159], ["stable", "OBSERVATION_MODIFIER", 359, 365]]], ["Such passaging in eggs would occur in transition and amplification of the reference virus to vaccine stock.", [["eggs", "ANATOMY", 18, 22], ["Such passaging in eggs", "PROBLEM", 0, 22], ["the reference virus to vaccine stock", "TREATMENT", 70, 106]]], ["The rescued virus was stable on continued serial passage in embryonated eggs, and we did not detect any change in nucleotide sequence of the haemagglutinin cleavage site after 16 passages.", [["eggs", "ANATOMY", 72, 76], ["nucleotide", "CHEMICAL", 114, 124], ["nucleotide", "CHEMICAL", 114, 124], ["haemagglutinin cleavage site", "DNA", 141, 169], ["The rescued virus", "PROBLEM", 0, 17], ["continued serial passage in embryonated eggs", "TREATMENT", 32, 76], ["any change in nucleotide sequence", "PROBLEM", 100, 133], ["the haemagglutinin cleavage site", "PROBLEM", 137, 169], ["virus", "OBSERVATION", 12, 17], ["stable", "OBSERVATION_MODIFIER", 22, 28]]], ["There was no evidence of changing pathogenicity of the virus and we noted only one dead embryo at passage 15.", [["embryo", "ANATOMY", 88, 94], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 88, 94], ["changing pathogenicity of the virus", "PROBLEM", 25, 60], ["no evidence of", "UNCERTAINTY", 10, 24], ["changing", "OBSERVATION_MODIFIER", 25, 33], ["pathogenicity", "OBSERVATION", 34, 47], ["virus", "OBSERVATION", 55, 60], ["dead embryo", "OBSERVATION", 83, 94]]], ["No haemagglutination activity was evident in this egg and no embryo death was seen in passage 16, which strongly suggests that the death was not related to virus replication.", [["egg", "ANATOMY", 50, 53], ["embryo", "ANATOMY", 61, 67], ["death", "DISEASE", 68, 73], ["death", "DISEASE", 131, 136], ["egg", "ORGANISM_SUBSTANCE", 50, 53], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 61, 67], ["haemagglutination activity", "PROBLEM", 3, 29], ["this egg", "PROBLEM", 45, 53], ["embryo death", "PROBLEM", 61, 73], ["the death", "PROBLEM", 127, 136], ["virus replication", "TREATMENT", 156, 173], ["haemagglutination activity", "OBSERVATION", 3, 29], ["no", "UNCERTAINTY", 58, 60], ["embryo death", "OBSERVATION", 61, 73], ["not related to", "UNCERTAINTY", 141, 155]]], ["Haemagglutination titres at each passage ranged from 512 to 2048 with no apparent trend of increasing or decreasing titres in subsequent passages.DiscussionThe rapid response in terms of potential vaccine reference virus production to the 2003 H5N1 outbreak differs strikingly from the response to the 1997 episode.", [["H5N1", "DISEASE", 244, 248], ["Haemagglutination titres", "TEST", 0, 24], ["decreasing titres", "PROBLEM", 105, 122], ["potential vaccine reference virus production", "PROBLEM", 187, 231], ["increasing", "OBSERVATION_MODIFIER", 91, 101], ["decreasing", "OBSERVATION_MODIFIER", 105, 115], ["titres", "OBSERVATION", 116, 122]]], ["This difference is attributable to the new scientific technology available in 2003 and, just as importantly, to the infrastructure for virus surveillance in Hong Kong developed since 1997.", [["virus surveillance", "TEST", 135, 153], ["new", "OBSERVATION_MODIFIER", 39, 42]]], ["The first case of H5N1 influenza in Hong Kong was in May, 1997; yet several months elapsed before this virus was finally characterised as an H5N1 virus.", [["influenza", "DISEASE", 23, 32], ["H5N1 influenza", "ORGANISM", 18, 32], ["H5N1 virus", "ORGANISM", 141, 151], ["H5N1 influenza", "SPECIES", 18, 32], ["H5N1 virus", "SPECIES", 141, 151], ["H5N1 virus", "SPECIES", 141, 151], ["H5N1 influenza", "PROBLEM", 18, 32], ["this virus", "PROBLEM", 98, 108], ["an H5N1 virus", "PROBLEM", 138, 151], ["H5N1 virus", "OBSERVATION", 141, 151]]], ["In 2003, the causative agent was identified only hours after admission of the patients to the hospital.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86]]], ["The increased awareness, surveillance, and availability of reagents to identify influenza viruses of all subtypes bode well for the rapid identification of viruses that arise from future interspecies transfer events and for the coordination of international vaccine development by WHO.", [["influenza viruses", "DISEASE", 80, 97], ["The increased awareness", "PROBLEM", 0, 23], ["surveillance", "TEST", 25, 37], ["reagents", "TREATMENT", 59, 67], ["influenza viruses", "PROBLEM", 80, 97], ["viruses", "PROBLEM", 156, 163], ["international vaccine development", "TREATMENT", 244, 277], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["viruses", "OBSERVATION", 156, 163]]], ["The timely distribution of candidate viruses is a very important step in the development of vaccines for pandemic emergencies.", [["viruses", "PROBLEM", 37, 44], ["vaccines", "TREATMENT", 92, 100], ["pandemic emergencies", "PROBLEM", 105, 125], ["viruses", "OBSERVATION", 37, 44]]], ["Despite the heightened security and documentation requirements for shipping and receiving potential bioterrorism agents, the H5N1 and SARS outbreaks have shown that in true emergencies, global distribution is feasible.DiscussionAlthough it is pertinent to prepare for future pandemics by stockpiling potential vaccine strains, the H5N1 situation in 2003-and the ongoing H5N1 outbreaks throughout Asia in 2004 (http://www.who.int)-have highlighted the fact that some of the focus of pandemic planning must go into the implementation of technology to rapidly produce vaccines from field isolates.", [["H5N1", "DISEASE", 125, 129], ["SARS", "DISEASE", 134, 138], ["H5N1", "DISEASE", 370, 374], ["shipping", "TREATMENT", 67, 75], ["potential bioterrorism agents", "TREATMENT", 90, 119], ["the H5N1", "PROBLEM", 121, 129], ["SARS outbreaks", "PROBLEM", 134, 148], ["vaccine strains", "PROBLEM", 310, 325], ["the H5N1 situation", "PROBLEM", 327, 345], ["the ongoing H5N1 outbreaks", "PROBLEM", 358, 384], ["pandemic planning", "TREATMENT", 482, 499], ["H5N1", "OBSERVATION", 370, 374]]], ["Although viruses similar to A/Hong Kong/213/03 (H5N1) had been circulating in bird populations, these viruses were antigenically distinct, despite high genetic similarities (Guan Y and Peiris JS, unpublished data).", [["A/Hong Kong/213/03 (H5N1", "ORGANISM", 28, 52], ["A/Hong Kong/213/03 (H5N1", "SPECIES", 28, 52], ["viruses", "PROBLEM", 9, 16], ["H5N1", "PROBLEM", 48, 52], ["these viruses", "PROBLEM", 96, 109], ["viruses", "OBSERVATION", 9, 16], ["viruses", "OBSERVATION", 102, 109]]], ["That the aminoacid differences are on the globular head of haemagglutinin and seem to be responsible for much of the antigenic difference means that even a vaccine previously prepared from genetically similar precursor viruses might not provide adequate protection.", [["head", "ANATOMY", 51, 55], ["aminoacid", "CHEMICAL", 9, 18], ["head", "ORGANISM_SUBDIVISION", 51, 55], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 59, 73], ["haemagglutinin", "PROTEIN", 59, 73], ["the aminoacid differences", "PROBLEM", 5, 30], ["a vaccine", "TREATMENT", 154, 163], ["similar precursor viruses", "PROBLEM", 201, 226], ["aminoacid differences", "OBSERVATION", 9, 30]]], ["We may well be faced with potential pandemic situations in the future and the rapid production of a matched vaccine will be needed-a point again highlighted by H5N1 outbreaks in 2004.", [["H5N1", "ORGANISM", 160, 164], ["potential pandemic situations", "PROBLEM", 26, 55], ["a matched vaccine", "TREATMENT", 98, 115]]], ["Although the reference virus described in this report was prepared from a virus isolated in a similar geographic region and only a year earlier, it shares only limited antigenic cross-reactivity to the 2004 H5N1 viruses.", [["2004 H5N1 viruses", "ORGANISM", 202, 219], ["the reference virus", "PROBLEM", 9, 28], ["a virus", "PROBLEM", 72, 79], ["H5N1 viruses", "OBSERVATION", 207, 219]]], ["Hyperimmune sheep serum samples produced against the purified haemagglutinin of \u232c213/PR8 has at least a six-fold reduced haemagglutination inhibitory activity against A/Vietnam/1203/04 as compared with A/Hong Kong/213/03.", [["serum samples", "ANATOMY", 18, 31], ["sheep", "ORGANISM", 12, 17], ["serum samples", "ORGANISM_SUBSTANCE", 18, 31], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 62, 76], ["\u232c213/PR8", "ORGANISM", 80, 88], ["sheep", "SPECIES", 12, 17], ["sheep", "SPECIES", 12, 17], ["A/Vietnam/1203/04", "SPECIES", 167, 184], ["A/Hong Kong/213/03", "SPECIES", 202, 220], ["Hyperimmune sheep serum samples", "TEST", 0, 31], ["the purified haemagglutinin", "TEST", 49, 76]]], ["As our findings show, we have the technical capabilities to respond rapidly to outbreaks with a safe and stable reference virus, but there is still much to be accomplished before such viruses can be fully used in pandemic and interpandemic influenza vaccine production.DiscussionThe use of reverse genetics introduces a number of new processes into influenza vaccine manufacture that are not encountered with standard reassortment methods.", [["influenza", "DISEASE", 240, 249], ["a safe and stable reference virus", "PROBLEM", 94, 127], ["such viruses", "PROBLEM", 179, 191], ["pandemic", "PROBLEM", 213, 221], ["interpandemic influenza vaccine production", "PROBLEM", 226, 268], ["influenza vaccine manufacture", "TREATMENT", 349, 378]]], ["One of the most obvious is the need for cultured cells.", [["cells", "ANATOMY", 49, 54], ["cells", "CELL", 49, 54], ["cultured cells", "CELL_LINE", 40, 54], ["cultured cells", "PROBLEM", 40, 54], ["most obvious", "OBSERVATION_MODIFIER", 11, 23]]], ["Although both Vero 18 and MDCK 19, 20 cells are in development as substrates for the growth of influenza vaccine, there are additional requirements for the use of cells in reverse genetics.", [["cells", "ANATOMY", 38, 43], ["cells", "ANATOMY", 163, 168], ["influenza", "DISEASE", 95, 104], ["Vero 18", "CELL", 14, 21], ["MDCK 19", "CELL", 26, 33], ["20 cells", "CELL", 35, 43], ["cells", "CELL", 163, 168], ["Vero 18", "CELL_LINE", 14, 21], ["MDCK 19", "CELL_LINE", 26, 33], ["Vero", "TEST", 14, 18], ["MDCK", "TEST", 26, 30], ["influenza vaccine", "TREATMENT", 95, 112]]], ["Unfortunately, the number of suitable cell lines is very small.", [["cell lines", "ANATOMY", 38, 48], ["cell lines", "CELL", 38, 48], ["cell lines", "CELL_LINE", 38, 48], ["suitable cell lines", "TREATMENT", 29, 48], ["suitable cell lines", "OBSERVATION", 29, 48], ["very", "OBSERVATION_MODIFIER", 52, 56], ["small", "OBSERVATION_MODIFIER", 57, 62]]], ["In addition to the regulatory requirements, the choice of cell is also limited by the technology.", [["cell", "ANATOMY", 58, 62], ["cell", "CELL", 58, 62]]], ["The plasmid based reverse-genetics systems 10 necessitates the use of cells from primate origin.", [["plasmid", "ANATOMY", 4, 11], ["cells", "ANATOMY", 70, 75], ["cells", "CELL", 70, 75], ["primate", "ORGANISM", 81, 88]]], ["The Vero cell line is probably the only option currently able to meet both regulatory and technical demands.", [["Vero cell line", "ANATOMY", 4, 18], ["Vero cell line", "CELL", 4, 18], ["Vero cell line", "CELL_LINE", 4, 18], ["The Vero cell line", "TREATMENT", 0, 18], ["Vero cell line", "OBSERVATION", 4, 18]]], ["We have shown that Vero cells can be used to successfully rescue H1N1, H3N2, H6N1, and H9N2 viruses on the PR8 backbone using the 8-plasmid system.", [["Vero cells", "ANATOMY", 19, 29], ["Vero cells", "CELL", 19, 29], ["H3N2, H6N1", "ORGANISM", 71, 81], ["H9N2 viruses", "ORGANISM", 87, 99], ["PR8", "ORGANISM", 107, 110], ["Vero cells", "CELL_LINE", 19, 29], ["H9N2", "SPECIES", 87, 91], ["H6N1", "SPECIES", 77, 81], ["H9N2 viruses", "SPECIES", 87, 99], ["Vero cells", "PROBLEM", 19, 29], ["H1N1", "PROBLEM", 65, 69], ["H3N2", "PROBLEM", 71, 75], ["H6N1", "TREATMENT", 77, 81], ["H9N2 viruses", "TREATMENT", 87, 99], ["the PR8 backbone", "TREATMENT", 103, 119], ["the 8-plasmid system", "TREATMENT", 126, 146], ["Vero cells", "OBSERVATION", 19, 29]]], ["21 Others have demonstrated the suitability of Vero cells for alternative influenza virus reverse-genetics systems.", [["Vero cells", "ANATOMY", 47, 57], ["Vero cells", "CELL", 47, 57], ["influenza virus", "ORGANISM", 74, 89], ["Vero cells", "CELL_LINE", 47, 57], ["Vero cells", "PROBLEM", 47, 57], ["alternative influenza virus", "TREATMENT", 62, 89]]], ["10 Although cultures of Vero cells are easily obtained, only cells from fully tested and licensed cell banks are likely to be acceptable for vaccine manufacture.", [["cultures", "ANATOMY", 12, 20], ["Vero cells", "ANATOMY", 24, 34], ["cells", "ANATOMY", 61, 66], ["cell", "ANATOMY", 98, 102], ["Vero cells", "CELL", 24, 34], ["cells", "CELL", 61, 66], ["cell", "CELL", 98, 102], ["Vero cells", "CELL_LINE", 24, 34], ["Vero", "SPECIES", 24, 28], ["cultures of Vero cells", "TEST", 12, 34], ["licensed cell banks", "TEST", 89, 108], ["vaccine manufacture", "TREATMENT", 141, 160], ["likely to be", "UNCERTAINTY", 113, 125]]], ["This issue must be acknowledged and access to such cells must be incorporated as part of future pandemic plans.DiscussionThat future threats of influenza pandemics will be addressed by the use of the technology described in this report seems inevitable.", [["cells", "ANATOMY", 51, 56], ["influenza pandemics", "DISEASE", 144, 163], ["cells", "CELL", 51, 56], ["future pandemic plans", "TREATMENT", 89, 110], ["influenza pandemics", "PROBLEM", 144, 163]]], ["Despite the presence of low pathogenic surrogate strains, the recent human death from influenza-like illness caused by highly pathogenic H7N7 virus in the Netherlands 22 reinforces the fact that future outbreaks will probably occur in which this reversegenetics technology provides the logical-and, possibly, the only-way to respond rapidly and effectively.", [["death", "DISEASE", 75, 80], ["influenza-like illness", "DISEASE", 86, 108], ["human", "ORGANISM", 69, 74], ["influenza-like illness", "ORGANISM", 86, 108], ["highly pathogenic H7N7 virus", "ORGANISM", 119, 147], ["human", "SPECIES", 69, 74], ["H7N7 virus", "SPECIES", 137, 147], ["human", "SPECIES", 69, 74], ["H7N7 virus", "SPECIES", 137, 147], ["low pathogenic surrogate strains", "PROBLEM", 24, 56], ["the recent human death", "PROBLEM", 58, 80], ["influenza", "PROBLEM", 86, 95], ["highly pathogenic H7N7 virus", "PROBLEM", 119, 147], ["low pathogenic", "OBSERVATION_MODIFIER", 24, 38], ["surrogate strains", "OBSERVATION", 39, 56], ["pathogenic", "OBSERVATION_MODIFIER", 126, 136], ["H7N7 virus", "OBSERVATION", 137, 147]]], ["Although our response to the outbreak of H5N1 influenza in 2003 has shown that current scientific capabilities are sufficient to respond to the threat, there are still legal and infrastructural barriers to be overcome.", [["influenza", "DISEASE", 46, 55], ["H5N1 influenza", "ORGANISM", 41, 55], ["H5N1 influenza", "SPECIES", 41, 55], ["H5N1 influenza", "PROBLEM", 41, 55]]], ["23 These barriers include licensing and intellectual property issues surrounding what is, essentially, a genetically modified organism.", [["licensing and intellectual property issues", "PROBLEM", 26, 68], ["a genetically modified organism", "PROBLEM", 103, 134]]], ["Yet, these difficulties are not insurmountable and pandemic scares such as the 2003 and ongoing 2004 H5N1 outbreaks are forcing commercial and regulatory parties to address these issues with some urgency.", [["H5N1", "DISEASE", 101, 105], ["insurmountable", "PROBLEM", 32, 46], ["pandemic scares", "PROBLEM", 51, 66], ["these issues", "PROBLEM", 173, 185], ["some urgency", "PROBLEM", 191, 203]]], ["With the development of the 2003 H5N1 vaccine reference virus, and ongoing attempts to create the same for the 2004 virus, the challenge in responding to a threat of an influenza pandemic must now be supported by the largescale manufacture of the vaccine and by clinical trials of a new vaccine manipulated by reverse genetics.ContributorsR J Webby, D R Perez, J S Coleman, J H Knight, E I Tuomanen, R G Webster designed the study; R J Webby did much of the construction of the vaccine seed virus; D R Perez developed and constructed plasmid templates; Y Guan and J S Peiris characterised and isolated the initial H5N1 virus; J E Rehg participated in the design and analysis of animal safety testing of the candidate H5N1 vaccine seed virus; E A Govorkova participated in the safety testing of the candidate H5N1 vaccine seed virus; L R McClain-Moss participated in the preparation of GMP documentation of the process and was involved in the reconstitution of the vaccine seed virus.", [["influenza", "DISEASE", 169, 178], ["GMP", "CHEMICAL", 885, 888], ["GMP", "CHEMICAL", 885, 888], ["2003 H5N1", "ORGANISM", 28, 37], ["H5N1", "ORGANISM", 717, 721], ["H5N1", "ORGANISM", 808, 812], ["GMP", "SIMPLE_CHEMICAL", 885, 888], ["seed virus", "ORGANISM", 972, 982], ["H5N1 virus", "SPECIES", 614, 624], ["H5N1 vaccine seed virus", "SPECIES", 717, 740], ["H5N1 vaccine seed virus", "SPECIES", 808, 831], ["H5N1 virus", "SPECIES", 614, 624], ["H5N1 vaccine seed virus", "SPECIES", 717, 740], ["E A Govorkova", "SPECIES", 742, 755], ["the 2003 H5N1 vaccine reference virus", "TREATMENT", 24, 61], ["an influenza pandemic", "PROBLEM", 166, 187], ["the vaccine", "TREATMENT", 243, 254], ["a new vaccine", "TREATMENT", 281, 294], ["the study", "TEST", 421, 430], ["the vaccine seed virus", "TREATMENT", 474, 496], ["D R Perez", "TREATMENT", 498, 507], ["constructed plasmid templates", "TREATMENT", 522, 551], ["the initial H5N1 virus", "PROBLEM", 602, 624], ["animal safety testing", "TEST", 678, 699], ["H5N1 vaccine", "TREATMENT", 717, 729], ["the safety testing", "TEST", 772, 790], ["H5N1 vaccine", "TREATMENT", 808, 820], ["L R McClain", "TREATMENT", 833, 844], ["the vaccine seed virus", "TREATMENT", 960, 982], ["influenza", "OBSERVATION", 169, 178]]]], "1f3611b58fccf13a8080f644988cf1f1cf137291": [["IntroductionHuman adenovirus (HAdV) is the most common cause of infection to the ocular surface, accounting for up to 75% of conjunctivitis cases.", [["ocular surface", "ANATOMY", 81, 95], ["infection to the ocular surface", "DISEASE", 64, 95], ["conjunctivitis", "DISEASE", 125, 139], ["IntroductionHuman adenovirus", "ORGANISM", 0, 28], ["HAdV", "ORGANISM", 30, 34], ["ocular surface", "MULTI-TISSUE_STRUCTURE", 81, 95], ["HAdV", "SPECIES", 30, 34], ["IntroductionHuman adenovirus (HAdV", "PROBLEM", 0, 34], ["infection", "PROBLEM", 64, 73], ["conjunctivitis cases", "PROBLEM", 125, 145], ["most common", "OBSERVATION_MODIFIER", 43, 54], ["infection", "OBSERVATION", 64, 73], ["ocular surface", "ANATOMY", 81, 95], ["conjunctivitis", "OBSERVATION", 125, 139]]], ["1 The most common presentation is pharyngoconjunctival fever (PCF), which often occurs in children and manifests clinically with fever, pharyngitis, rhinitis, follicular conjunctivitis, and regional lymphoid hyperplasia.", [["pharyngoconjunctival", "ANATOMY", 34, 54], ["follicular", "ANATOMY", 159, 169], ["lymphoid", "ANATOMY", 199, 207], ["pharyngoconjunctival fever", "DISEASE", 34, 60], ["PCF", "DISEASE", 62, 65], ["fever", "DISEASE", 129, 134], ["pharyngitis", "DISEASE", 136, 147], ["rhinitis", "DISEASE", 149, 157], ["follicular conjunctivitis", "DISEASE", 159, 184], ["lymphoid hyperplasia", "DISEASE", 199, 219], ["children", "ORGANISM", 90, 98], ["lymphoid hyperplasia", "PATHOLOGICAL_FORMATION", 199, 219], ["children", "SPECIES", 90, 98], ["pharyngoconjunctival fever (PCF)", "PROBLEM", 34, 66], ["fever", "PROBLEM", 129, 134], ["pharyngitis", "PROBLEM", 136, 147], ["rhinitis", "PROBLEM", 149, 157], ["follicular conjunctivitis", "PROBLEM", 159, 184], ["regional lymphoid hyperplasia", "PROBLEM", 190, 219], ["most common", "OBSERVATION_MODIFIER", 6, 17], ["pharyngoconjunctival", "OBSERVATION_MODIFIER", 34, 54], ["fever", "OBSERVATION", 55, 60], ["pharyngitis", "OBSERVATION", 136, 147], ["rhinitis", "OBSERVATION", 149, 157], ["follicular conjunctivitis", "OBSERVATION", 159, 184], ["regional lymphoid hyperplasia", "OBSERVATION", 190, 219]]], ["2 Epidemic keratoconjunctivitis (EKC) is the most severe ocular form and is distinguished by its ability to invade the corneal epithelium, ranging in presentation from a keratitis to persistent and recurrent subepithelial infiltrates (SEIs).", [["ocular", "ANATOMY", 57, 63], ["corneal epithelium", "ANATOMY", 119, 137], ["subepithelial infiltrates", "ANATOMY", 208, 233], ["keratoconjunctivitis", "DISEASE", 11, 31], ["EKC", "DISEASE", 33, 36], ["keratitis", "DISEASE", 170, 179], ["SEIs", "DISEASE", 235, 239], ["corneal epithelium", "TISSUE", 119, 137], ["subepithelial infiltrates", "PATHOLOGICAL_FORMATION", 208, 233], ["Epidemic keratoconjunctivitis", "PROBLEM", 2, 31], ["a keratitis", "PROBLEM", 168, 179], ["persistent and recurrent subepithelial infiltrates", "PROBLEM", 183, 233], ["Epidemic", "OBSERVATION_MODIFIER", 2, 10], ["keratoconjunctivitis", "OBSERVATION", 11, 31], ["most severe", "OBSERVATION_MODIFIER", 45, 56], ["corneal epithelium", "ANATOMY", 119, 137], ["ranging", "OBSERVATION_MODIFIER", 139, 146], ["keratitis", "OBSERVATION", 170, 179], ["persistent", "OBSERVATION_MODIFIER", 183, 193], ["recurrent", "OBSERVATION_MODIFIER", 198, 207], ["subepithelial", "OBSERVATION_MODIFIER", 208, 221], ["infiltrates", "OBSERVATION", 222, 233]]], ["HAdV is highly contagious due to its unique structure and ability to evade the normal host's immune system.", [["HAdV", "DISEASE", 0, 4], ["HAdV", "ORGANISM", 0, 4], ["immune system", "ANATOMICAL_SYSTEM", 93, 106], ["HAdV", "PROBLEM", 0, 4], ["normal host", "OBSERVATION", 79, 90]]], ["It is distinguished from other types of conjunctivitis in that it often involves the cornea, with potentially devastating visual complications.", [["cornea", "ANATOMY", 85, 91], ["conjunctivitis", "DISEASE", 40, 54], ["cornea", "ORGAN", 85, 91], ["conjunctivitis", "PROBLEM", 40, 54], ["potentially devastating visual complications", "PROBLEM", 98, 142], ["conjunctivitis", "OBSERVATION", 40, 54], ["cornea", "ANATOMY", 85, 91]]], ["These features contribute to a heavy economic burden and necessitate the establishment of a standard treatment protocol.", [["a heavy economic burden", "PROBLEM", 29, 52], ["a standard treatment protocol", "TREATMENT", 90, 119], ["heavy", "OBSERVATION_MODIFIER", 31, 36]]], ["1 In addition to the potential ocular manifestations of this virus, HAdV infections have the propensity to manifest systemically, in cases such as respiratory, urinary, and gastrointestinal tract (GIT) infections.", [["ocular", "ANATOMY", 31, 37], ["respiratory", "ANATOMY", 147, 158], ["urinary", "ANATOMY", 160, 167], ["gastrointestinal tract", "ANATOMY", 173, 195], ["GIT", "ANATOMY", 197, 200], ["HAdV infections", "DISEASE", 68, 83], ["respiratory, urinary, and gastrointestinal tract (GIT) infections", "DISEASE", 147, 212], ["HAdV", "ORGANISM", 68, 72], ["urinary", "ORGANISM_SUBDIVISION", 160, 167], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 173, 195], ["GIT", "ORGANISM_SUBDIVISION", 197, 200], ["this virus", "PROBLEM", 56, 66], ["HAdV infections", "PROBLEM", 68, 83], ["respiratory, urinary, and gastrointestinal tract (GIT) infections", "PROBLEM", 147, 212], ["urinary", "ANATOMY", 160, 167], ["gastrointestinal tract", "ANATOMY", 173, 195], ["infections", "OBSERVATION", 202, 212]]], ["This variety of presentations can infect a normal, healthy host, and also have an increased risk in immunocompromised individuals.", [["an increased risk in immunocompromised individuals", "PROBLEM", 79, 129], ["normal", "OBSERVATION", 43, 49], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["immunocompromised individuals", "OBSERVATION", 100, 129]]], ["Despite the detrimental effect that HAdV infections pose, there has yet to be an FDA-approved drug to treat these conditions, making management difficult.", [["HAdV infections", "DISEASE", 36, 51], ["HAdV", "ORGANISM", 36, 40], ["HAdV infections", "PROBLEM", 36, 51], ["these conditions", "PROBLEM", 108, 124], ["infections", "OBSERVATION", 41, 51]]], ["Even following the active phase of the disease, viral persistence and reactivation may occur.", [["the disease", "PROBLEM", 35, 46], ["viral persistence", "PROBLEM", 48, 65], ["reactivation", "PROBLEM", 70, 82], ["disease", "OBSERVATION", 39, 46], ["viral persistence", "OBSERVATION", 48, 65]]], ["Oral and topical antivirals have been considered as offlabel management solutions, but problems with efficacy, bioavailability, and therapeutic profiles have limited their use.", [["Oral", "ANATOMY", 0, 4], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["Oral and topical antivirals", "TREATMENT", 0, 27], ["offlabel management solutions", "TREATMENT", 52, 81]]], ["With regards to EKC, topical disinfection during active cases as well as treatment of corneal sequelae using corticosteroids and immunosuppressive agents show promise.", [["corneal", "ANATOMY", 86, 93], ["EKC", "CHEMICAL", 16, 19], ["corneal sequelae", "DISEASE", 86, 102], ["corneal", "MULTI-TISSUE_STRUCTURE", 86, 93], ["EKC", "PROBLEM", 16, 19], ["topical disinfection", "TREATMENT", 21, 41], ["active cases", "TREATMENT", 49, 61], ["corneal sequelae", "PROBLEM", 86, 102], ["corticosteroids", "TREATMENT", 109, 124], ["immunosuppressive agents", "TREATMENT", 129, 153], ["corneal", "ANATOMY", 86, 93]]], ["This review will focus on how persistence and dissemination of HAdV poses a significant challenge to the management of adenoviral keratoconjunctivitis.", [["HAdV", "DISEASE", 63, 67], ["adenoviral keratoconjunctivitis", "DISEASE", 119, 150], ["HAdV", "ORGANISM", 63, 67], ["adenoviral", "ORGANISM", 119, 129], ["adenoviral", "SPECIES", 119, 129], ["HAdV", "PROBLEM", 63, 67], ["the management", "TREATMENT", 101, 115], ["adenoviral keratoconjunctivitis", "PROBLEM", 119, 150], ["adenoviral keratoconjunctivitis", "OBSERVATION", 119, 150]]], ["Furthermore, current and future trends in prophylactic and therapeutic modalities for adenoviral keratoconjunctivitis will be discussed.VirologyHAdV belongs to the genus Mastadenovirus and family Adenoviridae.", [["adenoviral keratoconjunctivitis", "DISEASE", 86, 117], ["VirologyHAdV", "CHEMICAL", 136, 148], ["adenoviral", "ORGANISM", 86, 96], ["VirologyHAdV", "GENE_OR_GENE_PRODUCT", 136, 148], ["VirologyHAdV", "PROTEIN", 136, 148], ["adenoviral", "SPECIES", 86, 96], ["VirologyHAdV", "SPECIES", 136, 148], ["prophylactic", "TREATMENT", 42, 54], ["therapeutic modalities", "TREATMENT", 59, 81], ["adenoviral keratoconjunctivitis", "PROBLEM", 86, 117], ["VirologyHAdV", "TREATMENT", 136, 148], ["family Adenoviridae", "TREATMENT", 189, 208]]], ["It is a nonenveloped virus with a linear dsDNA genome and icosahedral capsids.", [["linear dsDNA genome", "DNA", 34, 53], ["a nonenveloped virus", "PROBLEM", 6, 26], ["a linear dsDNA genome", "TREATMENT", 32, 53], ["icosahedral capsids", "TREATMENT", 58, 77], ["nonenveloped", "OBSERVATION_MODIFIER", 8, 20], ["virus", "OBSERVATION", 21, 26], ["dsDNA genome", "OBSERVATION", 41, 53], ["icosahedral capsids", "OBSERVATION", 58, 77]]], ["HAdV consists of 7 groups classified through genomic sequence analysis.", [["HAdV", "ORGANISM", 0, 4], ["HAdV", "PROBLEM", 0, 4], ["genomic sequence analysis", "TEST", 45, 70]]], ["3 Adenoviral-based ocular surface infections are attributed to several subtypes of Group B and D HAdV.", [["ocular surface", "ANATOMY", 19, 33], ["ocular surface infections", "DISEASE", 19, 44], ["Adenoviral", "ORGANISM", 2, 12], ["D HAdV", "ORGANISM", 95, 101], ["Adenoviral-based ocular surface infections", "PROBLEM", 2, 44], ["Group B and D HAdV", "PROBLEM", 83, 101], ["based", "ANATOMY_MODIFIER", 13, 18], ["ocular", "ANATOMY", 19, 25], ["surface", "ANATOMY_MODIFIER", 26, 33], ["infections", "OBSERVATION", 34, 44], ["several subtypes", "OBSERVATION_MODIFIER", 63, 79]]], ["Generally, these viruses bind CD46, a ubiquitously expressed transmembrane protein, to infect the host.", [["transmembrane", "ANATOMY", 61, 74], ["CD46", "GENE_OR_GENE_PRODUCT", 30, 34], ["transmembrane", "CELLULAR_COMPONENT", 61, 74], ["CD46", "PROTEIN", 30, 34], ["ubiquitously expressed transmembrane protein", "PROTEIN", 38, 82]]], ["4,5 Exposure of the host to HAdV is made possible through the interaction between adenoviral fiber protein and primary host cellular receptors such as CD46, sialic acid, and heparin-sulfate proteoglycan, all of which promote the attachment and internalization of HAdV.", [["cellular", "ANATOMY", 124, 132], ["sialic acid", "CHEMICAL", 157, 168], ["heparin", "CHEMICAL", 174, 181], ["sialic acid", "CHEMICAL", 157, 168], ["HAdV", "ORGANISM", 28, 32], ["adenoviral fiber protein", "GENE_OR_GENE_PRODUCT", 82, 106], ["cellular", "CELL", 124, 132], ["CD46", "GENE_OR_GENE_PRODUCT", 151, 155], ["sialic acid", "SIMPLE_CHEMICAL", 157, 168], ["heparin-sulfate proteoglycan", "SIMPLE_CHEMICAL", 174, 202], ["HAdV", "ORGANISM", 263, 267], ["adenoviral fiber protein", "PROTEIN", 82, 106], ["primary host cellular receptors", "PROTEIN", 111, 142], ["CD46", "PROTEIN", 151, 155], ["adenoviral fiber protein", "TREATMENT", 82, 106], ["primary host cellular receptors", "PROBLEM", 111, 142], ["CD46", "TEST", 151, 155], ["sialic acid", "TREATMENT", 157, 168], ["heparin-sulfate proteoglycan", "TREATMENT", 174, 202], ["HAdV", "PROBLEM", 263, 267], ["host cellular receptors", "OBSERVATION", 119, 142]]], ["6, 7 Interactions between the penton base of the virus and vitronectin-binding integrins of the host support internalization and acidification of the endosome, triggering conformational changes to the viral capsid.", [["endosome", "ANATOMY", 150, 158], ["vitronectin-binding integrins", "GENE_OR_GENE_PRODUCT", 59, 88], ["endosome", "CELLULAR_COMPONENT", 150, 158], ["vitronectin", "PROTEIN", 59, 70], ["binding integrins", "PROTEIN", 71, 88], ["viral capsid", "PROTEIN", 201, 213], ["the virus", "TREATMENT", 45, 54], ["vitronectin-binding integrins", "TREATMENT", 59, 88], ["the host support internalization", "TREATMENT", 92, 124], ["acidification of the endosome", "PROBLEM", 129, 158], ["conformational changes", "PROBLEM", 171, 193], ["the viral capsid", "PROBLEM", 197, 213], ["virus", "OBSERVATION", 49, 54], ["viral capsid", "OBSERVATION", 201, 213]]], ["This process culminates in the release of viral DNA genome into the host nucleus, where viral replication occurs.", [["nucleus", "ANATOMY", 73, 80], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["nucleus", "CELLULAR_COMPONENT", 73, 80], ["viral DNA genome", "DNA", 42, 58], ["viral DNA genome into the host nucleus", "PROBLEM", 42, 80], ["viral replication", "PROBLEM", 88, 105], ["viral DNA genome", "OBSERVATION", 42, 58], ["host nucleus", "ANATOMY", 68, 80], ["viral replication", "OBSERVATION", 88, 105]]], ["2, [7] [8] [9] Challenges HAdV causes a lytic infection of the mucoepithelial cells of the conjunctiva and cornea as well as a latent infection of lymphoid and adenoid cells.", [["mucoepithelial cells", "ANATOMY", 63, 83], ["conjunctiva", "ANATOMY", 91, 102], ["cornea", "ANATOMY", 107, 113], ["lymphoid", "ANATOMY", 147, 155], ["adenoid cells", "ANATOMY", 160, 173], ["HAdV", "DISEASE", 26, 30], ["infection", "DISEASE", 46, 55], ["infection of lymphoid and adenoid cells", "DISEASE", 134, 173], ["[7] [8] [9]", "SIMPLE_CHEMICAL", 3, 14], ["HAdV", "ORGANISM", 26, 30], ["mucoepithelial cells", "CELL", 63, 83], ["conjunctiva", "ORGAN", 91, 102], ["cornea", "ORGAN", 107, 113], ["lymphoid", "CELL", 147, 155], ["adenoid cells", "CELL", 160, 173], ["mucoepithelial cells", "CELL_TYPE", 63, 83], ["lymphoid and adenoid cells", "CELL_TYPE", 147, 173], ["a lytic infection of the mucoepithelial cells of the conjunctiva and cornea", "PROBLEM", 38, 113], ["a latent infection of lymphoid and adenoid cells", "PROBLEM", 125, 173], ["lytic", "OBSERVATION_MODIFIER", 40, 45], ["infection", "OBSERVATION", 46, 55], ["mucoepithelial cells", "OBSERVATION", 63, 83], ["conjunctiva", "ANATOMY", 91, 102], ["cornea", "ANATOMY", 107, 113], ["latent", "OBSERVATION_MODIFIER", 127, 133], ["infection", "OBSERVATION", 134, 143], ["lymphoid", "ANATOMY", 147, 155], ["adenoid cells", "OBSERVATION", 160, 173]]], ["10 Members of Groups B and D HAdV cause both GIT and ocular infections.", [["GIT", "ANATOMY", 45, 48], ["ocular", "ANATOMY", 53, 59], ["ocular infections", "DISEASE", 53, 70], ["Groups B", "ORGANISM", 14, 22], ["D HAdV", "ORGANISM", 27, 33], ["GIT", "CANCER", 45, 48], ["ocular", "ORGAN", 53, 59], ["both GIT", "PROBLEM", 40, 48], ["ocular infections", "PROBLEM", 53, 70], ["GIT", "ANATOMY", 45, 48], ["ocular", "ANATOMY", 53, 59], ["infections", "OBSERVATION", 60, 70]]], ["See Table 1 for the subtypes of Group B and D HAdV.", [["D HAdV", "ORGANISM", 44, 50]]], ["11, 12 HAdV type 3, 7, and 21 of Group B can cause keratoconjunctivitis, urinary tract infection, respiratory infection, and GIT infection.", [["urinary tract", "ANATOMY", 73, 86], ["respiratory", "ANATOMY", 98, 109], ["GIT", "ANATOMY", 125, 128], ["keratoconjunctivitis", "DISEASE", 51, 71], ["urinary tract infection", "DISEASE", 73, 96], ["respiratory infection", "DISEASE", 98, 119], ["GIT infection", "DISEASE", 125, 138], ["urinary tract", "ORGANISM_SUBDIVISION", 73, 86], ["GIT", "ORGANISM_SUBDIVISION", 125, 128], ["keratoconjunctivitis", "PROBLEM", 51, 71], ["urinary tract infection", "PROBLEM", 73, 96], ["respiratory infection", "PROBLEM", 98, 119], ["GIT infection", "PROBLEM", 125, 138], ["keratoconjunctivitis", "OBSERVATION", 51, 71], ["urinary tract", "ANATOMY", 73, 86], ["infection", "OBSERVATION", 87, 96], ["respiratory", "ANATOMY", 98, 109], ["infection", "OBSERVATION", 110, 119], ["GIT", "ANATOMY", 125, 128], ["infection", "OBSERVATION", 129, 138]]], ["Group D HAdV can also cause both ocular and GIT infection.", [["ocular", "ANATOMY", 33, 39], ["GIT", "ANATOMY", 44, 47], ["ocular and GIT infection", "DISEASE", 33, 57], ["HAdV", "ORGANISM", 8, 12], ["GIT", "ORGAN", 44, 47], ["Group D HAdV", "PROBLEM", 0, 12], ["both ocular and GIT infection", "PROBLEM", 28, 57], ["ocular", "ANATOMY", 33, 39], ["GIT", "ANATOMY", 44, 47], ["infection", "OBSERVATION", 48, 57]]], ["Some group B HAdV subtypes infect the respiratory tract.", [["respiratory tract", "ANATOMY", 38, 55], ["B HAdV", "ORGANISM", 11, 17], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["Some group B HAdV subtypes infect the respiratory tract", "PROBLEM", 0, 55], ["group B", "OBSERVATION_MODIFIER", 5, 12], ["HAdV subtypes", "OBSERVATION_MODIFIER", 13, 26], ["infect", "OBSERVATION", 27, 33], ["respiratory tract", "ANATOMY", 38, 55]]], ["Group B HAdV including type 3, 7, 14, and 21 have been associated with acute respiratory distress (ARD) outbreaks.", [["respiratory", "ANATOMY", 77, 88], ["acute respiratory distress", "DISEASE", 71, 97], ["ARD", "DISEASE", 99, 102], ["Group B HAdV", "ORGANISM", 0, 12], ["type 3", "GENE_OR_GENE_PRODUCT", 23, 29], ["acute respiratory distress (ARD) outbreaks", "PROBLEM", 71, 113], ["HAdV", "OBSERVATION", 8, 12], ["associated with", "UNCERTAINTY", 55, 70], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory", "ANATOMY", 77, 88], ["distress", "OBSERVATION", 89, 97]]], ["2, 12 HAdV types that cause ARD are transmitted through aerosolized droplets.", [["ARD", "DISEASE", 28, 31], ["HAdV", "ORGANISM", 6, 10], ["ARD", "PROBLEM", 28, 31], ["aerosolized droplets", "TREATMENT", 56, 76], ["ARD", "OBSERVATION", 28, 31], ["aerosolized droplets", "OBSERVATION", 56, 76]]], ["It is important to note that both respiratory droplets and the fecal-oral transmission route from individuals with acute adenoviral infection, or even post-infection adenoviral shedding, play an important role in the transmission dynamics of HAdV infections.", [["respiratory droplets", "ANATOMY", 34, 54], ["fecal", "ANATOMY", 63, 68], ["oral", "ANATOMY", 69, 73], ["adenoviral infection", "DISEASE", 121, 141], ["infection", "DISEASE", 156, 165], ["HAdV infections", "DISEASE", 242, 257], ["fecal", "ORGANISM_SUBDIVISION", 63, 68], ["oral", "ORGANISM_SUBDIVISION", 69, 73], ["adenoviral", "ORGANISM", 121, 131], ["adenoviral", "ORGANISM", 166, 176], ["HAdV", "ORGANISM", 242, 246], ["adenoviral", "SPECIES", 121, 131], ["adenoviral", "SPECIES", 166, 176], ["HAdV", "SPECIES", 242, 246], ["both respiratory droplets", "PROBLEM", 29, 54], ["acute adenoviral infection", "PROBLEM", 115, 141], ["post-infection adenoviral shedding", "PROBLEM", 151, 185], ["HAdV infections", "PROBLEM", 242, 257], ["fecal", "ANATOMY", 63, 68], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["adenoviral", "ANATOMY", 121, 131], ["infection", "OBSERVATION", 132, 141], ["infection", "OBSERVATION", 156, 165], ["infections", "OBSERVATION", 247, 257]]], ["2, 13 Persistent HAdV secretions in the tears may also occur even years following the resolution of acute ocular infection.", [["secretions", "ANATOMY", 22, 32], ["tears", "ANATOMY", 40, 45], ["ocular", "ANATOMY", 106, 112], ["ocular infection", "DISEASE", 106, 122], ["HAdV", "ORGANISM", 17, 21], ["tears", "PATHOLOGICAL_FORMATION", 40, 45], ["ocular", "ORGAN", 106, 112], ["Persistent HAdV secretions in the tears", "PROBLEM", 6, 45], ["acute ocular infection", "PROBLEM", 100, 122], ["Persistent", "OBSERVATION_MODIFIER", 6, 16], ["HAdV", "OBSERVATION_MODIFIER", 17, 21], ["secretions", "OBSERVATION", 22, 32], ["tears", "OBSERVATION", 40, 45], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["ocular", "ANATOMY", 106, 112], ["infection", "OBSERVATION", 113, 122]]], ["T cells in tonsillar and adenoid lymphoid tissue serve as reservoirs for harboring HAdV, making it possible to develop latent adenoviral infections.", [["T cells", "ANATOMY", 0, 7], ["tonsillar", "ANATOMY", 11, 20], ["adenoid lymphoid tissue", "ANATOMY", 25, 48], ["adenoviral infections", "DISEASE", 126, 147], ["T cells", "CELL", 0, 7], ["tonsillar", "TISSUE", 11, 20], ["adenoid lymphoid tissue", "TISSUE", 25, 48], ["HAdV", "ORGANISM", 83, 87], ["adenoviral", "ORGANISM", 126, 136], ["T cells", "CELL_TYPE", 0, 7], ["HAdV", "SPECIES", 83, 87], ["adenoviral", "SPECIES", 126, 136], ["T cells in tonsillar and adenoid lymphoid tissue", "PROBLEM", 0, 48], ["harboring HAdV", "PROBLEM", 73, 87], ["latent adenoviral infections", "PROBLEM", 119, 147], ["tonsillar", "ANATOMY", 11, 20], ["adenoid lymphoid tissue", "OBSERVATION", 25, 48], ["latent", "OBSERVATION_MODIFIER", 119, 125], ["adenoviral", "OBSERVATION_MODIFIER", 126, 136], ["infections", "OBSERVATION", 137, 147]]], ["3, 13, 14 Reactivation of persistent latent adenovirus in the host is likely facilitated through the blockade of types I and II interferon (IFN) response that is required to inhibit expression of the HAdV E1A gene.", [["adenovirus", "ORGANISM", 44, 54], ["types I and II interferon", "GENE_OR_GENE_PRODUCT", 113, 138], ["IFN", "GENE_OR_GENE_PRODUCT", 140, 143], ["HAdV", "ORGANISM", 200, 204], ["E1A", "GENE_OR_GENE_PRODUCT", 205, 208], ["IFN", "PROTEIN", 140, 143], ["HAdV E1A gene", "DNA", 200, 213], ["persistent latent adenovirus in the host", "PROBLEM", 26, 66], ["II interferon (IFN)", "TREATMENT", 125, 144], ["persistent", "OBSERVATION_MODIFIER", 26, 36], ["latent", "OBSERVATION_MODIFIER", 37, 43], ["adenovirus", "OBSERVATION", 44, 54], ["HAdV E1A", "OBSERVATION", 200, 208]]], ["3 Immunosuppressive steroid therapy can suppress the production of cytokines including TNF-alpha, type I IFN, and type II IFN, as well as depleted T cells and NK cells.", [["T cells", "ANATOMY", 147, 154], ["NK cells", "ANATOMY", 159, 167], ["steroid", "CHEMICAL", 20, 27], ["steroid", "CHEMICAL", 20, 27], ["steroid", "SIMPLE_CHEMICAL", 20, 27], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 87, 96], ["type I IFN", "GENE_OR_GENE_PRODUCT", 98, 108], ["type II IFN", "GENE_OR_GENE_PRODUCT", 114, 125], ["T cells", "CELL", 147, 154], ["NK cells", "CELL", 159, 167], ["cytokines", "PROTEIN", 67, 76], ["TNF-alpha", "PROTEIN", 87, 96], ["type I IFN", "PROTEIN", 98, 108], ["type II IFN", "PROTEIN", 114, 125], ["depleted T cells", "CELL_TYPE", 138, 154], ["NK cells", "CELL_TYPE", 159, 167], ["Immunosuppressive steroid therapy", "TREATMENT", 2, 35], ["cytokines", "PROBLEM", 67, 76], ["TNF", "TEST", 87, 90], ["alpha", "PROBLEM", 91, 96], ["type I IFN", "PROBLEM", 98, 108], ["type II IFN", "PROBLEM", 114, 125], ["depleted T cells", "PROBLEM", 138, 154], ["NK cells", "PROBLEM", 159, 167], ["NK cells", "OBSERVATION", 159, 167]]], ["3, 15, 16 This inadvertently reduces the secretion of antiviral cytokines that play a major role in inhibiting viral replication.", [["3, 15, 16", "CHEMICAL", 0, 9], ["antiviral cytokines", "PROTEIN", 54, 73], ["antiviral cytokines", "TREATMENT", 54, 73], ["viral replication", "TREATMENT", 111, 128]]], ["Inhibition of the IFN response allows for expression of the HAdV E1A gene, which results in reactivation and replication of HAdV DNA in epithelial cell associated with latently infected lymphoid tissue and consequential dissemination of HAdV.", [["epithelial cell", "ANATOMY", 136, 151], ["lymphoid tissue", "ANATOMY", 186, 201], ["latently infected lymphoid tissue", "DISEASE", 168, 201], ["IFN", "GENE_OR_GENE_PRODUCT", 18, 21], ["HAdV", "ORGANISM", 60, 64], ["E1A", "GENE_OR_GENE_PRODUCT", 65, 68], ["HAdV", "ORGANISM", 124, 128], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["epithelial cell", "CELL", 136, 151], ["lymphoid tissue", "TISSUE", 186, 201], ["HAdV", "ORGANISM", 237, 241], ["IFN", "PROTEIN", 18, 21], ["HAdV E1A gene", "DNA", 60, 73], ["HAdV DNA", "DNA", 124, 132], ["epithelial cell", "CELL_TYPE", 136, 151], ["HAdV", "SPECIES", 124, 128], ["the HAdV E1A gene", "TREATMENT", 56, 73], ["HAdV DNA", "PROBLEM", 124, 132], ["epithelial cell", "PROBLEM", 136, 151], ["latently infected lymphoid tissue", "PROBLEM", 168, 201], ["HAdV", "PROBLEM", 237, 241], ["HAdV DNA", "OBSERVATION", 124, 132], ["epithelial cell", "OBSERVATION", 136, 151], ["latently", "OBSERVATION_MODIFIER", 168, 176], ["infected lymphoid tissue", "OBSERVATION", 177, 201]]], ["3 Thus, immunosuppression could facilitate dissemination of adenovirus into the community since subclinical adenoviral infection of tonsillar and adenoid lymphoid tissue serve as a source of transmitting adenoviruses, particularly in immunocompromised children with no prior exposure and immunity to a particular strain of adenovirus.", [["tonsillar", "ANATOMY", 132, 141], ["adenoid lymphoid tissue", "ANATOMY", 146, 169], ["adenoviral infection", "DISEASE", 108, 128], ["adenovirus", "ORGANISM", 60, 70], ["adenoviral", "ORGANISM", 108, 118], ["tonsillar", "CANCER", 132, 141], ["adenoid lymphoid tissue", "TISSUE", 146, 169], ["adenoviruses", "ORGANISM", 204, 216], ["children", "ORGANISM", 252, 260], ["adenovirus", "ORGANISM", 323, 333], ["children", "SPECIES", 252, 260], ["adenovirus", "SPECIES", 60, 70], ["adenoviral", "SPECIES", 108, 118], ["adenovirus", "SPECIES", 323, 333], ["immunosuppression", "TREATMENT", 8, 25], ["adenovirus", "PROBLEM", 60, 70], ["subclinical adenoviral infection of tonsillar and adenoid lymphoid tissue", "PROBLEM", 96, 169], ["transmitting adenoviruses", "PROBLEM", 191, 216], ["a particular strain of adenovirus", "PROBLEM", 300, 333], ["adenoviral", "ANATOMY", 108, 118], ["infection", "OBSERVATION", 119, 128], ["tonsillar", "ANATOMY", 132, 141], ["adenoid lymphoid tissue", "OBSERVATION", 146, 169]]], ["17 Additionally, asymptomatic passage of adenovirus in the stool of patients with previous adenoviral GIT infection can also occur.", [["stool", "ANATOMY", 59, 64], ["GIT", "ANATOMY", 102, 105], ["adenoviral GIT infection", "DISEASE", 91, 115], ["adenovirus", "ORGANISM", 41, 51], ["stool", "ORGANISM_SUBSTANCE", 59, 64], ["patients", "ORGANISM", 68, 76], ["adenoviral", "ORGANISM", 91, 101], ["GIT", "ORGANISM", 102, 105], ["patients", "SPECIES", 68, 76], ["adenovirus", "SPECIES", 41, 51], ["adenoviral", "SPECIES", 91, 101], ["asymptomatic passage of adenovirus", "PROBLEM", 17, 51], ["previous adenoviral GIT infection", "PROBLEM", 82, 115], ["asymptomatic", "OBSERVATION_MODIFIER", 17, 29], ["passage", "OBSERVATION_MODIFIER", 30, 37], ["adenovirus", "OBSERVATION", 41, 51], ["stool", "OBSERVATION", 59, 64], ["GIT", "ANATOMY", 102, 105], ["infection", "OBSERVATION", 106, 115]]], ["3, 11 Kosulin et al suggested that latent HAdV infection of the gut lymphoid cell could serve as a source of release of HAdV particles in the community.", [["gut lymphoid cell", "ANATOMY", 64, 81], ["HAdV infection", "DISEASE", 42, 56], ["HAdV", "ORGANISM", 42, 46], ["gut lymphoid cell", "CELL", 64, 81], ["HAdV", "ORGANISM", 120, 124], ["gut lymphoid cell", "CELL_TYPE", 64, 81], ["latent HAdV infection of the gut lymphoid cell", "PROBLEM", 35, 81], ["latent", "OBSERVATION_MODIFIER", 35, 41], ["HAdV", "OBSERVATION_MODIFIER", 42, 46], ["infection", "OBSERVATION", 47, 56], ["gut", "ANATOMY", 64, 67], ["lymphoid cell", "OBSERVATION", 68, 81]]], ["18 Garnett et al demonstrated the asymptomatic persistence of group C adenovirus in human mucosal T lymphocytes or lymphoid tissue following primary adenoviral infection.", [["mucosal T lymphocytes", "ANATOMY", 90, 111], ["lymphoid tissue", "ANATOMY", 115, 130], ["adenoviral infection", "DISEASE", 149, 169], ["adenovirus", "ORGANISM", 70, 80], ["human", "ORGANISM", 84, 89], ["mucosal T lymphocytes", "CELL", 90, 111], ["lymphoid tissue", "TISSUE", 115, 130], ["adenoviral", "ORGANISM", 149, 159], ["human mucosal T lymphocytes", "CELL_TYPE", 84, 111], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["adenoviral", "SPECIES", 149, 159], ["group C adenovirus in human mucosal T lymphocytes", "PROBLEM", 62, 111], ["lymphoid tissue", "PROBLEM", 115, 130], ["primary adenoviral infection", "PROBLEM", 141, 169], ["human mucosal", "ANATOMY", 84, 97], ["T lymphocytes", "OBSERVATION", 98, 111], ["lymphoid tissue", "OBSERVATION", 115, 130], ["adenoviral infection", "OBSERVATION", 149, 169]]], ["17 The stimulation of these adenovirus containing mucosal T-lymphocytes results in reactivation of latent HAdV with consequential leakage of reactivated viruses into intestinal epithelial cells, where adenoviruses undergo replication and subsequent shedding in stool.", [["mucosal T-lymphocytes", "ANATOMY", 50, 71], ["intestinal epithelial cells", "ANATOMY", 166, 193], ["stool", "ANATOMY", 261, 266], ["adenovirus", "ORGANISM", 28, 38], ["mucosal T-lymphocytes", "CELL", 50, 71], ["HAdV", "ORGANISM", 106, 110], ["intestinal epithelial cells", "CELL", 166, 193], ["adenoviruses", "ORGANISM", 201, 213], ["stool", "ORGANISM_SUBSTANCE", 261, 266], ["mucosal T-lymphocytes", "CELL_TYPE", 50, 71], ["intestinal epithelial cells", "CELL_TYPE", 166, 193], ["these adenovirus", "TREATMENT", 22, 38], ["latent HAdV", "PROBLEM", 99, 110], ["consequential leakage of reactivated viruses into intestinal epithelial cells", "PROBLEM", 116, 193], ["adenoviruses", "TREATMENT", 201, 213], ["replication", "TREATMENT", 222, 233], ["subsequent shedding in stool", "PROBLEM", 238, 266], ["mucosal", "ANATOMY", 50, 57], ["latent", "OBSERVATION_MODIFIER", 99, 105], ["leakage", "OBSERVATION_MODIFIER", 130, 137], ["reactivated viruses", "OBSERVATION", 141, 160], ["intestinal epithelial cells", "OBSERVATION", 166, 193], ["stool", "OBSERVATION", 261, 266]]], ["11, 17, [19] [20] [21] This is indicative of persistent subclinical HAdV infection of the gut-associated lymphoid tissue.", [["gut", "ANATOMY", 90, 93], ["lymphoid tissue", "ANATOMY", 105, 120], ["HAdV infection", "DISEASE", 68, 82], ["HAdV", "ORGANISM", 68, 72], ["gut", "ORGANISM_SUBDIVISION", 90, 93], ["lymphoid tissue", "TISSUE", 105, 120], ["persistent subclinical HAdV infection of the gut", "PROBLEM", 45, 93], ["associated lymphoid tissue", "PROBLEM", 94, 120], ["indicative of", "UNCERTAINTY", 31, 44], ["persistent", "OBSERVATION_MODIFIER", 45, 55], ["subclinical", "OBSERVATION_MODIFIER", 56, 67], ["HAdV", "OBSERVATION_MODIFIER", 68, 72], ["infection", "OBSERVATION", 73, 82], ["gut", "ANATOMY", 90, 93], ["lymphoid tissue", "OBSERVATION", 105, 120]]], ["20 Immunocompetent individuals are likely to shed less HAdV into their stool, in contrast to those who are immunocompromised, where significant amounts of HAdV are released.", [["stool", "ANATOMY", 71, 76], ["individuals", "ORGANISM", 19, 30], ["HAdV", "ORGANISM", 55, 59], ["stool", "ORGANISM_SUBSTANCE", 71, 76], ["HAdV", "ORGANISM", 155, 159], ["immunocompromised", "PROBLEM", 107, 124], ["HAdV", "PROBLEM", 155, 159], ["immunocompromised", "OBSERVATION", 107, 124], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["amounts", "OBSERVATION_MODIFIER", 144, 151], ["HAdV", "OBSERVATION", 155, 159]]], ["Immunocompromised individuals are also more likely to have reactivation of HAdV with productive infection of intestinal epithelial cells and consequential extensive viral dissemination in the community.", [["intestinal epithelial cells", "ANATOMY", 109, 136], ["infection", "DISEASE", 96, 105], ["individuals", "ORGANISM", 18, 29], ["HAdV", "ORGANISM", 75, 79], ["intestinal epithelial cells", "CELL", 109, 136], ["intestinal epithelial cells", "CELL_TYPE", 109, 136], ["HAdV", "SPECIES", 75, 79], ["Immunocompromised individuals", "PROBLEM", 0, 29], ["HAdV", "PROBLEM", 75, 79], ["productive infection of intestinal epithelial cells", "PROBLEM", 85, 136], ["consequential extensive viral dissemination in the community", "PROBLEM", 141, 201], ["productive", "OBSERVATION_MODIFIER", 85, 95], ["infection", "OBSERVATION", 96, 105], ["intestinal epithelial cells", "OBSERVATION", 109, 136], ["extensive", "OBSERVATION_MODIFIER", 155, 164], ["viral dissemination", "OBSERVATION", 165, 184]]], ["As such, in the immunocompromised state, reactivation of persistent latent HAdV is an essential cause of HAdV dissemination.", [["HAdV", "DISEASE", 75, 79], ["HAdV", "ORGANISM", 75, 79], ["HAdV", "ORGANISM", 105, 109], ["HAdV", "SPECIES", 75, 79], ["HAdV", "SPECIES", 105, 109], ["persistent latent HAdV", "PROBLEM", 57, 79], ["HAdV dissemination", "PROBLEM", 105, 123], ["persistent", "OBSERVATION_MODIFIER", 57, 67], ["latent", "OBSERVATION_MODIFIER", 68, 74], ["HAdV", "OBSERVATION", 75, 79], ["HAdV", "OBSERVATION_MODIFIER", 105, 109], ["dissemination", "OBSERVATION", 110, 123]]], ["18 These resultant, latent adenoviral infections are considered a significant challenge in managing and containing the virus within the community due to persistent adenoviral shedding and its high propensity of spread via hand-to-eye contact by those contaminated with fecal matter.", [["hand", "ANATOMY", 222, 226], ["eye", "ANATOMY", 230, 233], ["fecal matter", "ANATOMY", 269, 281], ["adenoviral infections", "DISEASE", 27, 48], ["adenoviral", "ORGANISM", 27, 37], ["adenoviral", "ORGANISM", 164, 174], ["fecal", "ORGANISM_SUBDIVISION", 269, 274], ["adenoviral", "SPECIES", 27, 37], ["latent adenoviral infections", "PROBLEM", 20, 48], ["the virus", "PROBLEM", 115, 124], ["persistent adenoviral shedding", "PROBLEM", 153, 183], ["latent", "OBSERVATION_MODIFIER", 20, 26], ["adenoviral infections", "OBSERVATION", 27, 48], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["challenge", "OBSERVATION", 78, 87], ["persistent", "OBSERVATION_MODIFIER", 153, 163], ["adenoviral", "OBSERVATION", 164, 174], ["eye", "ANATOMY", 230, 233], ["fecal matter", "OBSERVATION", 269, 281]]], ["18 Another significant challenge in managing adenoviral infections, particularly in Group D HAdV, is the propensity for this group to cause oculogenital infection.", [["oculogenital", "ANATOMY", 140, 152], ["adenoviral infections", "DISEASE", 45, 66], ["oculogenital infection", "DISEASE", 140, 162], ["adenoviral", "ORGANISM", 45, 55], ["Group D HAdV", "ORGANISM", 84, 96], ["adenoviral", "SPECIES", 45, 55], ["managing adenoviral infections", "PROBLEM", 36, 66], ["oculogenital infection", "PROBLEM", 140, 162], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["adenoviral", "ANATOMY", 45, 55], ["infections", "OBSERVATION", 56, 66], ["infection", "OBSERVATION", 153, 162]]], ["Several published cases have demonstrated that Group D HAdV can be associated with concurrent urethritis and conjunctivitis.", [["urethritis", "DISEASE", 94, 104], ["conjunctivitis", "DISEASE", 109, 123], ["Group D HAdV", "ORGANISM", 47, 59], ["Group D HAdV", "PROBLEM", 47, 59], ["concurrent urethritis", "PROBLEM", 83, 104], ["conjunctivitis", "PROBLEM", 109, 123], ["urethritis", "OBSERVATION", 94, 104], ["conjunctivitis", "OBSERVATION", 109, 123]]], ["[22] [23] [24] [25] [26] HAdV 19 and 37 specifically have been sequestered from genital tracts of young adults with EKC, indicating the possibility of sexual transmission.", [["genital tracts", "ANATOMY", 80, 94], ["[22] [23] [24] [25]", "CHEMICAL", 0, 19], ["EKC", "DISEASE", 116, 119], ["[22] [23] [24] [25] [26] HAdV 19", "SIMPLE_CHEMICAL", 0, 32], ["genital", "ORGANISM_SUBDIVISION", 80, 87], ["HAdV", "TEST", 25, 29], ["genital tracts", "ANATOMY", 80, 94], ["indicating the possibility of", "UNCERTAINTY", 121, 150]]], ["25, 26 Group D HAdV type 37, for example, has been isolated from sexually active men with adenoviral urethritis.", [["adenoviral urethritis", "DISEASE", 90, 111], ["men", "ORGANISM", 81, 84], ["adenoviral", "ORGANISM", 90, 100], ["men", "SPECIES", 81, 84], ["adenoviral urethritis", "PROBLEM", 90, 111], ["urethritis", "OBSERVATION", 101, 111]]], ["24 Additionally, Liddle et al discussed eight cases of individuals presenting with concurrent conjunctivitis and adenoviral urethritis.", [["conjunctivitis", "DISEASE", 94, 108], ["adenoviral urethritis", "DISEASE", 113, 134], ["individuals", "ORGANISM", 55, 66], ["adenoviral", "ORGANISM", 113, 123], ["concurrent conjunctivitis", "PROBLEM", 83, 108], ["adenoviral urethritis", "PROBLEM", 113, 134], ["conjunctivitis", "OBSERVATION", 94, 108], ["adenoviral urethritis", "OBSERVATION", 113, 134]]], ["23 Avolio et al also presented a case of two male patients with HAdV D37 associated urethritis and conjunctivitis, in which one of the spouses contracted adenoviral conjunctivitis via oculogenital contact.", [["HAdV D37", "DISEASE", 64, 72], ["urethritis", "DISEASE", 84, 94], ["conjunctivitis", "DISEASE", 99, 113], ["conjunctivitis", "DISEASE", 165, 179], ["patients", "ORGANISM", 50, 58], ["HAdV", "ORGANISM", 64, 68], ["adenoviral", "ORGANISM", 154, 164], ["patients", "SPECIES", 50, 58], ["HAdV D37 associated urethritis", "PROBLEM", 64, 94], ["conjunctivitis", "PROBLEM", 99, 113], ["adenoviral conjunctivitis", "PROBLEM", 154, 179], ["urethritis", "OBSERVATION", 84, 94], ["conjunctivitis", "OBSERVATION", 99, 113], ["adenoviral", "ANATOMY", 154, 164], ["conjunctivitis", "OBSERVATION", 165, 179]]], ["These cases highlight the importance of testing for the presence of adenovirus in clinical specimens collected from both urethral and conjunctival swab in men presenting with conjunctivitis, dysuria, and scant urethral discharge.", [["specimens", "ANATOMY", 91, 100], ["urethral", "ANATOMY", 121, 129], ["conjunctival swab", "ANATOMY", 134, 151], ["urethral", "ANATOMY", 210, 218], ["conjunctivitis", "DISEASE", 175, 189], ["dysuria", "DISEASE", 191, 198], ["adenovirus", "ORGANISM", 68, 78], ["urethral", "TISSUE", 121, 129], ["conjunctival swab", "TISSUE", 134, 151], ["men", "ORGANISM", 155, 158], ["urethral", "ORGAN", 210, 218], ["men", "SPECIES", 155, 158], ["testing", "TEST", 40, 47], ["adenovirus", "PROBLEM", 68, 78], ["clinical specimens", "TEST", 82, 100], ["conjunctivitis", "PROBLEM", 175, 189], ["dysuria", "PROBLEM", 191, 198], ["scant urethral discharge", "PROBLEM", 204, 228], ["adenovirus", "OBSERVATION", 68, 78], ["both", "ANATOMY_MODIFIER", 116, 120], ["urethral", "ANATOMY", 121, 129], ["conjunctival swab", "ANATOMY", 134, 151], ["conjunctivitis", "OBSERVATION", 175, 189], ["dysuria", "OBSERVATION", 191, 198], ["urethral", "ANATOMY", 210, 218]]], ["22ManagementDue to the aforementioned HAdV characteristics and its interactions with host cells, HAdV has demonstrated a high likelihood of evading the immune response leading to infection.", [["cells", "ANATOMY", 90, 95], ["infection", "DISEASE", 179, 188], ["HAdV", "ORGANISM", 38, 42], ["host cells", "CELL", 85, 95], ["HAdV", "ORGANISM", 97, 101], ["host cells", "CELL_TYPE", 85, 95], ["infection", "PROBLEM", 179, 188], ["infection", "OBSERVATION", 179, 188]]], ["Additional research on its many modes of transmission contributes to the highly contagious nature of HAdV and dissemination into the community.", [["HAdV", "ORGANISM", 101, 105], ["HAdV", "SPECIES", 101, 105], ["HAdV", "PROBLEM", 101, 105], ["HAdV", "OBSERVATION", 101, 105]]], ["Large-scale epidemics lead to high social and economic burdens, making health education in infected patients an invaluable tool to limit spread.", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["Large-scale epidemics", "PROBLEM", 0, 21], ["high social and economic burdens", "PROBLEM", 30, 62], ["-scale", "OBSERVATION_MODIFIER", 5, 11], ["high", "OBSERVATION_MODIFIER", 30, 34], ["social", "OBSERVATION_MODIFIER", 35, 41]]], ["Preventative methods require that patients exercise frequent hand washing with soaps and to keep hands dry, avoiding eye rubbing.", [["hand", "ANATOMY", 61, 65], ["eye", "ANATOMY", 117, 120], ["patients", "ORGANISM", 34, 42], ["hand", "ORGANISM_SUBDIVISION", 61, 65], ["hands", "ORGANISM_SUBDIVISION", 97, 102], ["eye", "ORGAN", 117, 120], ["patients", "SPECIES", 34, 42], ["Preventative methods", "TREATMENT", 0, 20], ["patients exercise frequent hand washing", "TREATMENT", 34, 73], ["soaps", "TREATMENT", 79, 84], ["eye rubbing", "PROBLEM", 117, 128], ["hands", "ANATOMY", 97, 102], ["eye", "ANATOMY", 117, 120], ["rubbing", "OBSERVATION", 121, 128]]], ["Children are to be encouraged to stay home during the infectious phase to limit the spread of disease.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["disease", "PROBLEM", 94, 101]]], ["Contact with infected towels, soap, bedding, door handles, etc. should also be avoided.", [["infected towels", "OBSERVATION", 13, 28]]], ["Following resolution of the virus, bedding, and towels used by the infected individual should be washed thoroughly and exposed under sunshine (solar ultraviolet radiation) to further ensure elimination of the virus.", [["the virus", "PROBLEM", 24, 33], ["towels", "TREATMENT", 48, 54], ["solar ultraviolet radiation", "TREATMENT", 143, 170], ["the virus", "PROBLEM", 205, 214], ["virus", "OBSERVATION", 28, 33], ["infected", "OBSERVATION", 67, 75], ["virus", "OBSERVATION", 209, 214]]], ["27 EKC outbreaks are also commonly spread through ophthalmology clinics, warranting the need to evaluate disinfection procedures for ophthalmic instruments.", [["EKC", "DISEASE", 3, 6], ["disinfection procedures", "TREATMENT", 105, 128], ["ophthalmic instruments", "TREATMENT", 133, 155]]], ["Methods of spread include tonometry probes, tips of contaminated eye drop bottles, and foreign body removal instruments.", [["eye", "ANATOMY", 65, 68], ["body", "ANATOMY", 95, 99], ["eye", "ORGANISM_SUBDIVISION", 65, 68], ["body", "ORGANISM_SUBDIVISION", 95, 99], ["tonometry probes", "TREATMENT", 26, 42], ["contaminated eye drop bottles", "TREATMENT", 52, 81], ["foreign body removal instruments", "TREATMENT", 87, 119], ["tips", "OBSERVATION_MODIFIER", 44, 48], ["eye", "ANATOMY", 65, 68], ["foreign body", "OBSERVATION", 87, 99]]], ["A study comparing the efficacy of hydrogen peroxide disinfection versus alcohol swabs determined that there was a more significant reduction in log growth using hydrogen peroxide.", [["hydrogen peroxide", "CHEMICAL", 34, 51], ["alcohol", "CHEMICAL", 72, 79], ["hydrogen peroxide", "CHEMICAL", 161, 178], ["hydrogen peroxide", "CHEMICAL", 34, 51], ["alcohol", "CHEMICAL", 72, 79], ["hydrogen peroxide", "CHEMICAL", 161, 178], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 34, 51], ["alcohol", "SIMPLE_CHEMICAL", 72, 79], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 161, 178], ["A study", "TEST", 0, 7], ["hydrogen peroxide disinfection", "TREATMENT", 34, 64], ["alcohol swabs", "TEST", 72, 85], ["hydrogen peroxide", "TREATMENT", 161, 178], ["hydrogen peroxide", "OBSERVATION", 34, 51], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["reduction", "OBSERVATION_MODIFIER", 131, 140], ["log growth", "OBSERVATION_MODIFIER", 144, 154]]], ["The use of disposable prisms is also an option, though many times this method is of limited use due to cost.", [["disposable prisms", "TREATMENT", 11, 28]]], ["28, 29 Because of these unique viral characteristics, ubiquity of HAdV, and its potential for epidemic, several treatment modalities have been investigated to establish an effective treatment protocol.", [["HAdV", "ORGANISM", 66, 70], ["HAdV", "PROBLEM", 66, 70], ["epidemic", "PROBLEM", 94, 102], ["several treatment modalities", "TREATMENT", 104, 132], ["an effective treatment protocol", "TREATMENT", 169, 200], ["viral", "OBSERVATION", 31, 36]]], ["However, at this stage, there is no FDA-approved antiviral treatment for HAdV infections.Povidone-Iodine IrrigationThough molecular iodine has long been established as an effective antiseptic agent, its formidable toxicity upon DovePress contact to mucosal surfaces deterred it for use in clinical the clinical setting.", [["mucosal", "ANATOMY", 249, 256], ["HAdV infections", "DISEASE", 73, 88], ["Povidone-Iodine", "CHEMICAL", 89, 104], ["iodine", "CHEMICAL", 132, 138], ["toxicity", "DISEASE", 214, 222], ["DovePress", "CHEMICAL", 228, 237], ["Povidone-Iodine", "CHEMICAL", 89, 104], ["iodine", "CHEMICAL", 132, 138], ["HAdV", "ORGANISM", 73, 77], ["Povidone-Iodine", "SIMPLE_CHEMICAL", 89, 104], ["iodine", "SIMPLE_CHEMICAL", 132, 138], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 249, 265], ["HAdV", "SPECIES", 73, 77], ["FDA", "PROBLEM", 36, 39], ["antiviral treatment", "TREATMENT", 49, 68], ["HAdV infections", "PROBLEM", 73, 88], ["Povidone", "TREATMENT", 89, 97], ["Iodine Irrigation", "TREATMENT", 98, 115], ["molecular iodine", "TREATMENT", 122, 138], ["an effective antiseptic agent", "TREATMENT", 168, 197], ["mucosal surfaces", "TREATMENT", 249, 265], ["no", "UNCERTAINTY", 33, 35], ["infections", "OBSERVATION", 78, 88]]], ["30 However, combining iodine with povidone allowed for this antiseptic to be safely and routinely used in the ophthalmic setting, and has even shown promise in the management of EKC affected individuals.", [["iodine", "CHEMICAL", 22, 28], ["povidone", "CHEMICAL", 34, 42], ["EKC", "DISEASE", 178, 181], ["iodine", "CHEMICAL", 22, 28], ["povidone", "CHEMICAL", 34, 42], ["iodine", "SIMPLE_CHEMICAL", 22, 28], ["povidone", "SIMPLE_CHEMICAL", 34, 42], ["povidone", "TREATMENT", 34, 42], ["this antiseptic", "TREATMENT", 55, 70], ["EKC affected individuals", "PROBLEM", 178, 202]]], ["Povidone-iodine (PVI) is a broad-spectrum microbicide solution, which exists in multiple forms that are easily accessible, and a cost-effective disinfectant agent.", [["Povidone-iodine", "CHEMICAL", 0, 15], ["PVI", "CHEMICAL", 17, 20], ["Povidone-iodine", "CHEMICAL", 0, 15], ["PVI", "CHEMICAL", 17, 20], ["Povidone-iodine", "SIMPLE_CHEMICAL", 0, 15], ["PVI", "SIMPLE_CHEMICAL", 17, 20], ["Povidone", "TREATMENT", 0, 8], ["iodine (PVI", "TREATMENT", 9, 20], ["a broad-spectrum microbicide solution", "TREATMENT", 25, 62], ["a cost-effective disinfectant agent", "TREATMENT", 127, 162]]], ["Since its discovery, it has been routinely utilized in the medical field as an antiseptic agent for laboratory and surgical purposes.", [["an antiseptic agent", "TREATMENT", 76, 95], ["laboratory and surgical purposes", "TEST", 100, 132]]], ["Furthermore, it has found much purpose in the ophthalmic setting as an effective disinfecting solution due to its proven toxicity against viruses, bacteria, parasites, fungi, yeasts, molds, and protozoans.", [["toxicity", "DISEASE", 121, 129], ["an effective disinfecting solution", "TREATMENT", 68, 102], ["its proven toxicity", "PROBLEM", 110, 129], ["viruses", "PROBLEM", 138, 145], ["bacteria", "PROBLEM", 147, 155], ["parasites", "PROBLEM", 157, 166], ["fungi", "PROBLEM", 168, 173], ["yeasts", "PROBLEM", 175, 181], ["protozoans", "PROBLEM", 194, 204]]], ["31 Diluted forms of PVI are commercially sold as Betadine (Alcon Laboratories, Inc., Fort Worth, TX 76134) in 5% and 10% concentrations and can be further weakened as medical use requires.", [["PVI", "CHEMICAL", 20, 23], ["Betadine", "CHEMICAL", 49, 57], ["TX 76134", "CHEMICAL", 97, 105], ["Betadine", "CHEMICAL", 49, 57], ["Betadine", "SIMPLE_CHEMICAL", 49, 57], ["PVI", "TREATMENT", 20, 23], ["Betadine", "TREATMENT", 49, 57], ["TX", "TREATMENT", 97, 99], ["PVI", "OBSERVATION", 20, 23]]], ["It is critical to note that, unlike other antiseptics, PVI does not lose antimicrobial activity with decreased available iodine concentration in solution when a diluent is added.", [["PVI", "CHEMICAL", 55, 58], ["iodine", "CHEMICAL", 121, 127], ["PVI", "CHEMICAL", 55, 58], ["iodine", "CHEMICAL", 121, 127], ["iodine", "SIMPLE_CHEMICAL", 121, 127], ["other antiseptics", "TREATMENT", 36, 53], ["PVI", "TREATMENT", 55, 58], ["decreased available iodine concentration in solution", "TREATMENT", 101, 153], ["a diluent", "TREATMENT", 159, 168]]], ["30 The mode of action requires the oxidation of pathogen nucleotides, amino acids, and proteins, damaging vital bacterial cellular mechanisms.", [["cellular", "ANATOMY", 122, 130], ["amino acids", "CHEMICAL", 70, 81], ["nucleotides", "CHEMICAL", 57, 68], ["amino acids", "CHEMICAL", 70, 81], ["amino acids", "AMINO_ACID", 70, 81], ["cellular", "CELL", 122, 130], ["the oxidation", "TREATMENT", 31, 44], ["pathogen nucleotides", "TREATMENT", 48, 68], ["amino acids", "TREATMENT", 70, 81], ["proteins", "TREATMENT", 87, 95], ["damaging vital bacterial cellular mechanisms", "PROBLEM", 97, 141], ["bacterial cellular mechanisms", "OBSERVATION", 112, 141]]], ["32 Additionally, in vitro investigation indicates that PVI impedes the host's inflammatory response to a viral pathogen by affecting both host and pathogen parameters.", [["PVI", "CHEMICAL", 55, 58], ["vitro investigation", "TEST", 20, 39], ["PVI", "PROBLEM", 55, 58], ["the host's inflammatory response", "PROBLEM", 67, 99], ["a viral pathogen", "PROBLEM", 103, 119], ["PVI", "OBSERVATION", 55, 58]]], ["33 This may give insight into how inoffice PVI irrigation may alleviate inflammatory symptoms associated with EKC.", [["PVI", "CHEMICAL", 43, 46], ["EKC", "CHEMICAL", 110, 113], ["PVI", "CHEMICAL", 43, 46], ["PVI irrigation", "TREATMENT", 43, 57], ["inflammatory symptoms", "PROBLEM", 72, 93], ["EKC", "PROBLEM", 110, 113]]], ["Specific pathogen consequences include inhibition of production and release of exotoxins (such as \u03b1-hemolysin, phospholipase C, and lipase) and suppression of bacterial enzymes (such as elastase and \u00dfglucuronidase).", [["\u03b1-hemolysin", "GENE_OR_GENE_PRODUCT", 98, 109], ["phospholipase C", "GENE_OR_GENE_PRODUCT", 111, 126], ["lipase", "GENE_OR_GENE_PRODUCT", 132, 138], ["bacterial enzymes", "GENE_OR_GENE_PRODUCT", 159, 176], ["elastase", "GENE_OR_GENE_PRODUCT", 186, 194], ["\u00dfglucuronidase", "GENE_OR_GENE_PRODUCT", 199, 213], ["exotoxins", "PROTEIN", 79, 88], ["\u03b1-hemolysin", "PROTEIN", 98, 109], ["phospholipase C", "PROTEIN", 111, 126], ["lipase", "PROTEIN", 132, 138], ["bacterial enzymes", "PROTEIN", 159, 176], ["elastase", "PROTEIN", 186, 194], ["\u00dfglucuronidase", "PROTEIN", 199, 213], ["inhibition of production", "TREATMENT", 39, 63], ["exotoxins", "PROBLEM", 79, 88], ["\u03b1-hemolysin", "TREATMENT", 98, 109], ["phospholipase C", "TEST", 111, 126], ["lipase", "TEST", 132, 138], ["bacterial enzymes", "TEST", 159, 176], ["elastase and \u00dfglucuronidase", "TREATMENT", 186, 213], ["lipase", "ANATOMY", 132, 138]]], ["32 Host factors involve modulation of antioxidant and free radical activity, inhibition of inflammatory effector cells and mediators (such as TNF-\u03b1 and \u00df-galactosidase), inhibiting matrix metalloproteinase production, and enhancing healing signals via activation of T cells and macrophages.", [["inflammatory effector cells", "ANATOMY", 91, 118], ["T cells", "ANATOMY", 266, 273], ["macrophages", "ANATOMY", 278, 289], ["inflammatory effector cells", "CELL", 91, 118], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 142, 147], ["\u00df-galactosidase", "GENE_OR_GENE_PRODUCT", 152, 167], ["matrix metalloproteinase", "GENE_OR_GENE_PRODUCT", 181, 205], ["T cells", "CELL", 266, 273], ["macrophages", "CELL", 278, 289], ["inflammatory effector cells", "CELL_TYPE", 91, 118], ["TNF", "PROTEIN", 142, 145], ["\u00df-galactosidase", "PROTEIN", 152, 167], ["matrix metalloproteinase", "PROTEIN", 181, 205], ["T cells", "CELL_TYPE", 266, 273], ["macrophages", "CELL_TYPE", 278, 289], ["antioxidant", "TREATMENT", 38, 49], ["free radical activity", "TREATMENT", 54, 75], ["inflammatory effector cells", "PROBLEM", 91, 118], ["TNF", "TEST", 142, 145], ["\u00df-galactosidase", "TEST", 152, 167], ["inhibiting matrix metalloproteinase production", "PROBLEM", 170, 216], ["enhancing healing signals", "PROBLEM", 222, 247], ["radical activity", "OBSERVATION", 59, 75], ["inflammatory", "OBSERVATION_MODIFIER", 91, 103], ["enhancing", "OBSERVATION_MODIFIER", 222, 231], ["healing", "OBSERVATION", 232, 239], ["macrophages", "ANATOMY", 278, 289]]], ["32 Globally, PVI characteristics that make it ideal for clinical use include broad antimicrobial spectrum, lack of resistance, ability to penetrate biofilms, low cytotoxicity, suitable tolerability, and overall favorable risk/benefit profile.", [["biofilms", "ANATOMY", 148, 156], ["broad antimicrobial spectrum", "TREATMENT", 77, 105], ["low cytotoxicity", "PROBLEM", 158, 174], ["PVI", "OBSERVATION", 13, 16], ["low cytotoxicity", "OBSERVATION_MODIFIER", 158, 174]]], ["32 Such versatility, ease of access, and ubiquitous use in antisepsis have been further promoted by biochemical characteristics of the compound.", [["antisepsis", "TREATMENT", 59, 69]]], ["The combination of a synthetic carrier homopolymer (2-pyrrolidnone, 1-ethenyl-), which has no innate germicidal ability, and iodine forms PVI.", [["2-pyrrolidnone, 1-ethenyl-)", "CHEMICAL", 52, 79], ["iodine", "CHEMICAL", 125, 131], ["2-pyrrolidnone", "CHEMICAL", 52, 66], ["1-ethenyl-)", "CHEMICAL", 68, 79], ["iodine", "CHEMICAL", 125, 131], ["PVI", "CHEMICAL", 138, 141], ["2-pyrrolidnone", "SIMPLE_CHEMICAL", 52, 66], ["1-ethenyl-)", "SIMPLE_CHEMICAL", 68, 79], ["iodine", "SIMPLE_CHEMICAL", 125, 131], ["a synthetic carrier homopolymer", "TREATMENT", 19, 50], ["pyrrolidnone", "TREATMENT", 54, 66], ["iodine forms PVI", "TREATMENT", 125, 141]]], ["34 In aqueous form, free iodine is released into solution from the PVI complex, which is what provides the microbicidal activity.", [["iodine", "CHEMICAL", 25, 31], ["iodine", "CHEMICAL", 25, 31], ["PVI", "CHEMICAL", 67, 70], ["iodine", "SIMPLE_CHEMICAL", 25, 31], ["PVI", "SIMPLE_CHEMICAL", 67, 70], ["PVI complex", "PROTEIN", 67, 78], ["free iodine", "TREATMENT", 20, 31], ["PVI", "ANATOMY", 67, 70], ["microbicidal activity", "OBSERVATION", 107, 128]]], ["32 Studies have shown that PVI exhibits antimicrobial activity proportional to the concentration of free iodine released in any given solution of specified dilution, regardless of PVI concentration.", [["PVI", "CHEMICAL", 27, 30], ["iodine", "CHEMICAL", 105, 111], ["PVI", "CHEMICAL", 180, 183], ["PVI", "CHEMICAL", 27, 30], ["iodine", "CHEMICAL", 105, 111], ["PVI", "CHEMICAL", 180, 183], ["PVI", "SIMPLE_CHEMICAL", 27, 30], ["iodine", "SIMPLE_CHEMICAL", 105, 111], ["PVI", "SIMPLE_CHEMICAL", 180, 183], ["32 Studies", "TEST", 0, 10], ["PVI", "PROBLEM", 27, 30], ["antimicrobial activity", "PROBLEM", 40, 62], ["free iodine", "TREATMENT", 100, 111], ["specified dilution", "TREATMENT", 146, 164], ["PVI concentration", "TREATMENT", 180, 197], ["PVI", "OBSERVATION", 27, 30], ["antimicrobial activity", "OBSERVATION", 40, 62]]], ["30 In addition to its welldocumented antimicrobial activity, a study examining the virucidal efficacy of 0.01%, 0.1%, 1%, and 10% PVI demonstrated that 0.1% solution was actually the most effective against HAdV 3, as it maximized free iodine concentration.", [["PVI", "CHEMICAL", 130, 133], ["iodine", "CHEMICAL", 235, 241], ["iodine", "CHEMICAL", 235, 241], ["PVI", "SIMPLE_CHEMICAL", 130, 133], ["HAdV", "ORGANISM", 206, 210], ["iodine", "SIMPLE_CHEMICAL", 235, 241], ["a study", "TEST", 61, 68], ["the virucidal efficacy", "TEST", 79, 101], ["10% PVI", "TREATMENT", 126, 133], ["HAdV", "PROBLEM", 206, 210], ["free iodine concentration", "TREATMENT", 230, 255], ["antimicrobial activity", "OBSERVATION", 37, 59]]], ["30 Specifically, PVI formulations have been proven effective against non-enveloped human viruses including HAdV, although, it has been postulated to be adenoviral type dependent.", [["PVI", "CHEMICAL", 17, 20], ["human", "ORGANISM", 83, 88], ["HAdV", "ORGANISM", 107, 111], ["adenoviral", "ORGANISM", 152, 162], ["human", "SPECIES", 83, 88], ["human viruses", "SPECIES", 83, 96], ["HAdV", "SPECIES", 107, 111], ["PVI formulations", "TREATMENT", 17, 33], ["non-enveloped human viruses", "PROBLEM", 69, 96], ["HAdV", "PROBLEM", 107, 111], ["adenoviral type dependent", "PROBLEM", 152, 177], ["viruses", "OBSERVATION", 89, 96], ["postulated to be", "UNCERTAINTY", 135, 151], ["adenoviral type", "OBSERVATION", 152, 167]]], ["35, 36 PVI has been shown to demonstrate virucidal reductions for ocular HAdV types 3, 4, 5, 7, and 8 at 1-5 mins and types 37, and 64 at 15-60 mins for various concentrations.", [["ocular", "ANATOMY", 66, 72], ["PVI", "TREATMENT", 7, 10], ["virucidal reductions", "TREATMENT", 41, 61], ["ocular HAdV types", "PROBLEM", 66, 83], ["virucidal", "OBSERVATION", 41, 50]]], ["36 This may indicate that time of exposure, not concentration of PVI, to disinfection is critical and that virucidal activity for PVI at different concentrations may require temporal consideration when evaluating specific virus types.", [["PVI", "CHEMICAL", 65, 68], ["PVI", "CHEMICAL", 130, 133], ["PVI", "CHEMICAL", 130, 133], ["PVI", "SIMPLE_CHEMICAL", 130, 133], ["PVI", "TREATMENT", 65, 68], ["disinfection", "TREATMENT", 73, 85], ["virucidal activity", "TREATMENT", 107, 125], ["PVI at different concentrations", "TREATMENT", 130, 161], ["specific virus types", "PROBLEM", 213, 233], ["PVI", "OBSERVATION", 65, 68]]], ["Though PVI has been tested in vitro, in animal models, and clinically for its use in disinfection and wound healing for many decades, the use of a PVI irrigation in-office for EKC remains off-label.", [["wound", "ANATOMY", 102, 107], ["PVI", "CHEMICAL", 7, 10], ["PVI", "CHEMICAL", 147, 150], ["EKC", "CHEMICAL", 176, 179], ["PVI", "CHEMICAL", 7, 10], ["PVI", "CHEMICAL", 147, 150], ["wound", "PATHOLOGICAL_FORMATION", 102, 107], ["PVI", "PROBLEM", 7, 10], ["disinfection", "TREATMENT", 85, 97], ["wound healing", "PROBLEM", 102, 115], ["a PVI irrigation", "TREATMENT", 145, 161], ["EKC", "PROBLEM", 176, 179], ["PVI", "OBSERVATION", 7, 10], ["wound", "ANATOMY", 102, 107], ["healing", "OBSERVATION_MODIFIER", 108, 115]]], ["32 The theory behind in-office PVI irrigation is to reduce viral load on the ocular surface and to decrease viral shedding.", [["ocular surface", "ANATOMY", 77, 91], ["PVI", "CHEMICAL", 31, 34], ["ocular surface", "MULTI-TISSUE_STRUCTURE", 77, 91], ["PVI irrigation", "TREATMENT", 31, 45], ["viral load on the ocular surface", "PROBLEM", 59, 91], ["viral shedding", "PROBLEM", 108, 122], ["viral load", "OBSERVATION", 59, 69], ["ocular", "ANATOMY", 77, 83], ["decrease", "OBSERVATION_MODIFIER", 99, 107], ["viral shedding", "OBSERVATION", 108, 122]]], ["A commonly implemented protocol in clinical practice involves anesthetizing the affected eye(s), then instilling a pre-irrigation NSAID drop, followed by four to five drops of 5% PVI solution.", [["eye", "ANATOMY", 89, 92], ["PVI", "CHEMICAL", 179, 182], ["eye", "ORGAN", 89, 92], ["A commonly implemented protocol", "TREATMENT", 0, 31], ["a pre-irrigation NSAID drop", "TREATMENT", 113, 140], ["5% PVI solution", "TREATMENT", 176, 191], ["eye", "ANATOMY", 89, 92]]], ["The patient then rolls his or her closed eye(s) for 60 s to maximize exposure (including swabbing of the eyelid margins), followed by lavage of the ocular surface with sterile saline irrigation solution ( Figure 1 ).", [["eye", "ANATOMY", 41, 44], ["eyelid margins", "ANATOMY", 105, 119], ["ocular surface", "ANATOMY", 148, 162], ["patient", "ORGANISM", 4, 11], ["eye", "ORGAN", 41, 44], ["eyelid margins", "MULTI-TISSUE_STRUCTURE", 105, 119], ["patient", "SPECIES", 4, 11], ["swabbing of the eyelid margins", "TREATMENT", 89, 119], ["sterile saline irrigation solution", "TREATMENT", 168, 202], ["eye", "ANATOMY", 41, 44], ["eyelid", "ANATOMY", 105, 111], ["ocular", "ANATOMY", 148, 154]]], ["Finally, Figure 1 Set up for in-office povidone-iodine irrigation.", [["povidone-iodine", "CHEMICAL", 39, 54], ["povidone-iodine", "CHEMICAL", 39, 54], ["povidone-iodine", "SIMPLE_CHEMICAL", 39, 54], ["povidone", "TREATMENT", 39, 47], ["iodine irrigation", "TREATMENT", 48, 65]]], ["From left to right: nitrile gloves, topical anesthetic, topical NSAID, betadine, 5% solution, saline solution, and folded paper towel for saline rinse. a post-irrigation NSAID drop is instilled.", [["betadine", "CHEMICAL", 71, 79], ["nitrile", "CHEMICAL", 20, 27], ["betadine", "CHEMICAL", 71, 79], ["NSAID", "SIMPLE_CHEMICAL", 64, 69], ["betadine", "SIMPLE_CHEMICAL", 71, 79], ["saline", "SIMPLE_CHEMICAL", 94, 100], ["nitrile gloves", "TREATMENT", 20, 34], ["topical anesthetic", "TREATMENT", 36, 54], ["topical NSAID", "TREATMENT", 56, 69], ["betadine", "TREATMENT", 71, 79], ["saline solution", "TREATMENT", 94, 109], ["saline rinse", "TREATMENT", 138, 150], ["a post-irrigation NSAID drop", "TREATMENT", 152, 180], ["left", "ANATOMY_MODIFIER", 5, 9], ["right", "ANATOMY_MODIFIER", 13, 18], ["nitrile gloves", "OBSERVATION", 20, 34], ["NSAID drop", "OBSERVATION", 170, 180]]], ["Anecdotally, patients may report exasperation of their conjunctivitis symptoms for 12-24 hrs after this procedure; however, the overall risk/benefit consideration regularly tips the decision in favor of preforming PVI irrigation.", [["conjunctivitis", "DISEASE", 55, 69], ["PVI", "CHEMICAL", 214, 217], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["their conjunctivitis symptoms", "PROBLEM", 49, 78], ["this procedure", "TREATMENT", 99, 113], ["PVI irrigation", "TREATMENT", 214, 228], ["conjunctivitis", "OBSERVATION", 55, 69]]], ["32 Interestingly, Cheung et al have indicated that multiple types of adenovirus can be involved in a single outbreak and as PVI has proven viricidal activity in multiple ocular types of HAdV, it would be sensible to consider PVI irrigation to decrease colonization of the ocular surface in this disease picture.", [["ocular", "ANATOMY", 170, 176], ["ocular surface", "ANATOMY", 272, 286], ["PVI", "CHEMICAL", 124, 127], ["HAdV", "DISEASE", 186, 190], ["PVI", "CHEMICAL", 225, 228], ["PVI", "CHEMICAL", 225, 228], ["adenovirus", "ORGANISM", 69, 79], ["HAdV", "ORGANISM", 186, 190], ["ocular surface", "MULTI-TISSUE_STRUCTURE", 272, 286], ["adenovirus", "SPECIES", 69, 79], ["HAdV", "SPECIES", 186, 190], ["adenovirus", "PROBLEM", 69, 79], ["PVI", "TREATMENT", 124, 127], ["viricidal activity", "PROBLEM", 139, 157], ["HAdV", "PROBLEM", 186, 190], ["PVI irrigation", "TREATMENT", 225, 239], ["this disease picture", "PROBLEM", 290, 310], ["multiple", "OBSERVATION_MODIFIER", 51, 59], ["adenovirus", "OBSERVATION", 69, 79], ["multiple", "OBSERVATION_MODIFIER", 161, 169], ["ocular types", "OBSERVATION_MODIFIER", 170, 182], ["decrease", "OBSERVATION_MODIFIER", 243, 251], ["colonization", "OBSERVATION", 252, 264], ["ocular", "ANATOMY", 272, 278], ["surface", "OBSERVATION_MODIFIER", 279, 286], ["disease", "OBSERVATION", 295, 302]]], ["37 The most powerful tool in limiting the severity of adenoviral conjunctivitis outbreaks includes reduction of viral shedding and limiting contamination of objects, workspaces, and surfaces in public places to avoid horizontal transmission, as mentioned previously in this manuscript.", [["conjunctivitis", "DISEASE", 65, 79], ["adenoviral", "ORGANISM", 54, 64], ["adenoviral", "SPECIES", 54, 64], ["adenoviral conjunctivitis outbreaks", "PROBLEM", 54, 89], ["viral shedding", "PROBLEM", 112, 126], ["horizontal transmission", "PROBLEM", 217, 240], ["adenoviral", "ANATOMY", 54, 64], ["conjunctivitis", "OBSERVATION", 65, 79], ["reduction", "OBSERVATION_MODIFIER", 99, 108], ["viral shedding", "OBSERVATION", 112, 126]]], ["38 Gargling or flushing with PVI has been postulated as an effective measure in disrupting the transmission of respiratory viral spread.", [["respiratory", "ANATOMY", 111, 122], ["PVI", "CHEMICAL", 29, 32], ["respiratory viral spread", "DISEASE", 111, 135], ["PVI", "TREATMENT", 29, 32], ["respiratory viral spread", "PROBLEM", 111, 135], ["respiratory", "ANATOMY", 111, 122], ["viral spread", "OBSERVATION", 123, 135]]], ["39 Hence, PVI irrigation can be a powerful tool to help in the reduction of transmission of adenoviral keratoconjunctivitis.Povidone-Iodine IrrigationPVI has also shown value in treatment formulations.", [["PVI", "CHEMICAL", 10, 13], ["adenoviral keratoconjunctivitis", "DISEASE", 92, 123], ["Povidone-Iodine", "CHEMICAL", 124, 139], ["PVI", "CHEMICAL", 10, 13], ["Povidone-Iodine", "CHEMICAL", 124, 139], ["adenoviral", "ORGANISM", 92, 102], ["Povidone-Iodine", "SIMPLE_CHEMICAL", 124, 139], ["adenoviral", "SPECIES", 92, 102], ["PVI irrigation", "TREATMENT", 10, 24], ["adenoviral keratoconjunctivitis", "PROBLEM", 92, 123], ["Povidone", "TREATMENT", 124, 132], ["Iodine IrrigationPVI", "TREATMENT", 133, 153], ["treatment formulations", "TREATMENT", 178, 200], ["adenoviral keratoconjunctivitis", "OBSERVATION", 92, 123]]], ["A large clinical trial for the use of 1.25% PVI ophthalmic solution in the treatment of pediatric conjunctivitis displayed efficacy in treatment of bacterial, chlamydial, and viral conjunctivitis.", [["PVI", "CHEMICAL", 44, 47], ["conjunctivitis", "DISEASE", 98, 112], ["viral conjunctivitis", "DISEASE", 175, 195], ["PVI", "CHEMICAL", 44, 47], ["1.25% PVI ophthalmic solution", "TREATMENT", 38, 67], ["pediatric conjunctivitis", "PROBLEM", 88, 112], ["bacterial, chlamydial", "PROBLEM", 148, 169], ["viral conjunctivitis", "PROBLEM", 175, 195], ["large", "OBSERVATION_MODIFIER", 2, 7], ["conjunctivitis", "OBSERVATION", 98, 112], ["bacterial", "OBSERVATION_MODIFIER", 148, 157], ["chlamydial", "OBSERVATION", 159, 169], ["viral conjunctivitis", "OBSERVATION", 175, 195]]], ["40 Interestingly, a clinical trial looking at 0.5% PVI (in combination with artificial tears at pH 4.2 for enhanced tolerability) for the treatment of adenoviral keratoconjunctivitis found faster recovery from disease at two weeks, with three drops administered thrice daily.", [["PVI", "CHEMICAL", 51, 54], ["adenoviral keratoconjunctivitis", "DISEASE", 151, 182], ["PVI", "CHEMICAL", 51, 54], ["adenoviral", "ORGANISM", 151, 161], ["adenoviral", "SPECIES", 151, 161], ["PVI", "TREATMENT", 51, 54], ["artificial tears at pH", "TREATMENT", 76, 98], ["enhanced tolerability", "TREATMENT", 107, 128], ["adenoviral keratoconjunctivitis", "PROBLEM", 151, 182], ["disease", "PROBLEM", 210, 217], ["adenoviral keratoconjunctivitis", "OBSERVATION", 151, 182]]], ["34Antiviral TherapyAntiviral activity against systemic HAdV infections has been thoroughly studied and paved the way for its more focused evaluation for the treatment of the ocular manifestations of this virus.", [["ocular", "ANATOMY", 174, 180], ["HAdV infections", "DISEASE", 55, 70], ["HAdV", "ORGANISM", 55, 59], ["ocular", "ORGAN", 174, 180], ["HAdV", "SPECIES", 55, 59], ["34Antiviral TherapyAntiviral activity", "TREATMENT", 0, 37], ["systemic HAdV infections", "PROBLEM", 46, 70], ["evaluation", "TEST", 138, 148], ["the treatment", "TREATMENT", 153, 166], ["the ocular manifestations", "PROBLEM", 170, 195], ["this virus", "PROBLEM", 199, 209], ["infections", "OBSERVATION", 60, 70], ["ocular", "ANATOMY", 174, 180]]], ["Besides the aforementioned forms of keratoconjunctivitis, HAdV may also cause upper and lower respiratory tract disease, hemorrhagic cystitis, and gastroenteritis due to its propensity to infect mucosal epithelium.", [["lower respiratory tract", "ANATOMY", 88, 111], ["mucosal epithelium", "ANATOMY", 195, 213], ["keratoconjunctivitis", "DISEASE", 36, 56], ["HAdV", "DISEASE", 58, 62], ["upper and lower respiratory tract disease", "DISEASE", 78, 119], ["hemorrhagic cystitis", "DISEASE", 121, 141], ["gastroenteritis", "DISEASE", 147, 162], ["HAdV", "ORGANISM", 58, 62], ["upper", "ORGANISM_SUBDIVISION", 78, 83], ["tract", "ORGANISM_SUBDIVISION", 106, 111], ["mucosal epithelium", "TISSUE", 195, 213], ["keratoconjunctivitis", "PROBLEM", 36, 56], ["HAdV", "PROBLEM", 58, 62], ["upper and lower respiratory tract disease", "PROBLEM", 78, 119], ["hemorrhagic cystitis", "PROBLEM", 121, 141], ["gastroenteritis", "PROBLEM", 147, 162], ["infect mucosal epithelium", "PROBLEM", 188, 213], ["keratoconjunctivitis", "OBSERVATION", 36, 56], ["may also cause", "UNCERTAINTY", 63, 77], ["upper", "ANATOMY_MODIFIER", 78, 83], ["lower", "ANATOMY_MODIFIER", 88, 93], ["respiratory tract", "ANATOMY", 94, 111], ["disease", "OBSERVATION", 112, 119], ["hemorrhagic", "OBSERVATION_MODIFIER", 121, 132], ["cystitis", "OBSERVATION", 133, 141], ["gastroenteritis", "OBSERVATION", 147, 162], ["mucosal epithelium", "OBSERVATION", 195, 213]]], ["3, 41, 42 Respiratory infection is typically mild and self-limiting in immunocompetent individuals, but in rare cases, severe respiratory infection and pneumonia may result in acute respiratory distress syndrome (ARDS).", [["respiratory", "ANATOMY", 126, 137], ["respiratory", "ANATOMY", 182, 193], ["Respiratory infection", "DISEASE", 10, 31], ["respiratory infection", "DISEASE", 126, 147], ["pneumonia", "DISEASE", 152, 161], ["acute respiratory distress syndrome", "DISEASE", 176, 211], ["ARDS", "DISEASE", 213, 217], ["individuals", "ORGANISM", 87, 98], ["Respiratory infection", "PROBLEM", 10, 31], ["immunocompetent individuals", "PROBLEM", 71, 98], ["severe respiratory infection", "PROBLEM", 119, 147], ["pneumonia", "PROBLEM", 152, 161], ["acute respiratory distress syndrome", "PROBLEM", 176, 211], ["ARDS", "PROBLEM", 213, 217], ["Respiratory", "OBSERVATION_MODIFIER", 10, 21], ["infection", "OBSERVATION", 22, 31], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["self-limiting", "OBSERVATION_MODIFIER", 54, 67], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["respiratory", "ANATOMY", 126, 137], ["infection", "OBSERVATION", 138, 147], ["pneumonia", "OBSERVATION", 152, 161], ["acute", "OBSERVATION_MODIFIER", 176, 181], ["respiratory distress syndrome", "OBSERVATION", 182, 211]]], ["Additionally, in immunocompromised patients undergoing hematopoietic stem cell or solid organ transplantation, disseminated infections can be life-threatening, particularly in the pediatric population.", [["hematopoietic stem cell", "ANATOMY", 55, 78], ["solid organ", "ANATOMY", 82, 93], ["infections", "DISEASE", 124, 134], ["patients", "ORGANISM", 35, 43], ["hematopoietic stem cell", "CELL", 55, 78], ["organ", "ORGAN", 88, 93], ["hematopoietic stem cell", "CELL_TYPE", 55, 78], ["patients", "SPECIES", 35, 43], ["hematopoietic stem cell", "TREATMENT", 55, 78], ["solid organ transplantation", "TREATMENT", 82, 109], ["disseminated infections", "PROBLEM", 111, 134], ["immunocompromised", "OBSERVATION_MODIFIER", 17, 34], ["hematopoietic stem cell", "OBSERVATION", 55, 78], ["solid organ transplantation", "OBSERVATION", 82, 109], ["disseminated", "OBSERVATION_MODIFIER", 111, 123], ["infections", "OBSERVATION", 124, 134]]], ["3 Despite thorough investigation on the role of antiviral treatment both systemically and topically, there remains no standard of care.", [["thorough investigation", "TEST", 10, 32], ["antiviral treatment", "TREATMENT", 48, 67]]], ["Possible therapeutic benefits have been demonstrated through the use of antiviral drugs such as ganciclovir, ribavirin, and cidofovir.", [["ganciclovir", "CHEMICAL", 96, 107], ["ribavirin", "CHEMICAL", 109, 118], ["cidofovir", "CHEMICAL", 124, 133], ["ganciclovir", "CHEMICAL", 96, 107], ["ribavirin", "CHEMICAL", 109, 118], ["cidofovir", "CHEMICAL", 124, 133], ["ganciclovir", "SIMPLE_CHEMICAL", 96, 107], ["ribavirin", "SIMPLE_CHEMICAL", 109, 118], ["cidofovir", "SIMPLE_CHEMICAL", 124, 133], ["antiviral drugs", "TREATMENT", 72, 87], ["ganciclovir", "TREATMENT", 96, 107], ["ribavirin", "TREATMENT", 109, 118], ["cidofovir", "TREATMENT", 124, 133]]], ["[41] [42] [43] [44] Ganciclovir (GCV), a synthetic nucleoside analog of 2\u02b9-deoxyguanosine, has been proven effective in the inhibition of the herpes family of viruses, specifically herpes simplex types 1 and 2, varicella-zoster virus, cytomegalovirus, and Epstein-Barr.", [["[41] [42] [43] [44] Ganciclovir", "CHEMICAL", 0, 31], ["GCV", "CHEMICAL", 33, 36], ["nucleoside", "CHEMICAL", 51, 61], ["2\u02b9-deoxyguanosine", "CHEMICAL", 72, 89], ["herpes", "DISEASE", 142, 148], ["herpes simplex", "DISEASE", 181, 195], ["varicella-zoster virus", "DISEASE", 211, 233], ["cytomegalovirus", "DISEASE", 235, 250], ["[41] [42] [43] [44] Ganciclovir", "CHEMICAL", 0, 31], ["GCV", "CHEMICAL", 33, 36], ["nucleoside", "CHEMICAL", 51, 61], ["2\u02b9-deoxyguanosine", "CHEMICAL", 72, 89], ["[41] [42] [43] [44] Ganciclovir", "SIMPLE_CHEMICAL", 0, 31], ["GCV", "SIMPLE_CHEMICAL", 33, 36], ["nucleoside", "SIMPLE_CHEMICAL", 51, 61], ["2\u02b9-deoxyguanosine", "SIMPLE_CHEMICAL", 72, 89], ["herpes", "ORGANISM", 142, 148], ["herpes simplex types 1", "ORGANISM", 181, 203], ["2", "GENE_OR_GENE_PRODUCT", 208, 209], ["varicella-zoster virus", "ORGANISM", 211, 233], ["cytomegalovirus", "ORGANISM", 235, 250], ["Epstein-Barr", "ORGANISM", 256, 268], ["herpes simplex", "SPECIES", 181, 195], ["varicella-zoster virus", "SPECIES", 211, 233], ["varicella-zoster virus", "SPECIES", 211, 233], ["Ganciclovir (GCV", "TREATMENT", 20, 36], ["a synthetic nucleoside analog", "TREATMENT", 39, 68], ["deoxyguanosine", "TREATMENT", 75, 89], ["viruses", "PROBLEM", 159, 166], ["herpes simplex types", "TEST", 181, 201], ["varicella-zoster virus", "PROBLEM", 211, 233], ["cytomegalovirus", "PROBLEM", 235, 250], ["zoster virus", "ANATOMY", 221, 233]]], ["In a series of experiments utilizing Syrian, immunocompromised hamsters infected with HAdV 5, GCV was able to suppress viral replication in the liver, a method that may involve the direct inhibition of DNA polymerase.", [["liver", "ANATOMY", 144, 149], ["immunocompromised hamsters infected", "DISEASE", 45, 80], ["GCV", "CHEMICAL", 94, 97], ["Syrian", "ORGANISM", 37, 43], ["hamsters", "ORGANISM", 63, 71], ["HAdV 5", "ORGANISM", 86, 92], ["GCV", "SIMPLE_CHEMICAL", 94, 97], ["liver", "ORGAN", 144, 149], ["DNA", "CELLULAR_COMPONENT", 202, 205], ["DNA polymerase", "PROTEIN", 202, 216], ["hamsters", "SPECIES", 63, 71], ["GCV", "SPECIES", 94, 97], ["HAdV", "PROBLEM", 86, 90], ["GCV", "TREATMENT", 94, 97], ["viral replication in the liver", "PROBLEM", 119, 149], ["a method", "TREATMENT", 151, 159], ["DNA polymerase", "PROBLEM", 202, 216], ["liver", "ANATOMY", 144, 149]]], ["It was proposed that GCV inhibited the advancement of viral infection into the late phase.", [["GCV", "CHEMICAL", 21, 24], ["viral infection", "DISEASE", 54, 69], ["GCV", "CHEMICAL", 21, 24], ["GCV", "SIMPLE_CHEMICAL", 21, 24], ["GCV", "TREATMENT", 21, 24], ["viral infection", "PROBLEM", 54, 69], ["viral infection", "OBSERVATION", 54, 69], ["late phase", "OBSERVATION_MODIFIER", 79, 89]]], ["Systemically, GCV was able to mitigate the effects of HAdV infection in these hamsters, decreasing the rate of mortality.", [["GCV", "CHEMICAL", 14, 17], ["HAdV infection", "DISEASE", 54, 68], ["GCV", "CHEMICAL", 14, 17], ["GCV", "SIMPLE_CHEMICAL", 14, 17], ["HAdV", "ORGANISM", 54, 58], ["hamsters", "ORGANISM", 78, 86], ["HAdV", "SPECIES", 54, 58], ["hamsters", "SPECIES", 78, 86], ["GCV", "TREATMENT", 14, 17], ["HAdV infection", "PROBLEM", 54, 68], ["infection", "OBSERVATION", 59, 68]]], ["This led to the investigation of GCV in the treatment of ocular infections of HAdV.", [["ocular", "ANATOMY", 57, 63], ["GCV", "CHEMICAL", 33, 36], ["ocular infections", "DISEASE", 57, 74], ["HAdV", "DISEASE", 78, 82], ["GCV", "CHEMICAL", 33, 36], ["GCV", "SIMPLE_CHEMICAL", 33, 36], ["ocular", "ORGANISM_SUBDIVISION", 57, 63], ["HAdV", "ORGANISM", 78, 82], ["the investigation", "TEST", 12, 29], ["GCV", "TREATMENT", 33, 36], ["ocular infections of HAdV", "PROBLEM", 57, 82], ["ocular", "ANATOMY", 57, 63], ["infections", "OBSERVATION", 64, 74]]], ["43, 44 The ophthalmic gel form (ganciclovir 0.15%, Virgan \u00ae ; Farmila-Thea, Milan, Italy) has been the standard of care for the treatment of acute ocular herpetic keratitis, yet it has not been standardized in the management of adenoviral keratoconjunctivitis, particularly since studies in human subjects are lacking.", [["ocular", "ANATOMY", 147, 153], ["ganciclovir", "CHEMICAL", 32, 43], ["ocular herpetic keratitis", "DISEASE", 147, 172], ["adenoviral keratoconjunctivitis", "DISEASE", 228, 259], ["ganciclovir", "CHEMICAL", 32, 43], ["ganciclovir", "SIMPLE_CHEMICAL", 32, 43], ["adenoviral", "ORGANISM", 228, 238], ["human", "ORGANISM", 291, 296], ["human", "SPECIES", 291, 296], ["adenoviral", "SPECIES", 228, 238], ["human", "SPECIES", 291, 296], ["The ophthalmic gel form (ganciclovir", "TREATMENT", 7, 43], ["Virgan", "TREATMENT", 51, 57], ["Farmila", "TREATMENT", 62, 69], ["the treatment", "TREATMENT", 124, 137], ["acute ocular herpetic keratitis", "PROBLEM", 141, 172], ["adenoviral keratoconjunctivitis", "PROBLEM", 228, 259], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["ocular", "ANATOMY", 147, 153], ["herpetic keratitis", "OBSERVATION", 154, 172], ["adenoviral keratoconjunctivitis", "OBSERVATION", 228, 259]]], ["43, 44 Current research suggests, however, that with off-label topical use, GCV inhibits the replication of HAdV that leads to ocular infection.", [["ocular", "ANATOMY", 127, 133], ["GCV", "CHEMICAL", 76, 79], ["ocular infection", "DISEASE", 127, 143], ["GCV", "CHEMICAL", 76, 79], ["GCV", "SIMPLE_CHEMICAL", 76, 79], ["HAdV", "ORGANISM", 108, 112], ["ocular", "ORGAN", 127, 133], ["HAdV", "SPECIES", 108, 112], ["GCV", "TREATMENT", 76, 79], ["HAdV", "PROBLEM", 108, 112], ["ocular infection", "PROBLEM", 127, 143], ["ocular", "ANATOMY", 127, 133], ["infection", "OBSERVATION", 134, 143]]], ["[43] [44] [45] [46] In one study, Huang et al investigated the antiviral activity of GCV against HAdV types 3, 4, 8, 19, and 37 using polymerase chain reaction (PCR) and concluded that there was a significant, dose-dependent inhibitory effect on those serotypes responsible for EKC.", [["GCV", "CHEMICAL", 85, 88], ["EKC", "CHEMICAL", 278, 281], ["GCV", "CHEMICAL", 85, 88], ["[43] [44] [45] [46", "SIMPLE_CHEMICAL", 0, 18], ["GCV", "SIMPLE_CHEMICAL", 85, 88], ["HAdV", "ORGANISM", 97, 101], ["one study", "TEST", 23, 32], ["polymerase chain reaction", "TEST", 134, 159], ["PCR", "TEST", 161, 164], ["dependent inhibitory effect", "PROBLEM", 215, 242], ["EKC", "PROBLEM", 278, 281]]], ["46 Systemically, Bruno et al described the potential therapeutic effect of GCV in that the incidence of HAdV infections was significantly reduced in stem cell-transplant patients treated with GCV for human cytomegalovirus prophylaxis.", [["stem cell", "ANATOMY", 149, 158], ["GCV", "CHEMICAL", 75, 78], ["HAdV infections", "DISEASE", 104, 119], ["GCV", "CHEMICAL", 192, 195], ["GCV", "CHEMICAL", 75, 78], ["GCV", "CHEMICAL", 192, 195], ["GCV", "SIMPLE_CHEMICAL", 75, 78], ["HAdV", "ORGANISM", 104, 108], ["stem cell", "CELL", 149, 158], ["patients", "ORGANISM", 170, 178], ["GCV", "SIMPLE_CHEMICAL", 192, 195], ["human", "ORGANISM", 200, 205], ["cytomegalovirus", "ORGANISM", 206, 221], ["patients", "SPECIES", 170, 178], ["human", "SPECIES", 200, 205], ["HAdV", "SPECIES", 104, 108], ["human cytomegalovirus", "SPECIES", 200, 221], ["GCV", "TREATMENT", 75, 78], ["HAdV infections", "PROBLEM", 104, 119], ["GCV", "TREATMENT", 192, 195], ["human cytomegalovirus prophylaxis", "TREATMENT", 200, 233], ["HAdV", "OBSERVATION_MODIFIER", 104, 108], ["infections", "OBSERVATION", 109, 119], ["stem cell", "OBSERVATION", 149, 158], ["cytomegalovirus prophylaxis", "OBSERVATION", 206, 233]]], ["45 Sun et al conducted a study utilizing a series of eye drops to treat active EKC infections, including GCV ophthalmic gel, interferon eye drops, a tobramycin-dexamethasone combo, and topical diclofenac sodium.", [["eye", "ANATOMY", 53, 56], ["eye", "ANATOMY", 136, 139], ["EKC infections", "DISEASE", 79, 93], ["GCV", "CHEMICAL", 105, 108], ["tobramycin", "CHEMICAL", 149, 159], ["dexamethasone", "CHEMICAL", 160, 173], ["diclofenac sodium", "CHEMICAL", 193, 210], ["tobramycin", "CHEMICAL", 149, 159], ["dexamethasone", "CHEMICAL", 160, 173], ["diclofenac sodium", "CHEMICAL", 193, 210], ["eye", "ORGAN", 53, 56], ["eye", "ORGAN", 136, 139], ["tobramycin", "SIMPLE_CHEMICAL", 149, 159], ["dexamethasone", "SIMPLE_CHEMICAL", 160, 173], ["diclofenac sodium", "SIMPLE_CHEMICAL", 193, 210], ["a study", "TEST", 23, 30], ["eye drops", "TREATMENT", 53, 62], ["active EKC infections", "PROBLEM", 72, 93], ["GCV ophthalmic gel", "TREATMENT", 105, 123], ["interferon eye drops", "TREATMENT", 125, 145], ["a tobramycin", "TREATMENT", 147, 159], ["dexamethasone combo", "TREATMENT", 160, 179], ["topical diclofenac sodium", "TREATMENT", 185, 210], ["active", "OBSERVATION_MODIFIER", 72, 78], ["EKC infections", "OBSERVATION", 79, 93]]], ["In this study, interferon was administered with the purpose of inhibiting viral replication, while GCV was used for its antiviral properties.", [["interferon", "CHEMICAL", 15, 25], ["GCV", "CHEMICAL", 99, 102], ["GCV", "CHEMICAL", 99, 102], ["interferon", "GENE_OR_GENE_PRODUCT", 15, 25], ["GCV", "SIMPLE_CHEMICAL", 99, 102], ["interferon", "PROTEIN", 15, 25], ["this study", "TEST", 3, 13], ["interferon", "TREATMENT", 15, 25], ["inhibiting viral replication", "TREATMENT", 63, 91], ["GCV", "TREATMENT", 99, 102], ["its antiviral properties", "TREATMENT", 116, 140]]], ["To improve efficacy and limit potential ocular side effects, such as inflammation, congestion, and edema, tobramycindexamethasone and diclofenac sodium treatments were also employed.", [["ocular", "ANATOMY", 40, 46], ["inflammation", "DISEASE", 69, 81], ["congestion", "DISEASE", 83, 93], ["edema", "DISEASE", 99, 104], ["tobramycindexamethasone", "CHEMICAL", 106, 129], ["diclofenac sodium", "CHEMICAL", 134, 151], ["tobramycindexamethasone", "CHEMICAL", 106, 129], ["diclofenac sodium", "CHEMICAL", 134, 151], ["edema", "PATHOLOGICAL_FORMATION", 99, 104], ["tobramycindexamethasone", "SIMPLE_CHEMICAL", 106, 129], ["diclofenac", "SIMPLE_CHEMICAL", 134, 144], ["ocular side effects", "PROBLEM", 40, 59], ["inflammation", "PROBLEM", 69, 81], ["congestion", "PROBLEM", 83, 93], ["edema", "PROBLEM", 99, 104], ["tobramycindexamethasone", "TREATMENT", 106, 129], ["diclofenac sodium treatments", "TREATMENT", 134, 162], ["inflammation", "OBSERVATION", 69, 81], ["congestion", "OBSERVATION", 83, 93], ["edema", "OBSERVATION", 99, 104]]], ["This combination of drugs demonstrated a 91.76% cure rate in a 6-week treatment period, with low risk of side effects limited to transient corneal epithelial defects and elevated intraocular pressure.", [["corneal epithelial", "ANATOMY", 139, 157], ["intraocular", "ANATOMY", 179, 190], ["corneal epithelial defects", "DISEASE", 139, 165], ["corneal epithelial", "TISSUE", 139, 157], ["intraocular", "IMMATERIAL_ANATOMICAL_ENTITY", 179, 190], ["drugs", "TREATMENT", 20, 25], ["side effects", "PROBLEM", 105, 117], ["transient corneal epithelial defects", "PROBLEM", 129, 165], ["elevated intraocular pressure", "PROBLEM", 170, 199], ["transient", "OBSERVATION_MODIFIER", 129, 138], ["corneal epithelial defects", "OBSERVATION", 139, 165], ["elevated", "OBSERVATION_MODIFIER", 170, 178], ["intraocular pressure", "OBSERVATION", 179, 199]]], ["While EKC is often considered to be self-limiting, this study concluded that the proposed treatment plan, specifically during the early phase of the disease, could markedly reduce the patient's symptoms, shorten the course of the disease, and lessen the risk of corneal complications.", [["corneal", "ANATOMY", 262, 269], ["EKC", "CHEMICAL", 6, 9], ["patient", "ORGANISM", 184, 191], ["corneal", "TISSUE", 262, 269], ["patient", "SPECIES", 184, 191], ["this study", "TEST", 51, 61], ["the disease", "PROBLEM", 145, 156], ["the patient's symptoms", "PROBLEM", 180, 202], ["the disease", "PROBLEM", 226, 237], ["corneal complications", "PROBLEM", 262, 283], ["disease", "OBSERVATION", 149, 156], ["corneal", "ANATOMY", 262, 269], ["complications", "OBSERVATION", 270, 283]]], ["27 Valganciclovir is a pro-drug of GCV that inhibits replication of adenoviral genomic DNA via blockade of HAdV DNA polymerase.", [["Valganciclovir", "CHEMICAL", 3, 17], ["GCV", "CHEMICAL", 35, 38], ["Valganciclovir", "CHEMICAL", 3, 17], ["GCV", "CHEMICAL", 35, 38], ["Valganciclovir", "SIMPLE_CHEMICAL", 3, 17], ["GCV", "SIMPLE_CHEMICAL", 35, 38], ["adenoviral", "ORGANISM", 68, 78], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["HAdV", "ORGANISM", 107, 111], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["adenoviral genomic DNA", "DNA", 68, 90], ["HAdV DNA polymerase", "PROTEIN", 107, 126], ["adenoviral", "SPECIES", 68, 78], ["Valganciclovir", "TREATMENT", 3, 17], ["a pro-drug of GCV", "TREATMENT", 21, 38], ["adenoviral genomic DNA", "TREATMENT", 68, 90], ["HAdV DNA polymerase", "PROBLEM", 107, 126]]], ["However, because HAdV lacks thymidine kinase, a known target for valganciclovir, it would likely become a challenge in the treatment of adenoviral keratoconjunctivitis.", [["thymidine", "CHEMICAL", 28, 37], ["valganciclovir", "CHEMICAL", 65, 79], ["adenoviral keratoconjunctivitis", "DISEASE", 136, 167], ["thymidine", "CHEMICAL", 28, 37], ["valganciclovir", "CHEMICAL", 65, 79], ["HAdV", "ORGANISM", 17, 21], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 28, 44], ["valganciclovir", "SIMPLE_CHEMICAL", 65, 79], ["adenoviral", "ORGANISM", 136, 146], ["thymidine kinase", "PROTEIN", 28, 44], ["adenoviral", "SPECIES", 136, 146], ["HAdV lacks thymidine kinase", "PROBLEM", 17, 44], ["valganciclovir", "TREATMENT", 65, 79], ["adenoviral keratoconjunctivitis", "PROBLEM", 136, 167], ["thymidine kinase", "OBSERVATION", 28, 44], ["adenoviral keratoconjunctivitis", "OBSERVATION", 136, 167]]], ["47 Ribavirin and cidofovir have also been shown to exhibit antiviral activity against HAdV in vitro.", [["Ribavirin", "CHEMICAL", 3, 12], ["cidofovir", "CHEMICAL", 17, 26], ["Ribavirin", "CHEMICAL", 3, 12], ["cidofovir", "CHEMICAL", 17, 26], ["Ribavirin", "SIMPLE_CHEMICAL", 3, 12], ["cidofovir", "SIMPLE_CHEMICAL", 17, 26], ["HAdV", "ORGANISM", 86, 90], ["HAdV", "SPECIES", 86, 90], ["Ribavirin", "TREATMENT", 3, 12], ["cidofovir", "TREATMENT", 17, 26], ["antiviral activity", "TREATMENT", 59, 77]]], ["However, many of these systemic antiviral therapies lead to the risk of significant side effects.", [["these systemic antiviral therapies", "TREATMENT", 17, 51], ["significant side effects", "PROBLEM", 72, 96]]], ["Cidofovir (CDV) is an acyclic nucleoside phosphonate and nucleotide analog of cytosine.", [["Cidofovir", "CHEMICAL", 0, 9], ["CDV", "CHEMICAL", 11, 14], ["nucleoside phosphonate", "CHEMICAL", 30, 52], ["nucleotide", "CHEMICAL", 57, 67], ["cytosine", "CHEMICAL", 78, 86], ["Cidofovir", "CHEMICAL", 0, 9], ["acyclic nucleoside phosphonate", "CHEMICAL", 22, 52], ["nucleotide", "CHEMICAL", 57, 67], ["cytosine", "CHEMICAL", 78, 86], ["Cidofovir", "SIMPLE_CHEMICAL", 0, 9], ["CDV", "ORGANISM", 11, 14], ["nucleoside phosphonate", "SIMPLE_CHEMICAL", 30, 52], ["nucleotide", "SIMPLE_CHEMICAL", 57, 67], ["cytosine", "SIMPLE_CHEMICAL", 78, 86], ["CDV", "SPECIES", 11, 14], ["Cidofovir (CDV)", "TREATMENT", 0, 15], ["an acyclic nucleoside phosphonate", "TREATMENT", 19, 52], ["nucleotide analog of cytosine", "TREATMENT", 57, 86]]], ["It is converted by cells to its diphosphate form and binds to the HAdV DNA polymerase, causing viral DNA chain termination and viral inhibition.", [["cells", "ANATOMY", 19, 24], ["diphosphate", "CHEMICAL", 32, 43], ["diphosphate", "CHEMICAL", 32, 43], ["cells", "CELL", 19, 24], ["diphosphate", "SIMPLE_CHEMICAL", 32, 43], ["HAdV", "ORGANISM", 66, 70], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["HAdV DNA polymerase", "PROTEIN", 66, 85], ["viral DNA chain", "PROTEIN", 95, 110], ["the HAdV DNA polymerase", "TEST", 62, 85], ["viral DNA chain termination", "TREATMENT", 95, 122], ["viral inhibition", "PROBLEM", 127, 143], ["viral inhibition", "OBSERVATION", 127, 143]]], ["13, 44 Intravenous cidofovir is often used in transplant clinics with only mild efficacy.", [["cidofovir", "CHEMICAL", 19, 28], ["cidofovir", "CHEMICAL", 19, 28], ["cidofovir", "SIMPLE_CHEMICAL", 19, 28], ["Intravenous cidofovir", "TREATMENT", 7, 28], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["efficacy", "OBSERVATION", 80, 88]]], ["This is due to poor cellular uptake because of its phosphate group, leading to accumulation of the drug in the renal tubules and, when used systemically, leads to nephrotoxicity.", [["cellular", "ANATOMY", 20, 28], ["renal tubules", "ANATOMY", 111, 124], ["phosphate", "CHEMICAL", 51, 60], ["nephrotoxicity", "DISEASE", 163, 177], ["phosphate", "CHEMICAL", 51, 60], ["cellular", "CELL", 20, 28], ["phosphate", "SIMPLE_CHEMICAL", 51, 60], ["renal tubules", "TISSUE", 111, 124], ["poor cellular uptake", "PROBLEM", 15, 35], ["its phosphate group", "PROBLEM", 47, 66], ["the drug in the renal tubules", "PROBLEM", 95, 124], ["nephrotoxicity", "PROBLEM", 163, 177], ["due to", "UNCERTAINTY", 8, 14], ["poor", "OBSERVATION_MODIFIER", 15, 19], ["cellular uptake", "OBSERVATION", 20, 35], ["renal tubules", "ANATOMY", 111, 124], ["nephrotoxicity", "OBSERVATION", 163, 177]]], ["44, 46 Locally, CDV may also cause ocular toxicity around the skin of eyelids and conjunctiva.", [["ocular", "ANATOMY", 35, 41], ["skin", "ANATOMY", 62, 66], ["eyelids", "ANATOMY", 70, 77], ["conjunctiva", "ANATOMY", 82, 93], ["ocular toxicity", "DISEASE", 35, 50], ["CDV", "ORGANISM", 16, 19], ["ocular", "ORGAN", 35, 41], ["skin", "ORGAN", 62, 66], ["eyelids", "ORGAN", 70, 77], ["conjunctiva", "ORGAN", 82, 93], ["CDV", "SPECIES", 16, 19], ["CDV", "PROBLEM", 16, 19], ["ocular toxicity", "PROBLEM", 35, 50], ["may also cause", "UNCERTAINTY", 20, 34], ["ocular toxicity", "OBSERVATION", 35, 50], ["skin", "ANATOMY", 62, 66], ["eyelids", "ANATOMY", 70, 77], ["conjunctiva", "ANATOMY", 82, 93]]], ["46 Similarly, ribavirin also results in poor systemic side effects and safety profile, associated with extravascular hemolysis, anemia, and bone marrow suppression.", [["extravascular", "ANATOMY", 103, 116], ["bone marrow", "ANATOMY", 140, 151], ["ribavirin", "CHEMICAL", 14, 23], ["hemolysis", "DISEASE", 117, 126], ["anemia", "DISEASE", 128, 134], ["bone marrow suppression", "DISEASE", 140, 163], ["ribavirin", "CHEMICAL", 14, 23], ["ribavirin", "SIMPLE_CHEMICAL", 14, 23], ["extravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 116], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 140, 151], ["ribavirin", "TREATMENT", 14, 23], ["poor systemic side effects", "PROBLEM", 40, 66], ["safety profile", "TEST", 71, 85], ["extravascular hemolysis", "PROBLEM", 103, 126], ["anemia", "PROBLEM", 128, 134], ["bone marrow suppression", "PROBLEM", 140, 163], ["ribavirin", "OBSERVATION", 14, 23], ["extravascular hemolysis", "OBSERVATION", 103, 126], ["anemia", "OBSERVATION", 128, 134], ["bone", "ANATOMY", 140, 144], ["marrow suppression", "OBSERVATION", 145, 163]]], ["Due to these discoveries, it is necessary to determine an effective antiviral with a high therapeutic index for the treatment of HAdV associated infections.", [["HAdV", "DISEASE", 129, 133], ["infections", "DISEASE", 145, 155], ["HAdV", "ORGANISM", 129, 133], ["HAdV", "SPECIES", 129, 133], ["a high therapeutic index", "TREATMENT", 83, 107], ["HAdV associated infections", "PROBLEM", 129, 155], ["infections", "OBSERVATION", 145, 155]]], ["46 In animal models, CDV was administered utilizing topical and intrastromal inoculation three times per day for 20 consecutive days; the results displayed significant effectivity against HAdV type 5 when compared to the placebo group, reducing both viral shedding and the severity of subepithelial infiltrates.", [["subepithelial infiltrates", "ANATOMY", 285, 310], ["CDV", "ORGANISM", 21, 24], ["HAdV type 5", "ORGANISM", 188, 199], ["subepithelial infiltrates", "PATHOLOGICAL_FORMATION", 285, 310], ["CDV", "SPECIES", 21, 24], ["HAdV type 5", "SPECIES", 188, 199], ["CDV", "TREATMENT", 21, 24], ["topical and intrastromal inoculation", "TREATMENT", 52, 88], ["HAdV type 5", "PROBLEM", 188, 199], ["both viral shedding", "PROBLEM", 245, 264], ["subepithelial infiltrates", "PROBLEM", 285, 310], ["viral", "OBSERVATION", 250, 255], ["severity", "OBSERVATION_MODIFIER", 273, 281], ["subepithelial", "ANATOMY_MODIFIER", 285, 298], ["infiltrates", "OBSERVATION", 299, 310]]], ["This study showed great promise in the future of cidofovir for the treatment of ocular HAdV infections in the future.", [["ocular", "ANATOMY", 80, 86], ["cidofovir", "CHEMICAL", 49, 58], ["ocular HAdV infections", "DISEASE", 80, 102], ["cidofovir", "CHEMICAL", 49, 58], ["cidofovir", "SIMPLE_CHEMICAL", 49, 58], ["HAdV", "ORGANISM", 87, 91], ["This study", "TEST", 0, 10], ["cidofovir", "TREATMENT", 49, 58], ["ocular HAdV infections", "PROBLEM", 80, 102], ["great", "OBSERVATION_MODIFIER", 18, 23], ["ocular", "ANATOMY", 80, 86], ["HAdV", "OBSERVATION", 87, 91]]], ["48 Additionally, early systemic administration of CDV in immunocompetent patients with HAdV pneumonia was an effective treatment strategy.", [["CDV", "CHEMICAL", 50, 53], ["HAdV pneumonia", "DISEASE", 87, 101], ["CDV", "ORGANISM", 50, 53], ["patients", "ORGANISM", 73, 81], ["HAdV", "ORGANISM", 87, 91], ["patients", "SPECIES", 73, 81], ["CDV", "SPECIES", 50, 53], ["CDV", "TREATMENT", 50, 53], ["HAdV pneumonia", "PROBLEM", 87, 101], ["an effective treatment strategy", "TREATMENT", 106, 137], ["pneumonia", "OBSERVATION", 92, 101]]], ["42 Due to the positive results in the aforementioned studies, CDV was tested as a prophylactic measure due to the epidemic nature of HAdV.", [["HAdV", "DISEASE", 133, 137], ["CDV", "ORGANISM", 62, 65], ["HAdV", "ORGANISM", 133, 137], ["CDV", "SPECIES", 62, 65], ["the aforementioned studies", "TEST", 34, 60], ["CDV", "PROBLEM", 62, 65], ["a prophylactic measure", "TREATMENT", 80, 102], ["HAdV", "PROBLEM", 133, 137]]], ["Romanowski et al determined that antiviral prophylaxis with 1% and 0.5% concentrations of CDV significantly reduced viral replication of HAdV type 5 in animal models, giving promise to the use of CDV in prophylaxis.", [["CDV", "CHEMICAL", 90, 93], ["HAdV type 5", "CHEMICAL", 137, 148], ["CDV", "ORGANISM", 90, 93], ["HAdV type 5", "ORGANISM", 137, 148], ["CDV", "ORGANISM", 196, 199], ["CDV", "SPECIES", 90, 93], ["HAdV type 5", "SPECIES", 137, 148], ["CDV", "SPECIES", 196, 199], ["antiviral prophylaxis", "TREATMENT", 33, 54], ["CDV", "TREATMENT", 90, 93], ["CDV in prophylaxis", "TREATMENT", 196, 214], ["viral replication", "OBSERVATION", 116, 133], ["HAdV type", "OBSERVATION_MODIFIER", 137, 146]]], ["49 Despite favorable outcomes of cidofovir's antiviral activity in rabbit models, several studies discussed the significant side effects to the ocular surface, which is a potential limitation for therapeutic use.", [["ocular surface", "ANATOMY", 144, 158], ["cidofovir", "CHEMICAL", 33, 42], ["cidofovir", "CHEMICAL", 33, 42], ["cidofovir", "SIMPLE_CHEMICAL", 33, 42], ["rabbit", "ORGANISM", 67, 73], ["ocular surface", "MULTI-TISSUE_STRUCTURE", 144, 158], ["rabbit", "SPECIES", 67, 73], ["rabbit", "SPECIES", 67, 73], ["cidofovir's antiviral activity in rabbit models", "TREATMENT", 33, 80], ["several studies", "TEST", 82, 97], ["antiviral activity", "OBSERVATION", 45, 63], ["ocular", "ANATOMY", 144, 150]]], ["Gordon et al described the effects of topical cidofovir in uninfected animals, determining that there was consistent clinically significant ocular toxicity at a total dose exceeding 15mg over 10 days.", [["ocular", "ANATOMY", 140, 146], ["cidofovir", "CHEMICAL", 46, 55], ["ocular toxicity", "DISEASE", 140, 155], ["cidofovir", "CHEMICAL", 46, 55], ["cidofovir", "SIMPLE_CHEMICAL", 46, 55], ["ocular", "ORGAN", 140, 146], ["topical cidofovir", "TREATMENT", 38, 55], ["significant ocular toxicity", "PROBLEM", 128, 155], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["ocular toxicity", "OBSERVATION", 140, 155]]], ["50 Significant eyelid redness and conjunctival hyperemia were also described in additional studies as well as nasolacrimal blockage and lacrimation.", [["eyelid", "ANATOMY", 15, 21], ["conjunctival", "ANATOMY", 34, 46], ["nasolacrimal", "ANATOMY", 110, 122], ["eyelid redness", "DISEASE", 15, 29], ["hyperemia", "DISEASE", 47, 56], ["nasolacrimal blockage", "DISEASE", 110, 131], ["nasolacrimal", "PATHOLOGICAL_FORMATION", 110, 122], ["Significant eyelid redness", "PROBLEM", 3, 29], ["conjunctival hyperemia", "PROBLEM", 34, 56], ["additional studies", "TEST", 80, 98], ["nasolacrimal blockage", "PROBLEM", 110, 131], ["lacrimation", "PROBLEM", 136, 147], ["Significant", "OBSERVATION_MODIFIER", 3, 14], ["eyelid", "ANATOMY", 15, 21], ["redness", "OBSERVATION", 22, 29], ["conjunctival hyperemia", "OBSERVATION", 34, 56], ["nasolacrimal", "ANATOMY", 110, 122], ["blockage", "OBSERVATION", 123, 131], ["lacrimation", "OBSERVATION", 136, 147]]], ["50, 51 Even at lower and presumably ineffective dosages, 3.5 mg of cidofovir continued exhibit significant ocular surface toxicity in vivo.", [["ocular surface", "ANATOMY", 107, 121], ["cidofovir", "CHEMICAL", 67, 76], ["ocular surface toxicity", "DISEASE", 107, 130], ["cidofovir", "CHEMICAL", 67, 76], ["cidofovir", "SIMPLE_CHEMICAL", 67, 76], ["cidofovir", "TREATMENT", 67, 76], ["significant ocular surface toxicity", "PROBLEM", 95, 130], ["ineffective", "OBSERVATION_MODIFIER", 36, 47], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["ocular", "OBSERVATION_MODIFIER", 107, 113], ["surface toxicity", "OBSERVATION", 114, 130]]], ["52 Resistance to CDV is likely due to changes in amino acid sequence within the encoded DNA polymerase genes in resistant HAdV, which has been suggested to confer resistance of adenovirus to CDV.", [["CDV", "DISEASE", 17, 20], ["amino acid", "CHEMICAL", 49, 59], ["amino acid", "CHEMICAL", 49, 59], ["CDV", "ORGANISM", 17, 20], ["amino acid", "AMINO_ACID", 49, 59], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["HAdV", "ORGANISM", 122, 126], ["adenovirus", "ORGANISM", 177, 187], ["CDV", "ORGANISM", 191, 194], ["encoded DNA polymerase genes", "DNA", 80, 108], ["CDV", "SPECIES", 17, 20], ["adenovirus", "SPECIES", 177, 187], ["CDV", "SPECIES", 191, 194], ["CDV", "PROBLEM", 17, 20], ["changes in amino acid sequence", "PROBLEM", 38, 68], ["resistant HAdV", "PROBLEM", 112, 126], ["adenovirus", "PROBLEM", 177, 187], ["likely due to", "UNCERTAINTY", 24, 37]]], ["Drug resistance poses a significant challenge to the management of adenoviral keratoconjunctivitis in the clinical setting.", [["adenoviral keratoconjunctivitis", "DISEASE", 67, 98], ["adenoviral", "ORGANISM", 67, 77], ["adenoviral", "SPECIES", 67, 77], ["the management", "TREATMENT", 49, 63], ["adenoviral keratoconjunctivitis", "PROBLEM", 67, 98], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["adenoviral keratoconjunctivitis", "OBSERVATION", 67, 98]]], ["53 Romanowski et al were able to demonstrate that HAdV type 5 that are resistant to topical CVD therapy are less likely to constitute a significant challenge in management of adenoviral keratoconjunctivitis in immunocompetent patients.", [["CVD", "DISEASE", 92, 95], ["adenoviral keratoconjunctivitis", "DISEASE", 175, 206], ["HAdV type 5", "ORGANISM", 50, 61], ["adenoviral", "ORGANISM", 175, 185], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 226, 234], ["adenoviral", "SPECIES", 175, 185], ["HAdV type 5", "PROBLEM", 50, 61], ["topical CVD therapy", "TREATMENT", 84, 103], ["management", "TREATMENT", 161, 171], ["adenoviral keratoconjunctivitis", "PROBLEM", 175, 206], ["significant", "OBSERVATION_MODIFIER", 136, 147], ["adenoviral keratoconjunctivitis", "OBSERVATION", 175, 206]]], ["Drugresistant viruses usually pose a minimal threat in immunocompetent patients, but CDV-resistant HAdV can retain their ability to replicate in permissive ocular epithelial cells.", [["ocular epithelial cells", "ANATOMY", 156, 179], ["patients", "ORGANISM", 71, 79], ["CDV-resistant HAdV", "ORGANISM", 85, 103], ["ocular epithelial cells", "CELL", 156, 179], ["permissive ocular epithelial cells", "CELL_TYPE", 145, 179], ["patients", "SPECIES", 71, 79], ["CDV", "SPECIES", 85, 88], ["Drugresistant viruses", "PROBLEM", 0, 21], ["CDV", "PROBLEM", 85, 88], ["resistant HAdV", "PROBLEM", 89, 103], ["permissive ocular epithelial cells", "PROBLEM", 145, 179], ["viruses", "OBSERVATION", 14, 21], ["minimal", "OBSERVATION_MODIFIER", 37, 44], ["threat", "OBSERVATION_MODIFIER", 45, 51], ["ocular epithelial cells", "OBSERVATION", 156, 179]]], ["54 Another major challenge to the use of CDV for treating adenoviral keratoconjunctivitis is its propensity to lead to toxicity, which manifests as persistent epiphora from lacrimal canalicular blockade.", [["lacrimal canalicular", "ANATOMY", 173, 193], ["CDV", "CHEMICAL", 41, 44], ["adenoviral keratoconjunctivitis", "DISEASE", 58, 89], ["toxicity", "DISEASE", 119, 127], ["epiphora", "DISEASE", 159, 167], ["lacrimal canalicular blockade", "DISEASE", 173, 202], ["CDV", "ORGANISM", 41, 44], ["adenoviral", "ORGANISM", 58, 68], ["lacrimal canalicular", "MULTI-TISSUE_STRUCTURE", 173, 193], ["CDV", "SPECIES", 41, 44], ["adenoviral", "SPECIES", 58, 68], ["CDV", "TREATMENT", 41, 44], ["adenoviral keratoconjunctivitis", "PROBLEM", 58, 89], ["toxicity", "PROBLEM", 119, 127], ["persistent epiphora", "PROBLEM", 148, 167], ["lacrimal canalicular blockade", "TREATMENT", 173, 202], ["keratoconjunctivitis", "OBSERVATION", 69, 89], ["persistent", "OBSERVATION_MODIFIER", 148, 158], ["epiphora", "OBSERVATION", 159, 167], ["lacrimal", "ANATOMY", 173, 181], ["canalicular blockade", "OBSERVATION", 182, 202]]], ["53 As such, despite its potential, its high toxicity profile and poor bioavailability make CDV a less than ideal treatment option for the treatment of HAdV associated infections, both systemically and locally.Antiviral TherapyThe solution to these challenges led to the investigation of brincidofovir (BCV), a lipid-linked derivative of CDV, which allows for cells to uptake the drug more readily when administered orally.", [["cells", "ANATOMY", 359, 364], ["toxicity", "DISEASE", 44, 52], ["HAdV", "DISEASE", 151, 155], ["infections", "DISEASE", 167, 177], ["brincidofovir", "CHEMICAL", 287, 300], ["brincidofovir", "CHEMICAL", 287, 300], ["CDV", "ORGANISM", 91, 94], ["HAdV", "ORGANISM", 151, 155], ["brincidofovir", "SIMPLE_CHEMICAL", 287, 300], ["BCV", "SIMPLE_CHEMICAL", 302, 305], ["lipid", "SIMPLE_CHEMICAL", 310, 315], ["CDV", "ORGANISM", 337, 340], ["cells", "CELL", 359, 364], ["CDV", "SPECIES", 91, 94], ["HAdV", "SPECIES", 151, 155], ["CDV", "SPECIES", 337, 340], ["its high toxicity profile", "PROBLEM", 35, 60], ["CDV", "PROBLEM", 91, 94], ["ideal treatment option", "TREATMENT", 107, 129], ["HAdV associated infections", "PROBLEM", 151, 177], ["Antiviral Therapy", "TREATMENT", 209, 226], ["The solution", "TREATMENT", 226, 238], ["brincidofovir (BCV", "TREATMENT", 287, 305], ["CDV", "PROBLEM", 337, 340], ["cells", "PROBLEM", 359, 364], ["infections", "OBSERVATION", 167, 177]]], ["13, 44, 55 Following cellular uptake, the lipid component is cleaved by phospholipases, leaving CDV.", [["cellular", "ANATOMY", 21, 29], ["cellular", "CELL", 21, 29], ["lipid", "SIMPLE_CHEMICAL", 42, 47], ["CDV", "ORGANISM", 96, 99], ["phospholipases", "PROTEIN", 72, 86], ["CDV", "SPECIES", 96, 99], ["cellular uptake", "TEST", 21, 36], ["the lipid component", "PROBLEM", 38, 57], ["cellular uptake", "OBSERVATION", 21, 36]]], ["This allows for similar antiviral efficacy as seen with CDV, but without the subsequent nephrotoxicity.", [["nephrotoxicity", "DISEASE", 88, 102], ["CDV", "ORGANISM", 56, 59], ["CDV", "SPECIES", 56, 59], ["CDV", "PROBLEM", 56, 59], ["the subsequent nephrotoxicity", "PROBLEM", 73, 102], ["nephrotoxicity", "OBSERVATION", 88, 102]]], ["Averbuch et al. reported successful use of BCV in the treatment of adenoviral infection in a patient with primary immunodeficiency whereas Florescu et al demonstrated that it was clinically beneficial in treating adenoviral infection in immunocompromised individuals who were at risk of disseminated HAdV infection.", [["adenoviral infection", "DISEASE", 67, 87], ["primary immunodeficiency", "DISEASE", 106, 130], ["adenoviral infection", "DISEASE", 213, 233], ["HAdV infection", "DISEASE", 300, 314], ["BCV", "ORGANISM", 43, 46], ["adenoviral", "ORGANISM", 67, 77], ["patient", "ORGANISM", 93, 100], ["adenoviral", "ORGANISM", 213, 223], ["HAdV", "ORGANISM", 300, 304], ["patient", "SPECIES", 93, 100], ["BCV", "SPECIES", 43, 46], ["adenoviral", "SPECIES", 67, 77], ["adenoviral", "SPECIES", 213, 223], ["BCV", "TREATMENT", 43, 46], ["adenoviral infection", "PROBLEM", 67, 87], ["primary immunodeficiency", "PROBLEM", 106, 130], ["adenoviral infection", "PROBLEM", 213, 233], ["disseminated HAdV infection", "PROBLEM", 287, 314], ["adenoviral", "ANATOMY", 67, 77], ["infection", "OBSERVATION", 78, 87], ["infection", "OBSERVATION", 224, 233], ["disseminated", "OBSERVATION_MODIFIER", 287, 299], ["HAdV", "OBSERVATION_MODIFIER", 300, 304], ["infection", "OBSERVATION", 305, 314]]], ["56 It was suggested that BCV could be a potential anti-adenoviral therapeutic agent.", [["BCV", "ORGANISM", 25, 28], ["BCV", "SPECIES", 25, 28], ["BCV", "PROBLEM", 25, 28], ["a potential anti-adenoviral therapeutic agent", "TREATMENT", 38, 83]]], ["57 Though this drug shows promise, there is still a need for more conclusive research regarding the effectivity and safety profile of BCV systemically, as well as its potential for the treatment of adenoviral ocular infections.", [["ocular", "ANATOMY", 209, 215], ["ocular infections", "DISEASE", 209, 226], ["BCV", "ORGANISM", 134, 137], ["adenoviral", "ORGANISM", 198, 208], ["ocular", "ORGANISM_SUBDIVISION", 209, 215], ["BCV", "SPECIES", 134, 137], ["adenoviral", "SPECIES", 198, 208], ["adenoviral ocular infections", "PROBLEM", 198, 226], ["adenoviral ocular", "OBSERVATION", 198, 215], ["infections", "OBSERVATION", 216, 226]]], ["13, 44 When antiviral comparison is made, ganciclovir appears to be the most favorable in terms of antiviral activity and limited systemic or local side effects.", [["ganciclovir", "CHEMICAL", 42, 53], ["ganciclovir", "CHEMICAL", 42, 53], ["ganciclovir", "SIMPLE_CHEMICAL", 42, 53], ["antiviral comparison", "TREATMENT", 12, 32], ["ganciclovir", "TREATMENT", 42, 53], ["antiviral activity", "TREATMENT", 99, 117], ["limited systemic or local side effects", "PROBLEM", 122, 160], ["antiviral activity", "OBSERVATION", 99, 117]]], ["46Immunoglobulin (Ig)-Based TherapyIn 2001, Goosens et al discussed the antiviral activity of anti-Ad IgG on gene transfer to synovial fluid.", [["synovial fluid", "ANATOMY", 126, 140], ["46Immunoglobulin", "SIMPLE_CHEMICAL", 0, 16], ["Ig", "GENE_OR_GENE_PRODUCT", 18, 20], ["anti-Ad IgG", "GENE_OR_GENE_PRODUCT", 94, 105], ["synovial fluid", "ORGANISM_SUBSTANCE", 126, 140], ["anti-Ad IgG", "PROTEIN", 94, 105], ["46Immunoglobulin (Ig)", "TREATMENT", 0, 21], ["anti-Ad IgG", "TREATMENT", 94, 105], ["synovial", "ANATOMY", 126, 134], ["fluid", "OBSERVATION", 135, 140]]], ["This was attributed to the antibodies' ability to target adenoviral capsid proteins, subsequently inhibiting infection by the virus.", [["infection", "DISEASE", 109, 118], ["adenoviral", "ORGANISM", 57, 67], ["antibodies", "PROTEIN", 27, 37], ["adenoviral capsid proteins", "PROTEIN", 57, 83], ["the antibodies' ability", "PROBLEM", 23, 46], ["adenoviral capsid proteins", "PROBLEM", 57, 83], ["infection", "PROBLEM", 109, 118], ["the virus", "PROBLEM", 122, 131], ["infection", "OBSERVATION", 109, 118]]], ["58 Topically, immunoglobulin (Ig) may offer the same effect on ocular tissue and prevent transmission and replication of the virus, to some degree.", [["ocular tissue", "ANATOMY", 63, 76], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 14, 28], ["Ig", "GENE_OR_GENE_PRODUCT", 30, 32], ["ocular tissue", "TISSUE", 63, 76], ["immunoglobulin", "PROTEIN", 14, 28], ["Ig", "PROTEIN", 30, 32], ["immunoglobulin (Ig", "TREATMENT", 14, 32], ["ocular tissue", "PROBLEM", 63, 76], ["the virus", "PROBLEM", 121, 130], ["ocular tissue", "ANATOMY", 63, 76]]], ["In addition to its antiviral properties, Ig has the added benefit of antiinflammatory effects, which can aid in sub-epithelial infiltrate management.", [["epithelial", "ANATOMY", 116, 126], ["Ig", "GENE_OR_GENE_PRODUCT", 41, 43], ["epithelial", "TISSUE", 116, 126], ["Ig", "PROTEIN", 41, 43], ["its antiviral properties", "TREATMENT", 15, 39], ["antiinflammatory effects", "TREATMENT", 69, 93], ["sub-epithelial infiltrate management", "TREATMENT", 112, 148], ["sub", "OBSERVATION_MODIFIER", 112, 115], ["epithelial", "ANATOMY", 116, 126], ["infiltrate", "OBSERVATION", 127, 137]]], ["59 Nwanegbo et al found that Ig was actually comparable to cidofovir in its antiviral activity.", [["cidofovir", "CHEMICAL", 59, 68], ["cidofovir", "CHEMICAL", 59, 68], ["Ig", "GENE_OR_GENE_PRODUCT", 29, 31], ["cidofovir", "SIMPLE_CHEMICAL", 59, 68], ["Ig", "PROTEIN", 29, 31], ["cidofovir", "TREATMENT", 59, 68], ["antiviral activity", "OBSERVATION", 76, 94]]], ["While cidofovir acts intracellularly to block DNA replication, Ig neutralizes the virus on the ocular surface.", [["ocular surface", "ANATOMY", 95, 109], ["cidofovir", "CHEMICAL", 6, 15], ["cidofovir", "CHEMICAL", 6, 15], ["cidofovir", "SIMPLE_CHEMICAL", 6, 15], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["Ig", "GENE_OR_GENE_PRODUCT", 63, 65], ["ocular surface", "MULTI-TISSUE_STRUCTURE", 95, 109], ["Ig", "PROTEIN", 63, 65], ["cidofovir acts", "TREATMENT", 6, 20], ["block DNA replication", "TREATMENT", 40, 61], ["Ig neutralizes", "TREATMENT", 63, 77], ["virus", "OBSERVATION", 82, 87], ["ocular", "ANATOMY", 95, 101], ["surface", "ANATOMY_MODIFIER", 102, 109]]], ["In comparison to cidofovir and saline titers, Ig was more effective during the acute phase of the infection.", [["cidofovir", "CHEMICAL", 17, 26], ["infection", "DISEASE", 98, 107], ["cidofovir", "CHEMICAL", 17, 26], ["cidofovir", "SIMPLE_CHEMICAL", 17, 26], ["saline", "SIMPLE_CHEMICAL", 31, 37], ["Ig", "GENE_OR_GENE_PRODUCT", 46, 48], ["Ig", "PROTEIN", 46, 48], ["cidofovir and saline titers", "TREATMENT", 17, 44], ["Ig", "TREATMENT", 46, 48], ["the infection", "PROBLEM", 94, 107], ["more effective", "OBSERVATION_MODIFIER", 53, 67], ["infection", "OBSERVATION", 98, 107]]], ["59 It worked to aid in the clearance of the virus, shortening the duration of the infection, and thereby limiting the transmission of the virus.", [["infection", "DISEASE", 82, 91], ["the virus", "PROBLEM", 40, 49], ["the infection", "PROBLEM", 78, 91], ["the virus", "PROBLEM", 134, 143], ["infection", "OBSERVATION", 82, 91]]], ["Additionally, Ig may be beneficial in prophylaxis to prevent clinical infections.", [["infections", "DISEASE", 70, 80], ["Ig", "GENE_OR_GENE_PRODUCT", 14, 16], ["Ig", "PROTEIN", 14, 16], ["Ig", "TREATMENT", 14, 16], ["prophylaxis", "TREATMENT", 38, 49], ["clinical infections", "PROBLEM", 61, 80], ["infections", "OBSERVATION", 70, 80]]], ["Though both cidofovir and Ig were effective in this study, cidofovir demonstrated a significantly shorter duration of viral shedding.", [["cidofovir", "CHEMICAL", 12, 21], ["cidofovir", "CHEMICAL", 59, 68], ["cidofovir", "CHEMICAL", 12, 21], ["cidofovir", "CHEMICAL", 59, 68], ["cidofovir", "SIMPLE_CHEMICAL", 12, 21], ["Ig", "GENE_OR_GENE_PRODUCT", 26, 28], ["cidofovir", "SIMPLE_CHEMICAL", 59, 68], ["Ig", "PROTEIN", 26, 28], ["cidofovir and Ig", "TREATMENT", 12, 28], ["this study", "TEST", 47, 57], ["cidofovir", "TREATMENT", 59, 68], ["viral shedding", "PROBLEM", 118, 132]]], ["This is likely due to the mechanism of intracellularmediated adenoviral DNA polymerase-blocking activities and prolonged tissue half-life after rapid uptake into cells.", [["tissue", "ANATOMY", 121, 127], ["cells", "ANATOMY", 162, 167], ["adenoviral", "ORGANISM", 61, 71], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["tissue", "TISSUE", 121, 127], ["cells", "CELL", 162, 167], ["intracellularmediated adenoviral DNA polymerase", "PROTEIN", 39, 86], ["intracellularmediated adenoviral DNA polymerase", "PROBLEM", 39, 86], ["blocking activities", "PROBLEM", 87, 106], ["rapid uptake into cells", "PROBLEM", 144, 167], ["likely due to", "UNCERTAINTY", 8, 21]]], ["This study yielded promising results in the future of topical Ig use on ocular HAdV infections.", [["ocular", "ANATOMY", 72, 78], ["ocular HAdV infections", "DISEASE", 72, 94], ["Ig", "GENE_OR_GENE_PRODUCT", 62, 64], ["HAdV", "ORGANISM", 79, 83], ["Ig", "PROTEIN", 62, 64], ["This study", "TEST", 0, 10], ["topical Ig use", "TREATMENT", 54, 68], ["ocular HAdV infections", "PROBLEM", 72, 94], ["infections", "OBSERVATION", 84, 94]]], ["The limitation lies in product consistency as Ig is derived from serum pooled by various donors, though anti-adenoviral efficacy appears stable over different lots.", [["serum", "ANATOMY", 65, 70], ["Ig", "GENE_OR_GENE_PRODUCT", 46, 48], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["donors", "ORGANISM", 89, 95], ["Ig", "PROTEIN", 46, 48], ["various donors", "PROBLEM", 81, 95], ["anti-adenoviral efficacy", "PROBLEM", 104, 128], ["stable", "OBSERVATION_MODIFIER", 137, 143]]], ["59, 60 Topical Anti-Inflammatory TherapyImmunoglobulin (Ig)-Based TherapyCorneal involvement in EKC occurs in approximately 80% of cases, varying in presentation as a superficial punctate keratitis, focal epithelial punctate keratitis, subepithelial infiltrate (SEI) formation, and reduced corneal sensitivity.", [["focal epithelial", "ANATOMY", 199, 215], ["subepithelial infiltrate", "ANATOMY", 236, 260], ["corneal", "ANATOMY", 290, 297], ["EKC", "DISEASE", 96, 99], ["keratitis", "DISEASE", 188, 197], ["keratitis", "DISEASE", 225, 234], ["SEI", "DISEASE", 262, 265], ["TherapyImmunoglobulin", "SIMPLE_CHEMICAL", 33, 54], ["Ig", "GENE_OR_GENE_PRODUCT", 56, 58], ["epithelial", "TISSUE", 205, 215], ["subepithelial", "TISSUE", 236, 249], ["corneal", "TISSUE", 290, 297], ["Topical Anti-Inflammatory TherapyImmunoglobulin (Ig)", "TREATMENT", 7, 59], ["a superficial punctate keratitis", "PROBLEM", 165, 197], ["focal epithelial punctate keratitis", "PROBLEM", 199, 234], ["subepithelial infiltrate (SEI) formation", "PROBLEM", 236, 276], ["reduced corneal sensitivity", "PROBLEM", 282, 309], ["superficial", "OBSERVATION_MODIFIER", 167, 178], ["punctate", "OBSERVATION_MODIFIER", 179, 187], ["keratitis", "OBSERVATION", 188, 197], ["focal", "OBSERVATION_MODIFIER", 199, 204], ["epithelial", "ANATOMY_MODIFIER", 205, 215], ["punctate", "OBSERVATION_MODIFIER", 216, 224], ["keratitis", "OBSERVATION", 225, 234], ["subepithelial", "OBSERVATION_MODIFIER", 236, 249], ["infiltrate", "OBSERVATION", 250, 260], ["reduced", "OBSERVATION_MODIFIER", 282, 289], ["corneal sensitivity", "OBSERVATION", 290, 309]]], ["1,2,12,61 SEIs specifically will often manifest anywhere from one to three weeks following the acute phase of the infection.", [["infection", "DISEASE", 114, 123], ["the infection", "PROBLEM", 110, 123], ["infection", "OBSERVATION", 114, 123]]], ["Histologically they are comprised of residual antigen and lymphocytic accumulations that adhere to stromal cells in the cornea.", [["lymphocytic", "ANATOMY", 58, 69], ["stromal cells", "ANATOMY", 99, 112], ["cornea", "ANATOMY", 120, 126], ["stromal cells", "CELL", 99, 112], ["cornea", "ORGAN", 120, 126], ["stromal cells", "CELL_TYPE", 99, 112], ["residual antigen", "PROBLEM", 37, 53], ["lymphocytic accumulations", "PROBLEM", 58, 83], ["stromal cells in the cornea", "PROBLEM", 99, 126], ["residual", "OBSERVATION_MODIFIER", 37, 45], ["antigen", "OBSERVATION_MODIFIER", 46, 53], ["lymphocytic accumulations", "OBSERVATION", 58, 83], ["stromal cells", "OBSERVATION", 99, 112], ["cornea", "ANATOMY", 120, 126]]], ["62 This clinical finding may persist for months to years following resolution of the conjunctivitis, leading to subjective visual disturbances, such as decreased vision, photophobia, halos, and the development of irregular astigmatism.", [["conjunctivitis", "DISEASE", 85, 99], ["visual disturbances", "DISEASE", 123, 142], ["decreased vision", "DISEASE", 152, 168], ["photophobia", "DISEASE", 170, 181], ["halos", "DISEASE", 183, 188], ["astigmatism", "DISEASE", 223, 234], ["the conjunctivitis", "PROBLEM", 81, 99], ["subjective visual disturbances", "PROBLEM", 112, 142], ["decreased vision", "PROBLEM", 152, 168], ["photophobia", "PROBLEM", 170, 181], ["halos", "PROBLEM", 183, 188], ["irregular astigmatism", "PROBLEM", 213, 234], ["conjunctivitis", "OBSERVATION", 85, 99], ["irregular", "OBSERVATION_MODIFIER", 213, 222], ["astigmatism", "OBSERVATION", 223, 234]]], ["Due to their chronicity and visual impact, treatments including anti-inflammatory and immunosuppressive agents have been investigated to treat as well as prevent SEIs, though they often end up resolving without scarring or corneal neovascularization formation.", [["corneal", "ANATOMY", 223, 230], ["SEIs", "DISEASE", 162, 166], ["scarring", "DISEASE", 211, 219], ["neovascularization", "DISEASE", 231, 249], ["corneal", "TISSUE", 223, 230], ["treatments", "TREATMENT", 43, 53], ["anti-inflammatory", "TREATMENT", 64, 81], ["immunosuppressive agents", "TREATMENT", 86, 110], ["SEIs", "PROBLEM", 162, 166], ["scarring", "PROBLEM", 211, 219], ["corneal neovascularization formation", "PROBLEM", 223, 259], ["chronicity", "OBSERVATION", 13, 23], ["without", "UNCERTAINTY", 203, 210], ["scarring", "OBSERVATION", 211, 219], ["corneal", "ANATOMY", 223, 230], ["neovascularization", "OBSERVATION", 231, 249]]], ["2, 12, 62 Research demonstrates that mild corticosteroid treatment administered topically approximately three times per day can significantly improve EKC symptoms and, if used in the short term, acute phase of the disease, does not lead to significant ocular side effects.", [["ocular", "ANATOMY", 252, 258], ["mild corticosteroid treatment", "TREATMENT", 37, 66], ["EKC symptoms", "PROBLEM", 150, 162], ["the disease", "PROBLEM", 210, 221], ["significant ocular side effects", "PROBLEM", 240, 271], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["corticosteroid treatment", "OBSERVATION", 42, 66], ["disease", "OBSERVATION", 214, 221]]], ["There is also additional benefit in the use of topical corticosteroids once the acute phase of the infection resolves, for the remaining, persistent SEIs.", [["infection", "DISEASE", 99, 108], ["SEIs", "DISEASE", 149, 153], ["SEIs", "PATHOLOGICAL_FORMATION", 149, 153], ["topical corticosteroids", "TREATMENT", 47, 70], ["the infection", "PROBLEM", 95, 108], ["persistent SEIs", "PROBLEM", 138, 153], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["infection", "OBSERVATION", 99, 108], ["persistent", "OBSERVATION_MODIFIER", 138, 148], ["SEIs", "OBSERVATION", 149, 153]]], ["2, 63 While chronic corticosteroid treatment has been proven to reduce these findings, a significant challenge to this mode of treatment is the risk of complications of long-term use, including glaucoma and cataract formation.", [["glaucoma", "ANATOMY", 194, 202], ["glaucoma", "DISEASE", 194, 202], ["cataract", "DISEASE", 207, 215], ["chronic corticosteroid treatment", "TREATMENT", 12, 44], ["treatment", "TREATMENT", 127, 136], ["glaucoma", "PROBLEM", 194, 202], ["cataract formation", "PROBLEM", 207, 225], ["chronic", "OBSERVATION_MODIFIER", 12, 19], ["corticosteroid", "OBSERVATION", 20, 34], ["glaucoma", "OBSERVATION", 194, 202], ["cataract", "OBSERVATION", 207, 215]]], ["[64] [65] [66] [67] [68] [69] Additionally, corticosteroid treatment of SEIs can result in a 17.5% recurrence rate and consequential, unsuccessful drug tapering.", [["SEIs", "DISEASE", 72, 76], ["[64] [65] [66] [67] [68]", "CHEMICAL", 0, 24], ["[64] [65] [66] [67] [68] [69]", "SIMPLE_CHEMICAL", 0, 29], ["corticosteroid", "SIMPLE_CHEMICAL", 44, 58], ["SEIs", "SIMPLE_CHEMICAL", 72, 76], ["corticosteroid treatment of SEIs", "TREATMENT", 44, 76], ["a 17.5% recurrence rate", "PROBLEM", 91, 114], ["unsuccessful drug tapering", "TREATMENT", 134, 160]]], ["70 If discontinued abruptly, these viral antigens continue to attract lymphocytes, causing persistence of SEIs.", [["lymphocytes", "ANATOMY", 70, 81], ["SEIs", "DISEASE", 106, 110], ["lymphocytes", "CELL", 70, 81], ["SEIs", "PATHOLOGICAL_FORMATION", 106, 110], ["viral antigens", "PROTEIN", 35, 49], ["lymphocytes", "CELL_TYPE", 70, 81], ["these viral antigens", "PROBLEM", 29, 49], ["lymphocytes", "PROBLEM", 70, 81], ["SEIs", "PROBLEM", 106, 110]]], ["62, 66 Excimer laser ablation can be helpful in such cases.", [["Excimer laser ablation", "TREATMENT", 7, 29]]], ["63 In a study comparing topical loteprednol with dexamethasone, similar outcomes in SEI treatment were observed.", [["loteprednol", "CHEMICAL", 32, 43], ["dexamethasone", "CHEMICAL", 49, 62], ["SEI", "CHEMICAL", 84, 87], ["loteprednol", "CHEMICAL", 32, 43], ["dexamethasone", "CHEMICAL", 49, 62], ["loteprednol", "SIMPLE_CHEMICAL", 32, 43], ["dexamethasone", "SIMPLE_CHEMICAL", 49, 62], ["a study", "TEST", 6, 13], ["topical loteprednol", "TREATMENT", 24, 43], ["dexamethasone", "TREATMENT", 49, 62], ["SEI treatment", "TREATMENT", 84, 97]]], ["This is significant because milder topical steroid forms, such as loteprednol, are known to have less risk of adverse effects.", [["steroid", "CHEMICAL", 43, 50], ["loteprednol", "CHEMICAL", 66, 77], ["steroid", "CHEMICAL", 43, 50], ["loteprednol", "CHEMICAL", 66, 77], ["loteprednol", "SIMPLE_CHEMICAL", 66, 77], ["milder topical steroid forms", "TREATMENT", 28, 56], ["adverse effects", "PROBLEM", 110, 125], ["significant", "OBSERVATION_MODIFIER", 8, 19]]], ["71 However, it is important to note that short-term treatment with topical steroids of limited potency may also delay viral clearance.", [["steroids", "CHEMICAL", 75, 83], ["steroids", "CHEMICAL", 75, 83], ["short-term treatment", "TREATMENT", 41, 61], ["topical steroids", "TREATMENT", 67, 83]]], ["72 Nonsteroidal anti-inflammatory drugs (NSAIDs) are another alternative to corticosteroids, in that they are approved for topical, ocular use and exhibit antiinflammatory effects without the substantial risk of glaucoma and cataract effect seen with steroid use.", [["ocular", "ANATOMY", 132, 138], ["glaucoma", "ANATOMY", 212, 220], ["glaucoma", "DISEASE", 212, 220], ["cataract", "DISEASE", 225, 233], ["steroid", "CHEMICAL", 251, 258], ["corticosteroids", "CHEMICAL", 76, 91], ["steroid", "CHEMICAL", 251, 258], ["NSAIDs", "SIMPLE_CHEMICAL", 41, 47], ["steroid", "SIMPLE_CHEMICAL", 251, 258], ["Nonsteroidal anti-inflammatory drugs", "TREATMENT", 3, 39], ["NSAIDs", "TREATMENT", 41, 47], ["corticosteroids", "TREATMENT", 76, 91], ["topical", "TREATMENT", 123, 130], ["antiinflammatory effects", "TREATMENT", 155, 179], ["glaucoma", "PROBLEM", 212, 220], ["cataract effect", "PROBLEM", 225, 240], ["steroid use", "TREATMENT", 251, 262], ["glaucoma", "OBSERVATION", 212, 220], ["cataract", "OBSERVATION", 225, 233]]], ["These agents work on the arachidonic acid pathway by inhibiting cyclooxygenase and, subsequently, the formation of prostaglandins, thromboxane, and prostacyclin.", [["arachidonic acid", "CHEMICAL", 25, 41], ["prostaglandins", "CHEMICAL", 115, 129], ["thromboxane", "CHEMICAL", 131, 142], ["prostacyclin", "CHEMICAL", 148, 160], ["arachidonic acid", "CHEMICAL", 25, 41], ["prostaglandins", "CHEMICAL", 115, 129], ["thromboxane", "CHEMICAL", 131, 142], ["prostacyclin", "CHEMICAL", 148, 160], ["arachidonic acid", "SIMPLE_CHEMICAL", 25, 41], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 64, 78], ["prostaglandins", "SIMPLE_CHEMICAL", 115, 129], ["thromboxane", "SIMPLE_CHEMICAL", 131, 142], ["prostacyclin", "SIMPLE_CHEMICAL", 148, 160], ["cyclooxygenase", "PROTEIN", 64, 78], ["the arachidonic acid pathway", "TREATMENT", 21, 49], ["cyclooxygenase", "TREATMENT", 64, 78], ["prostaglandins", "TREATMENT", 115, 129], ["thromboxane", "TREATMENT", 131, 142], ["prostacyclin", "TREATMENT", 148, 160]]], ["With specificity to ocular uses, they have been shown to be effective in cases of allergic conjunctivitis, alkali burns, herpetic uveitis, ocular trauma, and pre/post-operative cataract and refractive surgeries.", [["ocular", "ANATOMY", 20, 26], ["ocular", "ANATOMY", 139, 145], ["allergic conjunctivitis", "DISEASE", 82, 105], ["alkali burns", "DISEASE", 107, 119], ["herpetic uveitis", "DISEASE", 121, 137], ["ocular trauma", "DISEASE", 139, 152], ["cataract", "DISEASE", 177, 185], ["allergic conjunctivitis", "PROBLEM", 82, 105], ["alkali burns", "PROBLEM", 107, 119], ["herpetic uveitis", "PROBLEM", 121, 137], ["ocular trauma", "PROBLEM", 139, 152], ["pre/post-operative cataract", "PROBLEM", 158, 185], ["refractive surgeries", "TREATMENT", 190, 210], ["allergic conjunctivitis", "OBSERVATION", 82, 105], ["alkali burns", "OBSERVATION", 107, 119], ["herpetic uveitis", "OBSERVATION", 121, 137], ["ocular", "ANATOMY", 139, 145], ["trauma", "OBSERVATION", 146, 152], ["post-operative cataract", "OBSERVATION", 162, 185], ["refractive surgeries", "OBSERVATION", 190, 210]]], ["73- 76 Gordon et al were the first to investigate NSAID effects on adenoviral replication, specifically ketorolac tromethamine and diclofenac sodium ophthalmic solutions.", [["ketorolac tromethamine", "CHEMICAL", 104, 126], ["diclofenac sodium", "CHEMICAL", 131, 148], ["ketorolac tromethamine", "CHEMICAL", 104, 126], ["diclofenac sodium", "CHEMICAL", 131, 148], ["NSAID", "SIMPLE_CHEMICAL", 50, 55], ["adenoviral", "ORGANISM", 67, 77], ["ketorolac tromethamine", "SIMPLE_CHEMICAL", 104, 126], ["diclofenac", "SIMPLE_CHEMICAL", 131, 141], ["NSAID effects", "TREATMENT", 50, 63], ["adenoviral replication", "TREATMENT", 67, 89], ["ketorolac tromethamine", "TREATMENT", 104, 126], ["diclofenac sodium ophthalmic solutions", "TREATMENT", 131, 169]]], ["During both the early and late phases of infection, the effect of NSAIDs on viral titers did not differ from control groups, nor did it affect the duration of viral shedding.", [["infection", "DISEASE", 41, 50], ["NSAIDs", "CHEMICAL", 66, 72], ["NSAIDs", "SIMPLE_CHEMICAL", 66, 72], ["infection", "PROBLEM", 41, 50], ["NSAIDs", "TREATMENT", 66, 72], ["viral titers", "TEST", 76, 88], ["viral shedding", "PROBLEM", 159, 173], ["late phases", "OBSERVATION_MODIFIER", 26, 37], ["infection", "OBSERVATION", 41, 50]]], ["In contrast, prednisolone treatment was shown to prolong viral shedding.", [["prednisolone", "CHEMICAL", 13, 25], ["prednisolone", "CHEMICAL", 13, 25], ["prednisolone", "SIMPLE_CHEMICAL", 13, 25], ["prednisolone treatment", "TREATMENT", 13, 35]]], ["73 As it pertained to sub-epithelial infiltrates, treatment with diclofenac or ketorolac did not yield a statistically significant reduction when compared to control groups, whereas prednisolone did.", [["sub-epithelial", "ANATOMY", 22, 36], ["diclofenac", "CHEMICAL", 65, 75], ["ketorolac", "CHEMICAL", 79, 88], ["prednisolone", "CHEMICAL", 182, 194], ["diclofenac", "CHEMICAL", 65, 75], ["ketorolac", "CHEMICAL", 79, 88], ["prednisolone", "CHEMICAL", 182, 194], ["epithelial", "TISSUE", 26, 36], ["diclofenac", "SIMPLE_CHEMICAL", 65, 75], ["ketorolac", "SIMPLE_CHEMICAL", 79, 88], ["prednisolone", "SIMPLE_CHEMICAL", 182, 194], ["epithelial infiltrates", "PROBLEM", 26, 48], ["diclofenac", "TREATMENT", 65, 75], ["ketorolac", "TREATMENT", 79, 88], ["prednisolone", "TREATMENT", 182, 194], ["sub", "OBSERVATION_MODIFIER", 22, 25], ["epithelial", "ANATOMY", 26, 36], ["infiltrates", "OBSERVATION", 37, 48]]], ["This study suggests that NSAIDs are not likely to have any clinically significant antiviral effects.", [["NSAIDs", "CHEMICAL", 25, 31], ["NSAIDs", "SIMPLE_CHEMICAL", 25, 31], ["This study", "TEST", 0, 10], ["NSAIDs", "TREATMENT", 25, 31], ["any clinically significant antiviral effects", "PROBLEM", 55, 99], ["not likely", "UNCERTAINTY", 36, 46], ["antiviral effects", "OBSERVATION", 82, 99]]], ["73 It is important to note that even though NSAIDs offer a higher safety profile with long-term use in comparison to topical corticosteroids, they do not seem to be useful in cases of HAdV-associated conjunctivitis.", [["conjunctivitis", "DISEASE", 200, 214], ["NSAIDs", "SIMPLE_CHEMICAL", 44, 50], ["HAdV", "ORGANISM", 184, 188], ["NSAIDs", "TREATMENT", 44, 50], ["topical corticosteroids", "TREATMENT", 117, 140], ["HAdV", "PROBLEM", 184, 188], ["conjunctivitis", "PROBLEM", 200, 214], ["conjunctivitis", "OBSERVATION", 200, 214]]], ["They are also not without complication and associated with risk of corneal melt.", [["corneal", "ANATOMY", 67, 74], ["corneal", "TISSUE", 67, 74], ["complication", "PROBLEM", 26, 38], ["corneal melt", "PROBLEM", 67, 79], ["not without", "UNCERTAINTY", 14, 25], ["corneal melt", "OBSERVATION", 67, 79]]], ["74 Pseudomembranes are marked by fibrin rich exudation lacking blood or lymphatic vessels, while true membranes are formed by coalescence of the exudation over the substantia propria of mucous membranes; both are common in adenoviral keratoconjunctivitis and may hemorrhage upon removal.", [["Pseudomembranes", "ANATOMY", 3, 18], ["blood", "ANATOMY", 63, 68], ["lymphatic vessels", "ANATOMY", 72, 89], ["membranes", "ANATOMY", 102, 111], ["substantia propria", "ANATOMY", 164, 182], ["mucous membranes", "ANATOMY", 186, 202], ["adenoviral keratoconjunctivitis", "DISEASE", 223, 254], ["hemorrhage", "DISEASE", 263, 273], ["fibrin", "GENE_OR_GENE_PRODUCT", 33, 39], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 72, 89], ["membranes", "CELLULAR_COMPONENT", 102, 111], ["substantia propria", "TISSUE", 164, 182], ["mucous membranes", "CELLULAR_COMPONENT", 186, 202], ["adenoviral", "ORGANISM", 223, 233], ["fibrin", "PROTEIN", 33, 39], ["adenoviral", "SPECIES", 223, 233], ["Pseudomembranes", "PROBLEM", 3, 18], ["fibrin rich exudation lacking blood or lymphatic vessels", "PROBLEM", 33, 89], ["true membranes", "PROBLEM", 97, 111], ["the exudation", "PROBLEM", 141, 154], ["mucous membranes", "PROBLEM", 186, 202], ["adenoviral keratoconjunctivitis", "PROBLEM", 223, 254], ["hemorrhage", "PROBLEM", 263, 273], ["removal", "TREATMENT", 279, 286], ["marked", "OBSERVATION_MODIFIER", 23, 29], ["fibrin rich", "OBSERVATION", 33, 44], ["exudation", "OBSERVATION_MODIFIER", 45, 54], ["lacking blood", "OBSERVATION", 55, 68], ["lymphatic vessels", "ANATOMY", 72, 89], ["coalescence", "OBSERVATION_MODIFIER", 126, 137], ["exudation", "OBSERVATION_MODIFIER", 145, 154], ["substantia propria", "ANATOMY", 164, 182], ["mucous membranes", "ANATOMY", 186, 202], ["adenoviral keratoconjunctivitis", "OBSERVATION", 223, 254], ["hemorrhage", "OBSERVATION", 263, 273]]], ["1 Histopathological studies indicate the presence of fibrin, neutrophils, macrophages, effector lymphocytes, and activated dendritic cells in these films.", [["neutrophils", "ANATOMY", 61, 72], ["macrophages", "ANATOMY", 74, 85], ["effector lymphocytes", "ANATOMY", 87, 107], ["dendritic cells", "ANATOMY", 123, 138], ["fibrin", "GENE_OR_GENE_PRODUCT", 53, 59], ["neutrophils", "CELL", 61, 72], ["macrophages", "CELL", 74, 85], ["effector lymphocytes", "CELL", 87, 107], ["dendritic cells", "CELL", 123, 138], ["fibrin", "PROTEIN", 53, 59], ["neutrophils", "CELL_TYPE", 61, 72], ["macrophages", "CELL_TYPE", 74, 85], ["effector lymphocytes", "CELL_TYPE", 87, 107], ["activated dendritic cells", "CELL_TYPE", 113, 138], ["Histopathological studies", "TEST", 2, 27], ["fibrin, neutrophils", "PROBLEM", 53, 72], ["macrophages", "PROBLEM", 74, 85], ["effector lymphocytes", "PROBLEM", 87, 107], ["activated dendritic cells", "PROBLEM", 113, 138], ["these films", "TEST", 142, 153], ["fibrin", "OBSERVATION", 53, 59], ["neutrophils", "ANATOMY", 61, 72], ["macrophages", "ANATOMY", 74, 85], ["effector lymphocytes", "OBSERVATION", 87, 107], ["dendritic cells", "OBSERVATION", 123, 138]]], ["1 Because pseudomembrane formation can present in severe cases of adenoviral keratoconjunctivitis in the setting of an intense inflammatory response (Figure 2 ), inoffice removal of the pseudomembrane could be beneficial in preventing further complications of conjunctival fibrosis and long-term sequelae.", [["pseudomembrane", "ANATOMY", 10, 24], ["pseudomembrane", "ANATOMY", 186, 200], ["conjunctival", "ANATOMY", 260, 272], ["adenoviral keratoconjunctivitis", "DISEASE", 66, 97], ["fibrosis", "DISEASE", 273, 281], ["pseudomembrane", "CANCER", 10, 24], ["adenoviral", "ORGANISM", 66, 76], ["pseudomembrane", "CANCER", 186, 200], ["conjunctival", "ORGAN", 260, 272], ["adenoviral", "SPECIES", 66, 76], ["pseudomembrane formation", "PROBLEM", 10, 34], ["adenoviral keratoconjunctivitis", "PROBLEM", 66, 97], ["an intense inflammatory response", "PROBLEM", 116, 148], ["inoffice removal", "TREATMENT", 162, 178], ["the pseudomembrane", "PROBLEM", 182, 200], ["conjunctival fibrosis", "PROBLEM", 260, 281], ["long-term sequelae", "PROBLEM", 286, 304], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["adenoviral keratoconjunctivitis", "OBSERVATION", 66, 97], ["intense", "OBSERVATION_MODIFIER", 119, 126], ["inflammatory", "OBSERVATION", 127, 139], ["conjunctival", "ANATOMY", 260, 272], ["fibrosis", "OBSERVATION", 273, 281], ["long-term sequelae", "OBSERVATION_MODIFIER", 286, 304]]], ["Additionally, pseudomembrane manifestation along with SEIs necessitates the need for topical anti-inflammatory management.Immunotherapy and Cardiotonic SteroidsCyclosporine, a non-steroidal immunomodulatory, was first developed in the 1970s as a novel drug to inhibit T cells both specifically and reversibly.", [["pseudomembrane", "ANATOMY", 14, 28], ["T cells", "ANATOMY", 268, 275], ["SEIs", "DISEASE", 54, 58], ["Cyclosporine", "CHEMICAL", 160, 172], ["Cyclosporine", "CHEMICAL", 160, 172], ["Cardiotonic SteroidsCyclosporine", "SIMPLE_CHEMICAL", 140, 172], ["T cells", "CELL", 268, 275], ["T cells", "CELL_TYPE", 268, 275], ["pseudomembrane manifestation", "PROBLEM", 14, 42], ["SEIs", "PROBLEM", 54, 58], ["topical anti-inflammatory management", "TREATMENT", 85, 121], ["Immunotherapy", "TREATMENT", 122, 135], ["Cardiotonic SteroidsCyclosporine", "TREATMENT", 140, 172], ["a non-steroidal immunomodulatory", "TREATMENT", 174, 206], ["T cells", "PROBLEM", 268, 275]]], ["Its first use was in whole organ transplants in attempts to avoid transplant rejection by tempering the host's own immune response.", [["organ", "ANATOMY", 27, 32], ["organ", "ORGAN", 27, 32], ["whole organ transplants", "TREATMENT", 21, 44], ["transplant rejection", "TREATMENT", 66, 86], ["rejection", "OBSERVATION", 77, 86]]], ["77 Ocular use in HAdV keratoconjunctivitis should be considered when there is a need to dampen the immune response as in corneal complications of the virus, especially when there are contraindications of using corticosteroids or to limit associated corticosteroid complications.Immunotherapy and Cardiotonic SteroidsTopical cyclosporine (both 1% and 2% concentrations) is an alternative option which, if used in the acute phase of adenoviral keratoconjunctivitis, is successful in both reducing the risk of developing corneal findings as well as the chronic treatment of persistent SEIs, with most cases resolving over a course of 3-4 weeks.", [["Ocular", "ANATOMY", 3, 9], ["corneal", "ANATOMY", 121, 128], ["corneal", "ANATOMY", 518, 525], ["HAdV keratoconjunctivitis", "DISEASE", 17, 42], ["cyclosporine", "CHEMICAL", 324, 336], ["adenoviral keratoconjunctivitis", "DISEASE", 431, 462], ["SEIs", "DISEASE", 582, 586], ["corticosteroids", "CHEMICAL", 210, 225], ["cyclosporine", "CHEMICAL", 324, 336], ["HAdV", "ORGANISM", 17, 21], ["corneal", "TISSUE", 121, 128], ["corticosteroids", "SIMPLE_CHEMICAL", 210, 225], ["Cardiotonic SteroidsTopical cyclosporine", "SIMPLE_CHEMICAL", 296, 336], ["adenoviral", "ORGANISM", 431, 441], ["corneal", "TISSUE", 518, 525], ["adenoviral", "SPECIES", 431, 441], ["HAdV keratoconjunctivitis", "PROBLEM", 17, 42], ["corneal complications of the virus", "PROBLEM", 121, 155], ["corticosteroids", "TREATMENT", 210, 225], ["corticosteroid complications", "PROBLEM", 249, 277], ["Immunotherapy", "TREATMENT", 278, 291], ["Cardiotonic SteroidsTopical cyclosporine", "TREATMENT", 296, 336], ["an alternative option", "TREATMENT", 372, 393], ["adenoviral keratoconjunctivitis", "PROBLEM", 431, 462], ["developing corneal findings", "PROBLEM", 507, 534], ["persistent SEIs", "PROBLEM", 571, 586], ["keratoconjunctivitis", "OBSERVATION", 22, 42], ["adenoviral keratoconjunctivitis", "OBSERVATION", 431, 462], ["corneal", "ANATOMY", 518, 525], ["chronic", "OBSERVATION_MODIFIER", 550, 557], ["persistent", "OBSERVATION_MODIFIER", 571, 581], ["SEIs", "OBSERVATION", 582, 586]]], ["64, 66, 69, 78 Okumus et al studied the efficacy of 0.05% cyclosporine (Restasis \u00ae , Allergan, Irvine, California, USA) once per day or once every other day, in treatment of SEIs secondary to adenoviral epidemic keratoconjunctivitis in cases persisting for more than three months.", [["cyclosporine", "CHEMICAL", 58, 70], ["SEIs", "DISEASE", 174, 178], ["keratoconjunctivitis", "DISEASE", 212, 232], ["cyclosporine", "CHEMICAL", 58, 70], ["Restasis", "CHEMICAL", 72, 80], ["cyclosporine", "SIMPLE_CHEMICAL", 58, 70], ["adenoviral", "ORGANISM", 192, 202], ["0.05% cyclosporine", "TREATMENT", 52, 70], ["Allergan", "TREATMENT", 85, 93], ["SEIs", "PROBLEM", 174, 178], ["adenoviral epidemic keratoconjunctivitis", "PROBLEM", 192, 232], ["epidemic", "OBSERVATION_MODIFIER", 203, 211], ["keratoconjunctivitis", "OBSERVATION", 212, 232]]], ["Patients in this study had also initially been treated with topical corticosteroids for several months with no regression, or who had to discontinue due to subsequent, elevated IOP.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["this study", "TEST", 12, 22], ["topical corticosteroids", "TREATMENT", 60, 83], ["elevated IOP", "PROBLEM", 168, 180], ["elevated", "OBSERVATION_MODIFIER", 168, 176], ["IOP", "OBSERVATION", 177, 180]]], ["After one month of 0.05% cyclosporine treatment, 81.75% of eyes had cleared SEIs while the remaining 18.2% had decreased in number.", [["eyes", "ANATOMY", 59, 63], ["cyclosporine", "CHEMICAL", 25, 37], ["SEIs", "DISEASE", 76, 80], ["cyclosporine", "CHEMICAL", 25, 37], ["cyclosporine", "SIMPLE_CHEMICAL", 25, 37], ["eyes", "ORGAN", 59, 63], ["0.05% cyclosporine treatment", "TREATMENT", 19, 47], ["decreased", "OBSERVATION_MODIFIER", 111, 120]]], ["No systemic or ocular side effects were observed.", [["ocular", "ANATOMY", 15, 21], ["systemic or ocular side effects", "PROBLEM", 3, 34], ["systemic", "OBSERVATION_MODIFIER", 3, 11], ["ocular", "OBSERVATION", 15, 21]]], ["Few cases (11.12%) in this study resulted in recurrence of SEIs after discontinuing treatment.", [["SEIs", "DISEASE", 59, 63], ["this study", "TEST", 22, 32], ["recurrence of SEIs", "PROBLEM", 45, 63], ["discontinuing treatment", "TREATMENT", 70, 93], ["SEIs", "ANATOMY", 59, 63]]], ["69 Cyclosporine is likely effective in these cases due to its action in the inhibition of T cell proliferation and activation, thereby reducing ocular surface inflammation.", [["T cell", "ANATOMY", 90, 96], ["ocular surface", "ANATOMY", 144, 158], ["Cyclosporine", "CHEMICAL", 3, 15], ["inflammation", "DISEASE", 159, 171], ["Cyclosporine", "CHEMICAL", 3, 15], ["Cyclosporine", "SIMPLE_CHEMICAL", 3, 15], ["T cell", "CELL", 90, 96], ["Cyclosporine", "TREATMENT", 3, 15], ["T cell proliferation", "TREATMENT", 90, 110], ["ocular surface inflammation", "PROBLEM", 144, 171], ["Cyclosporine", "OBSERVATION", 3, 15], ["likely", "UNCERTAINTY", 19, 25], ["effective", "OBSERVATION_MODIFIER", 26, 35], ["cell proliferation", "OBSERVATION", 92, 110], ["reducing", "OBSERVATION_MODIFIER", 135, 143], ["ocular", "OBSERVATION_MODIFIER", 144, 150], ["surface", "OBSERVATION_MODIFIER", 151, 158], ["inflammation", "OBSERVATION", 159, 171]]], ["77 It has been shown to be efficacious in various ocular diseases, such as vernal keratoconjunctivitis, ulcerative keratitis, Thygeson superficial punctate keratitis, herpes stromal keratitis, dry eye disease, superior limbic keratoconjunctivitis, and many others.", [["ocular", "ANATOMY", 50, 56], ["stromal", "ANATOMY", 174, 181], ["eye", "ANATOMY", 197, 200], ["superior limbic", "ANATOMY", 210, 225], ["ocular diseases", "DISEASE", 50, 65], ["vernal keratoconjunctivitis", "DISEASE", 75, 102], ["ulcerative keratitis", "DISEASE", 104, 124], ["keratitis", "DISEASE", 156, 165], ["herpes stromal keratitis", "DISEASE", 167, 191], ["dry eye disease", "DISEASE", 193, 208], ["superior limbic keratoconjunctivitis", "DISEASE", 210, 246], ["eye", "ORGAN", 197, 200], ["various ocular diseases", "PROBLEM", 42, 65], ["vernal keratoconjunctivitis", "PROBLEM", 75, 102], ["ulcerative keratitis", "PROBLEM", 104, 124], ["Thygeson superficial punctate keratitis", "PROBLEM", 126, 165], ["herpes stromal keratitis", "PROBLEM", 167, 191], ["dry eye disease", "PROBLEM", 193, 208], ["superior limbic keratoconjunctivitis", "PROBLEM", 210, 246], ["shown to be", "UNCERTAINTY", 15, 26], ["efficacious", "OBSERVATION_MODIFIER", 27, 38], ["various", "OBSERVATION_MODIFIER", 42, 49], ["ocular diseases", "OBSERVATION", 50, 65], ["vernal keratoconjunctivitis", "OBSERVATION", 75, 102], ["ulcerative", "OBSERVATION_MODIFIER", 104, 114], ["keratitis", "OBSERVATION", 115, 124], ["superficial", "OBSERVATION_MODIFIER", 135, 146], ["punctate", "OBSERVATION_MODIFIER", 147, 155], ["keratitis", "OBSERVATION", 156, 165], ["herpes stromal keratitis", "OBSERVATION", 167, 191], ["dry eye disease", "OBSERVATION", 193, 208], ["superior", "OBSERVATION_MODIFIER", 210, 218], ["limbic keratoconjunctivitis", "OBSERVATION", 219, 246]]], ["69, [79] [80] [81] Asena et al also evaluated treatment options for acute adenoviral keratoconjunctivitis using either topical 1% prednisolone acetate in conjunction with non-preserved artificial tears, topical 2% Cyclosporine A with non-preserved artificial tears, or non-preserved artificial tears alone.", [["tears", "ANATOMY", 259, 264], ["tears", "ANATOMY", 294, 299], ["keratoconjunctivitis", "DISEASE", 85, 105], ["prednisolone acetate", "CHEMICAL", 130, 150], ["Cyclosporine A", "CHEMICAL", 214, 228], ["prednisolone acetate", "CHEMICAL", 130, 150], ["Cyclosporine A", "CHEMICAL", 214, 228], ["[79] [80", "SIMPLE_CHEMICAL", 4, 12], ["adenoviral", "ORGANISM", 74, 84], ["prednisolone", "SIMPLE_CHEMICAL", 130, 142], ["acetate", "SIMPLE_CHEMICAL", 143, 150], ["Cyclosporine A", "SIMPLE_CHEMICAL", 214, 228], ["adenoviral", "SPECIES", 74, 84], ["treatment options", "TREATMENT", 46, 63], ["acute adenoviral keratoconjunctivitis", "PROBLEM", 68, 105], ["topical 1% prednisolone acetate", "TREATMENT", 119, 150], ["non-preserved artificial tears", "TREATMENT", 171, 201], ["topical", "TREATMENT", 203, 210], ["Cyclosporine", "TREATMENT", 214, 226], ["non-preserved artificial tears", "TREATMENT", 234, 264], ["non-preserved artificial tears", "TREATMENT", 269, 299], ["artificial tears", "OBSERVATION", 248, 264], ["artificial tears", "OBSERVATION", 283, 299]]], ["In comparison to artificial tears alone, both the corticosteroid and cyclosporine groups exhibited improvement in symptoms as well as a shorter duration.", [["cyclosporine", "CHEMICAL", 69, 81], ["cyclosporine", "CHEMICAL", 69, 81], ["corticosteroid", "SIMPLE_CHEMICAL", 50, 64], ["cyclosporine", "SIMPLE_CHEMICAL", 69, 81], ["artificial tears", "TREATMENT", 17, 33], ["the corticosteroid and cyclosporine groups", "TREATMENT", 46, 88], ["symptoms", "PROBLEM", 114, 122], ["improvement", "OBSERVATION_MODIFIER", 99, 110]]], ["Both the Cyclosporine A and prednisolone groups were also similarly effective in preventing the development of SEIs when used during the active phase of infection, suggesting possible prophylactic benefit.", [["Cyclosporine A", "CHEMICAL", 9, 23], ["prednisolone", "CHEMICAL", 28, 40], ["SEIs", "DISEASE", 111, 115], ["infection", "DISEASE", 153, 162], ["Cyclosporine A", "CHEMICAL", 9, 23], ["prednisolone", "CHEMICAL", 28, 40], ["Cyclosporine A", "SIMPLE_CHEMICAL", 9, 23], ["prednisolone", "SIMPLE_CHEMICAL", 28, 40], ["SEIs", "SIMPLE_CHEMICAL", 111, 115], ["the Cyclosporine A and prednisolone groups", "TREATMENT", 5, 47], ["SEIs", "PROBLEM", 111, 115], ["infection", "PROBLEM", 153, 162], ["prophylactic benefit", "TREATMENT", 184, 204], ["Cyclosporine", "OBSERVATION", 9, 21], ["infection", "OBSERVATION", 153, 162], ["suggesting possible", "UNCERTAINTY", 164, 183]]], ["72 Tacrolimus is another immunosuppressive agent that also demonstrates anti-inflammatory activity.", [["Tacrolimus", "CHEMICAL", 3, 13], ["Tacrolimus", "CHEMICAL", 3, 13], ["Tacrolimus", "SIMPLE_CHEMICAL", 3, 13], ["Tacrolimus", "TREATMENT", 3, 13], ["another immunosuppressive agent", "TREATMENT", 17, 48], ["anti-inflammatory activity", "OBSERVATION", 72, 98]]], ["Like cyclosporine, tacrolimus' initial use was to prevent rejection in organ transplants.", [["organ", "ANATOMY", 71, 76], ["cyclosporine", "CHEMICAL", 5, 17], ["tacrolimus", "CHEMICAL", 19, 29], ["cyclosporine", "CHEMICAL", 5, 17], ["tacrolimus", "CHEMICAL", 19, 29], ["cyclosporine", "SIMPLE_CHEMICAL", 5, 17], ["tacrolimus", "SIMPLE_CHEMICAL", 19, 29], ["organ", "ORGAN", 71, 76], ["cyclosporine", "TREATMENT", 5, 17], ["tacrolimus", "TREATMENT", 19, 29], ["rejection", "PROBLEM", 58, 67], ["organ transplants", "TREATMENT", 71, 88], ["cyclosporine", "OBSERVATION", 5, 17], ["rejection", "OBSERVATION", 58, 67], ["organ", "ANATOMY", 71, 76], ["transplants", "OBSERVATION", 77, 88]]], ["However, despite similar effects, tacrolimus and cyclosporine differ in their chemical makeup.", [["tacrolimus", "CHEMICAL", 34, 44], ["cyclosporine", "CHEMICAL", 49, 61], ["tacrolimus", "CHEMICAL", 34, 44], ["cyclosporine", "CHEMICAL", 49, 61], ["tacrolimus", "SIMPLE_CHEMICAL", 34, 44], ["cyclosporine", "SIMPLE_CHEMICAL", 49, 61], ["tacrolimus", "TREATMENT", 34, 44], ["cyclosporine", "TREATMENT", 49, 61]]], ["Cyclosporine is a cyclic endecapeptide, in contrast to tacrolimus, which is a macrocyclic lactone.", [["Cyclosporine", "CHEMICAL", 0, 12], ["cyclic endecapeptide", "CHEMICAL", 18, 38], ["tacrolimus", "CHEMICAL", 55, 65], ["macrocyclic lactone", "CHEMICAL", 78, 97], ["Cyclosporine", "CHEMICAL", 0, 12], ["cyclic endecapeptide", "CHEMICAL", 18, 38], ["tacrolimus", "CHEMICAL", 55, 65], ["macrocyclic lactone", "CHEMICAL", 78, 97], ["Cyclosporine", "SIMPLE_CHEMICAL", 0, 12], ["cyclic endecapeptide", "SIMPLE_CHEMICAL", 18, 38], ["tacrolimus", "SIMPLE_CHEMICAL", 55, 65], ["macrocyclic lactone", "SIMPLE_CHEMICAL", 78, 97], ["Cyclosporine", "TREATMENT", 0, 12], ["a cyclic endecapeptide", "TREATMENT", 16, 38], ["tacrolimus", "TREATMENT", 55, 65], ["a macrocyclic lactone", "TREATMENT", 76, 97]]], ["Both are calcineurin inhibitors, an enzyme necessary for T cell replication.", [["T cell", "ANATOMY", 57, 63], ["calcineurin", "GENE_OR_GENE_PRODUCT", 9, 20], ["T cell", "CELL", 57, 63], ["calcineurin", "PROTEIN", 9, 20], ["calcineurin inhibitors", "TREATMENT", 9, 31], ["an enzyme", "TEST", 33, 42], ["T cell replication", "TREATMENT", 57, 75], ["calcineurin", "OBSERVATION", 9, 20]]], ["82, 83 When cyclosporine and tacrolimus enter T cells, they bind to their respective immunophilins, which are important proteins that interact with calcineurin, and inhibit their action.", [["T cells", "ANATOMY", 46, 53], ["cyclosporine", "CHEMICAL", 12, 24], ["tacrolimus", "CHEMICAL", 29, 39], ["cyclosporine", "CHEMICAL", 12, 24], ["tacrolimus", "CHEMICAL", 29, 39], ["cyclosporine", "SIMPLE_CHEMICAL", 12, 24], ["tacrolimus", "SIMPLE_CHEMICAL", 29, 39], ["T cells", "CELL", 46, 53], ["immunophilins", "GENE_OR_GENE_PRODUCT", 85, 98], ["calcineurin", "GENE_OR_GENE_PRODUCT", 148, 159], ["T cells", "CELL_TYPE", 46, 53], ["immunophilins", "PROTEIN", 85, 98], ["calcineurin", "PROTEIN", 148, 159], ["cyclosporine", "TREATMENT", 12, 24], ["tacrolimus enter T cells", "TREATMENT", 29, 53], ["calcineurin", "TREATMENT", 148, 159]]], ["Blocking calcineurin subsequently inhibits the transcription of several cytokines that are necessary to the immune pathway and response, particularly IL-2.", [["calcineurin", "GENE_OR_GENE_PRODUCT", 9, 20], ["IL-2", "GENE_OR_GENE_PRODUCT", 150, 154], ["calcineurin", "PROTEIN", 9, 20], ["cytokines", "PROTEIN", 72, 81], ["IL", "PROTEIN", 150, 152], ["Blocking calcineurin", "TREATMENT", 0, 20], ["several cytokines", "TREATMENT", 64, 81]]], ["This cytokine is integral in the maintenance, differentiation, and survival of CD4 + T cells and CD8 + T cells.", [["CD4 + T cells", "ANATOMY", 79, 92], ["CD8 + T cells", "ANATOMY", 97, 110], ["CD4", "GENE_OR_GENE_PRODUCT", 79, 82], ["CD8", "GENE_OR_GENE_PRODUCT", 97, 100], ["cytokine", "PROTEIN", 5, 13], ["CD4 + T cells", "CELL_TYPE", 79, 92], ["CD8 + T cells", "CELL_TYPE", 97, 110], ["CD4 + T cells", "PROBLEM", 79, 92], ["CD8 + T cells", "PROBLEM", 97, 110]]], ["70, [84] [85] [86] Topical tacrolimus 0.03% has ophthalmic uses, mainly in the treatment of giant papillary conjunctivitis and vernal keratoconjunctivitis.", [["papillary", "ANATOMY", 98, 107], ["tacrolimus", "CHEMICAL", 27, 37], ["giant papillary conjunctivitis", "DISEASE", 92, 122], ["vernal keratoconjunctivitis", "DISEASE", 127, 154], ["tacrolimus", "CHEMICAL", 27, 37], ["[84] [85] [86] Topical tacrolimus", "SIMPLE_CHEMICAL", 4, 37], ["Topical tacrolimus", "TREATMENT", 19, 37], ["giant papillary conjunctivitis", "PROBLEM", 92, 122], ["vernal keratoconjunctivitis", "PROBLEM", 127, 154], ["giant", "OBSERVATION_MODIFIER", 92, 97], ["papillary conjunctivitis", "OBSERVATION", 98, 122], ["vernal keratoconjunctivitis", "OBSERVATION", 127, 154]]], ["With regards to its effect on HAdV keratoconjunctivitis, tacrolimus was more effective than dexamethasone in the reduction of SEIs, and subsequently in the improvement of vision and symptomology.", [["HAdV keratoconjunctivitis", "DISEASE", 30, 55], ["tacrolimus", "CHEMICAL", 57, 67], ["dexamethasone", "CHEMICAL", 92, 105], ["SEIs", "DISEASE", 126, 130], ["tacrolimus", "CHEMICAL", 57, 67], ["dexamethasone", "CHEMICAL", 92, 105], ["HAdV", "ORGANISM", 30, 34], ["tacrolimus", "SIMPLE_CHEMICAL", 57, 67], ["dexamethasone", "SIMPLE_CHEMICAL", 92, 105], ["HAdV keratoconjunctivitis", "SPECIES", 30, 55], ["HAdV keratoconjunctivitis", "PROBLEM", 30, 55], ["tacrolimus", "TREATMENT", 57, 67], ["dexamethasone", "TREATMENT", 92, 105], ["symptomology", "PROBLEM", 182, 194], ["keratoconjunctivitis", "OBSERVATION", 35, 55]]], ["This study is significant in that tacrolimus was not only superior to topical corticosteroids in the resolution of clinical signs and symptoms but also offered a lower recurrence rate and no significant rise in IOP as is sometimes seen with steroid use.", [["tacrolimus", "CHEMICAL", 34, 44], ["steroid", "CHEMICAL", 241, 248], ["tacrolimus", "CHEMICAL", 34, 44], ["steroid", "CHEMICAL", 241, 248], ["tacrolimus", "SIMPLE_CHEMICAL", 34, 44], ["steroid", "SIMPLE_CHEMICAL", 241, 248], ["This study", "TEST", 0, 10], ["tacrolimus", "TREATMENT", 34, 44], ["topical corticosteroids", "TREATMENT", 70, 93], ["clinical signs", "PROBLEM", 115, 129], ["symptoms", "PROBLEM", 134, 142], ["a lower recurrence rate", "PROBLEM", 160, 183], ["significant rise in IOP", "PROBLEM", 191, 214], ["steroid use", "TREATMENT", 241, 252], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["no", "UNCERTAINTY", 188, 190], ["significant", "OBSERVATION_MODIFIER", 191, 202], ["rise", "OBSERVATION_MODIFIER", 203, 207], ["IOP", "OBSERVATION", 211, 214]]], ["Adverse effects were observed in 17.8% of patients using tacrolimus, manifesting as burning, redness, and foreign body sensation.", [["body", "ANATOMY", 114, 118], ["tacrolimus", "CHEMICAL", 57, 67], ["redness", "DISEASE", 93, 100], ["tacrolimus", "CHEMICAL", 57, 67], ["patients", "ORGANISM", 42, 50], ["tacrolimus", "SIMPLE_CHEMICAL", 57, 67], ["body", "ORGANISM_SUBDIVISION", 114, 118], ["patients", "SPECIES", 42, 50], ["Adverse effects", "PROBLEM", 0, 15], ["tacrolimus", "TREATMENT", 57, 67], ["burning", "PROBLEM", 84, 91], ["redness", "PROBLEM", 93, 100], ["foreign body sensation", "PROBLEM", 106, 128], ["redness", "OBSERVATION", 93, 100], ["foreign body", "OBSERVATION", 106, 118]]], ["70 Generally, for SEIs that are resistant to tapering of corticosteroid, tacrolimus 0.03% was proven to be an effective corticosteroid-sparing agent.", [["SEIs", "DISEASE", 18, 22], ["tacrolimus", "CHEMICAL", 73, 83], ["tacrolimus", "CHEMICAL", 73, 83], ["corticosteroid", "SIMPLE_CHEMICAL", 57, 71], ["tacrolimus", "SIMPLE_CHEMICAL", 73, 83], ["corticosteroid", "SIMPLE_CHEMICAL", 120, 134], ["SEIs", "PROBLEM", 18, 22], ["corticosteroid", "TREATMENT", 57, 71], ["tacrolimus", "TREATMENT", 73, 83], ["an effective corticosteroid-sparing agent", "TREATMENT", 107, 148]]], ["87 Another promising treatment for HAdV is adoptive T cell therapy.", [["T cell", "ANATOMY", 52, 58], ["HAdV", "DISEASE", 35, 39], ["HAdV", "ORGANISM", 35, 39], ["T cell", "CELL", 52, 58], ["HAdV", "SPECIES", 35, 39], ["HAdV", "PROBLEM", 35, 39], ["adoptive T cell therapy", "TREATMENT", 43, 66], ["cell therapy", "OBSERVATION", 54, 66]]], ["This involves the transfer of virus-specific T cells into Tcell-depleted patients to fight infection.", [["T cells", "ANATOMY", 45, 52], ["infection", "DISEASE", 91, 100], ["T cells", "CELL", 45, 52], ["Tcell", "CELL", 58, 63], ["patients", "ORGANISM", 73, 81], ["virus-specific T cells", "CELL_TYPE", 30, 52], ["patients", "SPECIES", 73, 81], ["virus", "TREATMENT", 30, 35], ["fight infection", "PROBLEM", 85, 100], ["infection", "OBSERVATION", 91, 100]]], ["HAdV-specific T cells are present in peripheral blood of healthy individuals in low frequencies; as a result, donor leukocytes were reportedly useful in patients with severe HAdV infection.", [["T cells", "ANATOMY", 14, 21], ["peripheral blood", "ANATOMY", 37, 53], ["leukocytes", "ANATOMY", 116, 126], ["HAdV infection", "DISEASE", 174, 188], ["HAdV", "ORGANISM", 0, 4], ["T cells", "CELL", 14, 21], ["peripheral blood", "ORGANISM_SUBSTANCE", 37, 53], ["donor leukocytes", "CELL", 110, 126], ["patients", "ORGANISM", 153, 161], ["HAdV", "ORGANISM", 174, 178], ["HAdV-specific T cells", "CELL_TYPE", 0, 21], ["donor leukocytes", "CELL_TYPE", 110, 126], ["patients", "SPECIES", 153, 161], ["HAdV", "PROBLEM", 0, 4], ["specific T cells", "PROBLEM", 5, 21], ["donor leukocytes", "TEST", 110, 126], ["severe HAdV infection", "PROBLEM", 167, 188], ["T cells", "OBSERVATION", 14, 21], ["peripheral", "ANATOMY_MODIFIER", 37, 47], ["blood", "ANATOMY", 48, 53], ["low frequencies", "OBSERVATION_MODIFIER", 80, 95], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["HAdV", "OBSERVATION_MODIFIER", 174, 178], ["infection", "OBSERVATION", 179, 188]]], ["HAdV-specific T cells play a significant role in viral clearance, and as such, adoptive transfer of HAdV-specific T cells would be an immunotherapeutic agent of immense benefit for patients at risk of disseminated adenoviral infection.", [["T cells", "ANATOMY", 14, 21], ["T cells", "ANATOMY", 114, 121], ["adenoviral infection", "DISEASE", 214, 234], ["HAdV", "ORGANISM", 0, 4], ["T cells", "CELL", 14, 21], ["HAdV", "ORGANISM", 100, 104], ["T cells", "CELL", 114, 121], ["patients", "ORGANISM", 181, 189], ["adenoviral", "ORGANISM", 214, 224], ["HAdV-specific T cells", "CELL_TYPE", 0, 21], ["HAdV-specific T cells", "CELL_TYPE", 100, 121], ["patients", "SPECIES", 181, 189], ["adenoviral", "SPECIES", 214, 224], ["HAdV", "PROBLEM", 0, 4], ["specific T cells", "PROBLEM", 5, 21], ["viral clearance", "TEST", 49, 64], ["HAdV", "PROBLEM", 100, 104], ["specific T cells", "PROBLEM", 105, 121], ["an immunotherapeutic agent", "TREATMENT", 131, 157], ["disseminated adenoviral infection", "PROBLEM", 201, 234], ["disseminated", "OBSERVATION_MODIFIER", 201, 213], ["adenoviral infection", "OBSERVATION", 214, 234]]], ["The method of adoptive T cell therapy involves harvested leukocytes that are stimulated and expanded in vitro using peptide-MHC I tetramers, instead of using lymphocytes derived from the same donor as the transplant which yielded results as early as two weeks.", [["T cell", "ANATOMY", 23, 29], ["leukocytes", "ANATOMY", 57, 67], ["lymphocytes", "ANATOMY", 158, 169], ["T cell", "CELL", 23, 29], ["leukocytes", "CELL", 57, 67], ["lymphocytes", "CELL", 158, 169], ["harvested leukocytes", "CELL_TYPE", 47, 67], ["MHC", "PROTEIN", 124, 127], ["I tetramers", "PROTEIN", 128, 139], ["lymphocytes", "CELL_TYPE", 158, 169], ["adoptive T cell therapy", "TREATMENT", 14, 37], ["harvested leukocytes", "PROBLEM", 47, 67], ["lymphocytes", "TREATMENT", 158, 169], ["the transplant", "TREATMENT", 201, 215]]], ["13, 44 This therapy along with antiviral use appears to be synergistic and efficacious.", [["This therapy", "TREATMENT", 7, 19], ["antiviral use", "TREATMENT", 31, 44], ["synergistic", "PROBLEM", 59, 70]]], ["44 Cardiotonic steroids digoxin and digitoxin have been suggested to offer a new strategy to target and suppress HAdV.", [["steroids", "CHEMICAL", 15, 23], ["digoxin", "CHEMICAL", 24, 31], ["digitoxin", "CHEMICAL", 36, 45], ["steroids", "CHEMICAL", 15, 23], ["digoxin", "CHEMICAL", 24, 31], ["digitoxin", "CHEMICAL", 36, 45], ["digoxin", "SIMPLE_CHEMICAL", 24, 31], ["digitoxin", "SIMPLE_CHEMICAL", 36, 45], ["HAdV", "ORGANISM", 113, 117], ["Cardiotonic steroids digoxin", "TREATMENT", 3, 31], ["digitoxin", "TREATMENT", 36, 45], ["a new strategy", "TREATMENT", 75, 89], ["HAdV", "PROBLEM", 113, 117]]], ["Historically, these drugs have been used to treat heart failure for over 200 years.", [["heart", "ANATOMY", 50, 55], ["heart failure", "DISEASE", 50, 63], ["heart", "ORGAN", 50, 55], ["these drugs", "TREATMENT", 14, 25], ["heart failure", "PROBLEM", 50, 63], ["heart", "ANATOMY", 50, 55], ["failure", "OBSERVATION", 56, 63]]], ["More recently, they have also shown efficacy in cancer treatments, in that treated patients demonstrated a lesser chance of relapse.", [["cancer", "ANATOMY", 48, 54], ["cancer", "DISEASE", 48, 54], ["cancer", "CANCER", 48, 54], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["cancer treatments", "TREATMENT", 48, 65], ["relapse", "PROBLEM", 124, 131], ["cancer", "OBSERVATION", 48, 54], ["lesser", "OBSERVATION_MODIFIER", 107, 113], ["relapse", "OBSERVATION", 124, 131]]], ["88 Hartley et al first noted its potential antiviral benefit, noting its efficacy against HAdV and herpesviruses.", [["HAdV and herpesviruses", "DISEASE", 90, 112], ["HAdV", "ORGANISM", 90, 94], ["herpesviruses", "ORGANISM", 99, 112], ["HAdV", "SPECIES", 90, 94], ["HAdV", "PROBLEM", 90, 94], ["herpesviruses", "PROBLEM", 99, 112], ["antiviral benefit", "OBSERVATION", 43, 60]]], ["89 This is due to the drugs inhibiting Na+/K+ ATPase on the cell surface, which leads to increased intracellular levels of NA+ and, subsequently, Ca++.", [["cell surface", "ANATOMY", 60, 72], ["intracellular", "ANATOMY", 99, 112], ["Na+", "CHEMICAL", 39, 42], ["K", "CHEMICAL", 43, 44], ["NA", "CHEMICAL", 123, 125], ["Ca", "CHEMICAL", 146, 148], ["Na+", "CHEMICAL", 39, 42], ["K+", "CHEMICAL", 43, 45], ["Ca++.", "CHEMICAL", 146, 151], ["Na+/K+ ATPase", "GENE_OR_GENE_PRODUCT", 39, 52], ["cell surface", "CELLULAR_COMPONENT", 60, 72], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 99, 112], ["NA+", "SIMPLE_CHEMICAL", 123, 126], ["Na+/K+ ATPase", "PROTEIN", 39, 52], ["the drugs", "TREATMENT", 18, 27], ["Na+", "TEST", 39, 42], ["ATPase on the cell surface", "PROBLEM", 46, 72], ["increased intracellular levels", "PROBLEM", 89, 119], ["NA", "TEST", 123, 125], ["Ca", "TEST", 146, 148], ["cell surface", "OBSERVATION_MODIFIER", 60, 72], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["intracellular levels", "OBSERVATION", 99, 119]]], ["Na+/K+ ATPase is an important cell signaling molecule, where binding with digoxin or digitoxin initiates multiple signaling cascades, influencing gene expression.", [["cell", "ANATOMY", 30, 34], ["Na+", "CHEMICAL", 0, 3], ["K", "CHEMICAL", 4, 5], ["digoxin", "CHEMICAL", 74, 81], ["digitoxin", "CHEMICAL", 85, 94], ["Na+/K+", "CHEMICAL", 0, 6], ["digoxin", "CHEMICAL", 74, 81], ["digitoxin", "CHEMICAL", 85, 94], ["Na+/K+ ATPase", "GENE_OR_GENE_PRODUCT", 0, 13], ["cell", "CELL", 30, 34], ["digoxin", "SIMPLE_CHEMICAL", 74, 81], ["digitoxin", "SIMPLE_CHEMICAL", 85, 94], ["Na+/K+ ATPase", "PROTEIN", 0, 13], ["cell signaling molecule", "PROTEIN", 30, 53], ["Na+", "TEST", 0, 3], ["K", "TEST", 4, 5], ["an important cell signaling molecule", "PROBLEM", 17, 53], ["digoxin", "TREATMENT", 74, 81], ["digitoxin", "TREATMENT", 85, 94], ["multiple signaling cascades", "PROBLEM", 105, 132], ["important cell", "OBSERVATION", 20, 34], ["signaling molecule", "OBSERVATION", 35, 53]]], ["These drugs also alter RNA splicing, which is necessary to HAdV replication.", [["HAdV", "ORGANISM", 59, 63], ["These drugs", "TREATMENT", 0, 11], ["alter RNA splicing", "PROBLEM", 17, 35]]], ["Preliminary data supports a concentration-dependent reduction in the number of infected cells and no apparent damage.", [["cells", "ANATOMY", 88, 93], ["cells", "CELL", 88, 93], ["infected cells", "CELL_TYPE", 79, 93], ["Preliminary data", "TEST", 0, 16], ["a concentration", "PROBLEM", 26, 41], ["dependent reduction", "PROBLEM", 42, 61], ["infected cells", "PROBLEM", 79, 93], ["apparent damage", "PROBLEM", 101, 116], ["dependent", "OBSERVATION_MODIFIER", 42, 51], ["reduction", "OBSERVATION_MODIFIER", 52, 61], ["infected cells", "OBSERVATION", 79, 93], ["no apparent", "UNCERTAINTY", 98, 109], ["damage", "OBSERVATION", 110, 116]]], ["Although there is known toxicity, particularly with long-term use of digoxin, the antiviral uses of cardiotonic steroids would be short term, negating the associated systemic complications.", [["toxicity", "DISEASE", 24, 32], ["digoxin", "CHEMICAL", 69, 76], ["cardiotonic steroids", "CHEMICAL", 100, 120], ["digoxin", "CHEMICAL", 69, 76], ["steroids", "CHEMICAL", 112, 120], ["digoxin", "SIMPLE_CHEMICAL", 69, 76], ["cardiotonic steroids", "SIMPLE_CHEMICAL", 100, 120], ["known toxicity", "PROBLEM", 18, 32], ["digoxin", "TREATMENT", 69, 76], ["cardiotonic steroids", "TREATMENT", 100, 120], ["the associated systemic complications", "PROBLEM", 151, 188], ["toxicity", "OBSERVATION", 24, 32], ["systemic", "OBSERVATION_MODIFIER", 166, 174], ["complications", "OBSERVATION", 175, 188]]], ["As such, these drugs seem to be efficacious against HAdV serotypes A-D and serve as potential treatment therapies for the treatment and prophylaxis of EKC.", [["EKC", "DISEASE", 151, 154], ["HAdV serotypes A-D", "ORGANISM", 52, 70], ["these drugs", "TREATMENT", 9, 20], ["HAdV serotypes A-D", "PROBLEM", 52, 70], ["potential treatment therapies", "TREATMENT", 84, 113], ["the treatment", "TREATMENT", 118, 131], ["prophylaxis of EKC", "TREATMENT", 136, 154]]], ["88 Thus, repurposing of these cardiotonic steroids as an antiviral agent for short-term treatment of adenoviral keratoconjunctivitis as well as a prophylactic for use in individuals in close contact with patients with epidemic keratoconjunctivitis.", [["steroids", "CHEMICAL", 42, 50], ["adenoviral keratoconjunctivitis", "DISEASE", 101, 132], ["keratoconjunctivitis", "DISEASE", 227, 247], ["steroids", "CHEMICAL", 42, 50], ["adenoviral", "ORGANISM", 101, 111], ["individuals", "ORGANISM", 170, 181], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["adenoviral", "SPECIES", 101, 111], ["these cardiotonic steroids", "TREATMENT", 24, 50], ["an antiviral agent", "TREATMENT", 54, 72], ["short-term treatment", "TREATMENT", 77, 97], ["adenoviral keratoconjunctivitis", "PROBLEM", 101, 132], ["epidemic keratoconjunctivitis", "PROBLEM", 218, 247], ["adenoviral keratoconjunctivitis", "OBSERVATION", 101, 132], ["keratoconjunctivitis", "OBSERVATION", 227, 247]]], ["88 Furthermore, Marrugal-Lorenzo et al reported that mifepristone, a synthetic steroid drug, possesses anti-adenoviral properties via its interference with viral entry into the nucleus.", [["nucleus", "ANATOMY", 177, 184], ["mifepristone", "CHEMICAL", 53, 65], ["steroid", "CHEMICAL", 79, 86], ["mifepristone", "CHEMICAL", 53, 65], ["steroid", "CHEMICAL", 79, 86], ["mifepristone", "SIMPLE_CHEMICAL", 53, 65], ["steroid", "SIMPLE_CHEMICAL", 79, 86], ["nucleus", "CELLULAR_COMPONENT", 177, 184], ["Marrugal-Lorenzo et al", "TREATMENT", 16, 38], ["mifepristone", "TREATMENT", 53, 65], ["a synthetic steroid drug", "TREATMENT", 67, 91], ["possesses anti-adenoviral properties", "TREATMENT", 93, 129], ["nucleus", "ANATOMY", 177, 184]]], ["As such, it could be repurposed for treating adenoviral infections.", [["adenoviral infections", "DISEASE", 45, 66], ["adenoviral", "ORGANISM", 45, 55], ["adenoviral", "SPECIES", 45, 55], ["adenoviral infections", "PROBLEM", 45, 66], ["infections", "OBSERVATION", 56, 66]]], ["90Combination Dexamethasone/PVI TreatmentThe potential benefits of PVI as well as topical immunosuppressive therapies gave rise to the development of combined PVI/steroid ophthalmic solutions.", [["Dexamethasone", "CHEMICAL", 14, 27], ["PVI", "CHEMICAL", 28, 31], ["PVI", "CHEMICAL", 67, 70], ["PVI", "CHEMICAL", 159, 162], ["steroid", "CHEMICAL", 163, 170], ["Dexamethasone", "CHEMICAL", 14, 27], ["PVI", "CHEMICAL", 28, 31], ["PVI", "CHEMICAL", 67, 70], ["PVI", "CHEMICAL", 159, 162], ["steroid", "CHEMICAL", 163, 170], ["Dexamethasone", "SIMPLE_CHEMICAL", 14, 27], ["PVI", "SIMPLE_CHEMICAL", 159, 162], ["steroid", "SIMPLE_CHEMICAL", 163, 170], ["Dexamethasone", "TREATMENT", 14, 27], ["PVI Treatment", "TREATMENT", 28, 41], ["PVI", "TREATMENT", 67, 70], ["topical immunosuppressive therapies", "TREATMENT", 82, 117], ["combined PVI", "TREATMENT", 150, 162], ["steroid ophthalmic solutions", "TREATMENT", 163, 191], ["PVI", "OBSERVATION", 159, 162]]], ["The idea of combining these elements is to employ the antiseptic properties of PVI in conjunction with symptomatic relief of inflammation, with the added benefit of reducing the risk and/or treatment of SEI formation and scarring.", [["PVI", "CHEMICAL", 79, 82], ["inflammation", "DISEASE", 125, 137], ["SEI", "DISEASE", 203, 206], ["scarring", "DISEASE", 221, 229], ["PVI", "CHEMICAL", 79, 82], ["SEI", "PATHOLOGICAL_FORMATION", 203, 206], ["the antiseptic properties", "TREATMENT", 50, 75], ["PVI", "TREATMENT", 79, 82], ["inflammation", "PROBLEM", 125, 137], ["treatment", "TREATMENT", 190, 199], ["SEI formation", "PROBLEM", 203, 216], ["scarring", "PROBLEM", 221, 229], ["inflammation", "OBSERVATION", 125, 137], ["scarring", "OBSERVATION", 221, 229]]], ["2, 52, 72, 91 Initial efficacy of combo PVI 0.4%/dexamethasone 0.1% dosed QID for five days was evaluated in a small study of nine eyes utilizing Rapid Pathogen Screening Adeno Detector-positive acute viral conjunctivitis.", [["eyes", "ANATOMY", 131, 135], ["PVI", "CHEMICAL", 40, 43], ["dexamethasone", "CHEMICAL", 49, 62], ["QID", "CHEMICAL", 74, 77], ["viral conjunctivitis", "DISEASE", 201, 221], ["dexamethasone", "CHEMICAL", 49, 62], ["dexamethasone", "SIMPLE_CHEMICAL", 49, 62], ["eyes", "ORGAN", 131, 135], ["combo PVI", "TREATMENT", 34, 43], ["dexamethasone", "TREATMENT", 49, 62], ["a small study", "TEST", 109, 122], ["Rapid Pathogen Screening", "TEST", 146, 170], ["Adeno Detector", "TEST", 171, 185], ["positive acute viral conjunctivitis", "PROBLEM", 186, 221], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["viral conjunctivitis", "OBSERVATION", 201, 221]]], ["91 The pilot study included both clinical (conjunctival injection and discharge) and serological (reduction of quantitative polymerase chain reaction titers and eradication of infectious virus as determined by cell culture with confirmatory immunofluorescence) endpoints.", [["conjunctival", "ANATOMY", 43, 55], ["cell", "ANATOMY", 210, 214], ["conjunctival", "MULTI-TISSUE_STRUCTURE", 43, 55], ["cell", "CELL", 210, 214], ["The pilot study", "TEST", 3, 18], ["clinical (conjunctival injection", "TREATMENT", 33, 65], ["serological (reduction of quantitative polymerase chain reaction titers", "TREATMENT", 85, 156], ["infectious virus", "PROBLEM", 176, 192], ["cell culture", "TEST", 210, 222], ["confirmatory immunofluorescence", "TEST", 228, 259]]], ["91 Combination treatment dosed QID for seven days has also been shown to improve clinical scores for scleral inflammation, ocular neovascularization, eyelid inflammation, friability of vasculature, inflammatory discharge, and epiphora as compared to treatment with 0.5% cidofovir, tobramycin/dexamethasone ophthalmic suspension, and balanced salt solution in rabbit models.", [["scleral", "ANATOMY", 101, 108], ["ocular", "ANATOMY", 123, 129], ["eyelid", "ANATOMY", 150, 156], ["vasculature", "ANATOMY", 185, 196], ["QID", "CHEMICAL", 31, 34], ["inflammation", "DISEASE", 109, 121], ["ocular neovascularization", "DISEASE", 123, 148], ["eyelid inflammation", "DISEASE", 150, 169], ["epiphora", "DISEASE", 226, 234], ["cidofovir", "CHEMICAL", 270, 279], ["tobramycin", "CHEMICAL", 281, 291], ["dexamethasone", "CHEMICAL", 292, 305], ["cidofovir", "CHEMICAL", 270, 279], ["tobramycin", "CHEMICAL", 281, 291], ["dexamethasone", "CHEMICAL", 292, 305], ["scleral", "TISSUE", 101, 108], ["ocular", "ORGAN", 123, 129], ["eyelid", "PATHOLOGICAL_FORMATION", 150, 156], ["vasculature", "MULTI-TISSUE_STRUCTURE", 185, 196], ["cidofovir", "SIMPLE_CHEMICAL", 270, 279], ["tobramycin", "SIMPLE_CHEMICAL", 281, 291], ["dexamethasone", "SIMPLE_CHEMICAL", 292, 305], ["rabbit", "ORGANISM", 359, 365], ["rabbit", "SPECIES", 359, 365], ["rabbit", "SPECIES", 359, 365], ["Combination treatment", "TREATMENT", 3, 24], ["scleral inflammation", "PROBLEM", 101, 121], ["ocular neovascularization", "PROBLEM", 123, 148], ["eyelid inflammation", "PROBLEM", 150, 169], ["friability of vasculature", "PROBLEM", 171, 196], ["inflammatory discharge", "PROBLEM", 198, 220], ["epiphora", "PROBLEM", 226, 234], ["treatment", "TREATMENT", 250, 259], ["cidofovir", "TREATMENT", 270, 279], ["tobramycin", "TREATMENT", 281, 291], ["dexamethasone ophthalmic suspension", "TREATMENT", 292, 327], ["balanced salt solution in rabbit models", "TREATMENT", 333, 372], ["scleral", "ANATOMY", 101, 108], ["inflammation", "OBSERVATION", 109, 121], ["ocular", "ANATOMY", 123, 129], ["neovascularization", "OBSERVATION", 130, 148], ["eyelid", "ANATOMY", 150, 156], ["inflammation", "OBSERVATION", 157, 169], ["friability", "OBSERVATION_MODIFIER", 171, 181], ["vasculature", "ANATOMY", 185, 196], ["inflammatory", "OBSERVATION_MODIFIER", 198, 210], ["epiphora", "OBSERVATION", 226, 234]]], ["52 Moreover, PVI/ dexamethasone combination has proven effective in reducing viral titers and delaying viral shedding.", [["PVI", "CHEMICAL", 13, 16], ["dexamethasone", "CHEMICAL", 18, 31], ["PVI", "CHEMICAL", 13, 16], ["dexamethasone", "CHEMICAL", 18, 31], ["dexamethasone", "SIMPLE_CHEMICAL", 18, 31], ["PVI/ dexamethasone combination", "TREATMENT", 13, 43], ["reducing viral titers", "PROBLEM", 68, 89], ["viral shedding", "PROBLEM", 103, 117], ["PVI", "OBSERVATION", 13, 16], ["viral titers", "OBSERVATION", 77, 89]]], ["52 When comparing PVI/dexamethasone combination treatment with that of dexamethasone alone, combination drops not only increase recovery but also, reduce the risk of development of SEIs more effectively than steroids alone.", [["PVI", "CHEMICAL", 18, 21], ["dexamethasone", "CHEMICAL", 22, 35], ["dexamethasone", "CHEMICAL", 71, 84], ["SEIs", "DISEASE", 181, 185], ["steroids", "CHEMICAL", 208, 216], ["PVI", "CHEMICAL", 18, 21], ["dexamethasone", "CHEMICAL", 22, 35], ["dexamethasone", "CHEMICAL", 71, 84], ["steroids", "CHEMICAL", 208, 216], ["dexamethasone", "SIMPLE_CHEMICAL", 22, 35], ["dexamethasone", "SIMPLE_CHEMICAL", 71, 84], ["steroids", "SIMPLE_CHEMICAL", 208, 216], ["PVI/dexamethasone", "TREATMENT", 18, 35], ["treatment", "TREATMENT", 48, 57], ["dexamethasone alone", "TREATMENT", 71, 90], ["SEIs", "PROBLEM", 181, 185], ["steroids", "TREATMENT", 208, 216]]], ["92 It is well documented that sole topical corticosteroid therapy has the risk of increased viral replication and prolonged shedding, further delaying the resolution of active infection.", [["infection", "DISEASE", 176, 185], ["sole topical corticosteroid therapy", "TREATMENT", 30, 65], ["increased viral replication", "PROBLEM", 82, 109], ["prolonged shedding", "PROBLEM", 114, 132], ["active infection", "PROBLEM", 169, 185], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["viral replication", "OBSERVATION", 92, 109], ["prolonged", "OBSERVATION_MODIFIER", 114, 123], ["active", "OBSERVATION_MODIFIER", 169, 175], ["infection", "OBSERVATION", 176, 185]]], ["This significant treatment challenge is alleviated with the addition of PVI.", [["PVI", "CHEMICAL", 72, 75], ["This significant treatment challenge", "TREATMENT", 0, 36], ["PVI", "TREATMENT", 72, 75], ["significant", "OBSERVATION_MODIFIER", 5, 16], ["treatment", "OBSERVATION", 17, 26]]], ["92 In addition to the mentioned treatment benefits, combination PVI/dexamethasone ophthalmic formulation displayed a favorable safety profile and was well tolerated when administered for up to 14 days.", [["PVI", "CHEMICAL", 64, 67], ["dexamethasone", "CHEMICAL", 68, 81], ["PVI", "CHEMICAL", 64, 67], ["dexamethasone", "CHEMICAL", 68, 81], ["PVI", "SIMPLE_CHEMICAL", 64, 67], ["dexamethasone", "SIMPLE_CHEMICAL", 68, 81], ["treatment benefits", "TREATMENT", 32, 50], ["combination PVI", "TREATMENT", 52, 67], ["dexamethasone ophthalmic formulation", "TREATMENT", 68, 104]]], ["93 There was also no statistically significant effect on intraocular pressure, as is often associated with topical corticosteroid use.", [["intraocular", "ANATOMY", 57, 68], ["intraocular", "MULTI-TISSUE_STRUCTURE", 57, 68], ["corticosteroid", "SIMPLE_CHEMICAL", 115, 129], ["intraocular pressure", "TEST", 57, 77], ["topical corticosteroid use", "TREATMENT", 107, 133], ["no", "UNCERTAINTY", 18, 20], ["statistically", "OBSERVATION_MODIFIER", 21, 34], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["effect", "OBSERVATION_MODIFIER", 47, 53], ["intraocular pressure", "OBSERVATION", 57, 77]]], ["Reported side effects were limited to increased stinging upon instillation when compared to treatment with palliative artificial tears.", [["side effects", "PROBLEM", 9, 21], ["increased stinging", "PROBLEM", 38, 56], ["instillation", "TREATMENT", 62, 74], ["treatment", "TREATMENT", 92, 101], ["palliative artificial tears", "TREATMENT", 107, 134], ["artificial tears", "OBSERVATION", 118, 134]]], ["94Surgical ManagementSurgical management is usually not required in adenoviral keratoconjunctivitis; however, it may be necessary in cases of significant fibrotic remodeling of the conjunctiva or sustained corneal scarring with visual consequence.", [["conjunctiva", "ANATOMY", 181, 192], ["corneal", "ANATOMY", 206, 213], ["keratoconjunctivitis", "DISEASE", 79, 99], ["corneal scarring", "DISEASE", 206, 222], ["adenoviral", "ORGANISM", 68, 78], ["conjunctiva", "ORGAN", 181, 192], ["corneal", "TISSUE", 206, 213], ["adenoviral", "SPECIES", 68, 78], ["94Surgical ManagementSurgical management", "TREATMENT", 0, 40], ["adenoviral keratoconjunctivitis", "PROBLEM", 68, 99], ["significant fibrotic remodeling of the conjunctiva", "PROBLEM", 142, 192], ["sustained corneal scarring", "PROBLEM", 196, 222], ["visual consequence", "PROBLEM", 228, 246], ["keratoconjunctivitis", "OBSERVATION", 79, 99], ["significant", "OBSERVATION_MODIFIER", 142, 153], ["fibrotic", "OBSERVATION", 154, 162], ["conjunctiva", "ANATOMY", 181, 192], ["corneal", "ANATOMY", 206, 213], ["scarring", "OBSERVATION", 214, 222]]], ["Membranes that develop on the mucosal surface can be differentiated into pseudomembranes or true membranes, with the latter being clinically distinguished by induced bleeding upon denuding.", [["Membranes", "ANATOMY", 0, 9], ["mucosal surface", "ANATOMY", 30, 45], ["pseudomembranes", "ANATOMY", 73, 88], ["membranes", "ANATOMY", 97, 106], ["bleeding", "DISEASE", 166, 174], ["mucosal surface", "CELLULAR_COMPONENT", 30, 45], ["membranes", "CELLULAR_COMPONENT", 97, 106], ["Membranes", "PROBLEM", 0, 9], ["true membranes", "PROBLEM", 92, 106], ["induced bleeding upon denuding", "PROBLEM", 158, 188], ["true membranes", "OBSERVATION", 92, 106], ["bleeding", "OBSERVATION", 166, 174]]], ["1 Persistence of pseudomembrane can lead to subepithelial fibrosis of the conjunctival mucosa, symblepharon formation, and punctal occlusion.", [["pseudomembrane", "ANATOMY", 17, 31], ["subepithelial", "ANATOMY", 44, 57], ["conjunctival mucosa", "ANATOMY", 74, 93], ["symblepharon", "ANATOMY", 95, 107], ["punctal", "ANATOMY", 123, 130], ["fibrosis", "DISEASE", 58, 66], ["symblepharon", "DISEASE", 95, 107], ["punctal occlusion", "DISEASE", 123, 140], ["pseudomembrane", "CANCER", 17, 31], ["subepithelial", "TISSUE", 44, 57], ["conjunctival mucosa", "MULTI-TISSUE_STRUCTURE", 74, 93], ["symblepharon", "MULTI-TISSUE_STRUCTURE", 95, 107], ["pseudomembrane", "PROBLEM", 17, 31], ["subepithelial fibrosis of the conjunctival mucosa", "PROBLEM", 44, 93], ["symblepharon formation", "PROBLEM", 95, 117], ["punctal occlusion", "PROBLEM", 123, 140], ["pseudomembrane", "OBSERVATION", 17, 31], ["subepithelial", "OBSERVATION_MODIFIER", 44, 57], ["fibrosis", "OBSERVATION", 58, 66], ["conjunctival mucosa", "ANATOMY", 74, 93], ["symblepharon formation", "OBSERVATION", 95, 117], ["punctal occlusion", "OBSERVATION", 123, 140]]], ["1 Thus, rare cases may require repair of the fornix and associated lid anatomy defect (entropion or ectropion).", [["fornix", "ANATOMY", 45, 51], ["lid", "ANATOMY", 67, 70], ["entropion", "DISEASE", 87, 96], ["ectropion", "DISEASE", 100, 109], ["fornix", "ORGAN", 45, 51], ["lid", "ORGANISM_SUBDIVISION", 67, 70], ["repair of the fornix", "TREATMENT", 31, 51], ["associated lid anatomy defect", "PROBLEM", 56, 85], ["entropion", "PROBLEM", 87, 96], ["ectropion", "PROBLEM", 100, 109], ["repair", "OBSERVATION", 31, 37], ["fornix", "ANATOMY_MODIFIER", 45, 51], ["lid", "OBSERVATION_MODIFIER", 67, 70], ["anatomy", "OBSERVATION_MODIFIER", 71, 78], ["defect", "OBSERVATION", 79, 85], ["entropion", "OBSERVATION", 87, 96]]], ["Furthermore, streptococcal co-infection may be present in severe cases, with membranes that can precipitate corneal perforation and necessitate treatment.", [["membranes", "ANATOMY", 77, 86], ["corneal", "ANATOMY", 108, 115], ["streptococcal co-infection", "DISEASE", 13, 39], ["corneal perforation", "DISEASE", 108, 127], ["membranes", "CELLULAR_COMPONENT", 77, 86], ["corneal", "TISSUE", 108, 115], ["streptococcal co-infection", "PROBLEM", 13, 39], ["membranes", "TREATMENT", 77, 86], ["corneal perforation", "PROBLEM", 108, 127], ["treatment", "TREATMENT", 144, 153], ["streptococcal", "OBSERVATION_MODIFIER", 13, 26], ["co-infection", "OBSERVATION", 27, 39], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["corneal", "ANATOMY", 108, 115], ["perforation", "OBSERVATION", 116, 127]]], ["95 For patients with chronic adenoviral corneal opacification following resolution of acute infection, phototherapeutic keratectomy (PTK) can be an alternative option to other corneal surgeries or transplants.", [["corneal", "ANATOMY", 40, 47], ["corneal", "ANATOMY", 176, 183], ["corneal opacification", "DISEASE", 40, 61], ["acute infection", "DISEASE", 86, 101], ["patients", "ORGANISM", 7, 15], ["adenoviral", "ORGANISM", 29, 39], ["corneal", "TISSUE", 40, 47], ["corneal", "TISSUE", 176, 183], ["patients", "SPECIES", 7, 15], ["adenoviral", "SPECIES", 29, 39], ["chronic adenoviral corneal opacification", "PROBLEM", 21, 61], ["acute infection", "PROBLEM", 86, 101], ["phototherapeutic keratectomy", "TREATMENT", 103, 131], ["corneal surgeries", "TREATMENT", 176, 193], ["transplants", "TREATMENT", 197, 208], ["chronic", "OBSERVATION_MODIFIER", 21, 28], ["adenoviral", "OBSERVATION", 29, 39], ["corneal", "ANATOMY", 40, 47], ["opacification", "OBSERVATION", 48, 61], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["infection", "OBSERVATION", 92, 101], ["phototherapeutic keratectomy", "OBSERVATION", 103, 131], ["corneal", "ANATOMY", 176, 183], ["surgeries", "OBSERVATION", 184, 193]]], ["Corneal transparency can be compromised, or corneal irregularity may result with sequelae from the immune response to pathogen.", [["Corneal", "ANATOMY", 0, 7], ["corneal", "ANATOMY", 44, 51], ["Corneal", "TISSUE", 0, 7], ["corneal", "TISSUE", 44, 51], ["corneal irregularity", "PROBLEM", 44, 64], ["sequelae", "PROBLEM", 81, 89], ["pathogen", "PROBLEM", 118, 126], ["transparency", "OBSERVATION", 8, 20], ["compromised", "OBSERVATION", 28, 39], ["corneal", "ANATOMY", 44, 51], ["irregularity", "OBSERVATION", 52, 64]]], ["Fortuitously, these scars are often superficial in nature by virtue of affecting the subepithelial layer.", [["scars", "ANATOMY", 20, 25], ["subepithelial layer", "ANATOMY", 85, 104], ["scars", "PATHOLOGICAL_FORMATION", 20, 25], ["subepithelial layer", "TISSUE", 85, 104], ["these scars", "PROBLEM", 14, 25], ["scars", "OBSERVATION", 20, 25], ["often", "OBSERVATION_MODIFIER", 30, 35], ["superficial", "OBSERVATION_MODIFIER", 36, 47], ["subepithelial", "ANATOMY_MODIFIER", 85, 98], ["layer", "ANATOMY_MODIFIER", 99, 104]]], ["Transepithelial PTK low dose mitomycin C has shown benefit in such cases with reported improvements in photophobia, best corrected vision, and contrast sensitivity.", [["mitomycin C", "CHEMICAL", 29, 40], ["photophobia", "DISEASE", 103, 114], ["mitomycin C", "CHEMICAL", 29, 40], ["mitomycin C", "SIMPLE_CHEMICAL", 29, 40], ["PTK", "PROTEIN", 16, 19], ["Transepithelial PTK low dose mitomycin C", "TREATMENT", 0, 40], ["photophobia", "PROBLEM", 103, 114], ["contrast sensitivity", "TEST", 143, 163]]], ["96 Furthermore, a decrease in coma, secondary astigmatism, and total higher-order aberrations have been noted after PTK for SEIs in adenoviral keratoconjunctivitis.", [["coma", "DISEASE", 30, 34], ["astigmatism", "DISEASE", 46, 57], ["SEIs", "DISEASE", 124, 128], ["adenoviral keratoconjunctivitis", "DISEASE", 132, 163], ["PTK", "GENE_OR_GENE_PRODUCT", 116, 119], ["adenoviral", "ORGANISM", 132, 142], ["PTK", "PROTEIN", 116, 119], ["a decrease in coma", "PROBLEM", 16, 34], ["secondary astigmatism", "PROBLEM", 36, 57], ["total higher-order aberrations", "PROBLEM", 63, 93], ["PTK", "TREATMENT", 116, 119], ["SEIs", "PROBLEM", 124, 128], ["adenoviral keratoconjunctivitis", "PROBLEM", 132, 163], ["decrease", "OBSERVATION_MODIFIER", 18, 26], ["coma", "OBSERVATION", 30, 34], ["secondary astigmatism", "OBSERVATION", 36, 57], ["adenoviral", "ANATOMY", 132, 142], ["keratoconjunctivitis", "OBSERVATION", 143, 163]]], ["97Conclusion and Future PerspectivesThough many consider adenoviral conjunctivitis a disease of self-limitation, the economic burden on affected individuals, high contagion risk, and potential long-term visual complications require a treatment protocol.", [["adenoviral conjunctivitis", "DISEASE", 57, 82], ["adenoviral", "ORGANISM", 57, 67], ["adenoviral conjunctivitis", "PROBLEM", 57, 82], ["self-limitation", "PROBLEM", 96, 111], ["the economic burden", "PROBLEM", 113, 132], ["affected individuals", "PROBLEM", 136, 156], ["high contagion risk", "PROBLEM", 158, 177], ["potential long-term visual complications", "PROBLEM", 183, 223], ["a treatment protocol", "TREATMENT", 232, 252], ["conjunctivitis", "OBSERVATION", 68, 82]]], ["Studies have indicated that the inflammatory process affecting the cornea begins in the prodromal period of adenoviral infections, thus questioning the theory of self-limitation and adding a potential factor immediate therapeutic management.", [["cornea", "ANATOMY", 67, 73], ["adenoviral infections", "DISEASE", 108, 129], ["cornea", "ORGAN", 67, 73], ["adenoviral", "ORGANISM", 108, 118], ["adenoviral", "SPECIES", 108, 118], ["Studies", "TEST", 0, 7], ["the inflammatory process", "PROBLEM", 28, 52], ["the cornea", "PROBLEM", 63, 73], ["adenoviral infections", "PROBLEM", 108, 129], ["a potential factor immediate therapeutic management", "TREATMENT", 189, 240], ["inflammatory", "OBSERVATION", 32, 44], ["cornea", "ANATOMY", 67, 73], ["adenoviral infections", "OBSERVATION", 108, 129]]], ["98 Dissemination of HAdV is also a significant health burden particularly in individuals with factors that put them at great risk of morbidity and mortality from adenoviral infection.", [["HAdV", "DISEASE", 20, 24], ["adenoviral infection", "DISEASE", 162, 182], ["HAdV", "ORGANISM", 20, 24], ["adenoviral", "ORGANISM", 162, 172], ["adenoviral", "SPECIES", 162, 172], ["HAdV", "PROBLEM", 20, 24], ["a significant health burden", "PROBLEM", 33, 60], ["morbidity", "PROBLEM", 133, 142], ["adenoviral infection", "PROBLEM", 162, 182], ["HAdV", "OBSERVATION", 20, 24], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["health", "OBSERVATION_MODIFIER", 47, 53], ["burden", "OBSERVATION", 54, 60], ["morbidity", "OBSERVATION", 133, 142], ["adenoviral infection", "OBSERVATION", 162, 182]]], ["These individuals include children, elderly, immunocompromised individual, patients with acute Graft versus Host disease, those on immunosuppressants, and so on.", [["Graft", "ANATOMY", 95, 100], ["acute Graft versus Host disease", "DISEASE", 89, 120], ["children", "ORGANISM", 26, 34], ["patients", "ORGANISM", 75, 83], ["children", "SPECIES", 26, 34], ["patients", "SPECIES", 75, 83], ["acute Graft versus Host disease", "PROBLEM", 89, 120], ["immunosuppressants", "TREATMENT", 131, 149], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["Graft versus Host disease", "OBSERVATION", 95, 120]]], ["Because there are no FDA-approved drugs to treat HAdV infection, eye care providers use multiple pharmaceuticals off-label to manage HAdV ocular infection.", [["eye", "ANATOMY", 65, 68], ["ocular", "ANATOMY", 138, 144], ["HAdV infection", "DISEASE", 49, 63], ["HAdV ocular infection", "DISEASE", 133, 154], ["HAdV", "ORGANISM", 49, 53], ["eye", "ORGAN", 65, 68], ["HAdV", "ORGANISM", 133, 137], ["ocular", "ORGAN", 138, 144], ["HAdV", "SPECIES", 49, 53], ["FDA", "TREATMENT", 21, 24], ["drugs", "TREATMENT", 34, 39], ["HAdV infection", "PROBLEM", 49, 63], ["eye care providers", "TREATMENT", 65, 83], ["multiple pharmaceuticals", "TREATMENT", 88, 112], ["HAdV ocular infection", "PROBLEM", 133, 154], ["no", "UNCERTAINTY", 18, 20], ["infection", "OBSERVATION", 54, 63], ["ocular", "ANATOMY", 138, 144], ["infection", "OBSERVATION", 145, 154]]], ["Finally, the propensity for latent HAdV to become reactivated and easily transmissible warrants the need for additional research in developing an effective, prophylactic antiviral drug.", [["HAdV", "ORGANISM", 35, 39], ["latent HAdV", "PROBLEM", 28, 39], ["additional research", "TREATMENT", 109, 128], ["prophylactic antiviral drug", "TREATMENT", 157, 184]]], ["New treatments under consideration include sialic acid analogs, cold atmospheric plasma (CAP), N-chlorotaurine, and even benzalkonium chloride (BAK).", [["sialic acid", "CHEMICAL", 43, 54], ["CAP", "CHEMICAL", 89, 92], ["N-chlorotaurine", "CHEMICAL", 95, 110], ["benzalkonium chloride", "CHEMICAL", 121, 142], ["BAK", "CHEMICAL", 144, 147], ["sialic acid", "CHEMICAL", 43, 54], ["N-chlorotaurine", "CHEMICAL", 95, 110], ["benzalkonium chloride", "CHEMICAL", 121, 142], ["BAK", "CHEMICAL", 144, 147], ["sialic acid", "SIMPLE_CHEMICAL", 43, 54], ["plasma", "ORGANISM_SUBSTANCE", 81, 87], ["CAP", "SIMPLE_CHEMICAL", 89, 92], ["N-chlorotaurine", "SIMPLE_CHEMICAL", 95, 110], ["benzalkonium chloride", "SIMPLE_CHEMICAL", 121, 142], ["BAK", "SIMPLE_CHEMICAL", 144, 147], ["New treatments", "TREATMENT", 0, 14], ["sialic acid analogs", "TREATMENT", 43, 62], ["cold atmospheric plasma (CAP)", "TREATMENT", 64, 93], ["chlorotaurine", "TREATMENT", 97, 110], ["even benzalkonium chloride", "TREATMENT", 116, 142]]], ["Sialic acid plays a role in initial attachment of fiber knobs in adenoviral virions while facilitating accumulation.", [["fiber knobs", "ANATOMY", 50, 61], ["virions", "ANATOMY", 76, 83], ["Sialic acid", "CHEMICAL", 0, 11], ["Sialic acid", "CHEMICAL", 0, 11], ["Sialic acid", "SIMPLE_CHEMICAL", 0, 11], ["fiber knobs", "CELLULAR_COMPONENT", 50, 61], ["adenoviral", "ORGANISM", 65, 75], ["Sialic acid", "TREATMENT", 0, 11], ["initial attachment of fiber knobs in adenoviral virions", "TREATMENT", 28, 83], ["adenoviral virions", "OBSERVATION", 65, 83]]], ["95 Sialic acid analogs have been theorized to block sialic acid-containing glycans which act as cellular receptors as a topical treatment.", [["cellular", "ANATOMY", 96, 104], ["Sialic acid", "CHEMICAL", 3, 14], ["Sialic acid", "CHEMICAL", 3, 14], ["Sialic acid", "SIMPLE_CHEMICAL", 3, 14], ["sialic acid-containing glycans", "SIMPLE_CHEMICAL", 52, 82], ["cellular", "CELL", 96, 104], ["cellular receptors", "PROTEIN", 96, 114], ["Sialic acid analogs", "TREATMENT", 3, 22], ["block sialic acid-containing glycans", "TREATMENT", 46, 82], ["cellular receptors", "TREATMENT", 96, 114], ["a topical treatment", "TREATMENT", 118, 137]]], ["95, 99 CAP is of use in dermatological disease and chronic wounds and has demonstrated adenoviral type-dependent antiviral effect that may be of benefit.", [["wounds", "ANATOMY", 59, 65], ["dermatological disease", "DISEASE", 24, 46], ["chronic wounds", "DISEASE", 51, 65], ["wounds", "PATHOLOGICAL_FORMATION", 59, 65], ["adenoviral", "ORGANISM", 87, 97], ["dermatological disease", "PROBLEM", 24, 46], ["chronic wounds", "PROBLEM", 51, 65], ["adenoviral type-dependent antiviral effect", "TREATMENT", 87, 129], ["chronic", "OBSERVATION_MODIFIER", 51, 58], ["wounds", "OBSERVATION", 59, 65], ["antiviral effect", "OBSERVATION", 113, 129]]], ["100 N-chlorotaurine, an endogenous antimicrobial agent, has been shown to shorten duration of illness and is well tolerated in in vitro and in vivo experiments; however, Phase II clinical trials were prematurely ended due to inability to meet primary and secondary endpoints.", [["N-chlorotaurine", "CHEMICAL", 4, 19], ["N-chlorotaurine", "CHEMICAL", 4, 19], ["N-chlorotaurine", "SIMPLE_CHEMICAL", 4, 19], ["chlorotaurine", "TREATMENT", 6, 19], ["an endogenous antimicrobial agent", "TREATMENT", 21, 54], ["inability to meet primary and secondary endpoints", "PROBLEM", 225, 274]]], ["101 These endpoints included clearing of bulbar conjunctiva, eradication of virus from tear film, fellow eye involvement, reduction of SEIs, and clearing of vision.", [["bulbar conjunctiva", "ANATOMY", 41, 59], ["eye", "ANATOMY", 105, 108], ["SEIs", "DISEASE", 135, 139], ["bulbar conjunctiva", "ORGANISM_SUBDIVISION", 41, 59], ["eye", "ORGAN", 105, 108], ["bulbar conjunctiva", "PROBLEM", 41, 59], ["virus", "PROBLEM", 76, 81], ["tear film", "TEST", 87, 96], ["SEIs", "PROBLEM", 135, 139], ["clearing of vision", "PROBLEM", 145, 163], ["clearing", "OBSERVATION_MODIFIER", 29, 37], ["bulbar conjunctiva", "ANATOMY", 41, 59], ["eye", "ANATOMY", 105, 108]]], ["102 BAK is a commonly found preservative in ophthalmic formulations typically present as 0.01% concentration.", [["BAK", "CHEMICAL", 4, 7], ["BAK", "GENE_OR_GENE_PRODUCT", 4, 7], ["ophthalmic formulations", "TREATMENT", 44, 67]]], ["Studies prove the effectivity of BAK as an antiviral agent against adenovirus in concentrations higher than 0.1%; however, note the disadvantage of ocular toxicity from the known disinfectant.", [["ocular", "ANATOMY", 148, 154], ["BAK", "CHEMICAL", 33, 36], ["ocular toxicity", "DISEASE", 148, 163], ["BAK", "CHEMICAL", 33, 36], ["BAK", "GENE_OR_GENE_PRODUCT", 33, 36], ["adenovirus", "ORGANISM", 67, 77], ["ocular", "ORGAN", 148, 154], ["adenovirus", "SPECIES", 67, 77], ["Studies", "TEST", 0, 7], ["BAK", "TREATMENT", 33, 36], ["an antiviral agent", "TREATMENT", 40, 58], ["adenovirus", "PROBLEM", 67, 77], ["ocular toxicity", "PROBLEM", 148, 163], ["ocular", "ANATOMY", 148, 154], ["disinfectant", "OBSERVATION", 179, 191]]], ["103 Future considerations in the management of adenoviral keratoconjunctivitis should require consideration of antisepsis and mitigation of sequelae from the host inflammatory response.", [["adenoviral keratoconjunctivitis", "DISEASE", 47, 78], ["adenoviral", "ORGANISM", 47, 57], ["adenoviral", "SPECIES", 47, 57], ["adenoviral keratoconjunctivitis", "PROBLEM", 47, 78], ["antisepsis", "TREATMENT", 111, 121], ["sequelae", "PROBLEM", 140, 148], ["the host inflammatory response", "PROBLEM", 154, 184], ["adenoviral keratoconjunctivitis", "OBSERVATION", 47, 78], ["host", "OBSERVATION_MODIFIER", 158, 162], ["inflammatory", "OBSERVATION_MODIFIER", 163, 175]]], ["Furthermore, special consideration for persistent latent HAdV subtypes and immunocompromised individuals is required.", [["HAdV", "ORGANISM", 57, 61], ["persistent latent HAdV subtypes", "PROBLEM", 39, 70], ["immunocompromised individuals", "PROBLEM", 75, 104], ["HAdV subtypes", "OBSERVATION_MODIFIER", 57, 70], ["immunocompromised", "OBSERVATION", 75, 92]]], ["Identification of exact mechanisms that underlie the adaptive immune response in adenoviral infections is prudent to the development of novel therapeutic sources.", [["adenoviral infections", "DISEASE", 81, 102], ["adenoviral", "ORGANISM", 81, 91], ["adenoviral", "SPECIES", 81, 91], ["adenoviral infections", "PROBLEM", 81, 102]]], ["However, the lack of animal models that accurately mimic complexity of human ocular anatomy while also illustrating proper replication and infection of human adenoviruses can prove decelerating for new discovery.", [["ocular", "ANATOMY", 77, 83], ["infection", "DISEASE", 139, 148], ["human", "ORGANISM", 71, 76], ["ocular", "ORGANISM_SUBDIVISION", 77, 83], ["human", "ORGANISM", 152, 157], ["adenoviruses", "ORGANISM", 158, 170], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 152, 157], ["human ocular anatomy", "PROBLEM", 71, 91], ["infection of human adenoviruses", "PROBLEM", 139, 170]]], ["95 Table 2 highlights the efficacy and adverse effects of antiviral and anti-inflammatory agents discussed in this review.", [["antiviral", "TREATMENT", 58, 67], ["anti-inflammatory agents", "TREATMENT", 72, 96]]], ["2, 46, 55, 63, 64, 66, 69, 87, In summary, there are several challenges regarding the treatment of adenoviral keratoconjunctivitis.", [["adenoviral keratoconjunctivitis", "DISEASE", 99, 130], ["adenoviral", "ORGANISM", 99, 109], ["adenoviral keratoconjunctivitis", "PROBLEM", 99, 130], ["adenoviral keratoconjunctivitis", "OBSERVATION", 99, 130]]], ["Though there are solutions to some Cidofovir Antiviral activity against HAdV5 exhibited in animal models.", [["Cidofovir", "CHEMICAL", 35, 44], ["HAdV5", "CHEMICAL", 72, 77], ["Cidofovir", "CHEMICAL", 35, 44], ["Cidofovir", "SIMPLE_CHEMICAL", 35, 44], ["HAdV5", "SIMPLE_CHEMICAL", 72, 77], ["HAdV5", "PROTEIN", 72, 77], ["HAdV5", "SPECIES", 72, 77], ["solutions", "TREATMENT", 17, 26], ["some Cidofovir Antiviral activity", "TREATMENT", 30, 63], ["HAdV5", "PROBLEM", 72, 77]]], ["105 Cidofovir 1% lowered the frequency of severe corneal opacities in patients with adenoviral keratoconjunctivitis.", [["corneal", "ANATOMY", 49, 56], ["Cidofovir", "CHEMICAL", 4, 13], ["corneal opacities", "DISEASE", 49, 66], ["adenoviral keratoconjunctivitis", "DISEASE", 84, 115], ["corneal", "TISSUE", 49, 56], ["patients", "ORGANISM", 70, 78], ["adenoviral", "ORGANISM", 84, 94], ["patients", "SPECIES", 70, 78], ["Cidofovir", "TREATMENT", 4, 13], ["severe corneal opacities", "PROBLEM", 42, 66], ["adenoviral keratoconjunctivitis", "PROBLEM", 84, 115], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["corneal", "ANATOMY", 49, 56], ["opacities", "OBSERVATION", 57, 66], ["adenoviral keratoconjunctivitis", "OBSERVATION", 84, 115]]], ["64, 106 Narrow therapeutic index when used topically; high doses for greater than one week associated with rare cases of lacrimal canalicular blockade in rabbit models.", [["lacrimal canalicular", "ANATOMY", 121, 141], ["lacrimal canalicular blockade", "DISEASE", 121, 150], ["lacrimal canalicular", "MULTI-TISSUE_STRUCTURE", 121, 141], ["rabbit", "ORGANISM", 154, 160], ["rabbit", "SPECIES", 154, 160], ["rabbit", "SPECIES", 154, 160], ["lacrimal canalicular blockade", "TREATMENT", 121, 150], ["lacrimal canalicular", "ANATOMY", 121, 141]]], ["107 Ganciclovir 3% ganciclovir reduced HAdV 5 replication and pathogenesis in animal models.", [["Ganciclovir", "CHEMICAL", 4, 15], ["ganciclovir", "CHEMICAL", 19, 30], ["ganciclovir", "CHEMICAL", 19, 30], ["ganciclovir", "SIMPLE_CHEMICAL", 19, 30], ["HAdV 5", "ORGANISM", 39, 45], ["Ganciclovir", "TREATMENT", 4, 15], ["ganciclovir reduced HAdV", "TREATMENT", 19, 43]]], ["108 Ganciclovir is efficacious against HAdV types that cause EKC.", [["Ganciclovir", "CHEMICAL", 4, 15], ["EKC", "DISEASE", 61, 64], ["Ganciclovir", "CHEMICAL", 4, 15], ["HAdV", "ORGANISM", 39, 43], ["Ganciclovir", "TREATMENT", 4, 15], ["HAdV types", "PROBLEM", 39, 49], ["EKC", "PROBLEM", 61, 64]]], ["46 Ganciclovir ophthalmic gel treatment prevents complications in adenoviral ocular infection.", [["ocular", "ANATOMY", 77, 83], ["adenoviral ocular infection", "DISEASE", 66, 93], ["adenoviral", "ORGANISM", 66, 76], ["ocular", "ORGAN", 77, 83], ["adenoviral", "SPECIES", 66, 76], ["Ganciclovir ophthalmic gel treatment", "TREATMENT", 3, 39], ["complications", "PROBLEM", 49, 62], ["adenoviral ocular infection", "PROBLEM", 66, 93], ["adenoviral ocular infection", "OBSERVATION", 66, 93]]], ["109 Transient blur following instillation, eye irritation, punctate keratitis, conjunctival hyperemia.", [["eye", "ANATOMY", 43, 46], ["conjunctival", "ANATOMY", 79, 91], ["eye irritation", "DISEASE", 43, 57], ["keratitis", "DISEASE", 68, 77], ["conjunctival hyperemia", "DISEASE", 79, 101], ["eye", "ORGAN", 43, 46], ["conjunctival", "TISSUE", 79, 91], ["Transient blur", "PROBLEM", 4, 18], ["instillation", "TREATMENT", 29, 41], ["eye irritation", "PROBLEM", 43, 57], ["punctate keratitis", "PROBLEM", 59, 77], ["conjunctival hyperemia", "PROBLEM", 79, 101], ["Transient blur", "OBSERVATION", 4, 18], ["eye", "ANATOMY", 43, 46], ["irritation", "OBSERVATION", 47, 57], ["punctate", "OBSERVATION_MODIFIER", 59, 67], ["keratitis", "OBSERVATION", 68, 77], ["conjunctival hyperemia", "OBSERVATION", 79, 101]]], ["108 Brincidofovir Brincidofovir has antiviral activity against adenoviruses.", [["Brincidofovir", "CHEMICAL", 4, 17], ["Brincidofovir", "CHEMICAL", 18, 31], ["Brincidofovir", "CHEMICAL", 18, 31], ["Brincidofovir", "SIMPLE_CHEMICAL", 18, 31], ["adenoviruses", "ORGANISM", 63, 75], ["Brincidofovir Brincidofovir", "TREATMENT", 4, 31], ["antiviral activity", "TREATMENT", 36, 54], ["adenoviruses", "PROBLEM", 63, 75], ["antiviral activity", "OBSERVATION", 36, 54]]], ["55 DovePress of these issues, more research is required to determine a standard protocol (Table 3) .", [["a standard protocol", "TREATMENT", 69, 88]]]], "PMC7211721": [], "5210693266b91a8e02cf60b855062d3f5274886b": [["IntroductionComplicated rhinosinusitis is defined as the sequelae of direct extension of acute rhinosinusitis to adjacent structures [1, 2] .", [["rhinosinusitis", "DISEASE", 24, 38], ["rhinosinusitis", "DISEASE", 95, 109], ["IntroductionComplicated rhinosinusitis", "PROBLEM", 0, 38], ["acute rhinosinusitis to adjacent structures", "PROBLEM", 89, 132], ["rhinosinusitis", "OBSERVATION", 24, 38], ["sequelae", "OBSERVATION_MODIFIER", 57, 65], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["rhinosinusitis", "OBSERVATION", 95, 109]]], ["Sequelae of complicated rhinosinusitis include orbital complications, such as preseptal cellulitis, subperiosteal abscess, orbital cellulitis, orbital abscess, and cavernous sinus thrombosis [1] [2] [3] [4] .", [["orbital", "ANATOMY", 47, 54], ["abscess", "ANATOMY", 114, 121], ["orbital", "ANATOMY", 123, 130], ["orbital abscess", "ANATOMY", 143, 158], ["cavernous sinus", "ANATOMY", 164, 179], ["rhinosinusitis", "DISEASE", 24, 38], ["orbital complications", "DISEASE", 47, 68], ["cellulitis", "DISEASE", 88, 98], ["subperiosteal abscess", "DISEASE", 100, 121], ["orbital cellulitis", "DISEASE", 123, 141], ["orbital abscess", "DISEASE", 143, 158], ["cavernous sinus thrombosis", "DISEASE", 164, 190], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 191, 206], ["complicated rhinosinusitis", "PROBLEM", 12, 38], ["orbital complications", "PROBLEM", 47, 68], ["preseptal cellulitis", "PROBLEM", 78, 98], ["subperiosteal abscess", "PROBLEM", 100, 121], ["orbital cellulitis", "PROBLEM", 123, 141], ["orbital abscess", "PROBLEM", 143, 158], ["cavernous sinus thrombosis", "PROBLEM", 164, 190], ["complicated", "OBSERVATION_MODIFIER", 12, 23], ["rhinosinusitis", "OBSERVATION", 24, 38], ["orbital", "ANATOMY", 47, 54], ["complications", "OBSERVATION", 55, 68], ["preseptal", "ANATOMY", 78, 87], ["cellulitis", "OBSERVATION", 88, 98], ["subperiosteal", "ANATOMY", 100, 113], ["abscess", "OBSERVATION", 114, 121], ["orbital", "ANATOMY", 123, 130], ["cellulitis", "OBSERVATION", 131, 141], ["orbital", "ANATOMY", 143, 150], ["abscess", "OBSERVATION", 151, 158], ["cavernous sinus", "ANATOMY", 164, 179], ["thrombosis", "OBSERVATION", 180, 190]]], ["Intracranial complications also can occur, resulting in meningitis, epidural abscess, subdural abscess, intracerebral abscess, and osteomyelitis of the frontal bone [5] .", [["Intracranial", "ANATOMY", 0, 12], ["epidural", "ANATOMY", 68, 76], ["subdural", "ANATOMY", 86, 94], ["intracerebral", "ANATOMY", 104, 117], ["frontal bone", "ANATOMY", 152, 164], ["Intracranial complications", "DISEASE", 0, 26], ["meningitis", "DISEASE", 56, 66], ["epidural abscess", "DISEASE", 68, 84], ["subdural abscess", "DISEASE", 86, 102], ["intracerebral abscess", "DISEASE", 104, 125], ["osteomyelitis", "DISEASE", 131, 144], ["epidural abscess", "PATHOLOGICAL_FORMATION", 68, 84], ["subdural abscess", "PATHOLOGICAL_FORMATION", 86, 102], ["intracerebral abscess", "PATHOLOGICAL_FORMATION", 104, 125], ["frontal bone", "MULTI-TISSUE_STRUCTURE", 152, 164], ["Intracranial complications", "PROBLEM", 0, 26], ["meningitis", "PROBLEM", 56, 66], ["epidural abscess", "PROBLEM", 68, 84], ["subdural abscess", "PROBLEM", 86, 102], ["intracerebral abscess", "PROBLEM", 104, 125], ["osteomyelitis of the frontal bone", "PROBLEM", 131, 164], ["complications", "OBSERVATION", 13, 26], ["meningitis", "OBSERVATION", 56, 66], ["epidural", "ANATOMY", 68, 76], ["abscess", "OBSERVATION", 77, 84], ["subdural", "ANATOMY", 86, 94], ["abscess", "OBSERVATION", 95, 102], ["intracerebral", "ANATOMY", 104, 117], ["abscess", "OBSERVATION", 118, 125], ["osteomyelitis", "OBSERVATION", 131, 144], ["frontal", "ANATOMY_MODIFIER", 152, 159], ["bone", "ANATOMY", 160, 164]]], ["Viral infections are the most common cause of rhinosinusitis and have been found to be a nidus for bacterial superinfection [6] .IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which on March 11, 2020 was declared a worldwide pandemic by the World Health Organization (WHO) known as Coronavirus disease 2019 (COVID- 19) , has not previously been associated with complicated rhinosinusitis.", [["Viral infections", "DISEASE", 0, 16], ["rhinosinusitis", "DISEASE", 46, 60], ["superinfection", "DISEASE", 109, 123], ["acute respiratory syndrome coronavirus", "DISEASE", 148, 186], ["Coronavirus disease", "DISEASE", 309, 328], ["COVID- 19", "CHEMICAL", 335, 344], ["rhinosinusitis", "DISEASE", 400, 414], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 129, 188], ["SARS-CoV-2", "ORGANISM", 190, 200], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 129, 186], ["SARS-CoV-2", "SPECIES", 190, 200], ["Viral infections", "PROBLEM", 0, 16], ["rhinosinusitis", "PROBLEM", 46, 60], ["bacterial superinfection", "PROBLEM", 99, 123], ["acute respiratory syndrome coronavirus", "PROBLEM", 148, 186], ["Coronavirus disease", "PROBLEM", 309, 328], ["COVID", "TEST", 335, 340], ["complicated rhinosinusitis", "PROBLEM", 388, 414], ["infections", "OBSERVATION", 6, 16], ["most common", "OBSERVATION_MODIFIER", 25, 36], ["rhinosinusitis", "OBSERVATION", 46, 60], ["nidus", "OBSERVATION", 89, 94], ["bacterial", "OBSERVATION_MODIFIER", 99, 108], ["superinfection", "OBSERVATION", 109, 123], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["respiratory syndrome", "OBSERVATION", 154, 174], ["Coronavirus disease", "OBSERVATION", 309, 328], ["not previously been associated with", "UNCERTAINTY", 352, 387], ["complicated", "OBSERVATION_MODIFIER", 388, 399], ["rhinosinusitis", "OBSERVATION", 400, 414]]], ["Since the WHO declaration, there has been evidence reporting high viral loads of SARS-CoV-2 in the sinonasal cavity and nasopharynx [7] .", [["sinonasal cavity", "ANATOMY", 99, 115], ["nasopharynx", "ANATOMY", 120, 131], ["SARS", "DISEASE", 81, 85], ["SARS-CoV-2", "ORGANISM", 81, 91], ["sinonasal cavity", "PATHOLOGICAL_FORMATION", 99, 115], ["nasopharynx", "ORGAN", 120, 131], ["SARS-CoV", "SPECIES", 81, 89], ["high viral loads of SARS", "PROBLEM", 61, 85], ["CoV", "TEST", 86, 89], ["high", "OBSERVATION_MODIFIER", 61, 65], ["viral loads", "OBSERVATION", 66, 77], ["sinonasal cavity", "ANATOMY", 99, 115], ["nasopharynx", "ANATOMY", 120, 131]]], ["As of July 18, 2020, over 14 million cases of COVID-19 have been reported worldwide with over 600,000 global deaths [8] .", [["deaths", "DISEASE", 109, 115], ["COVID", "TEST", 46, 51]]], ["In the Unites States (US), COVID-19 cases have continued to demonstrate an upward trend since March 2020, now with over 3.6 million documented cases [8] .", [["COVID", "TEST", 27, 32], ["an upward trend", "PROBLEM", 72, 87]]], ["Despite vast research being performed to elucidate the pathophysiology, patient characteristics, and treatment considerations, no case of complicated rhinosinusitis in COVID-19 patients to our knowledge has been described in the current otolaryngology literature.Illustrative Case IAn obese 15-year-old African American male with recent travel history presented to an outside emergency department (ED) with a three-day history of headaches, subjective fevers, nasal congestion, diarrhea, nausea, emesis, right periorbital swelling, pain, and blurred vision.", [["nasal", "ANATOMY", 460, 465], ["right periorbital", "ANATOMY", 504, 521], ["rhinosinusitis", "DISEASE", 150, 164], ["headaches", "DISEASE", 430, 439], ["fevers", "DISEASE", 452, 458], ["nasal congestion", "DISEASE", 460, 476], ["diarrhea", "DISEASE", 478, 486], ["nausea", "DISEASE", 488, 494], ["emesis", "DISEASE", 496, 502], ["periorbital swelling", "DISEASE", 510, 530], ["pain", "DISEASE", 532, 536], ["blurred vision", "DISEASE", 542, 556], ["patient", "ORGANISM", 72, 79], ["patients", "ORGANISM", 177, 185], ["nasal", "ORGANISM_SUBDIVISION", 460, 465], ["patient", "SPECIES", 72, 79], ["patients", "SPECIES", 177, 185], ["complicated rhinosinusitis", "PROBLEM", 138, 164], ["headaches", "PROBLEM", 430, 439], ["subjective fevers", "PROBLEM", 441, 458], ["nasal congestion", "PROBLEM", 460, 476], ["diarrhea", "PROBLEM", 478, 486], ["nausea", "PROBLEM", 488, 494], ["emesis", "PROBLEM", 496, 502], ["right periorbital swelling", "PROBLEM", 504, 530], ["pain", "PROBLEM", 532, 536], ["blurred vision", "PROBLEM", 542, 556], ["complicated", "OBSERVATION_MODIFIER", 138, 149], ["rhinosinusitis", "OBSERVATION", 150, 164], ["headaches", "OBSERVATION", 430, 439], ["fevers", "OBSERVATION", 452, 458], ["nasal", "ANATOMY", 460, 465], ["congestion", "OBSERVATION", 466, 476], ["diarrhea", "OBSERVATION", 478, 486], ["nausea", "OBSERVATION", 488, 494], ["right", "ANATOMY_MODIFIER", 504, 509], ["periorbital", "ANATOMY", 510, 521], ["swelling", "OBSERVATION", 522, 530], ["pain", "OBSERVATION", 532, 536], ["blurred vision", "OBSERVATION", 542, 556]]], ["Computed tomography (CT) revealed right-sided rhinosinusitis and an epidural collection posterior to the right frontal sinus (Fig. 1) .", [["epidural", "ANATOMY", 68, 76], ["right frontal sinus", "ANATOMY", 105, 124], ["rhinosinusitis", "DISEASE", 46, 60], ["frontal sinus", "MULTI-TISSUE_STRUCTURE", 111, 124], ["Computed tomography (CT)", "TEST", 0, 24], ["right-sided rhinosinusitis", "PROBLEM", 34, 60], ["an epidural collection", "PROBLEM", 65, 87], ["right", "ANATOMY_MODIFIER", 34, 39], ["sided", "ANATOMY_MODIFIER", 40, 45], ["rhinosinusitis", "OBSERVATION", 46, 60], ["epidural", "ANATOMY", 68, 76], ["collection", "OBSERVATION", 77, 87], ["posterior", "ANATOMY_MODIFIER", 88, 97], ["right", "ANATOMY_MODIFIER", 105, 110], ["frontal sinus", "ANATOMY", 111, 124], ["Fig", "OBSERVATION_MODIFIER", 126, 129]]], ["He was transferred to our facility.", [["He", "ORGANISM", 0, 2]]], ["The patient was febrile, tachycardic, and tachypneic, with a right-sided orbital cellulitis on exam.", [["febrile", "DISEASE", 16, 23], ["tachypneic", "DISEASE", 42, 52], ["cellulitis", "DISEASE", 81, 91], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["febrile", "PROBLEM", 16, 23], ["tachycardic", "PROBLEM", 25, 36], ["tachypneic", "PROBLEM", 42, 52], ["a right-sided orbital cellulitis", "PROBLEM", 59, 91], ["exam", "TEST", 95, 99], ["febrile", "OBSERVATION_MODIFIER", 16, 23], ["right", "ANATOMY_MODIFIER", 61, 66], ["sided", "ANATOMY_MODIFIER", 67, 72], ["orbital", "ANATOMY", 73, 80], ["cellulitis", "OBSERVATION", 81, 91]]], ["Nasal endoscopy revealed right middle meatal purulence and mucosal inflammation.", [["Nasal", "ANATOMY", 0, 5], ["right middle meatal", "ANATOMY", 25, 44], ["mucosal", "ANATOMY", 59, 66], ["inflammation", "DISEASE", 67, 79], ["mucosal", "PATHOLOGICAL_FORMATION", 59, 66], ["Nasal endoscopy", "TEST", 0, 15], ["right middle meatal purulence", "PROBLEM", 25, 54], ["mucosal inflammation", "PROBLEM", 59, 79], ["right", "ANATOMY_MODIFIER", 25, 30], ["middle meatal", "ANATOMY", 31, 44], ["purulence", "OBSERVATION", 45, 54], ["mucosal", "ANATOMY", 59, 66], ["inflammation", "OBSERVATION", 67, 79]]], ["He was neurologically intact.", [["He", "ORGANISM", 0, 2], ["intact", "OBSERVATION", 22, 28]]], ["Table 1 highlights his laboratory values.", [["his laboratory values", "TEST", 19, 40]]], ["SARS-CoV-2 ribonucleic acid (RNA) testing was positive.Illustrative Case IMultidisciplinary management approach with otolaryngology, ophthalmology, neurosurgery, infectious disease, and pediatrics was initiated.", [["SARS-CoV-2 ribonucleic acid", "CHEMICAL", 0, 27], ["infectious disease", "DISEASE", 162, 180], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV-2 ribonucleic acid", "RNA", 0, 27], ["SARS", "TEST", 0, 4], ["CoV-2 ribonucleic acid (RNA) testing", "TEST", 5, 41]]], ["Treatment consisted of vancomycin and ceftriaxone, tobramycin eye drops, nasal saline irrigation, intranasal oxymetazoline and fluticasone, and prophylactic levetiracetam.", [["eye", "ANATOMY", 62, 65], ["nasal", "ANATOMY", 73, 78], ["vancomycin", "CHEMICAL", 23, 33], ["ceftriaxone", "CHEMICAL", 38, 49], ["tobramycin", "CHEMICAL", 51, 61], ["oxymetazoline", "CHEMICAL", 109, 122], ["fluticasone", "CHEMICAL", 127, 138], ["levetiracetam", "CHEMICAL", 157, 170], ["vancomycin", "CHEMICAL", 23, 33], ["ceftriaxone", "CHEMICAL", 38, 49], ["tobramycin", "CHEMICAL", 51, 61], ["oxymetazoline", "CHEMICAL", 109, 122], ["fluticasone", "CHEMICAL", 127, 138], ["levetiracetam", "CHEMICAL", 157, 170], ["vancomycin", "SIMPLE_CHEMICAL", 23, 33], ["ceftriaxone", "SIMPLE_CHEMICAL", 38, 49], ["tobramycin", "SIMPLE_CHEMICAL", 51, 61], ["oxymetazoline", "SIMPLE_CHEMICAL", 109, 122], ["fluticasone", "SIMPLE_CHEMICAL", 127, 138], ["levetiracetam", "SIMPLE_CHEMICAL", 157, 170], ["Treatment", "TREATMENT", 0, 9], ["vancomycin", "TREATMENT", 23, 33], ["ceftriaxone", "TREATMENT", 38, 49], ["tobramycin eye drops", "TREATMENT", 51, 71], ["nasal saline irrigation", "TREATMENT", 73, 96], ["intranasal oxymetazoline", "TREATMENT", 98, 122], ["fluticasone", "TREATMENT", 127, 138], ["prophylactic levetiracetam", "TREATMENT", 144, 170], ["nasal", "ANATOMY", 73, 78]]], ["After no clinical improvement for 24 h, magnetic resonance imaging (MRI) revealed persistent rhinosinusitis, epidural collection, and superior ophthalmic vein https://doi.org/10.1016/j.amjoto.2020.102746 Received 9 September 2020 thrombosis (SOVT) (Fig. 2) .Illustrative Case IOn hospitalization day 3, he developed worsening chemosis, proptosis, and visual acuity.", [["epidural", "ANATOMY", 109, 117], ["rhinosinusitis", "DISEASE", 93, 107], ["thrombosis", "DISEASE", 230, 240], ["chemosis", "DISEASE", 326, 334], ["proptosis", "DISEASE", 336, 345], ["magnetic resonance imaging", "TEST", 40, 66], ["MRI", "TEST", 68, 71], ["persistent rhinosinusitis", "PROBLEM", 82, 107], ["epidural collection", "PROBLEM", 109, 128], ["thrombosis", "PROBLEM", 230, 240], ["worsening chemosis", "PROBLEM", 316, 334], ["proptosis", "PROBLEM", 336, 345], ["visual acuity", "PROBLEM", 351, 364], ["persistent", "OBSERVATION_MODIFIER", 82, 92], ["rhinosinusitis", "OBSERVATION", 93, 107], ["epidural", "ANATOMY", 109, 117], ["collection", "OBSERVATION", 118, 128], ["superior", "ANATOMY_MODIFIER", 134, 142], ["ophthalmic vein", "ANATOMY", 143, 158], ["thrombosis", "OBSERVATION", 230, 240], ["worsening", "OBSERVATION_MODIFIER", 316, 325], ["chemosis", "OBSERVATION", 326, 334], ["proptosis", "OBSERVATION", 336, 345], ["visual acuity", "OBSERVATION", 351, 364]]], ["He was taken to the operating room (OR) for endoscopic right maxillary antrostomy, total ethmoidectomy, and frontal sinusotomy (Fig. 3) .", [["maxillary", "ANATOMY", 61, 70], ["He", "ORGANISM", 0, 2], ["endoscopic right maxillary antrostomy", "TREATMENT", 44, 81], ["total ethmoidectomy", "TREATMENT", 83, 102], ["frontal sinusotomy", "TREATMENT", 108, 126], ["right", "ANATOMY_MODIFIER", 55, 60], ["maxillary", "ANATOMY", 61, 70], ["antrostomy", "OBSERVATION", 71, 81], ["total", "OBSERVATION_MODIFIER", 83, 88], ["ethmoidectomy", "OBSERVATION", 89, 102], ["frontal", "ANATOMY_MODIFIER", 108, 115], ["sinusotomy", "OBSERVATION", 116, 126]]], ["Only non-powered instrumentation was utilized.", [["non-powered instrumentation", "TREATMENT", 5, 32], ["instrumentation", "OBSERVATION", 17, 32]]], ["Intraoperative cultures grew coagulase-negative Staphylococcus.", [["coagulase-negative Staphylococcus", "GENE_OR_GENE_PRODUCT", 29, 62], ["coagulase", "PROTEIN", 29, 38], ["Intraoperative cultures", "TEST", 0, 23], ["coagulase", "TEST", 29, 38], ["Staphylococcus", "PROBLEM", 48, 62], ["negative Staphylococcus", "OBSERVATION", 39, 62]]], ["Postoperatively, he developed hypoxia to 89% on room air.", [["hypoxia", "DISEASE", 30, 37], ["hypoxia", "PROBLEM", 30, 37], ["hypoxia", "OBSERVATION", 30, 37]]], ["Chest x-ray revealed bilateral, patchy opacities.", [["opacities", "DISEASE", 39, 48], ["Chest x-ray", "TEST", 0, 11], ["bilateral, patchy opacities", "PROBLEM", 21, 48], ["bilateral", "ANATOMY_MODIFIER", 21, 30], ["patchy", "OBSERVATION_MODIFIER", 32, 38], ["opacities", "OBSERVATION", 39, 48]]], ["He was also started on metronidazole, hydroxychloroquine, enoxaparin, zinc, vitamin C, and thiamine.", [["metronidazole", "CHEMICAL", 23, 36], ["hydroxychloroquine", "CHEMICAL", 38, 56], ["enoxaparin", "CHEMICAL", 58, 68], ["zinc", "CHEMICAL", 70, 74], ["vitamin C", "CHEMICAL", 76, 85], ["thiamine", "CHEMICAL", 91, 99], ["metronidazole", "CHEMICAL", 23, 36], ["hydroxychloroquine", "CHEMICAL", 38, 56], ["enoxaparin", "CHEMICAL", 58, 68], ["zinc", "CHEMICAL", 70, 74], ["vitamin C", "CHEMICAL", 76, 85], ["thiamine", "CHEMICAL", 91, 99], ["He", "ORGANISM", 0, 2], ["metronidazole", "SIMPLE_CHEMICAL", 23, 36], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 38, 56], ["enoxaparin", "SIMPLE_CHEMICAL", 58, 68], ["zinc", "SIMPLE_CHEMICAL", 70, 74], ["vitamin C", "SIMPLE_CHEMICAL", 76, 85], ["thiamine", "SIMPLE_CHEMICAL", 91, 99], ["metronidazole", "TREATMENT", 23, 36], ["hydroxychloroquine", "TREATMENT", 38, 56], ["enoxaparin", "TREATMENT", 58, 68], ["zinc", "TREATMENT", 70, 74], ["vitamin C", "TREATMENT", 76, 85], ["thiamine", "TREATMENT", 91, 99]]], ["He necessitated transfer to the pediatric intensive care unit (PICU) for bilevel positive airway pressure (BiPAP) therapy.", [["airway", "ANATOMY", 90, 96], ["BiPAP", "CHEMICAL", 107, 112], ["airway", "MULTI-TISSUE_STRUCTURE", 90, 96], ["bilevel positive airway pressure", "TREATMENT", 73, 105], ["BiPAP) therapy", "TREATMENT", 107, 121], ["airway pressure", "OBSERVATION", 90, 105]]], ["His respiratory status improved with further uncomplicated hospital course.", [["respiratory", "ANATOMY", 4, 15], ["further uncomplicated hospital course", "TREATMENT", 37, 74], ["respiratory", "ANATOMY", 4, 15]]], ["He was continued to metronidazole and ceftriaxone for five weeks after discharge.", [["metronidazole", "CHEMICAL", 20, 33], ["ceftriaxone", "CHEMICAL", 38, 49], ["metronidazole", "CHEMICAL", 20, 33], ["ceftriaxone", "CHEMICAL", 38, 49], ["He", "ORGANISM", 0, 2], ["metronidazole", "SIMPLE_CHEMICAL", 20, 33], ["ceftriaxone", "SIMPLE_CHEMICAL", 38, 49], ["metronidazole", "TREATMENT", 20, 33], ["ceftriaxone", "TREATMENT", 38, 49]]], ["After completion of his antibiotic regimen, he was subsequently lost to follow-up.Illustrative Case IIA 12-year-old Egyptian male with seasonal allergies and remote history of adenotonsillectomy presented to an outside ED with nasal congestion and progressive right eye swelling for three days.", [["nasal", "ANATOMY", 227, 232], ["right eye", "ANATOMY", 260, 269], ["seasonal allergies", "DISEASE", 135, 153], ["adenotonsillectomy", "DISEASE", 176, 194], ["nasal congestion", "DISEASE", 227, 243], ["right eye swelling", "DISEASE", 260, 278], ["Case IIA", "CANCER", 95, 103], ["Egyptian", "ORGANISM", 116, 124], ["nasal", "ORGANISM_SUBDIVISION", 227, 232], ["eye", "ORGAN", 266, 269], ["his antibiotic regimen", "TREATMENT", 20, 42], ["seasonal allergies", "PROBLEM", 135, 153], ["adenotonsillectomy", "TREATMENT", 176, 194], ["nasal congestion", "PROBLEM", 227, 243], ["progressive right eye swelling", "PROBLEM", 248, 278], ["seasonal allergies", "OBSERVATION", 135, 153], ["adenotonsillectomy", "OBSERVATION", 176, 194], ["nasal", "ANATOMY", 227, 232], ["congestion", "OBSERVATION", 233, 243], ["progressive", "OBSERVATION_MODIFIER", 248, 259], ["right", "ANATOMY_MODIFIER", 260, 265], ["eye", "ANATOMY", 266, 269], ["swelling", "OBSERVATION", 270, 278]]], ["He was evaluated by his pediatrician the day prior and started on oral amoxicillin/clavulanate and ofloxacin eye drops.", [["oral", "ANATOMY", 66, 70], ["eye", "ANATOMY", 109, 112], ["amoxicillin/clavulanate", "CHEMICAL", 71, 94], ["ofloxacin", "CHEMICAL", 99, 108], ["amoxicillin", "CHEMICAL", 71, 82], ["clavulanate", "CHEMICAL", 83, 94], ["ofloxacin", "CHEMICAL", 99, 108], ["He", "ORGANISM", 0, 2], ["oral", "ORGANISM_SUBDIVISION", 66, 70], ["amoxicillin", "SIMPLE_CHEMICAL", 71, 82], ["clavulanate", "SIMPLE_CHEMICAL", 83, 94], ["ofloxacin", "SIMPLE_CHEMICAL", 99, 108], ["eye", "ORGAN", 109, 112], ["oral amoxicillin", "TREATMENT", 66, 82], ["clavulanate", "TREATMENT", 83, 94], ["ofloxacin eye drops", "TREATMENT", 99, 118]]], ["CT revealed right-sided rhinosinusitis and subperiosteal abscess (Fig. 4) .", [["subperiosteal abscess", "ANATOMY", 43, 64], ["rhinosinusitis", "DISEASE", 24, 38], ["subperiosteal abscess", "DISEASE", 43, 64], ["CT", "TEST", 0, 2], ["right-sided rhinosinusitis", "PROBLEM", 12, 38], ["subperiosteal abscess", "PROBLEM", 43, 64], ["right", "ANATOMY_MODIFIER", 12, 17], ["sided", "ANATOMY_MODIFIER", 18, 23], ["rhinosinusitis", "OBSERVATION", 24, 38], ["subperiosteal", "ANATOMY", 43, 56], ["abscess", "OBSERVATION", 57, 64]]], ["He was transferred to our facility.", [["He", "ORGANISM", 0, 2]]], ["Table 1 highlights his laboratory values.", [["his laboratory values", "TEST", 19, 40]]], ["SARS-CoV-2 RNA testing was positive.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS", "TEST", 0, 4], ["CoV-2 RNA testing", "TEST", 5, 22]]], ["Vancomycin and ceftriaxone were administered, and he was taken to the OR expediently by the ophthalmology team for right orbitotomy and drainage of abscess.", [["right orbitotomy", "ANATOMY", 115, 131], ["abscess", "ANATOMY", 148, 155], ["Vancomycin", "CHEMICAL", 0, 10], ["ceftriaxone", "CHEMICAL", 15, 26], ["abscess", "DISEASE", 148, 155], ["Vancomycin", "CHEMICAL", 0, 10], ["ceftriaxone", "CHEMICAL", 15, 26], ["Vancomycin", "SIMPLE_CHEMICAL", 0, 10], ["ceftriaxone", "SIMPLE_CHEMICAL", 15, 26], ["abscess", "PATHOLOGICAL_FORMATION", 148, 155], ["Vancomycin", "TREATMENT", 0, 10], ["ceftriaxone", "TREATMENT", 15, 26], ["right orbitotomy", "TREATMENT", 115, 131], ["drainage", "TREATMENT", 136, 144], ["abscess", "PROBLEM", 148, 155], ["right", "ANATOMY_MODIFIER", 115, 120], ["orbitotomy", "OBSERVATION", 121, 131], ["drainage", "OBSERVATION", 136, 144], ["abscess", "OBSERVATION", 148, 155]]], ["Intraoperatively, an extraconal collection with mucopurulence and hemorrhagic contents was evacuated.", [["mucopurulence", "DISEASE", 48, 61], ["hemorrhagic", "DISEASE", 66, 77], ["an extraconal collection", "PROBLEM", 18, 42], ["mucopurulence", "PROBLEM", 48, 61], ["hemorrhagic contents", "PROBLEM", 66, 86], ["extraconal", "ANATOMY", 21, 31], ["collection", "OBSERVATION", 32, 42], ["mucopurulence", "OBSERVATION", 48, 61], ["hemorrhagic", "OBSERVATION_MODIFIER", 66, 77], ["contents", "OBSERVATION", 78, 86], ["evacuated", "OBSERVATION_MODIFIER", 91, 100]]], ["Intraoperative cultures grew no organisms.", [["Intraoperative cultures", "TEST", 0, 23], ["organisms", "PROBLEM", 32, 41], ["no", "UNCERTAINTY", 29, 31]]], ["He was continued on vancomycin and ceftriaxone, intranasal oxymetazoline and fluticasone, nasal saline irrigations, and topical ocular tobramycin.", [["nasal", "ANATOMY", 90, 95], ["ocular", "ANATOMY", 128, 134], ["vancomycin", "CHEMICAL", 20, 30], ["ceftriaxone", "CHEMICAL", 35, 46], ["oxymetazoline", "CHEMICAL", 59, 72], ["fluticasone", "CHEMICAL", 77, 88], ["tobramycin", "CHEMICAL", 135, 145], ["vancomycin", "CHEMICAL", 20, 30], ["ceftriaxone", "CHEMICAL", 35, 46], ["oxymetazoline", "CHEMICAL", 59, 72], ["fluticasone", "CHEMICAL", 77, 88], ["tobramycin", "CHEMICAL", 135, 145], ["He", "ORGANISM", 0, 2], ["vancomycin", "SIMPLE_CHEMICAL", 20, 30], ["ceftriaxone", "SIMPLE_CHEMICAL", 35, 46], ["oxymetazoline", "SIMPLE_CHEMICAL", 59, 72], ["fluticasone", "SIMPLE_CHEMICAL", 77, 88], ["tobramycin", "SIMPLE_CHEMICAL", 135, 145], ["vancomycin", "TREATMENT", 20, 30], ["ceftriaxone", "TREATMENT", 35, 46], ["intranasal oxymetazoline", "TREATMENT", 48, 72], ["fluticasone", "TREATMENT", 77, 88], ["nasal saline irrigations", "TREATMENT", 90, 114], ["topical ocular tobramycin", "TREATMENT", 120, 145], ["nasal", "ANATOMY", 90, 95]]], ["His clinical status continued to improve, and he was discharged home with two-week course of amoxicillin/clavulanate and nasal irrigations.", [["nasal", "ANATOMY", 121, 126], ["amoxicillin/clavulanate", "CHEMICAL", 93, 116], ["amoxicillin", "CHEMICAL", 93, 104], ["clavulanate", "CHEMICAL", 105, 116], ["amoxicillin/clavulanate", "SIMPLE_CHEMICAL", 93, 116], ["nasal", "ORGANISM_SUBDIVISION", 121, 126], ["amoxicillin", "TREATMENT", 93, 104], ["clavulanate", "TREATMENT", 105, 116], ["nasal irrigations", "TREATMENT", 121, 138], ["nasal", "ANATOMY", 121, 126], ["irrigations", "OBSERVATION", 127, 138]]], ["He had resolution of his symptoms upon outpatient follow-up.", [["his symptoms", "PROBLEM", 21, 33]]], ["Interval imaging six weeks post discharge did reveal persistent right-sided rhinosinusitis with opacification of the maxillary, ethmoid, and frontal sinuses.", [["maxillary", "ANATOMY", 117, 126], ["ethmoid", "ANATOMY", 128, 135], ["frontal sinuses", "ANATOMY", 141, 156], ["rhinosinusitis", "DISEASE", 76, 90], ["maxillary", "ORGAN", 117, 126], ["ethmoid", "MULTI-TISSUE_STRUCTURE", 128, 135], ["frontal sinuses", "MULTI-TISSUE_STRUCTURE", 141, 156], ["Interval imaging", "TEST", 0, 16], ["persistent right-sided rhinosinusitis", "PROBLEM", 53, 90], ["opacification of the maxillary, ethmoid, and frontal sinuses", "PROBLEM", 96, 156], ["persistent", "OBSERVATION_MODIFIER", 53, 63], ["right", "ANATOMY_MODIFIER", 64, 69], ["sided", "ANATOMY_MODIFIER", 70, 75], ["rhinosinusitis", "OBSERVATION", 76, 90], ["opacification", "OBSERVATION", 96, 109], ["maxillary", "ANATOMY", 117, 126], ["ethmoid", "ANATOMY", 128, 135], ["frontal sinuses", "ANATOMY", 141, 156]]], ["He ultimately underwent right-sided endoscopic sinus surgery (ESS) for persistent sinus disease after further testing was negative for SARS-CoV-2 RNA.DiscussionViral upper respiratory infection (URI) has been linked to the development of acute bacterial rhinosinusitis [6] .", [["sinus", "ANATOMY", 47, 52], ["sinus", "ANATOMY", 82, 87], ["respiratory", "ANATOMY", 172, 183], ["sinus disease", "DISEASE", 82, 95], ["SARS", "DISEASE", 135, 139], ["upper respiratory infection", "DISEASE", 166, 193], ["URI", "DISEASE", 195, 198], ["bacterial rhinosinusitis", "DISEASE", 244, 268], ["sinus", "MULTI-TISSUE_STRUCTURE", 47, 52], ["sinus", "ORGAN", 82, 87], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 135, 145], ["SARS-CoV-2 RNA", "RNA", 135, 149], ["right-sided endoscopic sinus surgery", "TREATMENT", 24, 60], ["persistent sinus disease", "PROBLEM", 71, 95], ["further testing", "TEST", 102, 117], ["SARS", "PROBLEM", 135, 139], ["CoV", "TEST", 140, 143], ["DiscussionViral upper respiratory infection", "PROBLEM", 150, 193], ["URI", "PROBLEM", 195, 198], ["acute bacterial rhinosinusitis", "PROBLEM", 238, 268], ["right", "ANATOMY_MODIFIER", 24, 29], ["sided", "ANATOMY_MODIFIER", 30, 35], ["endoscopic sinus", "ANATOMY", 36, 52], ["surgery", "OBSERVATION", 53, 60], ["persistent", "OBSERVATION_MODIFIER", 71, 81], ["sinus", "ANATOMY", 82, 87], ["disease", "OBSERVATION", 88, 95], ["upper", "ANATOMY_MODIFIER", 166, 171], ["respiratory", "ANATOMY", 172, 183], ["infection", "OBSERVATION", 184, 193], ["acute", "OBSERVATION_MODIFIER", 238, 243], ["bacterial", "OBSERVATION_MODIFIER", 244, 253], ["rhinosinusitis", "OBSERVATION", 254, 268]]], ["This had previously been described by Marom et al., demonstrating the correlation between the presence of rhinovirus at initial URI and subsequent development of bacterial sinusitis in children [6] .", [["rhinovirus", "DISEASE", 106, 116], ["bacterial sinusitis", "DISEASE", 162, 181], ["rhinovirus", "ORGANISM", 106, 116], ["children", "ORGANISM", 185, 193], ["children", "SPECIES", 185, 193], ["rhinovirus", "PROBLEM", 106, 116], ["initial URI", "PROBLEM", 120, 131], ["bacterial sinusitis", "PROBLEM", 162, 181], ["rhinovirus", "OBSERVATION", 106, 116], ["URI", "OBSERVATION", 128, 131], ["bacterial", "OBSERVATION_MODIFIER", 162, 171], ["sinusitis", "OBSERVATION", 172, 181]]], ["Our cases highlight this issue in the context of the COVID-19 viral pandemic, and the unique challenges presented in their perioperative management.", [["viral pandemic", "DISEASE", 62, 76], ["COVID-19 viral", "ORGANISM", 53, 67], ["the COVID", "TEST", 49, 58], ["their perioperative management", "TREATMENT", 117, 147]]], ["To our knowledge, despite multiple novel viral pandemics over the past decade, no cases of complicated rhinosinusitis due to Middle East respiratory syndrome (MERS), SARS, or the current COVID-19 have been reported in the otolaryngology literature.", [["viral pandemics", "DISEASE", 41, 56], ["rhinosinusitis", "DISEASE", 103, 117], ["Middle East respiratory syndrome", "DISEASE", 125, 157], ["MERS", "DISEASE", 159, 163], ["SARS", "DISEASE", 166, 170], ["Middle East respiratory syndrome (MERS)", "SPECIES", 125, 164], ["complicated rhinosinusitis", "PROBLEM", 91, 117], ["Middle East respiratory syndrome", "PROBLEM", 125, 157], ["SARS", "PROBLEM", 166, 170], ["the current COVID", "TEST", 175, 192], ["complicated", "OBSERVATION_MODIFIER", 91, 102], ["rhinosinusitis", "OBSERVATION", 103, 117], ["Middle", "ANATOMY_MODIFIER", 125, 131], ["respiratory syndrome", "OBSERVATION", 137, 157]]], ["This report highlights the challenges presented in the management of acute, complicated rhinosinusitis with both orbital and intracranial complications in pediatric patients with concurrent COVID-19.DiscussionCOVID-19 as a viral illness in the pediatric population is still not well understood.", [["orbital", "ANATOMY", 113, 120], ["intracranial", "ANATOMY", 125, 137], ["rhinosinusitis", "DISEASE", 88, 102], ["orbital and intracranial complications", "DISEASE", 113, 151], ["viral illness", "DISEASE", 223, 236], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["acute, complicated rhinosinusitis", "PROBLEM", 69, 102], ["both orbital and intracranial complications", "PROBLEM", 108, 151], ["concurrent COVID", "TEST", 179, 195], ["a viral illness", "PROBLEM", 221, 236], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["complicated", "OBSERVATION_MODIFIER", 76, 87], ["rhinosinusitis", "OBSERVATION", 88, 102], ["orbital", "ANATOMY", 113, 120], ["intracranial", "ANATOMY", 125, 137], ["complications", "OBSERVATION", 138, 151]]], ["Xu et al. found that pediatric patients were 2.7 times less likely than adults to contract the illness [9] .", [["illness", "DISEASE", 95, 102], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["Research has suggested less severe disease manifestations in the pediatric population, however pediatric mortalities have been documented in the US [10] .", [["less severe disease manifestations", "PROBLEM", 23, 57], ["pediatric mortalities", "PROBLEM", 95, 116], ["less", "OBSERVATION_MODIFIER", 23, 27], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["disease", "OBSERVATION", 35, 42]]], ["The nasal cavity and nasopharynx are now well known reservoirs for the virus [7] .", [["nasal cavity", "ANATOMY", 4, 16], ["nasopharynx", "ANATOMY", 21, 32], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 4, 16], ["nasopharynx", "ORGAN", 21, 32], ["the virus", "PROBLEM", 67, 76], ["nasal cavity", "ANATOMY", 4, 16], ["nasopharynx", "ANATOMY", 21, 32]]], ["Additionally, it has previously been hypothesized that the presence of angiotensin-converting enzyme 2 (ACE2) receptors in the nasal epithelium is the underlying pathophysiological mechanism of the high incidence of anosmia reported in COVID-19 infection [11] .", [["nasal epithelium", "ANATOMY", 127, 143], ["angiotensin", "CHEMICAL", 71, 82], ["anosmia", "DISEASE", 216, 223], ["COVID-19", "CHEMICAL", 236, 244], ["infection", "DISEASE", 245, 254], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 71, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["nasal epithelium", "TISSUE", 127, 143], ["angiotensin-converting enzyme 2 (ACE2) receptors", "PROTEIN", 71, 119], ["COVID-19", "SPECIES", 236, 244], ["angiotensin-converting enzyme 2 (ACE2) receptors in the nasal epithelium", "PROBLEM", 71, 143], ["anosmia", "PROBLEM", 216, 223], ["COVID-19 infection", "PROBLEM", 236, 254], ["nasal epithelium", "ANATOMY", 127, 143], ["high", "OBSERVATION_MODIFIER", 198, 202]]], ["Consistent with prior epidemiological analyses regarding complicated rhinosinusitis, adolescents are at increased risk for intracranial complications due to the increased vascularity of the diploic bones [4] .", [["intracranial", "ANATOMY", 123, 135], ["bones", "ANATOMY", 198, 203], ["rhinosinusitis", "DISEASE", 69, 83], ["intracranial complications", "DISEASE", 123, 149], ["adolescents", "ORGANISM", 85, 96], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 135], ["bones", "ORGAN", 198, 203], ["adolescents", "SPECIES", 85, 96], ["prior epidemiological analyses", "TEST", 16, 46], ["complicated rhinosinusitis", "PROBLEM", 57, 83], ["intracranial complications", "PROBLEM", 123, 149], ["the increased vascularity of the diploic bones", "PROBLEM", 157, 203], ["complicated", "OBSERVATION_MODIFIER", 57, 68], ["rhinosinusitis", "OBSERVATION", 69, 83], ["intracranial", "ANATOMY", 123, 135], ["complications", "OBSERVATION", 136, 149], ["increased", "OBSERVATION_MODIFIER", 161, 170], ["vascularity", "OBSERVATION", 171, 182], ["diploic bones", "ANATOMY", 190, 203]]], ["Previous reports of severe COVID-19 infection in pediatric patients have been associated with lymphopenia and elevated c-reactive protein (CRP) [12] .", [["infection", "DISEASE", 36, 45], ["lymphopenia", "DISEASE", 94, 105], ["COVID-19", "ORGANISM", 27, 35], ["patients", "ORGANISM", 59, 67], ["c-reactive protein", "GENE_OR_GENE_PRODUCT", 119, 137], ["CRP", "GENE_OR_GENE_PRODUCT", 139, 142], ["c-reactive protein", "PROTEIN", 119, 137], ["CRP", "PROTEIN", 139, 142], ["patients", "SPECIES", 59, 67], ["severe COVID-19 infection", "PROBLEM", 20, 45], ["lymphopenia", "PROBLEM", 94, 105], ["elevated c-reactive protein (CRP)", "PROBLEM", 110, 143], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["infection", "OBSERVATION", 36, 45], ["associated with", "UNCERTAINTY", 78, 93], ["lymphopenia", "OBSERVATION", 94, 105], ["elevated", "OBSERVATION_MODIFIER", 110, 118]]], ["These above findings are consistent with our patients presentation in Case I. While elevated CRP has been found in multiple case series of complicated sinusitis, our patient's presentation CRP of 169 mg/dL is well above the average elevation previously documented in these reports (18 mg/dL) [3] .DiscussionPreviously published COVID-19 guidelines have recommended deferment of operative intervention and initiation of maximal medical therapy for 48-72 h in patients with \"complicated acute rhinosinusitis with orbital extension without vision or globe compromise\" [13] .", [["orbital", "ANATOMY", 511, 518], ["sinusitis", "DISEASE", 151, 160], ["rhinosinusitis", "DISEASE", 491, 505], ["patients", "ORGANISM", 45, 53], ["CRP", "GENE_OR_GENE_PRODUCT", 93, 96], ["sinusitis", "PATHOLOGICAL_FORMATION", 151, 160], ["patient", "ORGANISM", 166, 173], ["CRP", "GENE_OR_GENE_PRODUCT", 189, 192], ["patients", "ORGANISM", 458, 466], ["CRP", "PROTEIN", 93, 96], ["CRP", "PROTEIN", 189, 192], ["patients", "SPECIES", 45, 53], ["patient", "SPECIES", 166, 173], ["patients", "SPECIES", 458, 466], ["elevated CRP", "PROBLEM", 84, 96], ["complicated sinusitis", "PROBLEM", 139, 160], ["our patient's presentation CRP", "TEST", 162, 192], ["operative intervention", "TREATMENT", 378, 400], ["maximal medical therapy", "TREATMENT", 419, 442], ["complicated acute rhinosinusitis", "PROBLEM", 473, 505], ["orbital extension", "PROBLEM", 511, 528], ["vision", "PROBLEM", 537, 543], ["globe compromise", "PROBLEM", 547, 563], ["consistent with", "UNCERTAINTY", 25, 40], ["complicated", "OBSERVATION_MODIFIER", 139, 150], ["sinusitis", "OBSERVATION", 151, 160], ["acute", "OBSERVATION_MODIFIER", 485, 490], ["rhinosinusitis", "OBSERVATION", 491, 505], ["orbital", "ANATOMY", 511, 518]]], ["This is consistent with a recent systematic review by Wong et al. which recommended 48 h of parenteral antibiotic therapy for postseptal cellulitis in the pre-COVID-19 era [2] .", [["cellulitis", "DISEASE", 137, 147], ["parenteral antibiotic therapy", "TREATMENT", 92, 121], ["postseptal cellulitis", "PROBLEM", 126, 147], ["consistent with", "UNCERTAINTY", 8, 23], ["cellulitis", "OBSERVATION", 137, 147]]], ["Despite optimizing medical care, the clinical condition of the patient in Case I continued to worsen with the development of SOVT.", [["SOVT", "DISEASE", 125, 129], ["patient", "ORGANISM", 63, 70], ["SOVT", "CANCER", 125, 129], ["patient", "SPECIES", 63, 70], ["optimizing medical care", "TREATMENT", 8, 31], ["SOVT", "PROBLEM", 125, 129]]], ["Derangements in coagulation profiles and the resulting sequalae in patients with COVID-19 have been previously reported throughout the pandemic, including myocardial infarction, ischemic stroke, limb ischemia, and cerebral venous thrombosis among others [14] [15] [16] [17] .", [["myocardial", "ANATOMY", 155, 165], ["limb", "ANATOMY", 195, 199], ["cerebral venous", "ANATOMY", 214, 229], ["sequalae", "DISEASE", 55, 63], ["COVID-19", "CHEMICAL", 81, 89], ["myocardial infarction", "DISEASE", 155, 176], ["ischemic stroke", "DISEASE", 178, 193], ["limb ischemia", "DISEASE", 195, 208], ["cerebral venous thrombosis", "DISEASE", 214, 240], ["COVID-19", "CHEMICAL", 81, 89], ["patients", "ORGANISM", 67, 75], ["myocardial", "MULTI-TISSUE_STRUCTURE", 155, 165], ["limb", "ORGANISM_SUBDIVISION", 195, 199], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 214, 229], ["[14] [15] [16] [17]", "SIMPLE_CHEMICAL", 254, 273], ["patients", "SPECIES", 67, 75], ["Derangements in coagulation profiles", "PROBLEM", 0, 36], ["COVID", "TEST", 81, 86], ["myocardial infarction", "PROBLEM", 155, 176], ["ischemic stroke", "PROBLEM", 178, 193], ["limb ischemia", "PROBLEM", 195, 208], ["cerebral venous thrombosis", "PROBLEM", 214, 240], ["myocardial", "ANATOMY", 155, 165], ["infarction", "OBSERVATION", 166, 176], ["ischemic", "OBSERVATION_MODIFIER", 178, 186], ["stroke", "OBSERVATION", 187, 193], ["limb", "ANATOMY", 195, 199], ["ischemia", "OBSERVATION", 200, 208], ["cerebral venous", "ANATOMY", 214, 229], ["thrombosis", "OBSERVATION", 230, 240]]], ["Urgent ESS in Case I was felt necessary to decrease the risk of developing cavernous sinus thrombosis and further neurologic complications [1] .", [["cavernous sinus", "ANATOMY", 75, 90], ["neurologic", "ANATOMY", 114, 124], ["cavernous sinus thrombosis", "DISEASE", 75, 101], ["neurologic complications", "DISEASE", 114, 138], ["cavernous sinus", "MULTI-TISSUE_STRUCTURE", 75, 90], ["developing cavernous sinus thrombosis", "PROBLEM", 64, 101], ["further neurologic complications", "PROBLEM", 106, 138], ["cavernous sinus", "ANATOMY", 75, 90], ["thrombosis", "OBSERVATION", 91, 101]]], ["In contrast, Case II responded well to initial orbital abscess drainage and improved clinically without immediate need for ESS.", [["orbital abscess", "ANATOMY", 47, 62], ["abscess", "DISEASE", 55, 62], ["orbital abscess", "PATHOLOGICAL_FORMATION", 47, 62], ["Case II", "PROTEIN", 13, 20], ["initial orbital abscess drainage", "TREATMENT", 39, 71], ["ESS", "TEST", 123, 126], ["orbital", "ANATOMY", 47, 54], ["abscess", "OBSERVATION", 55, 62]]], ["ESS was eventually required, although this was able to be performed on an outpatient, non-emergent basis after the patient tested negative for SARS-CoV-2 RNA.DiscussionIn Case I, our patient was noted to experience new onset respiratory deterioration following operative intervention.", [["respiratory", "ANATOMY", 225, 236], ["SARS", "DISEASE", 143, 147], ["respiratory deterioration", "DISEASE", 225, 250], ["patient", "ORGANISM", 115, 122], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 143, 153], ["patient", "ORGANISM", 183, 190], ["SARS-CoV-2 RNA", "RNA", 143, 157], ["patient", "SPECIES", 115, 122], ["patient", "SPECIES", 183, 190], ["SARS", "PROBLEM", 143, 147], ["CoV", "TEST", 148, 151], ["new onset respiratory deterioration", "PROBLEM", 215, 250], ["operative intervention", "TREATMENT", 261, 283], ["respiratory", "ANATOMY", 225, 236], ["deterioration", "OBSERVATION", 237, 250]]], ["A retrospective review from Wuhan, China examined 34 patients who underwent surgery during the asymptomatic incubation period [18] .", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["surgery", "TREATMENT", 76, 83]]], ["44% of the patients subsequently required ICU admission for respiratory deterioration with a mortality rate of 20.5%.", [["respiratory", "ANATOMY", 60, 71], ["respiratory deterioration", "DISEASE", 60, 85], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["respiratory deterioration", "PROBLEM", 60, 85], ["a mortality rate", "TEST", 91, 107]]], ["A more recent and extensive review from 235 hospitals in 24 countries revealed postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection.", [["pulmonary", "ANATOMY", 93, 102], ["postoperative pulmonary complications", "DISEASE", 79, 116], ["SARS-CoV-2 infection", "DISEASE", 162, 182], ["pulmonary", "ORGAN", 93, 102], ["patients", "ORGANISM", 134, 142], ["CoV-2", "ORGANISM", 167, 172], ["patients", "SPECIES", 134, 142], ["postoperative pulmonary complications", "PROBLEM", 79, 116], ["perioperative SARS", "PROBLEM", 148, 166], ["CoV-2 infection", "PROBLEM", 167, 182], ["postoperative", "OBSERVATION_MODIFIER", 79, 92], ["pulmonary", "ANATOMY", 93, 102], ["complications", "OBSERVATION", 103, 116], ["infection", "OBSERVATION", 173, 182]]], ["The 30-day mortality in this patient cohort was noted to be 23.8% [19] .", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36]]], ["Worsening postoperative pulmonary status is consistent with our patient in Case I, highlighted by the necessity of PICU care and maximum non-invasive oxygen supplementation.", [["pulmonary", "ANATOMY", 24, 33], ["oxygen", "CHEMICAL", 150, 156], ["oxygen", "CHEMICAL", 150, 156], ["pulmonary", "ORGAN", 24, 33], ["patient", "ORGANISM", 64, 71], ["oxygen", "SIMPLE_CHEMICAL", 150, 156], ["patient", "SPECIES", 64, 71], ["Worsening postoperative pulmonary status", "PROBLEM", 0, 40], ["PICU care", "TREATMENT", 115, 124], ["maximum non-invasive oxygen supplementation", "TREATMENT", 129, 172], ["postoperative", "OBSERVATION_MODIFIER", 10, 23], ["pulmonary", "ANATOMY", 24, 33], ["status", "OBSERVATION", 34, 40], ["consistent with", "UNCERTAINTY", 44, 59], ["oxygen supplementation", "OBSERVATION", 150, 172]]], ["Possible pulmonary complications from undergoing general anesthesia (up to 10%) is a known risk although patients with concomitant SARS-CoV-2 infection seem to have increased risk, likely due to the pro-inflammatory cytokine and immunosuppressive responses to surgery and mechanical ventilation [20] [21] [22] .", [["pulmonary", "ANATOMY", 9, 18], ["pulmonary complications", "DISEASE", 9, 32], ["SARS-CoV-2 infection", "DISEASE", 131, 151], ["pulmonary", "ORGAN", 9, 18], ["patients", "ORGANISM", 105, 113], ["SARS-CoV-2", "ORGANISM", 131, 141], ["pro-inflammatory cytokine", "PROTEIN", 199, 224], ["patients", "SPECIES", 105, 113], ["pulmonary complications", "PROBLEM", 9, 32], ["general anesthesia", "TREATMENT", 49, 67], ["concomitant SARS", "PROBLEM", 119, 135], ["CoV-2 infection", "PROBLEM", 136, 151], ["the pro-inflammatory cytokine", "TREATMENT", 195, 224], ["immunosuppressive responses", "TREATMENT", 229, 256], ["surgery", "TREATMENT", 260, 267], ["mechanical ventilation", "TREATMENT", 272, 294], ["pulmonary", "ANATOMY", 9, 18], ["complications", "OBSERVATION", 19, 32], ["likely due to", "UNCERTAINTY", 181, 194]]], ["This provides further evidence to possibly raise the threshold for operative intervention in COVID-19 patients, with need for close postoperative monitoring.ConclusionCOVID-19 remains a novel threat to both the adult and pediatric populations.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["operative intervention", "TREATMENT", 67, 89], ["close postoperative monitoring", "TEST", 126, 156], ["ConclusionCOVID", "TEST", 157, 172]]], ["The cases provided in this report highlight the unique challenge of caring for pediatric patients presenting with complicated rhinosinusitis and concomitant COVID-19 infection.", [["rhinosinusitis", "DISEASE", 126, 140], ["infection", "DISEASE", 166, 175], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["complicated rhinosinusitis", "PROBLEM", 114, 140], ["concomitant COVID-19 infection", "PROBLEM", 145, 175], ["rhinosinusitis", "OBSERVATION", 126, 140], ["infection", "OBSERVATION", 166, 175]]], ["We recommend utilizing a multi-disciplinary approach in optimizing care of these patients when at all feasible.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["a multi-disciplinary approach", "TREATMENT", 23, 52]]], ["Further research is still needed to further elucidate the complex pathophysiology and optimal treatment algorithms of SARS-CoV-2 patients with complicated rhinosinusitis.Financial disclosuresNone.Declaration of competing interestNone.", [["SARS", "DISEASE", 118, 122], ["rhinosinusitis", "DISEASE", 155, 169], ["SARS-CoV-2", "ORGANISM", 118, 128], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["SARS-CoV", "SPECIES", 118, 126], ["the complex pathophysiology", "PROBLEM", 54, 81], ["SARS", "PROBLEM", 118, 122], ["complicated rhinosinusitis", "PROBLEM", 143, 169], ["complicated", "OBSERVATION_MODIFIER", 143, 154], ["rhinosinusitis", "OBSERVATION", 155, 169]]], ["Preoperative T1-weighted gadolinium enhanced magnetic resonance imaging scan of the brain and orbits of the patient in Case I demonstrating mucosal thickening of the ethmoid sinuses, enhancement of the periorbita, intraconal and extraconal fat infiltration and enhancement, and thrombosis of the right superior ophthalmic vein.", [["brain", "ANATOMY", 84, 89], ["mucosal", "ANATOMY", 140, 147], ["ethmoid sinuses", "ANATOMY", 166, 181], ["periorbita", "ANATOMY", 202, 212], ["intraconal", "ANATOMY", 214, 224], ["extraconal fat", "ANATOMY", 229, 243], ["right superior ophthalmic vein", "ANATOMY", 296, 326], ["gadolinium", "CHEMICAL", 25, 35], ["periorbita", "DISEASE", 202, 212], ["fat infiltration", "DISEASE", 240, 256], ["thrombosis", "DISEASE", 278, 288], ["gadolinium", "CHEMICAL", 25, 35], ["brain", "ORGAN", 84, 89], ["patient", "ORGANISM", 108, 115], ["mucosal", "TISSUE", 140, 147], ["ethmoid sinuses", "MULTI-TISSUE_STRUCTURE", 166, 181], ["periorbita", "CANCER", 202, 212], ["fat", "TISSUE", 240, 243], ["superior ophthalmic vein", "MULTI-TISSUE_STRUCTURE", 302, 326], ["patient", "SPECIES", 108, 115], ["Preoperative T1-weighted gadolinium enhanced magnetic resonance imaging scan of the brain", "TEST", 0, 89], ["mucosal thickening of the ethmoid sinuses", "PROBLEM", 140, 181], ["enhancement of the periorbita", "PROBLEM", 183, 212], ["intraconal and extraconal fat infiltration", "PROBLEM", 214, 256], ["thrombosis of the right superior ophthalmic vein", "PROBLEM", 278, 326], ["brain", "ANATOMY", 84, 89], ["orbits", "ANATOMY", 94, 100], ["mucosal", "ANATOMY_MODIFIER", 140, 147], ["thickening", "OBSERVATION", 148, 158], ["ethmoid sinuses", "ANATOMY", 166, 181], ["enhancement", "OBSERVATION_MODIFIER", 183, 194], ["periorbita", "ANATOMY", 202, 212], ["intraconal", "ANATOMY_MODIFIER", 214, 224], ["extraconal fat", "ANATOMY", 229, 243], ["infiltration", "OBSERVATION", 244, 256], ["enhancement", "OBSERVATION_MODIFIER", 261, 272], ["thrombosis", "OBSERVATION", 278, 288], ["right", "ANATOMY_MODIFIER", 296, 301], ["superior ophthalmic vein", "ANATOMY", 302, 326]]]], "PMC7079800": [["IntroductionFor most viruses, the capsid is an essential protein structure that encloses and protects the viral genome.", [["viral genome", "DNA", 106, 118], ["most viruses", "PROBLEM", 16, 28], ["an essential protein structure", "PROBLEM", 44, 74], ["the viral genome", "PROBLEM", 102, 118], ["protein structure", "OBSERVATION", 57, 74], ["viral genome", "OBSERVATION", 106, 118]]], ["Many viruses also have an envelope wrapping the viral capsid, which is usually derived from host cell membranes and incorporates some viral glycoproteins.", [["cell membranes", "ANATOMY", 97, 111], ["cell membranes", "CELLULAR_COMPONENT", 97, 111], ["viral glycoproteins", "PROTEIN", 134, 153], ["Many viruses", "PROBLEM", 0, 12], ["an envelope wrapping the viral capsid", "PROBLEM", 23, 60], ["host cell membranes", "PROBLEM", 92, 111], ["some viral glycoproteins", "PROBLEM", 129, 153], ["viruses", "OBSERVATION", 5, 12], ["envelope", "OBSERVATION_MODIFIER", 26, 34], ["wrapping", "OBSERVATION", 35, 43], ["viral capsid", "OBSERVATION", 48, 60], ["host cell membranes", "OBSERVATION", 92, 111], ["some", "OBSERVATION_MODIFIER", 129, 133], ["viral glycoproteins", "OBSERVATION", 134, 153]]], ["These proteins are important for virus attachment and penetration into host cells.IntroductionAlphaviruses have been extensively studied because they represent a good model for simple envelope RNA viruses.", [["cells", "ANATOMY", 76, 81], ["host cells", "CELL", 71, 81], ["Alphaviruses", "GENE_OR_GENE_PRODUCT", 94, 106], ["host cells", "CELL_TYPE", 71, 81], ["virus attachment", "PROBLEM", 33, 49], ["penetration into host cells", "PROBLEM", 54, 81], ["IntroductionAlphaviruses", "TREATMENT", 82, 106], ["simple envelope RNA viruses", "PROBLEM", 177, 204], ["RNA viruses", "OBSERVATION", 193, 204]]], ["Among alphaviruses, Semliki Forest virus (SFV), Sindbis virus (SIN), and Venezuelan Equine Encephalitis virus (VEE) have been characterized as the most representative members of this genus.", [["Equine Encephalitis", "DISEASE", 84, 103], ["VEE", "DISEASE", 111, 114], ["Semliki Forest virus", "ORGANISM", 20, 40], ["SFV", "ORGANISM", 42, 45], ["Sindbis virus", "ORGANISM", 48, 61], ["SIN", "ORGANISM", 63, 66], ["Venezuelan Equine Encephalitis virus", "ORGANISM", 73, 109], ["VEE", "ORGANISM", 111, 114], ["Semliki Forest virus", "SPECIES", 20, 40], ["SFV", "SPECIES", 42, 45], ["Sindbis virus", "SPECIES", 48, 61], ["Venezuelan", "SPECIES", 73, 83], ["Equine Encephalitis virus", "SPECIES", 84, 109], ["Semliki Forest virus", "SPECIES", 20, 40], ["SFV", "SPECIES", 42, 45], ["Sindbis virus", "SPECIES", 48, 61], ["SIN", "SPECIES", 63, 66], ["Venezuelan Equine Encephalitis virus", "SPECIES", 73, 109], ["VEE", "SPECIES", 111, 114], ["Among alphaviruses", "PROBLEM", 0, 18], ["Semliki Forest virus (SFV)", "PROBLEM", 20, 46], ["Sindbis virus", "PROBLEM", 48, 61], ["Venezuelan Equine Encephalitis virus", "PROBLEM", 73, 109], ["Semliki Forest virus", "OBSERVATION", 20, 40]]], ["Although SFV and SIN are able to infect and produce disease in humans, VEE and other closely related alphaviruses can cause lethal encephalitis and are considered a significant public health threat in many areas of South, Central and North America.", [["VEE", "DISEASE", 71, 74], ["alphaviruses", "DISEASE", 101, 113], ["encephalitis", "DISEASE", 131, 143], ["SFV", "ORGANISM", 9, 12], ["SIN", "GENE_OR_GENE_PRODUCT", 17, 20], ["humans", "ORGANISM", 63, 69], ["alphaviruses", "ORGANISM", 101, 113], ["humans", "SPECIES", 63, 69], ["SFV", "SPECIES", 9, 12], ["humans", "SPECIES", 63, 69], ["VEE", "SPECIES", 71, 74], ["SFV", "PROBLEM", 9, 12], ["disease in humans", "PROBLEM", 52, 69], ["VEE", "PROBLEM", 71, 74], ["alphaviruses", "PROBLEM", 101, 113], ["lethal encephalitis", "PROBLEM", 124, 143], ["SFV", "OBSERVATION", 9, 12], ["disease", "OBSERVATION", 52, 59], ["encephalitis", "OBSERVATION", 131, 143], ["significant", "OBSERVATION_MODIFIER", 165, 176], ["Central", "ANATOMY_MODIFIER", 222, 229]]], ["However, massive outbreaks of the SFV-related alphavirus chikungunya (CHIKV) in Indian Ocean islands and Asia, and more recently in the Americas, has produced a high morbidity, drawing worldwide attention to this type of viruses [1, 2].IntroductionAlphaviruses contain a single-stranded positive-sense RNA genome of 11\u201312 kb that is packaged into a nucleocapsid (NC) of icosahedral symmetry (T = 4) formed by 240 subunits of the capsid protein [3].", [["alphavirus chikungunya", "DISEASE", 46, 68], ["CHIKV", "DISEASE", 70, 75], ["SFV-related alphavirus chikungunya", "ORGANISM", 34, 68], ["CHIKV", "ORGANISM", 70, 75], ["Alphaviruses", "GENE_OR_GENE_PRODUCT", 248, 260], ["Alphaviruses", "PROTEIN", 248, 260], ["single-stranded positive-sense RNA genome", "DNA", 271, 312], ["240 subunits", "PROTEIN", 409, 421], ["capsid protein", "PROTEIN", 429, 443], ["alphavirus chikungunya", "SPECIES", 46, 68], ["CHIKV", "SPECIES", 70, 75], ["the SFV", "PROBLEM", 30, 37], ["related alphavirus chikungunya", "PROBLEM", 38, 68], ["CHIKV", "PROBLEM", 70, 75], ["a high morbidity", "PROBLEM", 159, 175], ["the capsid protein", "TEST", 425, 443], ["massive", "OBSERVATION_MODIFIER", 9, 16], ["outbreaks", "OBSERVATION_MODIFIER", 17, 26], ["SFV", "ANATOMY", 34, 37], ["alphavirus", "OBSERVATION_MODIFIER", 46, 56], ["chikungunya", "OBSERVATION", 57, 68]]], ["The NC is enveloped by a lipid bilayer containing 240 heterotrimers of glycoproteins E1 and E2, which mediate virus entry into target cells [4].", [["cells", "ANATOMY", 134, 139], ["E1", "GENE_OR_GENE_PRODUCT", 85, 87], ["E2", "GENE_OR_GENE_PRODUCT", 92, 94], ["cells", "CELL", 134, 139], ["glycoproteins E1", "PROTEIN", 71, 87], ["E2", "PROTEIN", 92, 94], ["target cells", "CELL_TYPE", 127, 139], ["The NC", "TREATMENT", 0, 6], ["a lipid bilayer", "TREATMENT", 23, 38], ["glycoproteins E1 and E2", "TREATMENT", 71, 94], ["NC", "OBSERVATION", 4, 6], ["target cells", "OBSERVATION", 127, 139]]], ["Viral entry takes place through endocytosis followed by low pH-mediated fusion of viral envelope and endosome membranes, disassembly of NC, and release of viral RNA into the cytoplasm (for a review see [5]).", [["endosome membranes", "ANATOMY", 101, 119], ["cytoplasm", "ANATOMY", 174, 183], ["endosome membranes", "CELLULAR_COMPONENT", 101, 119], ["NC", "GENE_OR_GENE_PRODUCT", 136, 138], ["cytoplasm", "ORGANISM_SUBSTANCE", 174, 183], ["NC", "PROTEIN", 136, 138], ["viral RNA", "RNA", 155, 164], ["Viral entry", "PROBLEM", 0, 11], ["low pH", "PROBLEM", 56, 62], ["viral envelope", "PROBLEM", 82, 96], ["endosome membranes", "PROBLEM", 101, 119], ["NC", "TREATMENT", 136, 138], ["viral RNA", "PROBLEM", 155, 164], ["viral envelope", "OBSERVATION", 82, 96], ["endosome membranes", "OBSERVATION", 101, 119], ["viral RNA", "OBSERVATION", 155, 164]]], ["Upon cell entry, viral RNA is translated to produce the replicase (Rep), formed by four nonstructural protein subunits (nsP1\u20134), which is able to synthesize a complementary minus-sense genomic RNA (\u2212RNA) during the early phase of infection.", [["cell", "ANATOMY", 5, 9], ["infection", "DISEASE", 230, 239], ["cell", "CELL", 5, 9], ["Rep", "GENE_OR_GENE_PRODUCT", 67, 70], ["nsP1\u20134", "GENE_OR_GENE_PRODUCT", 120, 126], ["viral RNA", "RNA", 17, 26], ["replicase", "PROTEIN", 56, 65], ["Rep", "PROTEIN", 67, 70], ["nonstructural protein subunits", "PROTEIN", 88, 118], ["nsP1\u20134", "PROTEIN", 120, 126], ["complementary minus-sense genomic RNA", "RNA", 159, 196], ["\u2212RNA", "RNA", 198, 202], ["viral RNA", "PROBLEM", 17, 26], ["four nonstructural protein subunits", "TREATMENT", 83, 118], ["sense genomic RNA (\u2212RNA", "PROBLEM", 179, 202], ["infection", "PROBLEM", 230, 239], ["cell entry", "OBSERVATION", 5, 15], ["viral RNA", "OBSERVATION", 17, 26], ["genomic RNA", "OBSERVATION", 185, 196], ["infection", "OBSERVATION", 230, 239]]], ["Then, Rep uses this \u2212RNA as template to amplify viral genomes and to synthesize a subgenomic RNA (sgRNA), which is translated to produce a large structural polyprotein (capsid\u2013p62\u20136K\u2013E1).", [["Rep", "GENE_OR_GENE_PRODUCT", 6, 9], ["sgRNA", "GENE_OR_GENE_PRODUCT", 98, 103], ["capsid\u2013p62\u20136K\u2013E1", "GENE_OR_GENE_PRODUCT", 169, 185], ["Rep", "PROTEIN", 6, 9], ["\u2212RNA", "RNA", 20, 24], ["viral genomes", "DNA", 48, 61], ["subgenomic RNA", "RNA", 82, 96], ["sgRNA", "PROTEIN", 98, 103], ["structural polyprotein", "PROTEIN", 145, 167], ["capsid\u2013p62", "PROTEIN", 169, 179], ["6K\u2013E1", "PROTEIN", 180, 185], ["this \u2212RNA", "TREATMENT", 15, 24], ["viral genomes", "PROBLEM", 48, 61], ["a subgenomic RNA", "PROBLEM", 80, 96], ["a large structural polyprotein", "PROBLEM", 137, 167], ["subgenomic RNA", "OBSERVATION", 82, 96], ["large", "OBSERVATION_MODIFIER", 139, 144], ["structural polyprotein", "OBSERVATION", 145, 167]]], ["The capsid protein contains a serine protease activity, which is responsible for its auto-proteolytical cleavage from the nascent chain.", [["serine", "CHEMICAL", 30, 36], ["capsid protein", "PROTEIN", 4, 18], ["serine protease", "PROTEIN", 30, 45], ["nascent chain", "PROTEIN", 122, 135], ["The capsid protein", "TEST", 0, 18], ["a serine protease activity", "TREATMENT", 28, 54], ["its auto-proteolytical cleavage", "TREATMENT", 81, 112], ["capsid protein", "OBSERVATION", 4, 18], ["protease activity", "OBSERVATION", 37, 54], ["nascent", "OBSERVATION_MODIFIER", 122, 129], ["chain", "OBSERVATION_MODIFIER", 130, 135]]], ["The rest of the polyprotein is processed in the ER into three envelope proteins (p62, 6K, and E1), which are then translocated to the plasma membrane. p62 and E1 associate to form heterotrimers and at a late stage of the transport process p62 is cleaved by the host enzyme furin, thus generating the E2 form and a small glycoprotein called E3.", [["ER", "ANATOMY", 48, 50], ["plasma membrane", "ANATOMY", 134, 149], ["E2", "CHEMICAL", 300, 302], ["ER", "GENE_OR_GENE_PRODUCT", 48, 50], ["p62", "GENE_OR_GENE_PRODUCT", 81, 84], ["6K", "GENE_OR_GENE_PRODUCT", 86, 88], ["E1", "GENE_OR_GENE_PRODUCT", 94, 96], ["plasma membrane", "CELLULAR_COMPONENT", 134, 149], ["p62", "GENE_OR_GENE_PRODUCT", 151, 154], ["E1", "GENE_OR_GENE_PRODUCT", 159, 161], ["p62", "GENE_OR_GENE_PRODUCT", 239, 242], ["furin", "GENE_OR_GENE_PRODUCT", 273, 278], ["E2", "GENE_OR_GENE_PRODUCT", 300, 302], ["E3", "GENE_OR_GENE_PRODUCT", 340, 342], ["ER", "PROTEIN", 48, 50], ["envelope proteins", "PROTEIN", 62, 79], ["p62", "PROTEIN", 81, 84], ["6K", "PROTEIN", 86, 88], ["E1", "PROTEIN", 94, 96], ["p62", "PROTEIN", 151, 154], ["E1", "PROTEIN", 159, 161], ["heterotrimers", "PROTEIN", 180, 193], ["p62", "PROTEIN", 239, 242], ["host enzyme", "PROTEIN", 261, 272], ["furin", "PROTEIN", 273, 278], ["E2 form", "PROTEIN", 300, 307], ["small glycoprotein", "PROTEIN", 314, 332], ["E3", "PROTEIN", 340, 342], ["p62", "TEST", 81, 84], ["p62", "TEST", 151, 154], ["heterotrimers", "PROBLEM", 180, 193], ["polyprotein", "OBSERVATION", 16, 27], ["plasma membrane", "OBSERVATION", 134, 149], ["small", "OBSERVATION_MODIFIER", 314, 319]]], ["E2 and E1 constitute the mature viral spikes [5].", [["E2", "CHEMICAL", 0, 2], ["E2", "GENE_OR_GENE_PRODUCT", 0, 2], ["E1", "GENE_OR_GENE_PRODUCT", 7, 9], ["E2", "PROTEIN", 0, 2], ["E1", "DNA", 7, 9], ["the mature viral spikes", "PROBLEM", 21, 44], ["mature", "OBSERVATION_MODIFIER", 25, 31], ["viral spikes", "OBSERVATION", 32, 44]]], ["E3 is lost in SIN, but remains on the virion surface in SFV.", [["surface", "ANATOMY", 45, 52], ["E3", "GENE_OR_GENE_PRODUCT", 0, 2], ["SIN", "GENE_OR_GENE_PRODUCT", 14, 17], ["SFV", "ORGANISM", 56, 59], ["E3", "PROTEIN", 0, 2], ["SFV", "SPECIES", 56, 59], ["lost", "OBSERVATION_MODIFIER", 6, 10], ["SIN", "OBSERVATION_MODIFIER", 14, 17], ["virion", "OBSERVATION", 38, 44], ["surface", "OBSERVATION_MODIFIER", 45, 52], ["SFV", "ANATOMY", 56, 59]]], ["In both SFV and SIN, the initial 100\u2013200 nucleotides of the capsid gene function as a translation enhancer, leading to very high levels of viral structural proteins in infected cells [6, 7].", [["cells", "ANATOMY", 177, 182], ["nucleotides", "CHEMICAL", 41, 52], ["SFV", "ORGANISM", 8, 11], ["SIN", "CELL", 16, 19], ["cells", "CELL", 177, 182], ["capsid gene", "DNA", 60, 71], ["translation enhancer", "DNA", 86, 106], ["viral structural proteins", "PROTEIN", 139, 164], ["infected cells", "CELL_TYPE", 168, 182], ["SFV", "SPECIES", 8, 11], ["a translation enhancer", "PROBLEM", 84, 106], ["viral structural proteins in infected cells", "PROBLEM", 139, 182], ["both", "ANATOMY_MODIFIER", 3, 7], ["SFV", "ANATOMY", 8, 11], ["viral structural proteins", "OBSERVATION", 139, 164], ["infected cells", "OBSERVATION", 168, 182]]], ["The generation of new viral particles (VPs) involves two processes that have been studied in great detail: (1) packaging of viral RNAs into NCs and (2) budding of NCs at the plasma membrane.", [["plasma membrane", "ANATOMY", 174, 189], ["NCs", "CELL", 140, 143], ["NCs", "GENE_OR_GENE_PRODUCT", 163, 166], ["plasma membrane", "CELLULAR_COMPONENT", 174, 189], ["viral RNAs", "RNA", 124, 134], ["new viral particles", "PROBLEM", 18, 37], ["viral RNAs into NCs", "TREATMENT", 124, 143], ["budding of NCs at the plasma membrane", "TREATMENT", 152, 189], ["new", "OBSERVATION_MODIFIER", 18, 21], ["viral particles", "OBSERVATION", 22, 37], ["viral RNAs", "OBSERVATION", 124, 134], ["plasma membrane", "ANATOMY", 174, 189]]], ["The capsid protein can assemble into NCs through specific interactions between capsid monomers and between these monomers and genomic viral RNA [8\u201311].", [["capsid protein", "PROTEIN", 4, 18], ["capsid monomers", "PROTEIN", 79, 94], ["genomic viral RNA", "RNA", 126, 143], ["The capsid protein", "TREATMENT", 0, 18], ["capsid monomers", "TREATMENT", 79, 94], ["viral RNA", "OBSERVATION", 134, 143]]], ["Neither the \u2212RNA nor the sgRNA are usually packaged into VPs, because they lack a specific packaging sequence located within the Rep gene.IntroductionThe budding process is driven by specific interactions between preformed NCs and spike glycoproteins E1 and E2, leading to the release of virus into the extracellular medium [12\u201315].", [["VPs", "ANATOMY", 57, 60], ["extracellular", "ANATOMY", 303, 316], ["E2", "CHEMICAL", 258, 260], ["sgRNA", "GENE_OR_GENE_PRODUCT", 25, 30], ["VPs", "GENE_OR_GENE_PRODUCT", 57, 60], ["Rep", "GENE_OR_GENE_PRODUCT", 129, 132], ["E1", "GENE_OR_GENE_PRODUCT", 251, 253], ["E2", "GENE_OR_GENE_PRODUCT", 258, 260], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 303, 316], ["\u2212RNA", "RNA", 12, 16], ["sgRNA", "DNA", 25, 30], ["VPs", "DNA", 57, 60], ["packaging sequence", "DNA", 91, 109], ["Rep gene", "DNA", 129, 137], ["E1", "PROTEIN", 251, 253], ["E2", "PROTEIN", 258, 260], ["the sgRNA", "PROBLEM", 21, 30], ["a specific packaging sequence", "PROBLEM", 80, 109], ["The budding process", "PROBLEM", 150, 169], ["spike glycoproteins E1 and E2", "TREATMENT", 231, 260], ["sgRNA", "OBSERVATION", 25, 30], ["budding process", "OBSERVATION", 154, 169], ["virus", "OBSERVATION", 288, 293]]], ["The expression of both capsid and envelope proteins in infected cells has been so far considered a requirement for alphavirus budding and propagation [16, 17].", [["cells", "ANATOMY", 64, 69], ["cells", "CELL", 64, 69], ["capsid and envelope proteins", "PROTEIN", 23, 51], ["infected cells", "CELL_TYPE", 55, 69], ["both capsid and envelope proteins in infected cells", "PROBLEM", 18, 69], ["alphavirus budding", "PROBLEM", 115, 133], ["infected cells", "OBSERVATION", 55, 69]]], ["Expression vectors based on several alphaviruses have been developed by replacing the region coding for the viral structural proteins with a heterologous gene of interest [18\u201320].", [["viral structural proteins", "PROTEIN", 108, 133], ["heterologous gene", "DNA", 141, 158], ["Expression vectors", "TREATMENT", 0, 18], ["several alphaviruses", "PROBLEM", 28, 48], ["the viral structural proteins", "PROBLEM", 104, 133], ["alphaviruses", "OBSERVATION", 36, 48]]], ["Vector RNAs can be packaged into VPs by co-transfecting them into cells together with helper RNAs coding for the structural proteins [19, 21, 22].IntroductionIn the present study, we show that SFV and SIN lacking the capsid gene can propagate in mammalian and mosquito cells.", [["VPs", "ANATOMY", 33, 36], ["cells", "ANATOMY", 66, 71], ["cells", "ANATOMY", 269, 274], ["VPs", "GENE_OR_GENE_PRODUCT", 33, 36], ["cells", "CELL", 66, 71], ["SFV", "ORGANISM", 193, 196], ["SIN", "GENE_OR_GENE_PRODUCT", 201, 204], ["mammalian", "CELL", 246, 255], ["mosquito cells", "CELL", 260, 274], ["Vector RNAs", "RNA", 0, 11], ["VPs", "PROTEIN", 33, 36], ["helper RNAs", "RNA", 86, 97], ["structural proteins", "PROTEIN", 113, 132], ["SIN", "DNA", 201, 204], ["capsid gene", "DNA", 217, 228], ["mammalian and mosquito cells", "CELL_TYPE", 246, 274], ["SFV", "SPECIES", 193, 196], ["Vector RNAs", "TREATMENT", 0, 11], ["VPs", "TREATMENT", 33, 36], ["the structural proteins", "TEST", 109, 132], ["the present study", "TEST", 161, 178], ["SFV", "PROBLEM", 193, 196], ["SFV", "OBSERVATION", 193, 196], ["mosquito cells", "OBSERVATION", 260, 274]]], ["This propagation is mediated by the envelope proteins and seems to occur through the production of infectious microvesicles (iMVs).", [["microvesicles", "ANATOMY", 110, 123], ["iMVs", "ANATOMY", 125, 129], ["microvesicles", "CELL", 110, 123], ["iMVs", "GENE_OR_GENE_PRODUCT", 125, 129], ["envelope proteins", "PROTEIN", 36, 53], ["infectious microvesicles", "CELL_TYPE", 99, 123], ["iMVs", "CELL_TYPE", 125, 129], ["the envelope proteins", "PROBLEM", 32, 53], ["infectious", "OBSERVATION", 99, 109]]], ["These iMVs, which display envelope proteins on their surface and contain viral RNA, are produced at the plasma membrane and are able to infect cells in a similar way as wild-type (wt) alphavirus.Cells ::: Materials and methodsBHK-21 cells (ATCC: CCL-10) were cultured in BHK Glasgow MEM (Gibco BRL, UK) supplemented with 5 % FCS, 10 % tryptose phosphate broth, 2 mM glutamine, and 20 mM HEPES (BHK complete medium).", [["surface", "ANATOMY", 53, 60], ["plasma membrane", "ANATOMY", 104, 119], ["cells", "ANATOMY", 143, 148], ["Cells", "ANATOMY", 195, 200], ["methodsBHK-21 cells", "ANATOMY", 219, 238], ["ATCC", "ANATOMY", 240, 244], ["CCL-10", "ANATOMY", 246, 252], ["tryptose phosphate", "CHEMICAL", 335, 353], ["glutamine", "CHEMICAL", 366, 375], ["tryptose phosphate", "CHEMICAL", 335, 353], ["glutamine", "CHEMICAL", 366, 375], ["HEPES", "CHEMICAL", 387, 392], ["iMVs", "GENE_OR_GENE_PRODUCT", 6, 10], ["surface", "CELLULAR_COMPONENT", 53, 60], ["plasma membrane", "CELLULAR_COMPONENT", 104, 119], ["cells", "CELL", 143, 148], ["wild-type (wt) alphavirus", "ORGANISM", 169, 194], ["Cells", "CELL", 195, 200], ["methodsBHK-21 cells", "CELL", 219, 238], ["ATCC", "CELL", 240, 244], ["CCL-10", "CELL", 246, 252], ["tryptose", "SIMPLE_CHEMICAL", 335, 343], ["glutamine", "AMINO_ACID", 366, 375], ["iMVs", "PROTEIN", 6, 10], ["envelope proteins", "PROTEIN", 26, 43], ["viral RNA", "RNA", 73, 82], ["methodsBHK-21 cells", "CELL_LINE", 219, 238], ["ATCC: CCL-10", "CELL_LINE", 240, 252], ["BHK Glasgow MEM (Gibco BRL", "SPECIES", 271, 297], ["These iMVs", "TEST", 0, 10], ["envelope proteins", "PROBLEM", 26, 43], ["viral RNA", "PROBLEM", 73, 82], ["alphavirus", "PROBLEM", 184, 194], ["Cells", "TEST", 195, 200], ["Materials", "TEST", 205, 214], ["methodsBHK", "TEST", 219, 229], ["cells", "TEST", 233, 238], ["ATCC", "TEST", 240, 244], ["CCL", "TEST", 246, 249], ["5 % FCS", "TREATMENT", 321, 328], ["10 % tryptose phosphate broth", "TREATMENT", 330, 359], ["2 mM glutamine", "TREATMENT", 361, 375], ["20 mM HEPES (BHK complete medium", "TREATMENT", 381, 413], ["envelope", "OBSERVATION_MODIFIER", 26, 34], ["proteins", "OBSERVATION", 35, 43], ["viral RNA", "OBSERVATION", 73, 82]]], ["HuH-7 (Japanese Collection of Research Bioresources Cell Bank: 0403), Hep3B (ATCC: HB-8064), and Vero (ATCC: CCL-81) cells were grown in DMEM (Gibco BRL) supplemented with 10 % FCS and 2 mM glutamine.", [["Hep3B (ATCC: HB-8064", "ANATOMY", 70, 90], ["Vero (ATCC: CCL-81) cells", "ANATOMY", 97, 122], ["BRL", "CHEMICAL", 149, 152], ["glutamine", "CHEMICAL", 190, 199], ["glutamine", "CHEMICAL", 190, 199], ["HuH-7", "CELL", 0, 5], ["Cell", "CELL", 52, 56], ["Hep3B", "CELL", 70, 75], ["ATCC: HB-8064", "CELL", 77, 90], ["Vero", "CELL", 97, 101], ["ATCC: CCL-81) cells", "CELL", 103, 122], ["Gibco BRL", "CELL", 143, 152], ["glutamine", "AMINO_ACID", 190, 199], ["Hep3B", "CELL_LINE", 70, 75], ["ATCC: HB-8064", "CELL_LINE", 77, 90], ["Vero (ATCC: CCL-81) cells", "CELL_LINE", 97, 122], ["Vero", "SPECIES", 97, 101], ["ATCC: HB-8064", "SPECIES", 77, 90], ["Vero (ATCC: CCL-81", "SPECIES", 97, 115], ["HuH", "TEST", 0, 3], ["Hep3B", "TEST", 70, 75], ["ATCC", "TEST", 77, 81], ["HB", "TEST", 83, 85], ["Vero", "TEST", 97, 101], ["ATCC", "TEST", 103, 107], ["CCL", "TEST", 109, 112], ["cells", "TEST", 117, 122], ["10 % FCS", "TREATMENT", 172, 180], ["2 mM glutamine", "TREATMENT", 185, 199]]], ["Aedes albopictus cell line C6/36 (ATCC: CRL-1660) was grown in Eagle\u2019s minimum essential medium, containing 10 % FCS.", [["cell line C6/36", "ANATOMY", 17, 32], ["ATCC", "ANATOMY", 34, 38], ["CRL-1660", "ANATOMY", 40, 48], ["CRL-1660", "CHEMICAL", 40, 48], ["cell line C6/36", "CELL", 17, 32], ["ATCC", "CELL", 34, 38], ["CRL-1660", "CELL", 40, 48], ["Aedes albopictus cell line C6/36", "CELL_LINE", 0, 32], ["ATCC: CRL-1660", "CELL_LINE", 34, 48], ["Aedes albopictus", "SPECIES", 0, 16], ["Aedes albopictus", "SPECIES", 0, 16], ["ATCC: CRL-1660)", "SPECIES", 34, 49], ["CRL", "TEST", 40, 43], ["medium", "OBSERVATION_MODIFIER", 89, 95]]], ["All media contained 100 \u03bcg/ml streptomycin and 100 IU/ml penicillin.Plasmids ::: Materials and methodsPlasmids pSFV-1, pSFV-LacZ, pSFV-helperS2, and pSFV-helper-C-S219A have already been described [22, 23].", [["streptomycin", "CHEMICAL", 30, 42], ["penicillin", "CHEMICAL", 57, 67], ["streptomycin", "CHEMICAL", 30, 42], ["penicillin", "CHEMICAL", 57, 67], ["streptomycin", "SIMPLE_CHEMICAL", 30, 42], ["penicillin", "SIMPLE_CHEMICAL", 57, 67], ["pSFV-1", "GENE_OR_GENE_PRODUCT", 111, 117], ["pSFV", "GENE_OR_GENE_PRODUCT", 119, 123], ["LacZ", "GENE_OR_GENE_PRODUCT", 124, 128], ["pSFV", "GENE_OR_GENE_PRODUCT", 130, 134], ["helperS2", "GENE_OR_GENE_PRODUCT", 135, 143], ["pSFV-helper-C-S219A", "GENE_OR_GENE_PRODUCT", 149, 168], ["pSFV-1", "DNA", 111, 117], ["pSFV", "DNA", 119, 123], ["LacZ", "DNA", 124, 128], ["pSFV", "DNA", 130, 134], ["helperS2", "DNA", 135, 143], ["pSFV", "DNA", 149, 153], ["C", "DNA", 161, 162], ["S219A", "DNA", 163, 168], ["All media", "TREATMENT", 0, 9], ["streptomycin", "TREATMENT", 30, 42], ["penicillin", "TREATMENT", 57, 67], ["Plasmids pSFV", "TEST", 102, 115], ["pSFV", "TEST", 119, 123]]], ["To construct pSFV-spike and pSFV-enh-spike, a fragment of 3.9 or 4.2 kb containing the sequence including \u201csubgenomic promoter + p62\u20136K\u2013E1 + 3\u2032UTR\u201d was obtained from pSFV-helper-E [22] or pSFV-helper-S2, respectively, by digestion with Xba I + Spe I and inserted into pSFV-1 digested with the same enzymes. pSFV-spike has the same structure as the one previously described [17].", [["pSFV", "GENE_OR_GENE_PRODUCT", 13, 17], ["pSFV", "GENE_OR_GENE_PRODUCT", 28, 32], ["p62", "GENE_OR_GENE_PRODUCT", 129, 132], ["pSFV-helper-S2", "GENE_OR_GENE_PRODUCT", 188, 202], ["Xba I + Spe I", "GENE_OR_GENE_PRODUCT", 236, 249], ["pSFV-1", "GENE_OR_GENE_PRODUCT", 268, 274], ["pSFV", "GENE_OR_GENE_PRODUCT", 307, 311], ["pSFV", "DNA", 13, 17], ["pSFV", "DNA", 28, 32], ["enh", "DNA", 33, 36], ["\u201csubgenomic promoter", "DNA", 106, 126], ["p62", "DNA", 129, 132], ["6K\u2013E1", "DNA", 133, 138], ["pSFV-helper-S2", "DNA", 188, 202], ["Xba I", "DNA", 236, 241], ["Spe I", "DNA", 244, 249], ["pSFV-1", "DNA", 268, 274], ["pSFV", "PROTEIN", 307, 311], ["pSFV", "TEST", 13, 17], ["spike", "PROBLEM", 18, 23], ["pSFV", "TEST", 28, 32], ["spike", "PROBLEM", 37, 42], ["a fragment", "PROBLEM", 44, 54], ["the sequence", "TEST", 83, 95], ["subgenomic promoter", "TEST", 107, 126], ["UTR\u201d", "TEST", 143, 147], ["pSFV", "TEST", 166, 170], ["pSFV", "TEST", 188, 192], ["the same enzymes", "TEST", 289, 305], ["spike", "PROBLEM", 312, 317], ["S2", "ANATOMY", 200, 202], ["spike", "OBSERVATION_MODIFIER", 312, 317]]], ["In pSFV-enh-spike, the ORF p62\u20136K\u2013E1 is fused to the sequence coding for the first 34 amino acids of the capsid (translation enhancer b1) using the foot and mouth disease virus 2A autoprotease as a linker [22, 24].", [["amino acids", "CHEMICAL", 86, 97], ["amino acids", "CHEMICAL", 86, 97], ["pSFV", "GENE_OR_GENE_PRODUCT", 3, 7], ["p62", "GENE_OR_GENE_PRODUCT", 27, 30], ["6K\u2013E1", "GENE_OR_GENE_PRODUCT", 31, 36], ["amino acids", "AMINO_ACID", 86, 97], ["translation enhancer b1", "GENE_OR_GENE_PRODUCT", 113, 136], ["foot and mouth disease virus 2A", "ORGANISM", 148, 179], ["pSFV", "PROTEIN", 3, 7], ["enh", "DNA", 8, 11], ["ORF", "DNA", 23, 26], ["p62", "PROTEIN", 27, 30], ["6K\u2013E1", "PROTEIN", 31, 36], ["capsid", "PROTEIN", 105, 111], ["translation enhancer b1", "DNA", 113, 136], ["foot and mouth disease virus 2A autoprotease", "PROTEIN", 148, 192], ["pSFV", "TEST", 3, 7], ["enh", "TEST", 8, 11], ["spike", "PROBLEM", 12, 17], ["the ORF p62", "TEST", 19, 30], ["the first 34 amino acids", "TREATMENT", 73, 97], ["the capsid (translation enhancer b1", "TREATMENT", 101, 136], ["mouth disease virus", "PROBLEM", 157, 176], ["foot", "ANATOMY", 148, 152], ["mouth", "ANATOMY", 157, 162]]], ["To construct pSFV-enh-spike\u03946K, plasmid pSFV-enh-spike was digested with NdeI and the 2.1 kb fragment spanning from position 708 in p62 to position 1171 in E1 genes was substituted by a synthetic fragment (Genescript, Piscataway, NJ) of 1.9 kb covering the same area, but in which the 6K sequence was completely deleted, as previously described [23].", [["plasmid", "ANATOMY", 32, 39], ["pSFV", "GENE_OR_GENE_PRODUCT", 13, 17], ["enh-spike\u03946K", "GENE_OR_GENE_PRODUCT", 18, 30], ["pSFV", "GENE_OR_GENE_PRODUCT", 40, 44], ["NdeI", "GENE_OR_GENE_PRODUCT", 73, 77], ["p62", "GENE_OR_GENE_PRODUCT", 132, 135], ["E1", "GENE_OR_GENE_PRODUCT", 156, 158], ["pSFV", "DNA", 13, 17], ["enh", "DNA", 18, 21], ["spike\u03946K", "DNA", 22, 30], ["pSFV", "DNA", 40, 44], ["enh", "DNA", 45, 48], ["NdeI", "DNA", 73, 77], ["2.1 kb fragment", "DNA", 86, 101], ["position 708", "DNA", 116, 128], ["p62", "PROTEIN", 132, 135], ["E1 genes", "DNA", 156, 164], ["synthetic fragment", "DNA", 186, 204], ["6K sequence", "DNA", 285, 296], ["enh", "TEST", 18, 21], ["plasmid pSFV", "TREATMENT", 32, 44], ["spike", "PROBLEM", 49, 54], ["NdeI", "TREATMENT", 73, 77], ["the 2.1 kb fragment", "PROBLEM", 82, 101], ["a synthetic fragment", "PROBLEM", 184, 204]]], ["To construct pSFV-enh-spike-GFP, we first generated an intermediate plasmid containing a multiple cloning site (mcs) between the end of the E1 gene and the 3\u2032UTR (pSFV-enh-spike-mcs) (information available upon request).", [["plasmid", "ANATOMY", 68, 75], ["pSFV", "GENE_OR_GENE_PRODUCT", 13, 17], ["GFP", "GENE_OR_GENE_PRODUCT", 28, 31], ["E1", "GENE_OR_GENE_PRODUCT", 140, 142], ["pSFV", "DNA", 13, 17], ["enh", "DNA", 18, 21], ["GFP", "DNA", 28, 31], ["intermediate plasmid", "DNA", 55, 75], ["multiple cloning site", "DNA", 89, 110], ["mcs", "DNA", 112, 115], ["E1 gene", "DNA", 140, 147], ["3\u2032UTR", "DNA", 156, 161], ["pSFV", "DNA", 163, 167], ["enh", "DNA", 168, 171], ["mcs", "DNA", 178, 181], ["an intermediate plasmid", "TREATMENT", 52, 75], ["a multiple cloning site", "TREATMENT", 87, 110], ["pSFV", "TEST", 163, 167], ["multiple", "OBSERVATION_MODIFIER", 89, 97]]], ["A PCR fragment spanning the sequence from the subgenomic promoter to the end of 3\u2032UTR was obtained from pSFV-GFP (kindly provided by Prof. P. Liljestr\u00f6m, Karolinska Institute, Sweden) and cloned into pSFV-enh-spike-mcs digested with Avr II (present in the mcs) and Spe I. To construct pSIN-spike, a PCR fragment containing SIN p62\u20136K\u2013E1 sequence was obtained using primers 5\u2032-TCTAGACCACCATGTCCGCAGCACCACTGGTCAC-3\u2032 (forward) and 5\u2032-GGGCCCTCATCTTCGTGTGCTAGTC-3\u2032 (reverse), using plasmid DHBB(5\u2032SIN) as template [21].", [["Avr II", "CHEMICAL", 233, 239], ["pSFV-GFP", "GENE_OR_GENE_PRODUCT", 104, 112], ["pSFV", "GENE_OR_GENE_PRODUCT", 200, 204], ["Avr II", "GENE_OR_GENE_PRODUCT", 233, 239], ["pSIN", "GENE_OR_GENE_PRODUCT", 285, 289], ["SIN p62", "GENE_OR_GENE_PRODUCT", 323, 330], ["PCR fragment", "DNA", 2, 14], ["subgenomic promoter", "DNA", 46, 65], ["3\u2032UTR", "DNA", 80, 85], ["pSFV", "DNA", 104, 108], ["GFP", "DNA", 109, 112], ["pSFV", "PROTEIN", 200, 204], ["enh", "DNA", 205, 208], ["mcs", "DNA", 215, 218], ["Avr II", "PROTEIN", 233, 239], ["mcs", "DNA", 256, 259], ["pSIN", "DNA", 285, 289], ["PCR fragment", "DNA", 299, 311], ["SIN p62\u20136K\u2013E1 sequence", "DNA", 323, 345], ["plasmid DHBB", "DNA", 477, 489], ["5\u2032SIN", "DNA", 490, 495], ["A PCR fragment", "PROBLEM", 0, 14], ["the sequence", "TEST", 24, 36], ["UTR", "TEST", 82, 85], ["Avr II", "TREATMENT", 233, 239], ["spike", "PROBLEM", 290, 295], ["a PCR fragment", "PROBLEM", 297, 311], ["primers", "TEST", 365, 372], ["TCTAGACCACCATGTCCGCAGCACCACTGGTCAC", "TEST", 376, 410], ["GGGCCCTCATCTTCGTGTGCTAGTC", "TEST", 431, 456], ["plasmid DHBB", "TREATMENT", 477, 489], ["fragment", "OBSERVATION_MODIFIER", 6, 14]]], ["In the forward primer, an ATG (underlined) and a ribosome-binding site (bold) were included, since they are not present in the p62 sequence.", [["p62", "GENE_OR_GENE_PRODUCT", 127, 130], ["forward primer", "DNA", 7, 21], ["ATG", "DNA", 26, 29], ["ribosome-binding site", "DNA", 49, 70], ["p62 sequence", "DNA", 127, 139], ["an ATG", "TREATMENT", 23, 29], ["a ribosome-binding site", "PROBLEM", 47, 70], ["ATG", "OBSERVATION", 26, 29]]], ["The 2.9 kb PCR fragment was digested with Xba I and Apa I (in italics in the forward and reverse primers, respectively) and cloned into the same sites in pSINrep5 [21].", [["Xba I", "GENE_OR_GENE_PRODUCT", 42, 47], ["Apa I", "GENE_OR_GENE_PRODUCT", 52, 57], ["2.9 kb PCR fragment", "DNA", 4, 23], ["Xba I", "DNA", 42, 47], ["Apa I", "DNA", 52, 57], ["italics", "DNA", 62, 69], ["forward and reverse primers", "DNA", 77, 104], ["The 2.9 kb PCR fragment", "PROBLEM", 0, 23], ["Xba I", "TEST", 42, 47], ["Apa I", "TEST", 52, 57], ["2.9 kb", "OBSERVATION_MODIFIER", 4, 10], ["fragment", "OBSERVATION_MODIFIER", 15, 23]]], ["A pSinRep5 vector expressing GFP was used for in vitro transcription of SIN-GFP RNA (kindly provided by T. Furuta, Kyoto University, Japan).Transfection of cells and production of viral particles (VPs) ::: Materials and methodsRNA synthesis and transfection into BHK, Hep3B, and Vero cells by electroporation was performed as described previously [18].", [["cells", "ANATOMY", 156, 161], ["BHK", "ANATOMY", 263, 266], ["Hep3B", "ANATOMY", 268, 273], ["Vero cells", "ANATOMY", 279, 289], ["pSinRep5", "GENE_OR_GENE_PRODUCT", 2, 10], ["GFP", "GENE_OR_GENE_PRODUCT", 29, 32], ["SIN-GFP", "GENE_OR_GENE_PRODUCT", 72, 79], ["cells", "CELL", 156, 161], ["BHK", "CELL", 263, 266], ["Hep3B", "CELL", 268, 273], ["Vero cells", "CELL", 279, 289], ["pSinRep5 vector", "DNA", 2, 17], ["GFP", "PROTEIN", 29, 32], ["SIN", "DNA", 72, 75], ["GFP RNA", "RNA", 76, 83], ["BHK", "CELL_LINE", 263, 266], ["Hep3B", "CELL_LINE", 268, 273], ["Vero cells", "CELL_LINE", 279, 289], ["BHK", "SPECIES", 263, 266], ["A pSinRep5 vector expressing GFP", "TREATMENT", 0, 32], ["Transfection of cells", "TREATMENT", 140, 161], ["methodsRNA synthesis", "TEST", 220, 240], ["transfection into BHK", "TREATMENT", 245, 266], ["Hep3B", "TEST", 268, 273], ["Vero cells", "TREATMENT", 279, 289], ["viral particles", "OBSERVATION", 180, 195], ["Hep3B", "ANATOMY", 268, 273]]], ["Electroporation of HuH-7 cells was performed as described by Robinson et al. [25].", [["HuH-7 cells", "ANATOMY", 19, 30], ["HuH-7 cells", "CELL", 19, 30], ["HuH-7 cells", "CELL_LINE", 19, 30], ["HuH", "TEST", 19, 22]]], ["C6/36 cells were transfected using Cellfectin\u00ae Reagent (Life Technologies).", [["C6/36 cells", "ANATOMY", 0, 11], ["C6/36 cells", "CELL", 0, 11], ["C6/36 cells", "CELL_LINE", 0, 11], ["C6/36 cells", "TEST", 0, 11], ["Cellfectin\u00ae Reagent (Life Technologies", "TREATMENT", 35, 73]]], ["Co-culture studies were performed by mixing electroporated and non-electroporated cells at 1:20 ratio and plating 106 cells/9.5 cm2 dish, resulting in confluent monolayers after cell attachment.Transfection of cells and production of viral particles (VPs) ::: Materials and methodsPackaging of recombinant SFV-LacZ or SFV-GFP RNAs into SFV VPs was performed as described [22].", [["cells", "ANATOMY", 82, 87], ["cells", "ANATOMY", 118, 123], ["monolayers", "ANATOMY", 161, 171], ["cell", "ANATOMY", 178, 182], ["cells", "ANATOMY", 210, 215], ["cells", "CELL", 82, 87], ["cells", "CELL", 118, 123], ["monolayers", "CELL", 161, 171], ["cell", "CELL", 178, 182], ["cells", "CELL", 210, 215], ["SFV", "ORGANISM", 306, 309], ["LacZ", "GENE_OR_GENE_PRODUCT", 310, 314], ["SFV", "ORGANISM", 318, 321], ["GFP", "GENE_OR_GENE_PRODUCT", 322, 325], ["SFV", "ORGANISM", 336, 339], ["non-electroporated cells", "CELL_LINE", 63, 87], ["recombinant SFV-LacZ or SFV-GFP RNAs", "DNA", 294, 330], ["SFV", "SPECIES", 306, 309], ["SFV", "SPECIES", 318, 321], ["SFV", "SPECIES", 336, 339], ["Co-culture studies", "TEST", 0, 18], ["plating 106 cells", "TEST", 106, 123], ["confluent monolayers after cell attachment", "PROBLEM", 151, 193], ["Transfection of cells", "TREATMENT", 194, 215], ["recombinant SFV", "TREATMENT", 294, 309], ["SFV VPs", "TREATMENT", 336, 343], ["9.5 cm2", "OBSERVATION_MODIFIER", 124, 131], ["confluent", "OBSERVATION_MODIFIER", 151, 160], ["monolayers", "OBSERVATION_MODIFIER", 161, 171], ["cell attachment", "OBSERVATION", 178, 193], ["viral particles", "OBSERVATION", 234, 249], ["SFV", "ANATOMY", 318, 321]]], ["Briefly, BHK cells were co-electroporated with each recombinant RNA and both SFV-helper-C-S219A and SFV-helper-S2 RNAs, providing in trans the capsid and envelope proteins, respectively.", [["BHK cells", "ANATOMY", 9, 18], ["BHK cells", "CELL", 9, 18], ["C-S219A", "GENE_OR_GENE_PRODUCT", 88, 95], ["SFV-helper-S2", "GENE_OR_GENE_PRODUCT", 100, 113], ["BHK cells", "CELL_LINE", 9, 18], ["recombinant RNA", "RNA", 52, 67], ["SFV-helper-C-S219A and SFV-helper-S2 RNAs", "DNA", 77, 118], ["capsid and envelope proteins", "PROTEIN", 143, 171], ["BHK", "SPECIES", 9, 12], ["BHK cells", "PROBLEM", 9, 18], ["each recombinant RNA", "PROBLEM", 47, 67], ["SFV", "TEST", 77, 80], ["C", "TEST", 88, 89], ["SFV", "TEST", 100, 103], ["SFV", "ANATOMY", 100, 103], ["S2 RNAs", "ANATOMY", 111, 118]]], ["Packaging of SFV-spike, SFV-enh-spike, and SFV-enh-spike-GFP into VPs was performed by co-electroporating BHK cells with each of these RNAs and helper-C-S219A RNA (Supplementary Fig. 1).", [["VPs", "ANATOMY", 66, 69], ["BHK cells", "ANATOMY", 106, 115], ["SFV", "ORGANISM", 13, 16], ["SFV", "ORGANISM", 24, 27], ["SFV", "ORGANISM", 43, 46], ["GFP", "GENE_OR_GENE_PRODUCT", 57, 60], ["VPs", "GENE_OR_GENE_PRODUCT", 66, 69], ["BHK cells", "CELL", 106, 115], ["C-S219A", "GENE_OR_GENE_PRODUCT", 151, 158], ["SFV-spike, SFV-enh-spike, and SFV-enh-spike-GFP", "DNA", 13, 60], ["VPs", "DNA", 66, 69], ["co-electroporating BHK cells", "CELL_LINE", 87, 115], ["S219A RNA", "RNA", 153, 162], ["SFV", "PROBLEM", 13, 16], ["spike", "PROBLEM", 17, 22], ["SFV", "PROBLEM", 24, 27], ["enh", "TEST", 28, 31], ["spike", "PROBLEM", 32, 37], ["SFV", "PROBLEM", 43, 46], ["enh", "TEST", 47, 50], ["spike", "PROBLEM", 51, 56], ["GFP into VPs", "PROBLEM", 57, 69], ["these RNAs", "TEST", 129, 139], ["SFV", "ANATOMY", 13, 16], ["spike", "OBSERVATION_MODIFIER", 17, 22], ["SFV", "ANATOMY", 24, 27], ["SFV", "ANATOMY", 43, 46]]], ["SFV VPs were harvested and purified by ultracentrifugation through a 20 % sucrose cushion as described previously [26].", [["sucrose", "CHEMICAL", 74, 81], ["sucrose", "CHEMICAL", 74, 81], ["SFV", "ORGANISM", 0, 3], ["SFV", "SPECIES", 0, 3], ["SFV VPs", "TREATMENT", 0, 7], ["a 20 % sucrose cushion", "TREATMENT", 67, 89], ["harvested", "OBSERVATION", 13, 22]]], ["For UV-inactivation, the total amount of SFV-LacZ VPs to be used was exposed to a 254 nm UV light (two cycles of 15 min) by using a uvgl-25 compact UV 4 W lamp (UVP, Upland, CA).", [["SFV", "ORGANISM", 41, 44], ["LacZ", "GENE_OR_GENE_PRODUCT", 45, 49], ["LacZ VPs", "PROTEIN", 45, 53], ["SFV", "SPECIES", 41, 44], ["UV-inactivation", "TREATMENT", 4, 19], ["SFV-LacZ VPs", "TREATMENT", 41, 53], ["a 254 nm UV light", "TREATMENT", 80, 97], ["a uvgl", "TREATMENT", 130, 136], ["SFV", "ANATOMY", 41, 44]]], ["After inactivation, the viral titre had decreased by a factor of >107.Purification of infectious microvesicles (iMVs) and control exosomes ::: Materials and methodsApproximately, 107 HuH-7 cells were electroporated with 50 \u03bcg of SFV-enh-spike in vitro-transcribed RNA by applying a pulse of 270 V and 950 \u03bcF using a Gene Pulser II electroporator (BioRad, Hercules, CA).", [["microvesicles", "ANATOMY", 97, 110], ["iMVs", "ANATOMY", 112, 116], ["exosomes", "ANATOMY", 130, 138], ["HuH-7 cells", "ANATOMY", 183, 194], ["microvesicles", "CELL", 97, 110], ["iMVs", "CELL", 112, 116], ["exosomes", "CELL", 130, 138], ["HuH-7 cells", "CELL", 183, 194], ["SFV", "ORGANISM", 229, 232], ["infectious microvesicles", "CELL_TYPE", 86, 110], ["iMVs", "CELL_TYPE", 112, 116], ["exosomes", "CELL_TYPE", 130, 138], ["HuH-7 cells", "CELL_LINE", 183, 194], ["transcribed RNA", "RNA", 252, 267], ["the viral titre", "TEST", 20, 35], ["infectious microvesicles", "PROBLEM", 86, 110], ["methods", "TEST", 157, 164], ["HuH", "TEST", 183, 186], ["SFV", "TEST", 229, 232], ["enh", "TEST", 233, 236], ["a pulse", "TEST", 280, 287], ["viral titre", "OBSERVATION", 24, 35], ["infectious", "OBSERVATION", 86, 96]]], ["These conditions resulted in approximately 50 % transfection efficiency.", [["approximately", "OBSERVATION_MODIFIER", 29, 42], ["50 %", "OBSERVATION_MODIFIER", 43, 47], ["transfection efficiency", "OBSERVATION", 48, 71]]], ["This process was repeated ten times to electroporate a total of 108 cells.", [["cells", "ANATOMY", 68, 73], ["cells", "CELL", 68, 73], ["108 cells", "CELL_LINE", 64, 73]]], ["Cells were incubated during 48 h at 33 \u00b0C, and the medium was clarified by centrifugation at 800g during 15 min to eliminate cell debris.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 125, 129], ["Cells", "CELL", 0, 5], ["cell", "CELL", 125, 129], ["cell debris", "PROBLEM", 125, 136], ["cell debris", "OBSERVATION", 125, 136]]], ["This procedure yielded a total amount of 1.5 \u00d7 107 \u00b1 1.6 \u00d7 106 IU (mean \u00b1 SD of eight independent iMV stocks).", [["This procedure", "TREATMENT", 0, 14], ["IU", "TEST", 63, 65], ["mean", "TEST", 67, 71], ["eight independent iMV stocks", "TREATMENT", 80, 108]]], ["To purify iMVs, the supernatant was filtered using a 0.22 \u03bcm filter, centrifuged at 10,000g during 2 h in a SW28 rotor (Beckman), and the pellet was resuspended in a total volume of 200 \u03bcl of TN buffer (50 mM Tris\u2013HCl, pH 7.4, 100 mM NaCl) for further use.", [["supernatant", "ANATOMY", 20, 31], ["Tris\u2013HCl", "CHEMICAL", 209, 217], ["NaCl", "CHEMICAL", 234, 238], ["Tris\u2013HCl", "CHEMICAL", 209, 217], ["NaCl", "CHEMICAL", 234, 238], ["iMVs", "GENE_OR_GENE_PRODUCT", 10, 14], ["TN", "SIMPLE_CHEMICAL", 192, 194], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 209, 217], ["iMVs", "PROTEIN", 10, 14], ["a 0.22 \u03bcm filter", "TREATMENT", 51, 67], ["a SW28 rotor (Beckman)", "TREATMENT", 106, 128], ["the pellet", "TREATMENT", 134, 144], ["TN buffer", "TREATMENT", 192, 201], ["Tris\u2013HCl", "TEST", 209, 217], ["pH", "TEST", 219, 221]]], ["The iMV recovery yield after the centrifugation step was of 50.1 \u00b1 22.9 % (n = 8).", [["the centrifugation step", "TEST", 29, 52]]], ["To determine the density of purified iMVs or VPs, corresponding samples were centrifuged through a 5\u201360 % sucrose gradient at 100,000g during 90 min.", [["samples", "ANATOMY", 64, 71], ["sucrose", "CHEMICAL", 106, 113], ["sucrose", "CHEMICAL", 106, 113], ["iMVs", "GENE_OR_GENE_PRODUCT", 37, 41], ["VPs", "SIMPLE_CHEMICAL", 45, 48], ["sucrose", "SIMPLE_CHEMICAL", 106, 113], ["iMVs", "PROTEIN", 37, 41], ["VPs", "PROBLEM", 45, 48], ["a 5\u201360 % sucrose gradient", "TREATMENT", 97, 122]]], ["After centrifugation, fractions of 1 ml were collected and analysed for infectivity and density.Purification of infectious microvesicles (iMVs) and control exosomes ::: Materials and methodsFor purification of control exosomes, we used standard protocols previously described [27].", [["microvesicles", "ANATOMY", 123, 136], ["iMVs", "ANATOMY", 138, 142], ["exosomes", "ANATOMY", 156, 164], ["exosomes", "ANATOMY", 218, 226], ["microvesicles", "CELL", 123, 136], ["iMVs", "CELL", 138, 142], ["exosomes", "CELL", 156, 164], ["exosomes", "CELL", 218, 226], ["infectious microvesicles", "CELL_TYPE", 112, 136], ["iMVs", "CELL_TYPE", 138, 142], ["exosomes", "CELL_TYPE", 156, 164], ["centrifugation", "TREATMENT", 6, 20], ["infectivity", "PROBLEM", 72, 83], ["infectious microvesicles", "PROBLEM", 112, 136], ["methods", "TREATMENT", 183, 190], ["purification of control exosomes", "TREATMENT", 194, 226], ["standard protocols", "TREATMENT", 236, 254], ["density", "OBSERVATION", 88, 95], ["infectious", "OBSERVATION", 112, 122]]], ["Briefly, untransfected HuH-7 cells were grown in medium containing 2 % FBS during 48 h.", [["HuH-7 cells", "ANATOMY", 23, 34], ["FBS", "ANATOMY", 71, 74], ["HuH-7 cells", "CELL", 23, 34], ["FBS", "ORGANISM_SUBSTANCE", 71, 74], ["untransfected HuH-7 cells", "CELL_LINE", 9, 34], ["HuH", "TEST", 23, 26], ["7 cells", "OBSERVATION_MODIFIER", 27, 34]]], ["Then, the medium was collected and clarified by centrifugation at 1500g for 15 min, yielding supernatants that were further clarified by centrifugation at 10,000g for 1 h.", [["supernatants", "ANATOMY", 93, 105]]], ["Exosomes in the clarified supernatants were pelleted at 100,000g through a 30 % sucrose cushion for 16 h.Infection of cells ::: Materials and methodsCells were infected with SFV VPs or iMVs as described earlier [18].", [["Exosomes", "ANATOMY", 0, 8], ["supernatants", "ANATOMY", 26, 38], ["cells", "ANATOMY", 118, 123], ["Cells", "ANATOMY", 149, 154], ["sucrose", "CHEMICAL", 80, 87], ["sucrose", "CHEMICAL", 80, 87], ["Exosomes", "CELL", 0, 8], ["cells", "CELL", 118, 123], ["Cells", "CELL", 149, 154], ["SFV", "ORGANISM", 174, 177], ["VPs", "GENE_OR_GENE_PRODUCT", 178, 181], ["iMVs", "GENE_OR_GENE_PRODUCT", 185, 189], ["SFV", "SPECIES", 174, 177], ["a 30 % sucrose cushion", "TREATMENT", 73, 95], ["SFV VPs", "TREATMENT", 174, 181]]], ["For titrations, cells infected with serial dilutions of VPs or iMVs were fixed with cold methanol at 24 or 6 h post-infection (h p.i.), respectively.", [["cells", "ANATOMY", 16, 21], ["methanol", "CHEMICAL", 89, 97], ["cells", "CELL", 16, 21], ["VPs", "SIMPLE_CHEMICAL", 56, 59], ["iMVs", "SIMPLE_CHEMICAL", 63, 67], ["cells infected", "PROBLEM", 16, 30], ["serial dilutions of VPs", "TREATMENT", 36, 59], ["iMVs", "TREATMENT", 63, 67], ["cold methanol", "TREATMENT", 84, 97], ["infection", "PROBLEM", 116, 125]]], ["Indirect immunofluorescence was performed to determine the titres as described [28].", [["Indirect immunofluorescence", "TEST", 0, 27]]], ["A rabbit antiserum specific for the nsP2 subunit of SFV Rep [29] or a murine polyclonal antiserum specific for the SFV envelope proteins was used as primary antibodies.", [["antiserum", "ANATOMY", 9, 18], ["antiserum", "ANATOMY", 88, 97], ["rabbit", "ORGANISM", 2, 8], ["antiserum", "ORGANISM_SUBSTANCE", 9, 18], ["nsP2", "GENE_OR_GENE_PRODUCT", 36, 40], ["SFV", "ORGANISM", 52, 55], ["Rep", "GENE_OR_GENE_PRODUCT", 56, 59], ["murine", "ORGANISM", 70, 76], ["SFV", "ORGANISM", 115, 118], ["nsP2 subunit", "PROTEIN", 36, 48], ["SFV Rep", "PROTEIN", 52, 59], ["SFV envelope proteins", "PROTEIN", 115, 136], ["primary antibodies", "PROTEIN", 149, 167], ["rabbit", "SPECIES", 2, 8], ["murine", "SPECIES", 70, 76], ["rabbit", "SPECIES", 2, 8], ["SFV", "SPECIES", 52, 55], ["SFV", "SPECIES", 115, 118], ["A rabbit antiserum", "TREATMENT", 0, 18], ["a murine polyclonal antiserum", "TREATMENT", 68, 97], ["the SFV envelope proteins", "PROBLEM", 111, 136]]], ["The latter was obtained by immunizing C57BL/6 mice intravenously with four doses of 107 VPs of SFV-enh-spike given every 2 weeks.", [["intravenously", "ANATOMY", 51, 64], ["C57BL/6 mice", "ORGANISM", 38, 50], ["SFV", "ORGANISM", 95, 98], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["SFV", "TREATMENT", 95, 98], ["enh", "TREATMENT", 99, 102]]], ["For neutralization studies, VP or iMV samples were incubated with 5 \u03bcg/ml RNAse during 20 min at 25 \u00b0C, 0.5 mg/ml proteinase K during 45 min at 37 \u00b0C, or with 1 % Triton X-100 during 1 h at 25 \u00b0C, respectively.", [["iMV samples", "ANATOMY", 34, 45], ["VP", "CHEMICAL", 28, 30], ["K", "CHEMICAL", 125, 126], ["Triton X-100", "CHEMICAL", 163, 175], ["VP", "SIMPLE_CHEMICAL", 28, 30], ["iMV samples", "CANCER", 34, 45], ["RNAse", "GENE_OR_GENE_PRODUCT", 74, 79], ["proteinase K", "GENE_OR_GENE_PRODUCT", 114, 126], ["Triton X-100", "SIMPLE_CHEMICAL", 163, 175], ["RNAse", "PROTEIN", 74, 79], ["iMV", "SPECIES", 34, 37], ["neutralization studies", "TEST", 4, 26], ["VP", "TEST", 28, 30], ["iMV samples", "TEST", 34, 45], ["1 % Triton", "TREATMENT", 159, 169]]], ["For neutralization of endosomal pH, cells were either incubated with 20 mM NH4Cl during adsorption (1 h) and/or a 4 h period after adsorption.", [["endosomal", "ANATOMY", 22, 31], ["cells", "ANATOMY", 36, 41], ["NH4Cl", "CHEMICAL", 75, 80], ["NH4Cl", "CHEMICAL", 75, 80], ["endosomal", "CELLULAR_COMPONENT", 22, 31], ["cells", "CELL", 36, 41], ["NH4Cl", "SIMPLE_CHEMICAL", 75, 80], ["endosomal pH", "TEST", 22, 34], ["20 mM NH4Cl", "TREATMENT", 69, 80], ["endosomal pH", "OBSERVATION", 22, 34]]], ["To determine the number of PFUs present in VP stocks, confluent monolayers of BHK cells were infected with different dilutions of the virus, the medium was removed after 1 h of adsorption, and overlay medium was added (BHK complete medium\u201310 % FCS and Glasgow MEM\u20130.2 % agarose, [1:1]).", [["monolayers", "ANATOMY", 64, 74], ["BHK cells", "ANATOMY", 78, 87], ["PFUs", "CANCER", 27, 31], ["monolayers", "CELL", 64, 74], ["BHK cells", "CELL", 78, 87], ["BHK cells", "CELL_LINE", 78, 87], ["BHK", "SPECIES", 78, 81], ["VP stocks", "TREATMENT", 43, 52], ["confluent monolayers of BHK cells", "PROBLEM", 54, 87], ["the virus", "PROBLEM", 130, 139], ["Glasgow MEM", "TREATMENT", 252, 263], ["VP stocks", "OBSERVATION", 43, 52], ["confluent", "OBSERVATION_MODIFIER", 54, 63], ["monolayers", "OBSERVATION_MODIFIER", 64, 74], ["BHK cells", "OBSERVATION", 78, 87]]], ["Cells were incubated for 72 h at 37 \u00b0C, fixed with 0.5 % glutaraldehyde in PBS, and stained with 0.1 % crystal violet in methanol\u2013H2O (20:80).Antibody labelling and electron microscopy ::: Materials and methodsImmunogold labelling of SFV-LacZ VPs and iMVs was performed using the protocol described by Gowen and co-workers [30], but omitting the use of detergent.", [["Cells", "ANATOMY", 0, 5], ["glutaraldehyde", "CHEMICAL", 57, 71], ["H2O", "CHEMICAL", 130, 133], ["glutaraldehyde", "CHEMICAL", 57, 71], ["methanol", "CHEMICAL", 121, 129], ["H2O", "CHEMICAL", 130, 133], ["Cells", "CELL", 0, 5], ["glutaraldehyde", "SIMPLE_CHEMICAL", 57, 71], ["violet", "SIMPLE_CHEMICAL", 111, 117], ["methanol\u2013H2O", "SIMPLE_CHEMICAL", 121, 133], ["SFV", "ORGANISM", 234, 237], ["LacZ", "GENE_OR_GENE_PRODUCT", 238, 242], ["iMVs", "CANCER", 251, 255], ["SFV-LacZ VPs", "DNA", 234, 246], ["iMVs", "DNA", 251, 255], ["Cells", "TEST", 0, 5], ["0.5 % glutaraldehyde in PBS", "TREATMENT", 51, 78], ["methanol\u2013H2O", "TREATMENT", 121, 133], ["Antibody labelling", "TEST", 142, 160], ["electron microscopy", "TEST", 165, 184], ["SFV", "TEST", 234, 237], ["LacZ VPs", "TREATMENT", 238, 246], ["iMVs", "TREATMENT", 251, 255], ["the protocol", "TREATMENT", 276, 288], ["detergent", "TREATMENT", 353, 362]]], ["Murine polyclonal antiserum specific for SFV envelope proteins was used as primary antibody, which was then detected by exposure to anti-mouse immunoglobulin G (IgG) conjugated to 10 nm colloidal gold (Sigma).", [["antiserum", "ANATOMY", 18, 27], ["Murine", "ORGANISM", 0, 6], ["antiserum", "ORGANISM_SUBSTANCE", 18, 27], ["SFV", "ORGANISM", 41, 44], ["anti-mouse immunoglobulin G", "GENE_OR_GENE_PRODUCT", 132, 159], ["IgG", "GENE_OR_GENE_PRODUCT", 161, 164], ["colloidal gold", "SIMPLE_CHEMICAL", 186, 200], ["SFV envelope proteins", "PROTEIN", 41, 62], ["primary antibody", "PROTEIN", 75, 91], ["anti-mouse immunoglobulin G", "PROTEIN", 132, 159], ["IgG", "PROTEIN", 161, 164], ["Murine", "SPECIES", 0, 6], ["anti-mouse", "SPECIES", 132, 142], ["Murine", "SPECIES", 0, 6], ["SFV", "SPECIES", 41, 44], ["Murine polyclonal antiserum", "TREATMENT", 0, 27], ["SFV envelope proteins", "PROBLEM", 41, 62], ["primary antibody", "TEST", 75, 91], ["anti-mouse immunoglobulin G (IgG)", "TREATMENT", 132, 165]]], ["The labelled samples were then stained using Nanovan (Nanoprobes, Yaphank, NY) prior to visualization at 30,000\u00d7 magnification by conventional electron microscopy using a JEOL JEM-1230 (Tokyo, Japan) microscope operating at 80 kV.", [["samples", "ANATOMY", 13, 20], ["The labelled samples", "TEST", 0, 20], ["Nanovan (Nanoprobes", "TREATMENT", 45, 64], ["visualization", "TEST", 88, 101]]], ["Images were recorded on a digital camera SC1000 ORIUS (Gatan, Germany).", [["Images", "TEST", 0, 6]]], ["Estimation of particle size was carried out using ImageJ [31].RT-PCR ::: Materials and methodsSamples containing purified VPs or iMVs were treated with 5 \u03bcg/ml RNAse, or mock incubated, during 40 min at 25 \u00b0C, and RNA was extracted first with phenol and then with chloroform in the presence of 10 \u03bcg of Poly-A Carrier RNA (Qiagen).", [["VPs", "ANATOMY", 122, 125], ["iMVs", "ANATOMY", 129, 133], ["phenol", "CHEMICAL", 243, 249], ["chloroform", "CHEMICAL", 264, 274], ["phenol", "CHEMICAL", 243, 249], ["chloroform", "CHEMICAL", 264, 274], ["VPs", "GENE_OR_GENE_PRODUCT", 122, 125], ["iMVs", "CELL", 129, 133], ["RNAse", "GENE_OR_GENE_PRODUCT", 160, 165], ["phenol", "SIMPLE_CHEMICAL", 243, 249], ["chloroform", "SIMPLE_CHEMICAL", 264, 274], ["VPs", "PROTEIN", 122, 125], ["iMVs", "CELL_TYPE", 129, 133], ["RT-PCR", "TEST", 62, 68], ["methodsSamples", "TEST", 87, 101], ["purified VPs", "TREATMENT", 113, 125], ["iMVs", "TREATMENT", 129, 133], ["phenol", "TREATMENT", 243, 249], ["chloroform", "TREATMENT", 264, 274], ["Poly-A Carrier RNA", "TREATMENT", 303, 321], ["particle size", "OBSERVATION_MODIFIER", 14, 27]]], ["RNA was precipitated with ethanol and 0.1 M sodium acetate, washed with 70 % ethanol, and resuspended in 20 \u03bcl of H20.", [["ethanol", "CHEMICAL", 26, 33], ["sodium acetate", "CHEMICAL", 44, 58], ["ethanol", "CHEMICAL", 77, 84], ["ethanol", "CHEMICAL", 26, 33], ["sodium acetate", "CHEMICAL", 44, 58], ["ethanol", "CHEMICAL", 77, 84], ["ethanol", "SIMPLE_CHEMICAL", 26, 33], ["sodium acetate", "SIMPLE_CHEMICAL", 44, 58], ["ethanol", "SIMPLE_CHEMICAL", 77, 84], ["RNA", "RNA", 0, 3], ["ethanol", "TREATMENT", 26, 33], ["0.1 M sodium acetate", "TREATMENT", 38, 58], ["H20", "TREATMENT", 114, 117]]], ["Two \u03bcg of RNA obtained in this way was mixed with 5 ng of in vitro-transcribed SFV-\u0394Rep-GFP RNA.", [["SFV", "ORGANISM", 79, 82], ["\u0394Rep", "GENE_OR_GENE_PRODUCT", 83, 87], ["GFP", "GENE_OR_GENE_PRODUCT", 88, 91], ["SFV-\u0394Rep-GFP RNA", "RNA", 79, 95], ["vitro", "TEST", 61, 66], ["SFV", "ANATOMY", 79, 82], ["GFP RNA", "OBSERVATION", 88, 95]]], ["This latter RNA does not contain the replicase sequence and was used as an internal control for the RT-PCR.", [["replicase sequence", "DNA", 37, 55], ["an internal control", "TREATMENT", 72, 91], ["the RT-PCR", "TEST", 96, 106]]], ["After DNAse treatment, RNAs were transcribed into cDNA with GoScript\u2122 Reverse Transcriptase (Promega) using a mix of random primers. cDNAs were quantified by real-time PCR with the GoTaq\u00ae 2-Step RT-qPCR System kit (Promega) using oligonucleotides 5\u2032-CTGTTCTCGACGCGTCGTC-3\u2032 (forward) and 5\u2032-GAGGTGTTTCCACGACCC-3\u2032 (reverse) to amplify a 202 nt fragment of nsP2 subunit of SFV Rep. GAPDH was amplified using primers 5\u2032-CCAAGGTCATCCATGACAAC-3\u2032 (forward) and 5\u2032-TGTCATACCAGGAAATGAGC-3\u2032 (reverse), and human \u03b2-actin with primers 5\u2032-AGAGCTACGAGCTGCCTGAC-3\u2032 (forward) and 5\u2032-AGCACTGTGTTGGCGTACAG-3\u2032 (reverse).", [["DNAse", "GENE_OR_GENE_PRODUCT", 6, 11], ["Promega", "GENE_OR_GENE_PRODUCT", 93, 100], ["nsP2", "GENE_OR_GENE_PRODUCT", 354, 358], ["SFV", "ORGANISM", 370, 373], ["GAPDH", "GENE_OR_GENE_PRODUCT", 379, 384], ["TGTCATACCAGGAAATGAGC-3", "GENE_OR_GENE_PRODUCT", 457, 479], ["human", "ORGANISM", 496, 501], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 502, 509], ["DNAse", "PROTEIN", 6, 11], ["RNAs", "RNA", 23, 27], ["cDNA", "DNA", 50, 54], ["GoScript\u2122 Reverse Transcriptase", "PROTEIN", 60, 91], ["cDNAs", "DNA", 133, 138], ["202 nt fragment", "DNA", 335, 350], ["nsP2 subunit", "PROTEIN", 354, 366], ["GAPDH", "PROTEIN", 379, 384], ["human \u03b2-actin", "DNA", 496, 509], ["human", "SPECIES", 496, 501], ["SFV", "SPECIES", 370, 373], ["human", "SPECIES", 496, 501], ["DNAse treatment", "TREATMENT", 6, 21], ["RNAs", "TREATMENT", 23, 27], ["GoScript\u2122 Reverse Transcriptase (Promega)", "TREATMENT", 60, 101], ["a mix of random primers", "TREATMENT", 108, 131], ["cDNAs", "TEST", 133, 138], ["PCR", "TEST", 168, 171], ["the GoTaq\u00ae", "TREATMENT", 177, 187], ["Step RT", "TREATMENT", 190, 197], ["System kit (Promega)", "TREATMENT", 203, 223], ["oligonucleotides", "TREATMENT", 230, 246], ["CTGTTCTCGACGCGTCGTC", "TEST", 250, 269], ["a 202 nt fragment of nsP2 subunit", "TREATMENT", 333, 366], ["GAPDH", "PROBLEM", 379, 384], ["primers", "TEST", 405, 412], ["CCAAGGTCATCCATGACAAC", "TEST", 416, 436], ["TGTCATACCAGGAAATGAGC", "TEST", 457, 477], ["human \u03b2-actin with primers", "TREATMENT", 496, 522], ["AGAGCTACGAGCTGCCTGAC", "TEST", 526, 546]]], ["GFP, used as internal control, was amplified with primers: 5\u2032-ACGGCAAGCTGACCCTGAA-3\u2032 (forward) and 5\u2032-GGGTGCTCAGGTAGTGGTT-3\u2032 (reverse).", [["GFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["GFP", "PROTEIN", 0, 3], ["GFP", "TEST", 0, 3], ["internal control", "TREATMENT", 13, 29], ["ACGGCAAGCTGACCCTGAA", "TEST", 62, 81], ["GGGTGCTCAGGTAGTGGTT", "TEST", 102, 121]]], ["For analysis of RNA present in cells, monolayers were collected at the indicated times after electroporation and RNA was extracted with the MaxWell 16 research system (Promega).", [["cells", "ANATOMY", 31, 36], ["monolayers", "ANATOMY", 38, 48], ["cells", "CELL", 31, 36], ["monolayers", "CELL", 38, 48], ["analysis", "TEST", 4, 12], ["RNA", "PROBLEM", 16, 19], ["monolayers", "TEST", 38, 48], ["electroporation and RNA", "TREATMENT", 93, 116]]], ["1.25 \u03bcg of RNA from each sample was analysed by quantitative RT-PCR as described above for iMVs.", [["sample", "ANATOMY", 25, 31], ["RNA from each sample", "TEST", 11, 31], ["PCR", "TEST", 64, 67], ["iMVs", "PROBLEM", 91, 95]]], ["To determine the relative levels of SFV plus- and minus-RNA strands, RNAs extracted from iMVs, VPs, or cells, were transcribed into cDNA using primers 5\u2032-GACGCGTCGTCAGCCAGGG-3\u2032 and 5\u2032-CCACGACCCCTGCACCTGC-3\u2032, which hybridize to the SFV nsP2 region and are complementary to the minus- and plus-RNA strands, respectively. cDNAs were quantified by real-time PCR using these last two oligonuleotides as described above.", [["iMVs", "ANATOMY", 89, 93], ["VPs", "ANATOMY", 95, 98], ["cells", "ANATOMY", 103, 108], ["SFV", "ORGANISM", 36, 39], ["iMVs", "GENE_OR_GENE_PRODUCT", 89, 93], ["VPs", "GENE_OR_GENE_PRODUCT", 95, 98], ["cells", "CELL", 103, 108], ["5\u2032-CCACGACCCCTGCACCTGC-3", "GENE_OR_GENE_PRODUCT", 181, 205], ["SFV", "ORGANISM", 231, 234], ["SFV plus- and minus-RNA strands", "RNA", 36, 67], ["RNAs", "RNA", 69, 73], ["iMVs", "CELL_TYPE", 89, 93], ["VPs", "CELL_TYPE", 95, 98], ["cDNA", "DNA", 132, 136], ["SFV nsP2 region", "DNA", 231, 246], ["minus- and plus-RNA strands", "DNA", 276, 303], ["cDNAs", "DNA", 319, 324], ["SFV", "SPECIES", 36, 39], ["SFV", "TEST", 36, 39], ["RNA strands", "PROBLEM", 56, 67], ["RNAs", "PROBLEM", 69, 73], ["iMVs", "TEST", 89, 93], ["VPs", "PROBLEM", 95, 98], ["primers", "TEST", 143, 150], ["GACGCGTCGTCAGCCAGGG", "TEST", 154, 173], ["cDNAs", "TEST", 319, 324], ["SFV", "ANATOMY", 36, 39], ["SFV nsP2", "ANATOMY", 231, 239], ["RNA strands", "OBSERVATION", 292, 303]]], ["Data were analysed using CFX Manager software (Bio-Rad).Analysis of protein expression by Western blot ::: Materials and methodsWhole cell lysates from SFV-transfected BHK or HuH-7 cells were obtained by incubation in a buffer containing 1 % IGEPAL (Sigma, St. Louis, MO), 50 mM Tris HCl pH 7.6, 150 mM NaCl, 2 mM EDTA, and 1 \u03bcg/ml PMSF (Sigma), cleared by centrifugation for 6 min at 6000 rpm in a refrigerated microcentrifuge, and quantified by Bradford assay. iMVs were obtained from the supernatant of electroporated HuH-7 cells, which was clarified by low speed centrifugation, filtered, and purified as described above.", [["cell lysates", "ANATOMY", 134, 146], ["BHK", "ANATOMY", 168, 171], ["HuH-7 cells", "ANATOMY", 175, 186], ["supernatant", "ANATOMY", 491, 502], ["HuH-7 cells", "ANATOMY", 521, 532], ["IGEPAL", "CHEMICAL", 242, 248], ["Tris HCl", "CHEMICAL", 279, 287], ["NaCl", "CHEMICAL", 303, 307], ["HCl", "CHEMICAL", 284, 287], ["NaCl", "CHEMICAL", 303, 307], ["EDTA", "CHEMICAL", 314, 318], ["PMSF", "CHEMICAL", 332, 336], ["cell lysates", "ORGANISM_SUBSTANCE", 134, 146], ["SFV", "ORGANISM", 152, 155], ["BHK", "CELL", 168, 171], ["HuH-7 cells", "CELL", 175, 186], ["IGEPAL", "SIMPLE_CHEMICAL", 242, 248], ["EDTA", "SIMPLE_CHEMICAL", 314, 318], ["PMSF", "SIMPLE_CHEMICAL", 332, 336], ["iMVs", "SIMPLE_CHEMICAL", 463, 467], ["HuH-7 cells", "CELL", 521, 532], ["SFV-transfected BHK", "CELL_LINE", 152, 171], ["HuH-7 cells", "CELL_LINE", 175, 186], ["iMVs", "PROTEIN", 463, 467], ["HuH-7 cells", "CELL_LINE", 521, 532], ["SFV", "SPECIES", 152, 155], ["BHK", "SPECIES", 168, 171], ["Whole cell lysates", "TEST", 128, 146], ["SFV", "TEST", 152, 155], ["HuH", "TEST", 175, 178], ["pH", "TEST", 288, 290], ["NaCl", "TEST", 303, 307], ["EDTA", "TEST", 314, 318], ["protein expression", "OBSERVATION", 68, 86]]], ["Purified VPs, iMVs, or cell lysates were analysed by SDS-PAGE in 10 % polyacrylamide gels, transferred to a nitrocellulose membrane, and incubated with the following primary antibodies: murine polyclonal antiserum against SFV envelope proteins (in this case, samples were run under non-reducing conditions to allow a good separation of E1 and E2 bands), murine monoclonal antibody against SFV capsid protein (clone C42 kindly provided by Dr. Irene Greiser-Wilke, Institute of Virology, Hannover, Germany) [32], rabbit polyclonal antisera specific for SFV nsP1 and nsP4 (kindly provided by Dr. Tero Ahola, University of Helsinki, Finland) or for nsP2 and nsP3 Rep subunits (generated in our laboratory), rabbit polyclonal antiserum specific for \u03b2-actin (Sigma), and murine monoclonal antibodies specific for human CD63 (Developmental Studies Hybridoma Bank, IA) and TSG101 (Abcam, Cambridge, UK).", [["VPs", "ANATOMY", 9, 12], ["iMVs", "ANATOMY", 14, 18], ["cell lysates", "ANATOMY", 23, 35], ["membrane", "ANATOMY", 123, 131], ["samples", "ANATOMY", 259, 266], ["polyacrylamide", "CHEMICAL", 70, 84], ["nitrocellulose", "CHEMICAL", 108, 122], ["VPs", "GENE_OR_GENE_PRODUCT", 9, 12], ["iMVs", "SIMPLE_CHEMICAL", 14, 18], ["cell lysates", "CELL", 23, 35], ["membrane", "CELLULAR_COMPONENT", 123, 131], ["murine", "ORGANISM", 186, 192], ["SFV", "ORGANISM", 222, 225], ["murine", "ORGANISM", 354, 360], ["SFV", "ORGANISM", 389, 392], ["rabbit", "ORGANISM", 511, 517], ["SFV", "ORGANISM", 551, 554], ["nsP1", "GENE_OR_GENE_PRODUCT", 555, 559], ["nsP4", "GENE_OR_GENE_PRODUCT", 564, 568], ["nsP2", "GENE_OR_GENE_PRODUCT", 645, 649], ["nsP3 Rep subunits", "GENE_OR_GENE_PRODUCT", 654, 671], ["rabbit", "ORGANISM", 703, 709], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 744, 751], ["Sigma", "GENE_OR_GENE_PRODUCT", 753, 758], ["murine", "ORGANISM", 765, 771], ["human", "ORGANISM", 807, 812], ["CD63", "GENE_OR_GENE_PRODUCT", 813, 817], ["TSG101", "GENE_OR_GENE_PRODUCT", 865, 871], ["Abcam", "GENE_OR_GENE_PRODUCT", 873, 878], ["VPs", "PROTEIN", 9, 12], ["iMVs", "PROTEIN", 14, 18], ["primary antibodies", "PROTEIN", 166, 184], ["SFV envelope proteins", "PROTEIN", 222, 243], ["E1", "PROTEIN", 336, 338], ["murine monoclonal antibody", "PROTEIN", 354, 380], ["SFV capsid protein", "PROTEIN", 389, 407], ["clone C42", "PROTEIN", 409, 418], ["SFV nsP1", "PROTEIN", 551, 559], ["nsP4", "PROTEIN", 564, 568], ["nsP2", "PROTEIN", 645, 649], ["nsP3 Rep subunits", "PROTEIN", 654, 671], ["\u03b2-actin", "PROTEIN", 744, 751], ["Sigma", "PROTEIN", 753, 758], ["murine monoclonal antibodies", "PROTEIN", 765, 793], ["human CD63", "PROTEIN", 807, 817], ["IA", "PROTEIN", 857, 859], ["TSG101", "PROTEIN", 865, 871], ["Abcam", "PROTEIN", 873, 878], ["murine", "SPECIES", 186, 192], ["murine", "SPECIES", 354, 360], ["rabbit", "SPECIES", 511, 517], ["rabbit", "SPECIES", 703, 709], ["murine", "SPECIES", 765, 771], ["human", "SPECIES", 807, 812], ["SFV", "SPECIES", 222, 225], ["SFV", "SPECIES", 389, 392], ["rabbit", "SPECIES", 511, 517], ["SFV", "SPECIES", 551, 554], ["rabbit", "SPECIES", 703, 709], ["human", "SPECIES", 807, 812], ["iMVs", "TREATMENT", 14, 18], ["cell lysates", "TEST", 23, 35], ["SDS", "TEST", 53, 56], ["a nitrocellulose membrane", "TREATMENT", 106, 131], ["murine polyclonal antiserum", "TREATMENT", 186, 213], ["SFV envelope proteins", "PROBLEM", 222, 243], ["E1 and E2 bands", "TREATMENT", 336, 351], ["murine monoclonal antibody", "TEST", 354, 380], ["SFV capsid protein", "TREATMENT", 389, 407], ["rabbit polyclonal antisera", "TREATMENT", 511, 537], ["SFV nsP1", "TREATMENT", 551, 559], ["nsP4", "PROBLEM", 564, 568], ["nsP2", "PROBLEM", 645, 649], ["nsP3 Rep subunits", "TREATMENT", 654, 671], ["rabbit polyclonal antiserum", "TREATMENT", 703, 730], ["murine monoclonal antibodies", "TEST", 765, 793], ["human CD63", "TEST", 807, 817], ["Developmental Studies", "TEST", 819, 840], ["VPs", "OBSERVATION", 9, 12]]], ["Peroxidase-conjugated goat anti-mouse (Thermo Fisher Scientific, Waltham, MA) and sheep anti-rabbit (Cell Signalling, Danvers, MA) antisera were used as secondary antibodies.", [["Cell", "ANATOMY", 101, 105], ["Peroxidase", "GENE_OR_GENE_PRODUCT", 0, 10], ["sheep", "ORGANISM", 82, 87], ["Cell", "CELL", 101, 105], ["goat anti-mouse", "PROTEIN", 22, 37], ["sheep anti-rabbit", "PROTEIN", 82, 99], ["secondary antibodies", "PROTEIN", 153, 173], ["goat", "SPECIES", 22, 26], ["anti-mouse", "SPECIES", 27, 37], ["sheep", "SPECIES", 82, 87], ["anti-rabbit", "SPECIES", 88, 99], ["goat", "SPECIES", 22, 26], ["sheep", "SPECIES", 82, 87], ["Peroxidase-conjugated goat anti-mouse", "TREATMENT", 0, 37], ["sheep anti-rabbit (Cell Signalling, Danvers, MA) antisera", "TREATMENT", 82, 139], ["secondary antibodies", "PROBLEM", 153, 173]]], ["Proteins were visualized using the Western Lightning Chemiluminescence Reagent Plus (Perkin Elmer Life Sciences, Waltham, MA).Animal manipulations ::: Materials and methodsFive weeks old C57BL/6 female mice were purchased from Harlan (Barcelona, Spain) and maintained under standard pathogen-free conditions according to the ethical institution\u2019s guidelines.", [["C57BL/6 female", "ORGANISM", 187, 201], ["mice", "ORGANISM", 202, 206], ["mice", "SPECIES", 202, 206], ["mice", "SPECIES", 202, 206]]], ["Vectors were injected intravenously at the indicated doses diluted in 100\u2013300 \u03bcl of saline (Fig. 7).", [["intravenously", "ANATOMY", 22, 35], ["Vectors", "ORGANISM", 0, 7], ["saline", "SIMPLE_CHEMICAL", 84, 90], ["Vectors", "TREATMENT", 0, 7], ["saline", "TREATMENT", 84, 90]]], ["At the indicated times, blood samples were obtained by orbital sinus bleeding, cells were removed by low-speed centrifugation, and the supernatant was frozen at \u221280 \u00b0C for subsequent virus assay.", [["blood samples", "ANATOMY", 24, 37], ["orbital sinus", "ANATOMY", 55, 68], ["cells", "ANATOMY", 79, 84], ["supernatant", "ANATOMY", 135, 146], ["orbital sinus bleeding", "DISEASE", 55, 77], ["blood samples", "ORGANISM_SUBSTANCE", 24, 37], ["orbital sinus", "MULTI-TISSUE_STRUCTURE", 55, 68], ["cells", "CELL", 79, 84], ["blood samples", "TEST", 24, 37], ["orbital sinus bleeding", "PROBLEM", 55, 77], ["subsequent virus assay", "PROBLEM", 172, 194], ["orbital sinus", "ANATOMY", 55, 68]]], ["At 48 h, a brain fraction was homogenized and suspended in EMEM with 2 % FBS to obtain a 10 % suspension (wt/vol), which was then centrifuged at 733\u00d7g for 10 min.", [["brain", "ANATOMY", 11, 16], ["FBS", "ANATOMY", 73, 76], ["brain", "ORGAN", 11, 16], ["FBS", "ORGANISM_SUBSTANCE", 73, 76], ["a brain fraction", "TEST", 9, 25], ["2 % FBS", "TREATMENT", 69, 76], ["brain", "ANATOMY", 11, 16]]], ["The supernatant was decanted, and the suspension was frozen at \u221280 \u00b0C for subsequent virus assay.", [["supernatant", "ANATOMY", 4, 15], ["the suspension", "TREATMENT", 34, 48], ["subsequent virus assay", "TEST", 74, 96]]], ["The number of infectious units present in the serum and brain homogenates was determined as described above.", [["serum", "ANATOMY", 46, 51], ["brain homogenates", "ANATOMY", 56, 73], ["serum", "ORGANISM_SUBSTANCE", 46, 51], ["brain homogenates", "ORGANISM_SUBSTANCE", 56, 73], ["infectious units", "TREATMENT", 14, 30], ["the serum", "TEST", 42, 51], ["number", "OBSERVATION_MODIFIER", 4, 10], ["infectious units", "OBSERVATION", 14, 30], ["brain", "ANATOMY", 56, 61]]], ["For RT-PCR analysis, mice were killed 48 h after treatment and 20 mg of the indicated tissues was homogenized in 200 \u03bcl of chilled 1-thioglycerol/homogenization solution using Fisherbrand\u2122 Disposable Pestle System (Fisher Scientific).", [["tissues", "ANATOMY", 86, 93], ["1-thioglycerol", "CHEMICAL", 131, 145], ["1-thioglycerol", "CHEMICAL", 131, 145], ["mice", "ORGANISM", 21, 25], ["tissues", "TISSUE", 86, 93], ["1-thioglycerol", "SIMPLE_CHEMICAL", 131, 145], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["RT-PCR analysis", "TEST", 4, 19], ["treatment", "TREATMENT", 49, 58], ["thioglycerol/homogenization solution", "TREATMENT", 133, 169]]], ["Samples were then processed on a MaxWell 16 research system (Promega) and analysed by quantitative RT-PCR as described above.Statistical analysis ::: Materials and methodsAll error terms are expressed as the standard deviation (SD).", [["Samples", "ANATOMY", 0, 7], ["quantitative RT-PCR", "TEST", 86, 105]]], ["Prism software (GraphPad Software Inc., San Diego, CA) was employed for statistical analysis.", [["statistical analysis", "TEST", 72, 92]]], ["Mann\u2013Whitney U test was used to compare two experimental groups.", [["Mann\u2013Whitney U test", "TEST", 0, 19]]], ["Paired t test was used in those experiments where the same samples were analysed for different parameters or under different treatments (Figs.", [["samples", "ANATOMY", 59, 66], ["Paired t test", "TEST", 0, 13], ["the same samples", "TEST", 50, 66]]], ["Two-way ANOVA followed by Tukey\u2019s post-tests was used for comparison among groups in Fig. 8b. p values <0.05 were considered to be statistically significant.Ethics statement ::: Materials and methodsMice were maintained under standard pathogen-free conditions according to our ethical institution\u2019s guidelines.", [["Mice", "ORGANISM", 199, 203], ["Mice", "SPECIES", 199, 203], ["Tukey\u2019s post-tests", "TEST", 26, 44], ["p values", "TEST", 94, 102], ["methodsMice", "TREATMENT", 192, 203]]], ["Animals were anesthetized with an intraperitoneal injection of a ketamine/xylazine mixture and killed by cervical dislocation.", [["intraperitoneal", "ANATOMY", 34, 49], ["cervical", "ANATOMY", 105, 113], ["ketamine", "CHEMICAL", 65, 73], ["xylazine", "CHEMICAL", 74, 82], ["cervical dislocation", "DISEASE", 105, 125], ["ketamine", "CHEMICAL", 65, 73], ["xylazine", "CHEMICAL", 74, 82], ["Animals", "ORGANISM", 0, 7], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 49], ["ketamine", "SIMPLE_CHEMICAL", 65, 73], ["xylazine", "SIMPLE_CHEMICAL", 74, 82], ["cervical", "ORGAN", 105, 113], ["an intraperitoneal injection", "TREATMENT", 31, 59], ["a ketamine/xylazine mixture", "TREATMENT", 63, 90], ["cervical dislocation", "PROBLEM", 105, 125], ["cervical", "ANATOMY", 105, 113], ["dislocation", "OBSERVATION", 114, 125]]], ["The protocol to perform the animal experiments described in this work was reviewed and approved by our local Institutional Animal Care and Use Committee (IACUC): Comit\u00e9 de \u00c9tica para la Experimentacion Animal de la Universidad de Navarra (protocol identification number: 105-14).", [["The protocol", "TREATMENT", 0, 12]]], ["Our local IAUCC adheres to the Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes.SFV and SIN devoid of capsid gene can propagate in cell culture ::: ResultsAn SFV vector containing the sequence of SFV envelope proteins (p62\u20136K\u2013E1) fused to the minimal SFV capsid translation enhancer (SFV-enh-spike) was initially constructed as a tool to generate a polyclonal antiserum against SFV envelope proteins (Supplementary Fig. 1).", [["cell", "ANATOMY", 228, 232], ["SFV", "ORGANISM", 177, 180], ["SIN", "GENE_OR_GENE_PRODUCT", 185, 188], ["cell", "CELL", 228, 232], ["SFV", "ORGANISM", 255, 258], ["SFV", "ORGANISM", 293, 296], ["p62\u20136K\u2013E1", "GENE_OR_GENE_PRODUCT", 316, 325], ["SFV", "ORGANISM", 381, 384], ["SFV envelope proteins", "GENE_OR_GENE_PRODUCT", 475, 496], ["SIN", "DNA", 185, 188], ["capsid gene", "DNA", 199, 210], ["SFV vector", "DNA", 255, 265], ["SFV envelope proteins", "PROTEIN", 293, 314], ["p62", "PROTEIN", 316, 319], ["6K\u2013E1", "PROTEIN", 320, 325], ["minimal SFV capsid translation enhancer", "DNA", 340, 379], ["SFV", "DNA", 381, 384], ["enh", "DNA", 385, 388], ["SFV envelope proteins", "PROTEIN", 475, 496], ["SFV", "SPECIES", 177, 180], ["SFV", "SPECIES", 255, 258], ["SFV", "SPECIES", 293, 296], ["SFV", "SPECIES", 348, 351], ["SFV", "SPECIES", 475, 478], ["the protection of animals", "TREATMENT", 122, 147], ["SFV", "PROBLEM", 177, 180], ["SFV envelope proteins", "TEST", 293, 314], ["p62", "TEST", 316, 319], ["the minimal SFV capsid translation enhancer", "PROBLEM", 336, 379], ["SFV", "TEST", 381, 384], ["a polyclonal antiserum", "TREATMENT", 444, 466], ["SFV envelope proteins", "TREATMENT", 475, 496], ["Supplementary Fig", "TREATMENT", 498, 515], ["SIN devoid", "OBSERVATION_MODIFIER", 185, 195], ["minimal", "OBSERVATION_MODIFIER", 340, 347], ["SFV capsid", "OBSERVATION", 348, 358], ["translation enhancer", "OBSERVATION", 359, 379]]], ["This vector was packaged into VPs by co-transfecting BHK-21 (BHK) cells with SFV-enh-spike and SFV-helper-C-S219A RNAs, the latter lacking the SFV packaging signal and providing the capsid gene in trans [22] (Supplementary Fig. 1).", [["VPs", "ANATOMY", 30, 33], ["BHK-21 (BHK) cells", "ANATOMY", 53, 71], ["VPs", "GENE_OR_GENE_PRODUCT", 30, 33], ["BHK-21 (BHK) cells", "CELL", 53, 71], ["SFV", "ORGANISM", 77, 80], ["enh", "GENE_OR_GENE_PRODUCT", 81, 84], ["SFV", "ORGANISM", 95, 98], ["C-S219A", "GENE_OR_GENE_PRODUCT", 106, 113], ["SFV", "ORGANISM", 143, 146], ["VPs", "DNA", 30, 33], ["BHK-21 (BHK) cells", "CELL_LINE", 53, 71], ["SFV-enh-spike and SFV-helper-C-S219A RNAs", "RNA", 77, 118], ["capsid gene", "DNA", 182, 193], ["SFV", "SPECIES", 143, 146], ["This vector", "TREATMENT", 0, 11], ["BHK", "TEST", 53, 56], ["cells", "TEST", 66, 71], ["SFV", "TEST", 77, 80], ["enh", "TEST", 81, 84], ["spike", "PROBLEM", 85, 90], ["SFV", "TEST", 95, 98], ["the capsid gene in trans", "TREATMENT", 178, 202], ["Supplementary Fig", "TREATMENT", 209, 226], ["SFV", "ANATOMY", 77, 80], ["SFV", "ANATOMY", 95, 98]]], ["In this last RNA, the S219A mutation in the capsid abolishes its proteolytic activity, preventing the processing of the structural polyprotein if a full-length genome is generated by recombination [22].", [["S219A", "GENE_OR_GENE_PRODUCT", 22, 27], ["full-length genome", "DNA", 148, 166], ["the S219A mutation", "PROBLEM", 18, 36]]], ["Unexpectedly, SFV-enh-spike VPs were able to mediate the spreading of viral protein expression in monolayers of different mammalian cell lines including BHK, Hep3B, HuH-7, and the mosquito cell line C6/36 (Fig. 1).", [["monolayers", "ANATOMY", 98, 108], ["cell lines", "ANATOMY", 132, 142], ["BHK", "ANATOMY", 153, 156], ["Hep3B", "ANATOMY", 158, 163], ["HuH-7", "ANATOMY", 165, 170], ["cell line C6/36", "ANATOMY", 189, 204], ["SFV", "ORGANISM", 14, 17], ["VPs", "GENE_OR_GENE_PRODUCT", 28, 31], ["monolayers", "CELL", 98, 108], ["mammalian cell lines", "CELL", 122, 142], ["BHK", "CELL", 153, 156], ["Hep3B", "CELL", 158, 163], ["HuH-7", "CELL", 165, 170], ["cell line C6/36", "CELL", 189, 204], ["SFV-enh-spike VPs", "DNA", 14, 31], ["mammalian cell lines", "CELL_LINE", 122, 142], ["BHK", "CELL_LINE", 153, 156], ["Hep3B", "CELL_LINE", 158, 163], ["HuH-7", "CELL_LINE", 165, 170], ["mosquito cell line C6/36", "CELL_LINE", 180, 204], ["SFV", "SPECIES", 14, 17], ["BHK", "SPECIES", 153, 156], ["SFV", "TEST", 14, 17], ["spike VPs", "PROBLEM", 22, 31], ["viral protein expression", "PROBLEM", 70, 94], ["different mammalian cell lines", "TREATMENT", 112, 142], ["BHK", "TEST", 153, 156], ["Hep3B", "TEST", 158, 163], ["HuH", "TEST", 165, 168], ["the mosquito cell line C6", "TEST", 176, 201], ["SFV", "OBSERVATION", 14, 17], ["viral protein expression", "OBSERVATION", 70, 94], ["mammalian cell lines", "OBSERVATION", 122, 142], ["Hep3B", "ANATOMY", 158, 163], ["mosquito cell line", "OBSERVATION", 180, 198]]], ["This effect was not due to the generation of replication-proficient virus (RPV), since no RPVs were detected by a plaque-forming unit (PFU) assay.", [["plaque", "ANATOMY", 114, 120], ["RPV", "ORGANISM", 75, 78], ["RPVs", "GENE_OR_GENE_PRODUCT", 90, 94], ["RPV", "SPECIES", 75, 78], ["replication", "PROBLEM", 45, 56], ["proficient virus", "PROBLEM", 57, 73], ["RPVs", "PROBLEM", 90, 94]]], ["In addition, propagation of this vector was not as efficient as that of wtSFV (Fig. 1b).", [["wtSFV", "PROTEIN", 72, 77], ["this vector", "TREATMENT", 28, 39]]], ["However, to rule out that recombinant genomes containing all or part of the capsid gene could have been generated during the packaging of SFV-enh-spike, BHK cells were electroporated only with SFV-enh-spike RNA, and co-cultured with non-electroporated cells at a 1:20 ratio (Fig. 2a).", [["BHK cells", "ANATOMY", 153, 162], ["cells", "ANATOMY", 252, 257], ["SFV", "ORGANISM", 138, 141], ["BHK cells", "CELL", 153, 162], ["SFV", "ORGANISM", 193, 196], ["cells", "CELL", 252, 257], ["recombinant genomes", "DNA", 26, 45], ["capsid gene", "DNA", 76, 87], ["enh", "DNA", 142, 145], ["BHK cells", "CELL_LINE", 153, 162], ["SFV-enh-spike RNA", "RNA", 193, 210], ["non-electroporated cells", "CELL_LINE", 233, 257], ["SFV", "SPECIES", 138, 141], ["BHK", "SPECIES", 153, 156], ["SFV", "SPECIES", 193, 196], ["recombinant genomes", "PROBLEM", 26, 45], ["SFV", "TEST", 138, 141], ["spike", "PROBLEM", 146, 151], ["BHK cells", "PROBLEM", 153, 162], ["SFV", "TEST", 193, 196], ["spike RNA", "PROBLEM", 201, 210], ["non-electroporated cells", "PROBLEM", 233, 257], ["SFV", "ANATOMY", 138, 141]]], ["As shown in Fig. 2b, SFV-enh-spike was able to propagate from transfected cells to neighbouring cells, reaching most cells in the monolayer at 36 h. p.i.", [["cells", "ANATOMY", 74, 79], ["cells", "ANATOMY", 96, 101], ["cells", "ANATOMY", 117, 122], ["monolayer", "ANATOMY", 130, 139], ["SFV", "ORGANISM", 21, 24], ["enh", "GENE_OR_GENE_PRODUCT", 25, 28], ["cells", "CELL", 74, 79], ["cells", "CELL", 96, 101], ["cells", "CELL", 117, 122], ["monolayer", "CELL", 130, 139], ["enh", "PROTEIN", 25, 28], ["transfected cells", "CELL_LINE", 62, 79], ["neighbouring cells", "CELL_TYPE", 83, 101], ["SFV", "TEST", 21, 24], ["spike", "PROBLEM", 29, 34], ["SFV", "ANATOMY", 21, 24]]], ["This effect was not observed in a co-culture of cells electroporated with SFV-LacZ RNA (Supplementary Fig. 1), which gives a pattern of individual cells at all analysed time points (Fig. 2b).", [["cells", "ANATOMY", 48, 53], ["cells", "ANATOMY", 147, 152], ["cells", "CELL", 48, 53], ["SFV", "ORGANISM", 74, 77], ["LacZ", "GENE_OR_GENE_PRODUCT", 78, 82], ["cells", "CELL", 147, 152], ["LacZ RNA", "RNA", 78, 86], ["SFV-LacZ RNA", "TREATMENT", 74, 86], ["individual cells", "PROBLEM", 136, 152], ["SFV", "ANATOMY", 74, 77]]], ["As observed with infected cells, the propagation of wtSFV from transfected cells was also more efficient than that of SFV-enh-spike (Fig. 2c).", [["cells", "ANATOMY", 26, 31], ["cells", "ANATOMY", 75, 80], ["cells", "CELL", 26, 31], ["SFV", "ORGANISM", 54, 57], ["cells", "CELL", 75, 80], ["SFV", "ORGANISM", 118, 121], ["infected cells", "CELL_TYPE", 17, 31], ["transfected cells", "CELL_LINE", 63, 80], ["SFV", "SPECIES", 54, 57], ["infected cells", "PROBLEM", 17, 31], ["wtSFV", "PROBLEM", 52, 57], ["transfected cells", "PROBLEM", 63, 80], ["SFV", "TEST", 118, 121], ["infected cells", "OBSERVATION", 17, 31], ["transfected cells", "OBSERVATION", 63, 80], ["SFV", "ANATOMY", 118, 121]]]], "b6d5e7fae9cb10b697ee57a5099e4cec83141463": [["studies in patients with mitral valve disease have identified atrial fibrillation (AF) as a risk factor (6, 7) , others have found pulmonary artery systolic pressures (PASPs) to be the most powerful predictor of TR progression (4) .", [["mitral valve", "ANATOMY", 25, 37], ["atrial", "ANATOMY", 62, 68], ["pulmonary artery", "ANATOMY", 131, 147], ["mitral valve disease", "DISEASE", 25, 45], ["atrial fibrillation", "DISEASE", 62, 81], ["AF", "DISEASE", 83, 85], ["pulmonary artery systolic pressures", "DISEASE", 131, 166], ["patients", "ORGANISM", 11, 19], ["mitral valve", "MULTI-TISSUE_STRUCTURE", 25, 37], ["atrial", "MULTI-TISSUE_STRUCTURE", 62, 68], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 131, 147], ["patients", "SPECIES", 11, 19], ["studies", "TEST", 0, 7], ["mitral valve disease", "PROBLEM", 25, 45], ["atrial fibrillation", "PROBLEM", 62, 81], ["AF", "PROBLEM", 83, 85], ["a risk factor", "PROBLEM", 90, 103], ["pulmonary artery systolic pressures", "PROBLEM", 131, 166], ["TR progression", "PROBLEM", 212, 226], ["mitral valve", "ANATOMY", 25, 37], ["disease", "OBSERVATION", 38, 45], ["atrial", "ANATOMY", 62, 68], ["fibrillation", "OBSERVATION", 69, 81], ["pulmonary artery", "ANATOMY", 131, 147], ["systolic pressures", "OBSERVATION", 148, 166]]], ["In a recent study (5) , neither increased PASP nor AF were associated with the rate of TR progression.", [["AF", "DISEASE", 51, 53], ["PASP", "GENE_OR_GENE_PRODUCT", 42, 46], ["PASP", "PROTEIN", 42, 46], ["a recent study", "TEST", 3, 17], ["increased PASP", "PROBLEM", 32, 46], ["AF", "PROBLEM", 51, 53], ["TR progression", "PROBLEM", 87, 101], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["PASP", "OBSERVATION", 42, 46]]]], "PMC7088539": [["Viral and bacterial decontamination ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionThe decontamination of S/D plasma is guaranteed by the treatment with both the solvent and the detergent, immunological neutralisation (due to the physiological presence of neutralising antibodies in the pool of plasma for fractionation), as well as by double filtration, which removes cells, cell fragments, and bacteria.", [["plasma", "ANATOMY", 96, 102], ["plasma", "ANATOMY", 146, 152], ["plasma", "ANATOMY", 331, 337], ["cells", "ANATOMY", 405, 410], ["cell fragments", "ANATOMY", 412, 426], ["plasma", "ORGANISM_SUBSTANCE", 96, 102], ["D", "SIMPLE_CHEMICAL", 144, 145], ["plasma", "ORGANISM_SUBSTANCE", 146, 152], ["plasma", "ORGANISM_SUBSTANCE", 331, 337], ["cells", "CELL", 405, 410], ["cell", "CELL", 412, 416], ["neutralising antibodies", "PROTEIN", 292, 315], ["The decontamination of S/D plasma", "TREATMENT", 119, 152], ["the treatment", "TREATMENT", 170, 183], ["the solvent", "TREATMENT", 194, 205], ["the detergent", "TREATMENT", 210, 223], ["immunological neutralisation", "PROBLEM", 225, 253], ["neutralising antibodies", "TREATMENT", 292, 315], ["double filtration", "TREATMENT", 372, 389], ["cell fragments", "PROBLEM", 412, 426], ["bacteria", "PROBLEM", 432, 440], ["bacterial decontamination", "OBSERVATION", 10, 35], ["cell fragments", "OBSERVATION", 412, 426], ["bacteria", "OBSERVATION_MODIFIER", 432, 440]]], ["S/D treatment is highly effective in disrupting lipid membranes and, therefore, guarantees a high level of safety with regards to all viruses with a lipid envelope (including human immunodeficiency virus, hepatitis B and C virus, and emerging ones such as the West Nile virus, Chikungunya virus, new influenza strains, and severe acute respiratory syndrome Coronavirus), bacteria, protozoa and intracellular viruses, such as cytomegalovirus, Epstein-Barr virus and human T cell leukaemia virus I and II [6].Viral and bacterial decontamination ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionIn addition, the treatment has a high reserve capacity provided by the 4-h incubation time; in fact, it reduces the virus load below detection levels in less than 2 min [6].", [["lipid membranes", "ANATOMY", 48, 63], ["intracellular", "ANATOMY", 394, 407], ["plasma", "ANATOMY", 603, 609], ["S/D", "CHEMICAL", 0, 3], ["human immunodeficiency virus, hepatitis B", "DISEASE", 175, 216], ["Chikungunya virus", "DISEASE", 277, 294], ["influenza", "DISEASE", 300, 309], ["acute respiratory syndrome Coronavirus", "DISEASE", 330, 368], ["human T cell leukaemia virus I", "DISEASE", 465, 495], ["S/D", "SIMPLE_CHEMICAL", 0, 3], ["lipid membranes", "CELLULAR_COMPONENT", 48, 63], ["human immunodeficiency virus", "ORGANISM", 175, 203], ["hepatitis B and C virus", "ORGANISM", 205, 228], ["West Nile virus", "ORGANISM", 260, 275], ["Chikungunya virus", "ORGANISM", 277, 294], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 394, 407], ["cytomegalovirus", "ORGANISM", 425, 440], ["Epstein-Barr virus", "ORGANISM", 442, 460], ["human T cell leukaemia virus I", "ORGANISM", 465, 495], ["plasma", "ORGANISM_SUBSTANCE", 603, 609], ["human immunodeficiency virus", "SPECIES", 175, 203], ["hepatitis B and C virus", "SPECIES", 205, 228], ["West Nile virus", "SPECIES", 260, 275], ["Chikungunya virus", "SPECIES", 277, 294], ["human", "SPECIES", 465, 470], ["human immunodeficiency virus", "SPECIES", 175, 203], ["hepatitis B and C virus", "SPECIES", 205, 228], ["West Nile virus", "SPECIES", 260, 275], ["Chikungunya virus", "SPECIES", 277, 294], ["Epstein-Barr virus", "SPECIES", 442, 460], ["human T cell leukaemia virus I", "SPECIES", 465, 495], ["S/D treatment", "TREATMENT", 0, 13], ["disrupting lipid membranes", "TREATMENT", 37, 63], ["all viruses", "PROBLEM", 130, 141], ["a lipid envelope", "PROBLEM", 147, 163], ["human immunodeficiency virus", "PROBLEM", 175, 203], ["hepatitis B", "PROBLEM", 205, 216], ["C virus", "PROBLEM", 221, 228], ["the West Nile virus", "PROBLEM", 256, 275], ["Chikungunya virus", "PROBLEM", 277, 294], ["new influenza strains", "PROBLEM", 296, 317], ["severe acute respiratory syndrome Coronavirus)", "PROBLEM", 323, 369], ["bacteria", "PROBLEM", 371, 379], ["protozoa", "PROBLEM", 381, 389], ["intracellular viruses", "PROBLEM", 394, 415], ["cytomegalovirus", "PROBLEM", 425, 440], ["Barr virus", "PROBLEM", 450, 460], ["human T cell leukaemia", "PROBLEM", 465, 487], ["the treatment", "TREATMENT", 639, 652], ["a high reserve capacity", "PROBLEM", 657, 680], ["detection levels", "TEST", 759, 775], ["lipid membranes", "OBSERVATION", 48, 63], ["severe", "OBSERVATION_MODIFIER", 323, 329], ["acute", "OBSERVATION_MODIFIER", 330, 335], ["respiratory syndrome Coronavirus", "OBSERVATION", 336, 368], ["intracellular viruses", "OBSERVATION", 394, 415], ["Barr virus", "OBSERVATION", 450, 460], ["cell leukaemia", "OBSERVATION", 473, 487], ["bacterial decontamination", "OBSERVATION", 517, 542]]], ["While the S/D process effectively destroys more than 5 logs of most enveloped viruses, the vaccinia virus is relatively resistant; this pathogen reduction technique is also less effective against non-enveloped viruses such as hepatitis A and parvovirus B19.", [["hepatitis A and parvovirus B19", "DISEASE", 226, 256], ["vaccinia virus", "ORGANISM", 91, 105], ["hepatitis A", "ORGANISM", 226, 237], ["parvovirus B19", "ORGANISM", 242, 256], ["parvovirus B19", "SPECIES", 242, 256], ["vaccinia virus", "SPECIES", 91, 105], ["hepatitis A", "SPECIES", 226, 237], ["parvovirus B19", "SPECIES", 242, 256], ["most enveloped viruses", "PROBLEM", 63, 85], ["the vaccinia virus", "PROBLEM", 87, 105], ["this pathogen reduction technique", "TREATMENT", 131, 164], ["non-enveloped viruses", "PROBLEM", 196, 217], ["hepatitis A", "PROBLEM", 226, 237], ["parvovirus B19", "PROBLEM", 242, 256], ["enveloped", "OBSERVATION_MODIFIER", 68, 77], ["viruses", "OBSERVATION", 78, 85], ["vaccinia virus", "OBSERVATION", 91, 105], ["relatively", "OBSERVATION_MODIFIER", 109, 119], ["resistant", "OBSERVATION_MODIFIER", 120, 129], ["viruses", "OBSERVATION", 210, 217], ["hepatitis", "OBSERVATION", 226, 235], ["parvovirus B19", "OBSERVATION", 242, 256]]], ["The risk of transmitting these infectious agents is reduced by the dilution of any initial viral load, the presence of neutralising antibodies in the plasma pools, the size of plasma pools (60\u2013380 L in comparison to 4,000\u201330,000 L of the pools from which plasma-derived medicinal products are produced) [6], the hydrophobic chromatography to which the product is subject, and by testing each plasma pool for the presence of genomic material [17].Viral and bacterial decontamination ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionThe concentrations of anti-hepatitis A antibodies in S/D plasma are 30 times the prophylactic dose and should warrant an adequate protection from this infection.", [["plasma", "ANATOMY", 150, 156], ["plasma", "ANATOMY", 176, 182], ["plasma", "ANATOMY", 255, 261], ["plasma", "ANATOMY", 392, 398], ["plasma", "ANATOMY", 542, 548], ["plasma", "ANATOMY", 622, 628], ["infection", "DISEASE", 716, 725], ["plasma", "ORGANISM_SUBSTANCE", 150, 156], ["plasma", "ORGANISM_SUBSTANCE", 176, 182], ["plasma", "ORGANISM_SUBSTANCE", 255, 261], ["plasma", "ORGANISM_SUBSTANCE", 392, 398], ["plasma", "ORGANISM_SUBSTANCE", 542, 548], ["anti-hepatitis A antibodies", "GENE_OR_GENE_PRODUCT", 587, 614], ["plasma", "ORGANISM_SUBSTANCE", 622, 628], ["neutralising antibodies", "PROTEIN", 119, 142], ["anti-hepatitis A antibodies", "PROTEIN", 587, 614], ["anti-hepatitis A", "SPECIES", 587, 603], ["transmitting these infectious agents", "PROBLEM", 12, 48], ["any initial viral load", "PROBLEM", 79, 101], ["neutralising antibodies", "PROBLEM", 119, 142], ["the plasma pools", "TEST", 146, 162], ["plasma pools", "TEST", 176, 188], ["plasma-derived medicinal products", "TREATMENT", 255, 288], ["the hydrophobic chromatography", "TEST", 308, 338], ["genomic material", "PROBLEM", 424, 440], ["anti-hepatitis A antibodies in S/D plasma", "TREATMENT", 587, 628], ["the prophylactic dose", "TREATMENT", 642, 663], ["an adequate protection", "TREATMENT", 683, 705], ["this infection", "PROBLEM", 711, 725], ["infectious", "OBSERVATION", 31, 41], ["viral load", "OBSERVATION", 91, 101], ["size", "OBSERVATION_MODIFIER", 168, 172], ["bacterial decontamination", "OBSERVATION", 456, 481], ["infection", "OBSERVATION", 716, 725]]], ["The concentrations of antibodies against parvovirus B19 are similar to those of intra-venous immunoglobulins used to treat chronic infections [12] but transfusion transmission of B19 has been reported with S/D plasma [18] and in the 1990s an outbreak of hepatitis A occurred with a factor VIII product [12].Viral and bacterial decontamination ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionIn conclusion, preclinical virus validation studies, clinical safety virological assessments, and extensive post-marketing clinical experience have clearly shown that the S/D treatment achieves a rapid, irreversible, and thorough inactivation of enveloped viruses.", [["plasma", "ANATOMY", 210, 216], ["plasma", "ANATOMY", 403, 409], ["parvovirus B19", "DISEASE", 41, 55], ["infections", "DISEASE", 131, 141], ["B19", "DISEASE", 179, 182], ["hepatitis A", "DISEASE", 254, 265], ["parvovirus B19", "ORGANISM", 41, 55], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 93, 108], ["B19", "ORGANISM", 179, 182], ["plasma", "ORGANISM_SUBSTANCE", 210, 216], ["plasma", "ORGANISM_SUBSTANCE", 403, 409], ["antibodies", "PROTEIN", 22, 32], ["intra-venous immunoglobulins", "PROTEIN", 80, 108], ["factor VIII product", "PROTEIN", 282, 301], ["parvovirus B19", "SPECIES", 41, 55], ["parvovirus B19", "SPECIES", 41, 55], ["B19", "SPECIES", 179, 182], ["hepatitis A", "SPECIES", 254, 265], ["The concentrations of antibodies", "TREATMENT", 0, 32], ["parvovirus B19", "PROBLEM", 41, 55], ["intra-venous immunoglobulins", "TREATMENT", 80, 108], ["chronic infections", "PROBLEM", 123, 141], ["transfusion transmission of B19", "PROBLEM", 151, 182], ["S/D plasma", "TEST", 206, 216], ["hepatitis A", "PROBLEM", 254, 265], ["a factor VIII product", "TREATMENT", 280, 301], ["preclinical virus validation studies", "TEST", 441, 477], ["clinical safety virological assessments", "TEST", 479, 518], ["the S/D treatment", "TREATMENT", 593, 610], ["enveloped viruses", "PROBLEM", 672, 689], ["chronic", "OBSERVATION_MODIFIER", 123, 130], ["infections", "OBSERVATION", 131, 141], ["hepatitis", "OBSERVATION", 254, 263], ["bacterial decontamination", "OBSERVATION", 317, 342], ["enveloped", "OBSERVATION_MODIFIER", 672, 681], ["viruses", "OBSERVATION", 682, 689]]], ["Moreover, the efficacy of the S/D treatment is highlighted by the fact that between 1991 and 2009 approximately 10 million units of S/D plasma were transfused without any documented case of transmission of HBV, HCV or HIV [6].Viral and bacterial decontamination ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionNevertheless, the \u201ctraditional\u201d S/D pathogen inactivation has only a limited prion clearance capacity as it is able to reduce the PrPSc by only 2.5 logs whereas a further extension of this removal capacity (more than 5 logs) has been recently warranted by the above mentioned \u201cmodified\u201d manufacturing process that includes a specific prion reduction step [6, 15, 16].Viral and bacterial decontamination ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionAlthough bacteria rarely contaminate FFP because of its storage conditions [19], the impact of S/D on bacterial growth and on the capacity of the complement to kill bacteria has been recently investigated and showed that the S/D treatment of plasma does not alter the bactericidal activity of the complement, and inactivates some gram-positive bacteria [20].Standardisation, dilution effect and other possible benefits ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionThe dilution and neutralisation of antibodies and allergens during the industrial process of S/D plasma pooling can reduce the incidence of allergic reactions in recipients and also result in a high level of final standardisation of the concentrations of labile and stable clotting factors and other plasma proteins, thus eliminating the biological variability between single units of FFP [9, 17, 21\u201323].Standardisation, dilution effect and other possible benefits ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionNeither anti-human leucocyte antigen (HLA) nor anti-human neutrophil antigen (HNA) antibodies are detectable in S/D plasma as they are diluted and neutralised by the presence of leukocytes or their fragments, which are then removed by the S/D treatment [24\u201326].", [["plasma", "ANATOMY", 136, 142], ["plasma", "ANATOMY", 322, 328], ["plasma", "ANATOMY", 808, 814], ["plasma", "ANATOMY", 1073, 1079], ["plasma", "ANATOMY", 1310, 1316], ["plasma", "ANATOMY", 1430, 1436], ["plasma", "ANATOMY", 1633, 1639], ["plasma", "ANATOMY", 1858, 1864], ["plasma", "ANATOMY", 1997, 2003], ["leukocytes", "ANATOMY", 2059, 2069], ["fragments", "ANATOMY", 2079, 2088], ["S/D", "CHEMICAL", 30, 33], ["HBV, HCV or HIV", "DISEASE", 206, 221], ["S/D", "CHEMICAL", 926, 929], ["allergic reactions", "DISEASE", 1473, 1491], ["D", "SIMPLE_CHEMICAL", 32, 33], ["plasma", "ORGANISM_SUBSTANCE", 136, 142], ["HBV", "ORGANISM", 206, 209], ["HCV", "ORGANISM", 211, 214], ["plasma", "ORGANISM_SUBSTANCE", 322, 328], ["plasma", "ORGANISM_SUBSTANCE", 808, 814], ["FFP", "SIMPLE_CHEMICAL", 868, 871], ["S/D", "SIMPLE_CHEMICAL", 926, 929], ["D", "SIMPLE_CHEMICAL", 1058, 1059], ["plasma", "ORGANISM_SUBSTANCE", 1073, 1079], ["plasma", "ORGANISM_SUBSTANCE", 1310, 1316], ["plasma", "ORGANISM_SUBSTANCE", 1430, 1436], ["recipients", "ORGANISM", 1495, 1505], ["clotting factors", "GENE_OR_GENE_PRODUCT", 1606, 1622], ["plasma", "ORGANISM_SUBSTANCE", 1633, 1639], ["plasma", "ORGANISM_SUBSTANCE", 1858, 1864], ["anti-human leucocyte antigen", "GENE_OR_GENE_PRODUCT", 1889, 1917], ["HLA", "GENE_OR_GENE_PRODUCT", 1919, 1922], ["anti-human neutrophil antigen", "GENE_OR_GENE_PRODUCT", 1928, 1957], ["HNA", "GENE_OR_GENE_PRODUCT", 1959, 1962], ["plasma", "ORGANISM_SUBSTANCE", 1997, 2003], ["leukocytes", "CELL", 2059, 2069], ["antibodies", "PROTEIN", 1368, 1378], ["clotting factors", "PROTEIN", 1606, 1622], ["plasma proteins", "PROTEIN", 1633, 1648], ["anti-human leucocyte antigen", "PROTEIN", 1889, 1917], ["HLA", "PROTEIN", 1919, 1922], ["anti-human neutrophil antigen (HNA) antibodies", "PROTEIN", 1928, 1974], ["leukocytes", "CELL_TYPE", 2059, 2069], ["HIV", "SPECIES", 218, 221], ["anti-human", "SPECIES", 1928, 1938], ["HBV", "SPECIES", 206, 209], ["HCV", "SPECIES", 211, 214], ["HIV", "SPECIES", 218, 221], ["the S/D treatment", "TREATMENT", 26, 43], ["S/D plasma", "TREATMENT", 132, 142], ["HBV", "PROBLEM", 206, 209], ["HCV", "PROBLEM", 211, 214], ["HIV", "PROBLEM", 218, 221], ["D pathogen inactivation", "TREATMENT", 379, 402], ["a limited prion clearance capacity", "PROBLEM", 412, 446], ["the PrPSc", "TEST", 471, 480], ["this removal capacity", "TREATMENT", 529, 550], ["a specific prion reduction step", "TREATMENT", 668, 699], ["IntroductionAlthough bacteria", "PROBLEM", 819, 848], ["FFP", "TREATMENT", 868, 871], ["its storage conditions", "PROBLEM", 883, 905], ["bacterial growth", "PROBLEM", 933, 949], ["kill bacteria", "PROBLEM", 991, 1004], ["the S/D treatment of plasma", "TREATMENT", 1052, 1079], ["some gram", "TEST", 1156, 1165], ["positive bacteria", "PROBLEM", 1166, 1183], ["The dilution", "TREATMENT", 1333, 1345], ["neutralisation of antibodies", "TREATMENT", 1350, 1378], ["allergens", "PROBLEM", 1383, 1392], ["S/D plasma pooling", "TREATMENT", 1426, 1444], ["allergic reactions", "PROBLEM", 1473, 1491], ["labile and stable clotting factors", "PROBLEM", 1588, 1622], ["other plasma proteins", "TEST", 1627, 1648], ["FFP", "TREATMENT", 1718, 1721], ["IntroductionNeither anti-human leucocyte antigen", "TEST", 1869, 1917], ["HLA", "TEST", 1919, 1922], ["anti-human neutrophil antigen", "TEST", 1928, 1957], ["HNA) antibodies", "TEST", 1959, 1974], ["leukocytes", "PROBLEM", 2059, 2069], ["their fragments", "PROBLEM", 2073, 2088], ["bacterial decontamination", "OBSERVATION", 236, 261], ["bacterial decontamination", "OBSERVATION", 722, 747], ["positive bacteria", "OBSERVATION_MODIFIER", 1166, 1183], ["allergic", "OBSERVATION", 1473, 1481], ["stable", "OBSERVATION_MODIFIER", 1599, 1605], ["clotting", "OBSERVATION", 1606, 1614], ["leukocytes", "OBSERVATION", 2059, 2069], ["fragments", "OBSERVATION_MODIFIER", 2079, 2088]]], ["For this reason countries using S/D FFP have not reported any transfusion-related acute lung injury (TRALI) case due to the transfusion of plasma [27, 28].Standardisation, dilution effect and other possible benefits ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionIn addition, the double filtration of S/D FFP removes residual cells and many of their fragments, thus reducing the possibility of allo-immunisation and cell-mediated adverse immunological reactions in the recipient [17].Standardisation, dilution effect and other possible benefits ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionRecently, 100 plasma samples obtained from voluntary blood donors in Germany were compared to six aliquots of different lots of S/D plasma through tandem mass spectrometry to assess the presence of drug residues.", [["lung", "ANATOMY", 88, 92], ["plasma", "ANATOMY", 139, 145], ["plasma", "ANATOMY", 276, 282], ["cells", "ANATOMY", 362, 367], ["fragments", "ANATOMY", 386, 395], ["cell", "ANATOMY", 452, 456], ["plasma", "ANATOMY", 641, 647], ["plasma samples", "ANATOMY", 678, 692], ["blood", "ANATOMY", 717, 722], ["plasma", "ANATOMY", 796, 802], ["acute lung injury", "DISEASE", 82, 99], ["TRALI", "DISEASE", 101, 106], ["lung", "ORGAN", 88, 92], ["plasma", "ORGANISM_SUBSTANCE", 139, 145], ["plasma", "ORGANISM_SUBSTANCE", 276, 282], ["S/D FFP", "SIMPLE_CHEMICAL", 337, 344], ["cells", "CELL", 362, 367], ["cell", "CELL", 452, 456], ["plasma", "ORGANISM_SUBSTANCE", 641, 647], ["plasma samples", "ORGANISM_SUBSTANCE", 678, 692], ["blood donors", "ORGANISM_SUBSTANCE", 717, 729], ["plasma", "ORGANISM_SUBSTANCE", 796, 802], ["S/D FFP", "TREATMENT", 32, 39], ["any transfusion", "PROBLEM", 58, 73], ["acute lung injury", "PROBLEM", 82, 99], ["the transfusion of plasma", "TREATMENT", 120, 145], ["the double filtration of S/D FFP", "TREATMENT", 312, 344], ["residual cells", "PROBLEM", 353, 367], ["their fragments", "PROBLEM", 380, 395], ["allo-immunisation", "PROBLEM", 430, 447], ["cell-mediated adverse immunological reactions", "PROBLEM", 452, 497], ["plasma samples", "TEST", 678, 692], ["voluntary blood donors", "TREATMENT", 707, 729], ["S/D plasma through tandem mass spectrometry", "TEST", 792, 835], ["drug residues", "PROBLEM", 862, 875], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["lung", "ANATOMY", 88, 92], ["injury", "OBSERVATION", 93, 99], ["residual cells", "OBSERVATION", 353, 367], ["fragments", "OBSERVATION", 386, 395], ["drug residues", "OBSERVATION", 862, 875]]], ["In 12 % of the analysed specimens, residues of diuretics, beta-receptor blocking agents, stimulants, or contraceptives were detected and they were all within or below levels commonly reported in cases of therapeutic usage.", [["specimens", "ANATOMY", 24, 33], ["diuretics", "SIMPLE_CHEMICAL", 47, 56], ["beta-receptor blocking agents", "SIMPLE_CHEMICAL", 58, 87], ["diuretics", "TREATMENT", 47, 56], ["beta-receptor blocking agents", "TREATMENT", 58, 87], ["stimulants", "TREATMENT", 89, 99], ["contraceptives", "TREATMENT", 104, 118]]], ["On the contrary, the analysis of the aliquots of S/D plasma preparations yielded no findings of drug residues.", [["plasma", "ANATOMY", 53, 59], ["plasma", "ORGANISM_SUBSTANCE", 53, 59], ["the analysis", "TEST", 17, 29], ["S/D plasma preparations", "TEST", 49, 72], ["drug residues", "PROBLEM", 96, 109], ["no findings of", "UNCERTAINTY", 81, 95], ["drug residues", "OBSERVATION", 96, 109]]], ["These results are attributed to the dilution and the liquid\u2013liquid and solid-phase extraction, which are included in the industrial production process of pathogen inactivated plasma [29].Standardisation, dilution effect and other possible benefits ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionOther methods for pathogen reduction of plasma currently in use exploit different mechanisms of actions and, consequently, generate a large quantity of reactive oxygen species (ROS).", [["plasma", "ANATOMY", 175, 181], ["plasma", "ANATOMY", 308, 314], ["plasma", "ANATOMY", 371, 377], ["oxygen", "CHEMICAL", 492, 498], ["ROS", "CHEMICAL", 508, 511], ["oxygen", "CHEMICAL", 492, 498], ["liquid\u2013liquid", "SIMPLE_CHEMICAL", 53, 66], ["plasma", "ORGANISM_SUBSTANCE", 175, 181], ["plasma", "ORGANISM_SUBSTANCE", 308, 314], ["plasma", "ORGANISM_SUBSTANCE", 371, 377], ["reactive oxygen species", "SIMPLE_CHEMICAL", 483, 506], ["ROS", "SIMPLE_CHEMICAL", 508, 511], ["the dilution", "TEST", 32, 44], ["the liquid\u2013liquid and solid-phase extraction", "TREATMENT", 49, 93], ["IntroductionOther methods", "TREATMENT", 319, 344], ["pathogen reduction of plasma", "TREATMENT", 349, 377], ["reactive oxygen species", "PROBLEM", 483, 506], ["large", "OBSERVATION_MODIFIER", 465, 470], ["quantity", "OBSERVATION_MODIFIER", 471, 479], ["reactive", "OBSERVATION_MODIFIER", 483, 491], ["oxygen species", "OBSERVATION", 492, 506]]], ["ROS have a key role in the damage of red blood cells and recently fostered an approach to improving the quality and efficacy of stored red cells focused on reducing oxidative damage by removing oxygen at the beginning of storage and maintaining the anaerobic state throughout the storage period [30].", [["red blood cells", "ANATOMY", 37, 52], ["red cells", "ANATOMY", 135, 144], ["ROS", "CHEMICAL", 0, 3], ["oxygen", "CHEMICAL", 194, 200], ["oxygen", "CHEMICAL", 194, 200], ["ROS", "SIMPLE_CHEMICAL", 0, 3], ["red blood cells", "CELL", 37, 52], ["red cells", "CELL", 135, 144], ["oxygen", "SIMPLE_CHEMICAL", 194, 200], ["red blood cells", "CELL_TYPE", 37, 52], ["red cells", "CELL_TYPE", 135, 144], ["red blood cells", "TEST", 37, 52], ["stored red cells", "PROBLEM", 128, 144], ["reducing oxidative damage", "PROBLEM", 156, 181], ["oxygen", "TREATMENT", 194, 200]]], ["Very recently Feys et al. [31] revealed the mechanism of damage to plasma constituents by riboflavin and light and showed that generated ROS played a direct role in adversely affecting the biomolecular integrity of relevant plasma constituents such as ADAMTS13, factor VIII and fibrinogen.", [["plasma", "ANATOMY", 67, 73], ["plasma", "ANATOMY", 224, 230], ["riboflavin", "CHEMICAL", 90, 100], ["ROS", "CHEMICAL", 137, 140], ["riboflavin", "CHEMICAL", 90, 100], ["plasma", "ORGANISM_SUBSTANCE", 67, 73], ["riboflavin", "SIMPLE_CHEMICAL", 90, 100], ["ROS", "SIMPLE_CHEMICAL", 137, 140], ["plasma", "ORGANISM_SUBSTANCE", 224, 230], ["ADAMTS13", "GENE_OR_GENE_PRODUCT", 252, 260], ["factor VIII", "GENE_OR_GENE_PRODUCT", 262, 273], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 278, 288], ["ADAMTS13", "PROTEIN", 252, 260], ["factor VIII", "PROTEIN", 262, 273], ["fibrinogen", "PROTEIN", 278, 288], ["damage to plasma constituents", "PROBLEM", 57, 86], ["riboflavin", "TREATMENT", 90, 100], ["ADAMTS13", "TEST", 252, 260], ["factor VIII", "TEST", 262, 273], ["fibrinogen", "TEST", 278, 288]]], ["In this case, plasma product integrity could be maintained by applying hypoxic conditions during the pathogen inactivation process.", [["plasma", "ANATOMY", 14, 20], ["plasma", "ORGANISM_SUBSTANCE", 14, 20], ["plasma product integrity", "TREATMENT", 14, 38], ["hypoxic conditions", "PROBLEM", 71, 89], ["the pathogen inactivation process", "PROBLEM", 97, 130], ["hypoxic conditions", "OBSERVATION", 71, 89]]], ["It is important to note that the formation of singlet oxygen upon illumination is part of the mechanism of action also of the methylene blue (MB) pathogen reduction system [32] whose efficacy is indeed increased in the presence of oxygen [12].Factor composition of solvent detergent treated plasma and possible changes related to the production process ::: Solvent detergent pathogen inactivation of fresh frozen plasma ::: IntroductionS/D plasma deriving from FFP units prepared and frozen through optimal collection and production procedures [33] has a moderate reduction of clotting factor and inhibitor activities and a final composition similar to FFP.", [["plasma", "ANATOMY", 291, 297], ["plasma", "ANATOMY", 413, 419], ["plasma", "ANATOMY", 440, 446], ["oxygen", "CHEMICAL", 54, 60], ["methylene blue", "CHEMICAL", 126, 140], ["MB", "CHEMICAL", 142, 144], ["oxygen", "CHEMICAL", 231, 237], ["oxygen", "CHEMICAL", 54, 60], ["methylene blue", "CHEMICAL", 126, 140], ["oxygen", "CHEMICAL", 231, 237], ["singlet oxygen", "SIMPLE_CHEMICAL", 46, 60], ["methylene blue", "SIMPLE_CHEMICAL", 126, 140], ["MB", "SIMPLE_CHEMICAL", 142, 144], ["oxygen", "SIMPLE_CHEMICAL", 231, 237], ["plasma", "ORGANISM_SUBSTANCE", 291, 297], ["plasma", "ORGANISM_SUBSTANCE", 413, 419], ["plasma", "ORGANISM_SUBSTANCE", 440, 446], ["clotting factor", "GENE_OR_GENE_PRODUCT", 577, 592], ["FFP", "SIMPLE_CHEMICAL", 653, 656], ["clotting factor", "PROTEIN", 577, 592], ["FFP", "PROTEIN", 653, 656], ["singlet oxygen", "TREATMENT", 46, 60], ["the methylene blue (MB) pathogen reduction system", "TREATMENT", 122, 171], ["IntroductionS/D plasma", "TREATMENT", 424, 446], ["FFP units", "TREATMENT", 461, 470], ["a moderate reduction of clotting factor", "TREATMENT", 553, 592], ["inhibitor activities", "TREATMENT", 597, 617], ["FFP", "TREATMENT", 653, 656], ["increased", "OBSERVATION_MODIFIER", 202, 211], ["moderate", "OBSERVATION_MODIFIER", 555, 563], ["reduction", "OBSERVATION_MODIFIER", 564, 573]]], ["Moreover, thanks to the filtration process, the high molecular weight multimers of von Willebrand factor (vWF) are absent.", [["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 83, 104], ["vWF", "GENE_OR_GENE_PRODUCT", 106, 109], ["von Willebrand factor", "PROTEIN", 83, 104], ["WF", "PROTEIN", 107, 109], ["the filtration process", "TEST", 20, 42], ["high", "OBSERVATION_MODIFIER", 48, 52]]], ["The metalloprotease ADAMTS13, implicated in the pathogenesis of TTP, is normal and stable up to 5 h, even after thawing and storage at room temperature [17].", [["TTP", "DISEASE", 64, 67], ["ADAMTS13", "GENE_OR_GENE_PRODUCT", 20, 28], ["TTP", "GENE_OR_GENE_PRODUCT", 64, 67], ["metalloprotease", "PROTEIN", 4, 19], ["ADAMTS13", "PROTEIN", 20, 28], ["The metalloprotease ADAMTS13", "TEST", 0, 28], ["TTP", "PROBLEM", 64, 67], ["TTP", "OBSERVATION", 64, 67], ["normal", "OBSERVATION", 72, 78], ["stable", "OBSERVATION_MODIFIER", 83, 89]]], ["S/D plasma also contains normal levels of factor H [34], a plasma glycoprotein involved in the control of the complement cascade and with a pathogenic role in atypical haemolytic uremic syndrome.", [["plasma", "ANATOMY", 4, 10], ["plasma", "ANATOMY", 59, 65], ["haemolytic uremic syndrome", "DISEASE", 168, 194], ["S/D", "GENE_OR_GENE_PRODUCT", 0, 3], ["plasma", "ORGANISM_SUBSTANCE", 4, 10], ["factor H [34]", "GENE_OR_GENE_PRODUCT", 42, 55], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["plasma glycoprotein", "PROTEIN", 59, 78], ["S/D plasma", "TEST", 0, 10], ["a plasma glycoprotein", "TREATMENT", 57, 78], ["atypical haemolytic uremic syndrome", "PROBLEM", 159, 194], ["normal", "OBSERVATION", 25, 31], ["atypical", "OBSERVATION_MODIFIER", 159, 167], ["haemolytic", "OBSERVATION_MODIFIER", 168, 178], ["uremic syndrome", "OBSERVATION", 179, 194]]], ["The percentage retention of selected factor is reported in Table 1.", [["percentage", "OBSERVATION_MODIFIER", 4, 14], ["retention", "OBSERVATION_MODIFIER", 15, 24]]], ["The content of factor VIII is about 20 % lower compared to the source FFP and the activity of protein S (PS) is reduced by about 35\u201340 % [6, 10].", [["factor VIII", "GENE_OR_GENE_PRODUCT", 15, 26], ["protein S", "GENE_OR_GENE_PRODUCT", 94, 103], ["factor VIII", "PROTEIN", 15, 26], ["FFP", "PROTEIN", 70, 73], ["protein S", "PROTEIN", 94, 103], ["factor VIII", "PROBLEM", 15, 26], ["FFP", "TREATMENT", 70, 73], ["the activity of protein S (PS", "TREATMENT", 78, 107], ["factor VIII", "OBSERVATION_MODIFIER", 15, 26]]], ["Reductions in this order of magnitude are not clinically significant due to the wide reference range (50\u2013200 %) for most clotting factors and inhibitors in single plasma units.", [["plasma", "ANATOMY", 163, 169], ["clotting factors", "GENE_OR_GENE_PRODUCT", 121, 137], ["plasma", "ORGANISM_SUBSTANCE", 163, 169], ["clotting factors", "PROTEIN", 121, 137], ["most clotting factors", "PROBLEM", 116, 137], ["inhibitors", "TREATMENT", 142, 152], ["single plasma units", "TREATMENT", 156, 175]]]], "7f302add8b117514b8393d55f49c3ded276faf94": [["Randomized efficacy trials take approximately 5.5 years from the initiation of enrollment to publication [1] , and 7 years or longer after adding the time from grant application submission to enrollment initiation.", [["Randomized efficacy trials", "TREATMENT", 0, 26]]], ["Extensive follow-up periods for relevant outcomes such as morbidity/mortality as well as delays in participant recruitment and publication can extend this time period to a decade or longer.", [["morbidity/mortality", "PROBLEM", 58, 77]]], ["For example, one explanation for the recently reported negative results of the SAMMPRIS trial was that stent technologies and surgery procedures had advanced substantially since study initiation [3, 4] .BackgroundThis protracted period from concept to publication is further exacerbated by the slow and limited uptake of research findings into practice.", [["the SAMMPRIS trial", "TREATMENT", 75, 93], ["stent technologies", "TREATMENT", 103, 121], ["surgery procedures", "TREATMENT", 126, 144], ["protracted", "OBSERVATION_MODIFIER", 218, 228]]], ["An Institute of Medicine report on clinical trials states that \"recognition is growing that the clinical trials enterprise in the United States faces substantial challenges impeding the efficient and effective conduct of clinical research to support the development of new medicines and evaluate existing therapies [7] .\"", [["new medicines", "TREATMENT", 269, 282], ["existing therapies", "TREATMENT", 296, 314]]], ["Clearly, our current research enterprise is too slow, inefficient, and cumbersome to meet the rapidly evolving demand.BackgroundWhat are needed are \"rapid-learning research systems\" that integrate researchers, funders, health systems, practitioners, and community partners asking clinically relevant questions, using efficient and innovative research designs, and leveraging rich, longitudinal data sets from millions of patients.", [["patients", "ORGANISM", 421, 429], ["patients", "SPECIES", 421, 429], ["too slow", "OBSERVATION_MODIFIER", 44, 52]]], ["These suggested approaches are viewed as a starting point for a dialogue among the health research community to challenge our current cumbersome research enterprise and to consider these or other approaches to maintain scientific rigor while speeding the process by which more responsive and relevant research findings are produced.Relevance and stakeholder engagementBroad stakeholder engagement involving patients, providers, health plans, policy makers and other relevant stakeholders may seem counterintuitive as a strategy to speed research, but this time investment has the potential to improve the recruitment and retention of study participants, thus increasing the pace of conducting the study.", [["patients", "ORGANISM", 407, 415], ["patients", "SPECIES", 407, 415], ["participants", "SPECIES", 640, 652], ["scientific rigor", "PROBLEM", 219, 235], ["conducting the study", "TEST", 682, 702]]], ["The Patient Centered Outcomes Research Institute (PCORI), for example, is creating public advisory groups and soliciting patient input on specific comparative effectiveness questions that are relevant to practitioners and stakeholders [10] .", [["patient", "ORGANISM", 121, 128], ["Patient", "SPECIES", 4, 11], ["patient", "SPECIES", 121, 128]]], ["An ongoing relationship between researchers, healthcare providers, health plans, and patients is critical to a better, faster research system.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93]]], ["Clinical trial recruitment is a major problem with about 90% of US trials failing to meet enrollment goals [7] .", [["Clinical trial recruitment", "TREATMENT", 0, 26], ["US trials", "TREATMENT", 64, 73]]], ["Like the HMO Research Network and the VA QUERI program, the HCSC will make available opportunities to conduct large-scale studies within well-organized healthcare delivery systems [11] .", [["large-scale studies", "TEST", 110, 129]]], ["Research embedded in organized delivery systems and networks enhances not only research relevance, but also facilitates recruitment, retention, study start-up, operations, data capture, and integration into practice.", [["Research embedded in organized delivery systems", "TREATMENT", 0, 47]]], ["Via innovative technologies, stakeholder feedback can be obtained efficiently to increase research relevance and responsiveness, even for researchers who are not fully integrated into the practice setting or community where their research findings are likely to be translated into practice.Rapid research designsTraditional study designs and procedures are wellestablished, rigorous, and notoriously slow and costly.", [["Traditional study", "TEST", 312, 329]]], ["This belabored research process typically begins with pilot trials that we posit have limited benefit, are used inappropriately to estimate effect size [14] , and often prematurely concretize a less than optimal intervention.", [["pilot trials", "TREATMENT", 54, 66], ["optimal intervention", "TREATMENT", 204, 224]]], ["Instead, we recommend replacing the traditional pilot trial with a more flexible iterative intervention testing and optimization approach, analogous to the agile software development process that places a premium on failing early to succeed later [15] .", [["the traditional pilot trial", "TREATMENT", 32, 59], ["a more flexible iterative intervention testing", "TREATMENT", 65, 111], ["optimization approach", "TREATMENT", 116, 137]]], ["For example, N-of-1 trial designs provide intervention development flexibility.", [["example", "TEST", 4, 11], ["N", "TEST", 13, 14], ["intervention development flexibility", "TREATMENT", 42, 78]]], ["With the increasing availability of intensive longitudinal data from wireless sensors and mobile devices, N-of-1 trials can be rapidly implemented and provide results congruent with a more personalized medicine approach [16] , and Bayesian analyses from a series of such trials [17] may provide sufficient evidence of generalizability to limit the need for a larger trial.Rapid research designsIntervention optimization designs such as fractional factorial and sequential multiple assignment research trials (SMART) are particularly valuable when the intervention development questions involve combinations or sequences of intervention components [18] .", [["intensive longitudinal data", "TEST", 36, 63], ["mobile devices", "TREATMENT", 90, 104], ["a larger trial", "TREATMENT", 357, 371], ["Intervention optimization designs", "TREATMENT", 394, 427], ["fractional factorial", "TREATMENT", 436, 456], ["intervention components", "TREATMENT", 623, 646]]], ["Some optimization approaches may take more time than the traditional pilot trial, but the pace of the overall research enterprise will be improved by more quickly discarding or modifying interventions that are unlikely to be found effective in larger and more expensive trials.Rapid research designsWithin the traditional RCT, researchers have a number of design decisions that can increase efficiency.", [["the traditional pilot trial", "TREATMENT", 53, 80], ["modifying interventions", "TREATMENT", 177, 200]]], ["Trials that utilize within-group designs in which participants serve as their own controls can speed the research process by reducing the number of study participants needed to detect outcomes, and can often simplify study procedures as well.", [["participants", "SPECIES", 50, 62], ["participants", "SPECIES", 154, 166], ["study procedures", "TEST", 217, 233]]], ["The Minimal Intervention Needed for Change (MINC) standard [20] provides a standard pragmatic comparison anchor across studies for comparative effectiveness research.", [["Change (MINC)", "TREATMENT", 36, 49], ["a standard pragmatic comparison anchor across studies", "TEST", 73, 126], ["Minimal", "OBSERVATION_MODIFIER", 4, 11]]], ["The VA is adopting a \"point of care\" randomization that computer-randomizes patients to different treatments, and then uses adaptive algorithms to change allocation of new patients as evidence accumulates [21] .", [["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 172, 180], ["care\" randomization", "TREATMENT", 31, 50], ["different treatments", "TREATMENT", 88, 108], ["adaptive algorithms", "TREATMENT", 124, 143]]], ["Recent technological advances make it possible to conduct \"automated RCTs\" in which the enrollment, random assignment, intervention delivery, and outcome assessments are fully automated.", [["intervention delivery", "TREATMENT", 119, 140], ["outcome assessments", "TEST", 146, 165]]], ["Results can be analyzed at the point where the maximal benefit of the intervention is hypothesized to occur.", [["the intervention", "TREATMENT", 66, 82]]], ["Longer-term outcomes can be modeled from these results, or one of the investigators can remain blind to conduct the follow-up portion of the study and publish the follow-up results separately.Rapid research designsIn addition to improving the efficiency of RCTs, we also need to consider alternative designs that may be more appropriate to the research question and provide more rapid and relevant answers.", [["the study", "TEST", 137, 146], ["alternative designs", "TREATMENT", 288, 307]]], ["A range of within-subject and quasi-experimental designs such as interrupted time series [22] , stepped wedge [23] , and regression discontinuity [24] may have less internal validity than the RCT, but offer a number of advantages [25] .", [["stepped wedge", "TEST", 96, 109], ["regression discontinuity", "PROBLEM", 121, 145], ["range", "OBSERVATION_MODIFIER", 2, 7]]], ["For example, these quasiexperimental approaches facilitated participation of the major Minnesota health insurers in the DIAMOND depression treatment program [26] .", [["depression", "DISEASE", 128, 138], ["the DIAMOND depression treatment program", "TREATMENT", 116, 156]]], ["These designs may be particularly appropriate for evaluating treatments already adopted in practice.Rapid review processesIt takes 9 to 11 months from NIH grant submission to funding [27] .", [["treatments", "TREATMENT", 61, 71], ["Rapid review processes", "PROBLEM", 100, 122]]], ["If revised and resubmitted, and assuming a six month revision period, it can take two years from initial submission to the award of a revised (A1) NIH grant application.", [["a revised (A1) NIH grant application", "TREATMENT", 132, 168]]], ["During this time, science and technology continue to advance; research partnerships, especially with nonresearch stakeholders, must be maintained; and the research questions may become less relevant or timely.Rapid review processesGrant review and funding processes could be streamlined in a number of ways.", [["Rapid review processes", "PROBLEM", 209, 231]]], ["In response to the SARS (Severe Acute Respiratory Syndrome) outbreak, the Canadian Institutes of Health Research developed and issued a funding announcement that resulted in 18 submissions within 2 weeks, and these submissions were reviewed and four approved for funding within 10 days of submission [31] .", [["SARS", "DISEASE", 19, 23], ["Acute Respiratory Syndrome", "DISEASE", 32, 58], ["the SARS (Severe Acute Respiratory Syndrome)", "PROBLEM", 15, 59], ["Severe", "OBSERVATION_MODIFIER", 25, 31], ["Acute", "OBSERVATION_MODIFIER", 32, 37], ["Respiratory Syndrome", "OBSERVATION", 38, 58]]], ["These rapid review examples clearly indicate that it is possible to review and fund research applications quickly when necessary, and that such rapid review systems should be considered for a broader range of research, including timely and pressing clinical and public health questions.Rapid review processesThe grant application review process could facilitate more rapid research not only by reviewing more efficiently, but also by placing a greater premium on more rapid and innovative research designs.", [["Rapid review processes", "PROBLEM", 286, 308]]], ["Despite the addition of innovation as an NIH review criteria, a recent study of grant applications revealed that novelty is associated with a 4.5 percentile point drop, and that feasibility concerns did not contribute substantially to this \"novelty penalty\" [32] .", [["a recent study", "TEST", 62, 76], ["a 4.5 percentile point drop", "PROBLEM", 140, 167]]], ["Slowness of research should be considered a risk, both to study participants who may continue in their assigned treatment even as newer treatments become available, and to the broader public who are delayed getting answers to relevant research questions.", [["participants", "SPECIES", 64, 76], ["treatment", "TREATMENT", 112, 121]]], ["Revisions to the Common Rule are anticipated to allow for a more flexible and rapid review process [33] .Rapid review processesOnline and open access publication practices have greatly reduced the time from acceptance to publication [34] but could be further facilitated by a better or more incentivized process for acquiring reviewers and obtaining reviews.", [["Rapid review processes", "PROBLEM", 105, 127], ["open access publication practices", "TREATMENT", 138, 171]]], ["As Green noted, new technologies for publication, systematic reviews, and dissemination of evidence-based guidelines reduce the time from research findings to practitioner adoption, but the publication and dissemination process should continue to be reviewed to further reduce the time lapses between the various stages of the dissemination and implementation process [9] .Infrastructure for rapid researchImproving our research infrastructure has the potential not only to speed the pace of research, but also increase its rigor and relevance.", [["systematic reviews", "TEST", 50, 68], ["the publication and dissemination process", "PROBLEM", 186, 227], ["dissemination", "OBSERVATION", 327, 340], ["increase", "OBSERVATION_MODIFIER", 511, 519]]], ["It is now possible to conduct some studies in weeks or months instead of years.", [["some studies", "TEST", 30, 42]]], ["The FDA mini-Sentinel system accesses 125 million patient records to generate several studies per week on drug safety questions [37] .", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57]]], ["Large biobanks are now coming on-line at Kaiser-Permanente, [38] the Veterans Health Administration [39] , the EN-CODE network, [40] , and the UK Biobank [41] .", [["biobanks", "OBSERVATION", 6, 14]]], ["Using these and other patient databases, researchers have been able to assess the unintended effects of treatments [42] and produce outcome findings comparable to RCTs [43] .Infrastructure for rapid researchLarge future investments are now being considered that could offer extraordinary opportunities for researchers and a faster, more efficient infrastructure for rapid learning research.", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["treatments", "TREATMENT", 104, 114], ["RCTs", "TEST", 163, 167], ["rapid researchLarge future investments", "TREATMENT", 193, 231]]], ["The NIH Director has proposed a new national patient-oriented research system with electronic health records databases, including genomics, for 20-30 million patients [44] , and PCORI recently released a funding announcement to support development of the National Patient Centered Clinical Research Network [10] .", [["patient", "ORGANISM", 45, 52], ["patients", "ORGANISM", 158, 166], ["patient", "SPECIES", 45, 52], ["patients", "SPECIES", 158, 166]]], ["The Big Data to Knowledge (BD2K) initiative [45] also provides the opportunity to leverage these large data sets for rapid research.Infrastructure for rapid researchResearchers can accelerate the collective pace of learning with greater attention to reporting comparable data.", [["rapid researchResearchers", "PROBLEM", 151, 176]]], ["Standardized outcome data are particularly problematic for patient-reported outcomes.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["Standardized outcome data", "TEST", 0, 25]]], ["To address this problem, there have been consensus measurement efforts such as PhenX [47] as well as efforts to co-calibrate various patient-reported outcome measures on a single metric [48] .Infrastructure for rapid researchThe National Research Council report on Precision Medicine calls for a new science commons and national learning system that will revolutionize biomedical research, clinical care, and public health [49] .", [["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140]]], ["One of the benefits of such a system is that researchers can more readily target drug approval studies to predicted high-response populations, and cut years from the drug research process.", [["high-response populations", "PROBLEM", 116, 141]]], ["Gleevec, an anti-cancer drug, was approved in a trial of only 54 patients because nearly all showed benefit [6] .", [["Gleevec", "CHEMICAL", 0, 7], ["Gleevec", "CHEMICAL", 0, 7], ["Gleevec", "SIMPLE_CHEMICAL", 0, 7], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["Gleevec", "TREATMENT", 0, 7], ["anti-cancer drug", "OBSERVATION", 12, 28]]], ["With targeted therapeutics and research, it took only four years from target discovery to drug approval for the lung cancer drug Xalkori [50] .", [["lung cancer", "ANATOMY", 112, 123], ["lung cancer", "DISEASE", 112, 123], ["Xalkori", "CHEMICAL", 129, 136], ["lung cancer", "CANCER", 112, 123], ["drug approval", "TREATMENT", 90, 103], ["the lung cancer drug Xalkori", "TREATMENT", 108, 136], ["lung", "ANATOMY", 112, 116], ["cancer", "OBSERVATION", 117, 123]]], ["Rapid learning systems of large patient populations appear to provide the infrastructure to rapidly evaluate treatments.ConclusionsWe have outlined a number of actions to enhance relevance, streamline design, speed review, and use new research infrastructures to make research more rapid, relevant, and responsive to the 21 st century demands on health research.", [["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["large patient populations", "PROBLEM", 26, 51], ["large", "OBSERVATION_MODIFIER", 26, 31]]], ["This transformation to a rapid research learning system will require a concerted effort by research funders, academic institutions, healthcare systems, researchers, and a variety of practice, community, and policy stakeholders to produce a culture change among the health research community.", [["This transformation", "PROBLEM", 0, 19], ["a culture change", "PROBLEM", 238, 254]]], ["Will we continue to use limited funds to support the currently slow and cumbersome research enterprise that produces costly results that may not be relevant or easily translated into practice, or are we willing to pursue alternative approaches that in other research disciplines have produced rapid and relevant improvements?ConclusionsThe rationale and opportunities for such a culture change have never been greater or rapid answers more needed.", [["alternative approaches", "TREATMENT", 221, 243], ["a culture change", "TEST", 377, 393]]], ["This call to streamline and speed the research process is also likely to be met with skepticism, especially among those who fear that methodological rigor might be compromised in a quest for greater efficiency.", [["methodological rigor", "PROBLEM", 134, 154]]]]}